Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient

ABSTRACT

A therapeutic vaccination method includes growing and harvesting viruses, bacteria, fungi, parasites, or tumor cells on a cell culture or other appropriate medium; killing the viruses, bacteria, fungi, parasites, or tumor cells in the cell culture or other appropriate medium with a dose of methylene blue; separating the dead viruses, bacteria, fungi, parasites, or tumor cells from a remainder of the cell culture or other appropriate medium using a filter and/or centrifuge; adding antivirals, antibacterials, antifungals, antiparasitics, and/or anti-neoplastic medications at non-toxic therapeutic concentrations to the dead viruses, bacteria, fungi, parasites, or tumor cells so as to form a therapeutic vaccine; and administering the therapeutic vaccine to a patient in need thereof to simultaneously produces a therapeutic response and a humoral and cellular immune response in the body of the patient without resulting in deleterious side effects to the patient.

CROSS-REFERENCE TO RELATED APPLICATIONS

This patent application claims priority to U.S. Provisional PatentApplication No. 63/162,986, entitled “Treatment And Prevention MethodsFor Respiratory Infections”, filed on Mar. 18, 2021; U.S. ProvisionalPatent Application No. 63/177,916, entitled “Treatment And PreventionMethods For Respiratory Infections”, filed on Apr. 21, 2021; U.S.Provisional Patent Application No. 63/181,948, entitled “Treatment AndPrevention Methods For Respiratory Infections”, filed on Apr. 29, 2021;U.S. Provisional Patent Application No. 63/209,331, entitled “TreatmentAnd Prevention Methods For Respiratory Infections”, filed on Jun. 10,2021; U.S. Provisional Patent Application No. 63/221,852, entitled“Treatment And Prevention Methods For Respiratory Infections”, filed onJul. 14, 2021; U.S. Provisional Patent Application No. 63/239,927,entitled “Treatment And Prevention Methods For Respiratory Infections”,filed on Sep. 1, 2021; and U.S. Provisional Patent Application No.63/306,042, entitled “Treatment And Prevention Methods For RespiratoryInfections”, filed on Feb. 2, 2022; and is a continuation-in-part ofapplication Ser. No. 17/180,784, entitled “Method Of Treating, Reducing,Or Alleviating A Medical Condition In A Patient”, filed Feb. 20, 2021,which claims priority to U.S. Provisional Patent Application No.63/039,959, entitled “Treatment And Prevention Methods For RespiratoryInfections”, filed on Jun. 16, 2020; U.S. Provisional Patent ApplicationNo. 63/055,770, entitled “Treatment And Prevention Methods ForRespiratory Infections”, filed on Jul. 23, 2020; U.S. Provisional PatentApplication No. 63/077,677, entitled “Treatment And Prevention MethodsFor Respiratory Infections”, filed on Sep. 13, 2020; U.S. ProvisionalPatent Application No. 63/106,319, entitled “Treatment And PreventionMethods For Respiratory Infections”, filed on Oct. 27, 2020; and U.S.Provisional Patent Application No. 63/131,761, entitled “Treatment AndPrevention Methods For Respiratory Infections”, filed on Dec. 29, 2020;and Ser. No. 17/180,784 is a continuation-in-part of application Ser.No. 16/861,128, entitled “Method Of Treating, Reducing, Or Alleviating AMedical Condition In A Patient”, filed Apr. 28, 2020, now U.S. Pat. No.10,925,889; which claims priority to U.S. Provisional Patent ApplicationNo. 62/839,738, entitled “Method Of Treating, Reducing, Or Alleviating AMedical Condition In A Patient”, filed on Apr. 28, 2019; and to U.S.Provisional Patent Application No. 63/016,258, entitled “TreatmentMethods For Respiratory Infections”, filed on Apr. 27, 2020, thedisclosure of each of which is hereby incorporated by reference as ifset forth in their entirety herein.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Not Applicable.

NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT

Not Applicable.

INCORPORATION BY REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISK

Not Applicable.

BACKGROUND OF THE INVENTION 1. Field of the Invention

The invention generally relates to treatment methods of treating,reducing, or alleviating a medical condition in a patient. Moreparticularly, the invention relates to combination therapy for thetreatment of various medical conditions, which include respiratoryinfections.

2. Background

Respiratory infections also involve inflammatory processes. Respiratoryinfections are mostly manifested as bacterial or viral infectionsaffecting the nose, throat, epiglottis, trachea, and the lungs. Oftenthese infections in the end stage can cause serious damage to the lungsas pneumonia and superinfection and serious consequences.

In an upper respiratory Infection (URI), the bacterial culprit is groupA streptococcal bacteria producing sinusitis and or bronchitis. Thecommon symptoms are redness of the throat and tonsils and moderatelyelevated temperature of about 38 degrees C. and enlarged cervical nodes.One of the symptoms of laryngotracheitis is roughness of the voice, etc.and positive culture of the organism.

The viral infection is caused often by influenza virus, Epstein Barrvirus, Herpes virus, etc. and can be diagnosed by available rapid testsfor antibody or polymerase chain reaction (PCR) viral proteins (e.g.,enzyme assays for reverse transcriptase in retroviruses), or virusparticles (e.g., by electron microscopy or Raman surface enhancespectroscopy, QuantiFERON-virus Gold test (QFV-G) and Surface-enhancedRaman scattering (SERS) for rapid detection of multiple viral antigensusing magnetic capture of SERS-active nanoparticles as known in theart). In Surface Enhanced Raman Spectroscopy (SERS), antibody conjugatedmagnetic or paramagnetic and gold nanoparticles/virus complex isenhanced by an external magnetic field detected by SERS where the signalof the specific virus, e.g., COVID-19 or its mutations, gene, bacteriapresent in blood, dry blood, serum, or nasal, throat swab, etc. isenhanced by laser excitation and recognized using principal componentanalysis (PCA) and hierarchical cluster analysis (HCA) as known in theart at low picomolar concentration. In a hospitalized patient, a bloodculture, sputum, nasal, skin, mouth conjunctival mucosa or urogenitalmucosa, aqueous, vitreous, CSF, joint fluid, etc. might be taken toverify the extent of the localized or systemic involvement of theviruses or bacteria, etc. The use of a single strand of DNA/antibody oraptamer coated nanoparticles can be used to recognize the RNA expressionof RNA viruses, etc. Management of these cases is done in general byoral and systemic antibiotics, penicillin, fluoroquinolones (e.g.,levofloxacin, moxifloxacin etc.), tetracycline and its derivatives andantivirals, etc. Hospitalization might be required in advanced casesaffecting the lung with the symptom of dyspnea. The viral infection ofthe upper respiratory tract is caused by a variety of viruses, amongthem, the most common are Rhinoviruses, Coxsackie viruses, Adenovirusesand Coronaviruses and Respiratory syncytial virus (RSV) and Epstein BarrVirus (EBV) causing a variety of disease manifestations, such asinfectious mononucleosis, or Cytomegalovirus. Rhinoviruses cause anumber of common cold infections in adults and are seasonal, appearingin fall and winter. These cause approximately 30-50% of colds in adults.The Adenovirus causes conjunctivitis and laryngitis. H. influenzae typeb (Hib) often causes epiglottitis in children, whereas influenza, Humanparainfluenza viruses (HPIVs) viruses and RSV cause laryngitis and somecause pelvic inflammatory diseases of various types. Most of the viralinfections are initiated by close contact, travel, or in patients withimmune suppression. In general vaccination can reduce a number of theseinfections. Some viruses are seen more often in male patients thanfemales, or during menstrual cycles etc. and some with preference inchildren, yet others in the elderly. Some of the viruses produceepidemic diseases such as Middle East respiratory syndrome, pandemicH1N1, and H7N9, thus affecting a large number of the population and canbe diagnosed by diagnosed by polymerase chain reaction (PCR) panels,etc. Therapy with antibiotics is ineffective in majorities of viralinfections unless it is accompanied by a bacterial superinfection.However some viruses, such as influenza viruses and COVID-19 grow in thepresence of the bacteria, therefore in these cases administration ofsome antibiotics such as tetracycline derivatives, a metalloproteinaseinhibitor, as inhalation combined with antiviral work synergistically.The antiviral therapies are effective, such as administration ofribavirin in lung transplant patients with Motavizumab. However, theyare not affordable for common viral infections, a second-generationanti-RSV antibody, or intravenous immunoglobin (RI-002).

Although influenza and parainfluenza viruses are often self-limited,unfortunately they can be associated with life threatening consequencesin patients after lung transplantation or immunosuppressed patients, andmay have a high mortality rate similar to RSV disease, and 20% ofpatients with SARS-CoV-2, COVID-19 or its mutations, have multi-organfailure due to cytokine storm.

Among viruses that cause epidemic or pandemic disease are severe acuterespiratory syndrome coronavirus (SARS-CoV-2) and COVID-19 or itsmutations, an RNA virus involving bird and mammals which was foundinitially in the Wuhan Seafood Wholesale market. By now, SARS-CoV-2,COVID-19 or its mutations, has affected every country in everycontinent. It is a highly contagious virus and survives 3-7 hours, andsometimes more hours on surfaces.

The SARS-CoV-2 and COVID-19 coronavirus affects the bronchoalveolar celllinings as seen with other Coronaviruses. The viruses utilize certainprotease proteins of these cells membrane to enter in the cell cytoplasmand utilize the genetic machinery of the cell to multiply. Theincubation time varies between 3-7 days or more, while the patientremains relatively asymptomatic. The transmission occurs by contact oraerosolized droplet sputum by sneezing or being close (less than 6 feet)from an infected person. Thus, one person can transmit the virus to manyothers. In addition, many patients who have recovered can still transmitthe virus to others. At present, at least six or more different coronalviruses have been recognized. Among these are SARS-CoV coronaviruscausing severe acute respiratory syndrome or MERS-CoV Middle Easternrespiratory syndrome and some that live in bats.

The mechanism of cell entry of the virus into the cell involves usingthe receptor binding domain (RBD) or the S protein of the virus toattach to the human receptor ACE2 of the alveoli cell where serineprotease cleaves the S protein of the virus and causes the binding ofthe virus to the cell membrane and facilitates entry in the cell. Amongthe symptoms of coronavirus, a high fever of 100 Fahrenheit or more, isa common finding in addition to cough, shortness of breath, chills,headache, sore throat, muscle pain and gastrointestinal symptoms, lossof smell or taste, urticaria or discoloration of the foot or toes, etc.,followed by laboratory finding of leukopenia, lymphocytopenia andthrombocytopenia, coagulopathy, increase in antiphospholipid antibodies,multiple infarcts, increased C-reactive protein greater than >10 mg/L,elevated lactate dehydrogenase (LDH), elevated creatinine, specificallyin patients with cytokine storm, similarly increased IFNγ and increasedpro-inflammatory ferritin, D-dimer. Cytokine storm induces damage tomany organs, such as heart, kidney, etc. A cytokine storm is oftenassociated with macrophage activation syndrome (MAS) and hemophagocyticlymphohistiocytosis (sHLH), increase in cytokines, such as tumornecrosis factor (TNF)-α, interferon (IFN)-γ, interleukin (IL)-1β, IL-2,IL-6, IL-7, IL-12, IL-18, and granulocyte colony-stimulating factor(GCSF). Interestingly, one finds also the anti-inflammatory stimuli,such as regulatory T cells, cytokines IL-10, transforming growth factor(TGF)-β. The latter can lead to pulmonary fibrosis when the patient hasrecovered, whereas the presence of IL-2, IL-6, IL-7, TNFα, IFNγ, andGCSF, indicates significant lung injury. Comorbidity conditions are oldage, male sex, asthma, heart disease, diabetes, kidney disease, etc.

At present, there is no definite therapy for the SARS-CoV-2, COVID-19 orits coronavirus mutations. In general, the early stages are treatedpalliative. Since fever is a relatively an early symptom, aspirin andTylenol are useful, but do not affect the replication of the virus.Protection against infection includes self-isolation quarantine, the useof a mask and gloves, and prevention of the virus spreads by sanitizingdrops and handwashing. At present, patients with dyspnea, are treatedwith inhalation of oxygen through the nose or by ventilator, increasingthe tissue oxygenation to a level of 92-96%. If a higher level isrequired, one has recommended the use of nonrebreather mask, with a flowrate up to 6-10 L while providing 100% FiO₂ (fraction of inspired oxygen(FiO20).

Inflammatory disease of the brain is called encephalitis. It is causedby viral or bacterial invasion of the brain through the circulation, butmost independently through the nasal mucosa and lamina cribrosa, a thinlayer of bone that separates the brain and cerebrospinal fluid from thenasal cavity, directly through the olfactory nerve that begins one sideinside from the nasal cavity with its receptors between the nasalepithelial cells, and ends with the olfactory bulb located inside theskull under the brain and another nerve “the trigeminal nerve” thattransmits sensation of touch or pain from the facial skin, or mouth,throat, and nasal mucosa to trigeminal ganglion cells located at thebrain.

The olfactory neurons are close to the nasal cavity and have access tothe subarachnoid space in the brain, therefore virus can migrate fromthe nasal cavity to the olfactory bulb and migrate to brain, thalamus,cerebrum, and cerebellum.

All viruses show a tropism for the olfactory epithelium, bovineherpesvirus 5 and equine herpesvirus 9 spread from the nasal mucosa tothe central nervous system (CNS) via the olfactory nerves, herpesvirus 6has been found in the nasal mucosa in healthy controls, multiplesclerosis patients, and patients with a loss of smell.

The bony structure of skull protects the brain which is surrounded bymeninges, consisting of dura mater, arachnoid and pita matter. Thecerebrospinal fluid is produced in the brain ventricle existing throughthe venous system of the meninges and through the lamina cribrosa, etc.and the lymphatic system of the nose.

The thigh junction of the endothelial cells and pericytes, astrocytesand epithelial cells of the arachnoid mainly prevent passage of theblood and its components including the potentially invasive pathogens inthe brain substance.

The brain is composed of many ganglion cells, microglia, astrocytes,dendritic cells, oligodendrocytes, etc. of which the neuronal cells andglial cells build the majority of cells. The cerebrospinal fluid (CSF)contains many migrating mononuclear cells, such as monocytes, anddendritic cells, T cells, B cells, macrophages, the T-cell exit thesubarachnoid space access the lymphatic system that drains in the nasalmucosal lymphatic system.

The viral and microbial pathogens can gain access to the brain passingthrough the damaged endothelial cells of the brain or spinal cordvessels through the circulation or alternatively through the olfactoryor trigeminal nerves directly bypassing all barriers of the brain.

The neurotrophic viruses often invade the nasal mucosa where theyproliferate then gain preferentially access to the olfactory nerve andthe brain and its vasculature inducing vasculitis and encephalitis,followed by the release of cytokines and enzymes such asmetalloproteinases, etc. enhances the degradation of the blood brainbarrier (BBB), with poring blood plasma, fibrinogen that is convertedinto fibrin in the brain, increased intraocular pressure, headache,changes in mental cognition, and difficulty of interaction and death ofthe neuronal cells.

Viruses constitute the majority of the pathogens involved in cases ofencephalitis. The infection produces a combined inflammation of thebrain substance and its vasculature (Vasculitis). Other viruses besideherpes virus that cause encephalitis are, influenza viruses,Epstein-Barr viruses, measles virus, enteroviruses, varicella-zostervirus and arboviruses, Japanese encephalitis virus, West Nile virus, andMurray Valley encephalitis virus.

In some cases, the encephalitis (brain inflammation) is caused byviruses which gain access to the brain through the circulation. However,more commonly, the nasal cavity and its mucosa are affected initially,and the viruses multiply there, before spreading to the vascularendothelial cells or brain through the lamina cribrosa, a thin plate ofbone between the nasal cavity and brain.

The pathogens induce vasculitis, breakdown of the blood brain barrierleading to further invasion of the bacteria or viruses affecting theganglion cell function, stimulating glial cell and immune cells,proliferation and migration in the affected area.

Viral encephalitis occurs after nasal invasion by the viruses, such ascommon cold, influenza viruses, coronaviruses, SARS-CoV-2, COVID-19 ortheir mutations, influenza viruses, herpes simplex, varicella zoster,shingles, but also measles, rubella and mumps, or Epstein-Barr virus(EBV), Ebola virus, enteroviruses, cytomegalovirus, other viruses suchas Zika chikungunya, and arboviruses that are transmitted via mosquitos'bites and subsequently affect the CNS, etc. or via circulation. Herpessimplex type 1 virus can become as deadly as some other viruses, such asEbola if not treated rapidly. Sever inflammatory process specifically inbacterial infection produces brain abscess.

Conjunctivitis is one of the most common infectious diseases of the eyeaffecting the conjunctiva, cornea or the lid, kwon askeratoconjunctivitis, or blepharoconjuctivitis. The acute inflammationis initiated by invading bacterial or viral organism such asstreptococcal or staphylococcal bacteria, etc. Bacterial conjunctivitisis associated with trichiasis, chronic blepharitis or dry eye. The mostcommonly viral pathogens are adenoviruses causing pinkeye or adenoviralepidemic keratoconjunctivitis (EKC) or herpes simplex virus (HSV)viruses. Other viral infection causing conjunctivitis arevaricella-zoster virus (VZV), picornavirus (enterovirus 70, CoxsackieA24), Poxvirus (molluscum contagiosum, vaccinia), and humanimmunodeficiency virus (HIV) or rarely, influenza virus, SARS-CoV-2,COVID-19 or their mutations, Epstein-Barr virus, paramyxovirus (measles,mumps, Newcastle), or rubella, Most of viral conjunctivitis, arecontagious and can be transmitted to others and to majorities of body'sorgans.

The COVID-19 virus or its mutations can induce numerous inflammatorydisorders in the including conjunctivitis scleritis, or nodularconjunctivitis and scleritis, uveitis and retinitis, and/or optic nervevasculitis.

The infection can be caused by the virus invasion directly, or theinflammation is caused by the presence of the cytokine released causinghyperemia of the conjunctiva. The diagnosis is done by detection of thevirus using PCR from the conjunctival fluid, saliva anterior chamberfluid or vitreous samples or from the nasal fluid which is drained inthe nose through the nasolacrimal duct or to the throat and lung, etc.

The patients with conjunctivitis have typically some pain, itching,watery or thick discharge associated with redness of the conjunctiva,photophobia, keratitis and lid swelling.

Conjunctivitis can also be caused as an allergic response to an externalantigen in children or adults known as vernal conjunctivitis often seenin warm season appearing as dot-like swelling involving the pre-cornealor limbal conjunctiva.

Giant papillary conjunctivitis is seen in people who do not toleratewearing contact lens. The symptoms involve the upper conjunctiva,usually under the upper lid. It is associated with increased mucusproduction and itching resembling venereal disease.

BRIEF SUMMARY OF EMBODIMENTS OF THE INVENTION

Accordingly, the present invention is directed to a method of treating,reducing, or alleviating a medical condition in a patient thatsubstantially obviates one or more problems resulting from thelimitations and deficiencies of the related art.

In accordance with one or more embodiments of the present invention,there is provided a method of treating, reducing, or alleviating amedical condition in a patient. The method includes administering to apatient in need thereof a biocompatible drug comprising one or moreantiviral medications together with one or more cell pathway inhibitorsdissolved in a non-toxic semifluorinated alkane or other liquids, thepatient having one or more respiratory tract inflammatory diseases, theone or more cell pathway inhibitors blocking an inflammatory response ofinflamed tissue without inhibiting an immune response of the patient,and the semifluorinated alkane evaporating quickly upon administrationto the patient so as to leave the biocompatible drug at a desiredtreatment location. The administration of the biocompatible drug to thepatient treats the one or more respiratory tract inflammatory diseases,reduces the symptoms associated with the one or more respiratory tractinflammatory diseases, and/or alleviates the one or more respiratorytract inflammatory diseases.

In a further embodiment of the present invention, the one or morerespiratory tract inflammatory diseases are selected from the groupconsisting of influenza, parainfluenza, severe acute respiratorysyndrome, a coronavirus, an Epstein-bar virus, a herpes virus, aninfection, and combinations thereof.

In yet a further embodiment, the one or more respiratory tractinflammatory diseases comprise a coronavirus, the coronavirus selectedfrom the group consisting of COVID-2, COVID-19, and combinationsthereof.

In still a further embodiment, the biocompatible drug further comprisesnanoparticles or microparticles used as a carrier of the biocompatibledrug; and the biocompatible drug with the semifluorinated alkane and thenanoparticles or microparticles is administered by inhalation to thepatient to treat one or more respiratory tract inflammatory diseases.

In yet a further embodiment, wherein the nanoparticle or microparticlecarriers comprise slow release polymeric nanoparticles ormicroparticles; and the semifluorinated alkane is used to transport thebiocompatible drug with the slow release polymeric nanoparticles ormicroparticles.

In still a further embodiment, the slow release polymeric nanoparticlesor microparticles are conjugated with a viral specific antibody whilecarrying at least two antiviral medications for intranasal inhalation tospecifically target one or more viruses, the viral specific antibodybeing obtained from plasma/serum of patients who have recovered from aviral infection or the viral specific antibody being produced in atissue culture using dead viruses cultured with T-cell lymphocytes ornatural killers that produce the viral specific antibody in addition toproducing exosomes or extracellular vesicles (ECV) that are both able tobe harvested.

In yet a further embodiment, the one or more antiviral medications areselected from the group consisting of medications preventing the virusentry in the cell, such as protease inhibitors, or prevention of virusmultiplication, such as transcription factor inhibitors, nucleosidereverse transcriptase inhibitor (NRTI) or polymerase inhibitor, etc.These one or more antiviral medications include, for example,amantadine, Lopinavir, linebacker and equivir, Arbidol, a nanoviricide,remdesivir, oseltamivir, ribavirin, and combinations thereof.

In still a further embodiment, the one or more cell pathway inhibitorsare selected from the group consisting of Rock inhibitors, Wntinhibitors, glycogen synthesis kinase 3 (GSK-3) inhibitors, integrininhibitors, IL-1 inhibitors, IL-6 inhibitors, and combinations thereof.

In yet a further embodiment, the biocompatible drug further comprisesone or more protease inhibitors in combination with the one or moreantiviral medications and the one or more cell pathway inhibitors.

In still a further embodiment, the method further comprises the step of,after treatment with the biocompatible drug, removing cytokines,enzymes, dead cells, from the circulation of the patient byplasmapheresis so as to prevent a cytokine storm.

In yet a further embodiment, the biocompatible drug is administered tothe patient by inhalation, orally, intravenously, or combinationsthereof.

In still a further embodiment, the biocompatible drug is administeredthrough the nasal mucosa to reach branches of the trigeminal nerve orolfactory nerve for delivery of the biocompatible drug to the brain,brain vasculature, and the cerebrospinal fluid where the semifluorinatedalkane rapidly evaporates at body temperature in the tissue leaving thebiocompatible drug at the desired treatment location.

In yet a further embodiment, the method further comprises administeringa stabilized hypochlorous acid, hypobromous acid (HOBr), bromamine, orchloramines, the stable N-chloro derivatives or chloramines, the stableN-chloro derivatives or N-chlorotaurine (NTC), dimethylated derivativesof NCT (N-chloro-2,2-dimethyltaurine [DM-NCT] andN,N-dichloro-2,2-dimethyltaurine [DM-NDCT] or Benzalkonium chloride andslow release polymeric nanoparticles carrying at least two of theantiviral medications together with one or more cell pathway inhibitorsand heparin or low molecular weight heparin, or with poly phenols, suchas catechin, found in fruit and vegetables, in a semifluorinated alkaneor a suitable medium, the administration being in the nose asinhalation, in spray or nebulized form to treat viral encephalitis orlung inflammation to kill one or more viruses and prevent the sideeffects of inflammation or as prophylaxis of viral infection in therespiratory tract, encephalitis, vasculitis, dementia.

In still a further embodiment, the method further comprisesadministering tocilizumab in combination with at least one antiviralmedication to treat a viral infection of the lung, viral brainencephalitis, and/or brain vasculitis; and administering at least onecell pathway inhibitor, Wnt inhibitor, GSK inhibitor, or integrininhibitor with or without complement pathway inhibitors such as C3inhibitors—AMY-101 (NCT04395456) and APL-9 (NCT04402060); C5inhibitors—eculizumab (NCT04346797 and NCT04355494), C1 esteraseinhibitors, which block the classical complement pathway, through noseinhalation by spraying, aerosolization, or nebulization to reach bothbrain and lung tissue, and to reduce the inflammatory process andeliminate the side effects of the infection.

In yet a further embodiment, the method further comprises administeringinterferon or pegylated interferon and another antiviral medication incombination with the one or more cell pathway inhibitors, where theinterferon or pegylated interferon acts as an antiviral in the upper andlower respiratory tract, thereby blocking the replication of the RNA andDNA of the viruses at an early stage of viral infection.

In still a further embodiment, the method further comprisesadministering a TMPRSS2 inhibitor and an ACE-2 inhibitor in combinationwith the one or more cell pathway inhibitors, where the TMPRSS2inhibitor inhibits entry of the virus into the cell.

In accordance with one or more other embodiments of the presentinvention, there is provided a method of preventing a medical conditionin a patient. The method includes administering prophylactically atreatment compound or substance to prevent the occurrence of a viralinfection, the treatment compound or substance being selected from thegroup consisting of one or more antiviral medications, one or more cellpathway inhibitors, a type of mouthwash, hydrogen peroxide,povidone-iodine, ethanol, chlorhexidine, cetylpyridinium chloride, anIL-1 inhibitor, an IL-6 inhibitor, an IL-8 inhibitor, and combinationsthereof. The treatment compound or substance is administered topically,intranasally, or as a mouthwash.

In a further embodiment of the present invention, the viral infection isCOVID-19, and the treatment compound or substance disrupts the COVID-19lipid envelope.

In yet a further embodiment, the method further comprises administeringa stabilized hypochlorous solution, or in chloramines, the stableN-chloro derivatives or chloramines, the stable N-chloro derivatives orN-chlorotaurine (NTC), dimethylated derivatives of NCT(N-chloro-2,2-dimethyltaurine [DM-NCT] andN,N-dichloro-2,2-dimethyltaurine [DM-NDCT], or Benzalkonium chloride ina semifluorinated alkane or liquid with slow release chitosanencapsulated nanoparticles in a saline solution or in oral form to passthrough the stomach to release a medication in the intestine to locallyprevent the intestinal side effect of the viral infection.

In still a further embodiment, the method further comprisesadministering prophylactically one or two antiviral medications as anasal spray, in aerosolized or nebulized form, or spray together withzinc in a saline solution orally in aliginate or chitosan encapsulatedbeads or nasally in polycaprolactone in a saline solution to damage theinvading viruses before entering the nasal mucosa.

In yet a further embodiment, the method further comprises administeringtamoxifen in combination with at least one antiviral medication to treata viral infection of the lung, viral brain encephalitis, and/or brainvasculitis; and administering at least one cell pathway inhibitor, Wntinhibitor, GSK inhibitor, and/or integrin inhibitor through the noseinhalation by spraying, aerosolization, or nebulization to reach bothbrain and lung tissue, and to reduce the inflammatory process andeliminate the side effects of the infection.

In accordance with yet one or more other embodiments of the presentinvention, there is provided a method of preventing a medical conditionin a patient. The method includes administering to a patient,experiencing a medical condition, one or more antiviral medicationstogether with one or more additional medications selected from the groupconsisting of one or more Wnt inhibitors, one or more Rock inhibitors,one or more GSK inhibitors, one or more integrin inhibitors, one or moreIL-6 inhibitors, one or more TGF beta inhibitors, one or moremacrolides, low molecular weight heparin, or with catechin in asemifluorinated alkane or a suitable medium and combinations thereof.The one or more antiviral medications and the one or more additionalmedications are administered orally, intranasally, intravenously,subcutaneously, topically, intraperitoneally, and/or by inhalation in asimultaneous, sequential, or separate manner.

In a further embodiment of the present invention, the medical conditionis selected from the group consisting of a lung viral infection, a brainviral infection, an intestinal viral infection, vasculitis, COVID-2,COVID-19, Alzheimer's disease, dementia, neuralgia, kidney disease,cardiac disease, encephalitis, and combinations thereof.

In yet a further embodiment, the medical condition is in a form of anend stage medical condition selected from the group consisting of an endstage lung infection, an end stage brain infection, encephalitis, andcombinations thereof; and wherein the one or more antiviral medicationscomprise a plurality of different antiviral medications to treat the endstage lung infection, the end stage brain infection, and/orencephalitis.

In still a further embodiment, the one or more additional medicationsadministered to the patient comprise low molecular weight heparin toenhance nerve repair and prevent blood coagulation so as to combat anoveractive immune response.

In yet a further embodiment, the one or more antiviral medicationsand/or the one or more additional medications are administered in aphysiological solution or semifluorinated alkane or a physiologicalliquid using polymeric slow release nanoparticles or microparticles,micelles, liposomes, and/or dendrimers and lipid nanoparticles (LNP) asa drug carrier, the polymeric slow release nanoparticles ormicroparticles comprising at least one of polylactic acid, polyglycolicacid, polycaprolactone, porous silicon, chitosan, and a polyethyleneglycol-polylactic acid (PEG-PLA) block copolymer.

In still a further embodiment, the slow release polymeric nanoparticlesor microparticles, micelles, liposomes, and/or dendrimers are conjugatedwith a viral specific antibody so as to form antibody-coated slowrelease polymeric nanoparticles or microparticles, antibody-coatedmicelles, antibody-coated liposomes, and/or antibody-coated dendrimersor antibody coated LNP.

In yet a further embodiment, the one or more antiviral medications areselected from the group consisting of amantadine, Lopinavir, linebackerand equivir, Arbidol, a nanoviricide, remdesivir, oseltamivir,ribavirin, and combinations thereof.

In still a further embodiment, the one or more additional medicationsadministered in a physiological solution or semifluorinated alkane or aphysiological liquid or any other suitable medium to the patientcomprise one or more Rock inhibitors in a form of botulinum toxin at apicogram concentration level.

In one embodiment, the semifluorinated alkane and medications areadministered preferably by nasal inhalation mouth inhalation, inhaler,as a spray, nanoparticles or microparticles, in a solution, or powder,or subcutaneous, or intramuscular, or intravenously, combined as acocktail or sequentially, orally etc.

In yet a further embodiment, the method further comprises administeringviral-like particles to induce humoral and cellular immune response andinterferon production for therapy and/or for vaccination of the patient.

In one embodiment, the method comprises administering 1-2 or morevaccines such as, dead organisms, or their proteins or mRNA such asModerna vaccine and Pfizer vaccine, or AstraZeneca vaccine and withviral like particles (VLP) or one or more adjuvants conjugated with theviral antigen at a lower concentration of vaccine than normally is givenand if needed an adjuvant in a semifluorinated alkane or in a solutionwith or without a pathway inhibitor or complement C1-C3-C5 inhibitoreither nasally by inhalation or intramuscularly or intravenouslyseparately or sequentially, or combined as a cocktail to reduce the sideeffects of the vaccines and increase the efficacy of the vaccination orto be repeated multiple times in an intervals of 3, 6, 9, or 12 months,etc. as needed, while the intranasal or inhalation simplifies for thepeople storing the vaccine at a low temperature using a homerefrigerator for self-administration in different intervals asprescribed by a doctor.

In one embodiment, a vaccine is prepared from viruses or bacteria,fungi, etc. in a semifluorinated alkane and a saline, etc. solutioncontaining riboflavin, methylene blue or another photosensitizer, withan adjuvant or viral like particles (VLP), etc., with or withoutanti-inflammatory cell pathway inhibitors or another anti-inflammatorycompound or antiviral or antibiotic, antifungal where the organism iskilled with or without radiation exposure, such as x-ray or cobaltradiation etc. or preferably UV radiation such as UVA, UVB, or UVCwavelength or another wavelength of a LED, diode or laser, etc., appliedto the entire pathogen in the container, Petri dish for a period of onesecond to 5 minutes or more and stored in a refrigerator with or withoutBenzalkonium chloride (BAC) or other compounds damaging DNA or RNA at alow temperature and can be used for repeated vaccination as needed bynasal or intramuscular, or oral administration, or as adjuvant toanother vaccine prepared by other means or used after initial use ofanother vaccine for the same organism, eliminating the need for the useof formalin, thimerosal, formaldehyde, glutaraldehyde, or heating athigh temperature, etc. which are toxic and produce excessive and lastinginflammation at the site of the administration or because of unpleasantsmell cannot be used for nasal spray or inhalation. In one embodiment,(1) (3-propiolactone (BPL) can also be used after culturing (viruses,bacteria, fungi, parasites or tumor cells) to damage DNA and RNA of theorganism, however, increasing its concentration of BPL more than 1:2000V/V (the concentration of 1 in 2000 w/v can be expressed as 0.05% w/v or0.5 mg/mL) damages the antigenicity of the protein, (2) therefore acombination of 3-propiolactone (BPL) at a low concentration withmethylene blue at concentrations of <2 micogram/ml, (3) plus one or twoantivirals (in viral infection), or antibiotics, (in bacterialinfection) or antiparasitics (e.g. in Malaria) or antifungals (e.g. inCandida infection) or antineoplastics (in any cancer) potentiate damageto RNA and DNA reducing the damage to the protein, proteoglycans, etc.antigenicity of the vaccine samples, (4) while killing the viruses,bacteria, parasites, fungi and tumor cells in the culture media for useas vaccine, (5) then the dead viruses, bacteria, parasites, fungi ortumor cells are ultimately filtered washed in a physiological solutionand other components, such as remaining methylene blue and3-propiolactone (BPL) are removed, and (6) the remaining proteins,saccharides, or glycoproteins of the organism are used with non-toxicdoses of antiviral, antibacterial, anti-fungal, anti-parasitic, and/orantineoplastic medication as a therapeutic vaccine.

In one embodiment, a vaccine cocktail is prepared from viruses orbacteria, fungi, etc. in a semifluorinated alkane and a saline etc.solution containing riboflavin or methylene blue (<1 microgram/ml) oranother photosensitizer, with an adjuvant with or without viral likeparticles (VLP), etc., with or without pathway inhibitors or anotheranti-inflammatory compound or antivirals or antibiotics, antifungalswhere the organism is killed with radiation exposure such as x-ray orcobalt radiation, etc. or preferably UV radiation, such as UVA, UVB orUVC wavelength or another wavelength of an LED, diode or laser, etc.,applied to the entire pathogen in the container, Petri dish for a periodof one second to 5 minutes or more and the solution, etc. is collected,filtered, and stored in a refrigerator with or without Benzalkoniumchloride (BAk) less than 0.01% at a low temperature and can be used forrepeated self-vaccination/administration as needed by nasal orintramuscular administration, or as adjuvant to another vaccine preparedby other means, such as mRNA vaccines or oral polymerase inhibitor,AT-527.etc. or used after initial use of another vaccine for the sameorganism, but self-administered preferably by inhalation or orally,weekly for 1-2 months or more intranasally as a spray or nebulization toeliminate all potential pathogens, such as viruses that might remain inthe nasal cavity, throat, pharynx, trachea, or in the alveoli andpotentially reactivate and induce an epidemic or pandemic infection.

In one embodiment, the vaccines are distributed as a single dosage to bestored in refrigerator and administrated intranasally, orally, orsubcutaneously by people for 1 to 3 months, up to 5 months or longer,etc. as needed.

In one embodiment, the vaccines are distributed in older patients as asingle dosage with spermidine and vitamin D to enhance their immuneresponse, to be stored in refrigerator and administrated intranasally,orally, or subcutaneously by people for 1 to 3 months, up to 5 months orlonger, etc. as needed.

In another embodiment, one or more anti-inflammatory agents, such asNSAIDs, combined with one or more vaccines along one or more cellinflammatory pathway inhibitors are administered to reduce a severeimmune response to vaccines in patients with allergic history.

In one embodiment, vaccine is administered in a semifluorinated alkanecombined with pathway inhibitors as a spray simultaneously orsequentially, with or without antibody-coated nanoparticles, etc., thecombination therapy can include a vaccine such as dead viruses or mRNAor antibodies against viral proteins such as spike proteins, etc., thevaccination also include medications such as low molecular weightheparin, Ebselen, catechin, mycophenolic acid or inflammatory cellpathway inhibitors or complement inhibitors that modify the severeimmune response such as bone ache, fever, malaise, headache, etc. orside effect after a second challenge with repeated vaccinations, orobserved immediately after administration of the vaccine combinationpreferably through the nose by inhalation though it can be givenintramuscularly or subcutaneously by an injector, etc. as known in theart.

In still a further embodiment, the method further comprisesadministering one or more serum antibodies conjugated with theviral-like particles to induce an enhanced cellular immune response andinterferon production in the patient.

In yet a further embodiment, during treatment or after treatment withthe one or more antiviral medications and/or the one or more additionalmedications, the method further comprises the step of removingcytokines, enzymes, and/or dead cells from the circulation of thepatient by kidney dialysis, blood dialysis, and/or plasmapheresis so asto suppress a cytokine storm.

In still a further embodiment, a vaccine is prepared from viruses placedin methylene blue solution, a derivative of phenothiazine, is preparedat a concentration of 0.25-1 mg/liter in semifluorinated alkanes or in afluid for nasal inhalation, oral, topical or intravenous administrationalone to act as an antioxidant, or with one or two antivirals such asEbselen or remdesivir, valacyclovir, etc. and one or more Wnt inhibitorsor anti-integrins, etc. or LMWH to treat viral respiratory tractinfections and/or CNS viral involvement prophylactically ortherapeutically.

In yet a further embodiment, when a patient has a severe viral kidney orliver disease, or viral respiratory disease, or viral brainencephalitis, an intravenous administration or oral or inhalation ortopical application of methylene Blue, which acts as antioxidant andconverts methemoglobin to hemoglobin and acts as an antiviral at aconcentration of 0.25-1 mg/liter or less than 1 nM concentration, withone or two antivirals, such as Ebselen or remdesivir, Favipiravir,doxycycline, nitazoxanide, valacyclovir for inhalation or oraladministration, etc. with one or more Wnt inhibitors or ananti-integrin, Rock inhibitor or GSK inhibitor, etc. and LMWH in asemifluorinated alkane or in a fluid containing bile salt to kill theviruses including influenza, COVID-19 and reduce severe inflammatoryprocesses followed with dialysis, hemodialysis, serum electrophoresis toremove unwanted toxins and creatinine, etc. and simultaneously act toprevent blood clothing after methylene blue administration.

In still a further embodiment, a vaccine is prepared from viruses orbacteria, fungi, etc. in a semifluorinated alkane and a saline, such asa bile salt, etc. solution containing riboflavin or methylene Blue oranother photosensitizer, or combined with β-propiolactone (BPL) with anadjuvant or viral-like particles (VLP), etc., with or without pathwayinhibitors or another anti-inflammatory compound or antiviral, such asremdesivir, Favipiravir, valacyclovir, administered by inhalation ororally, and with or without an antibiotic, such as tetracyclinederivatives and/or an antifungal where the organism is killed with orwithout radiation exposure to UV radiation, such as UVA, UVB, or UVCwavelengths or another wavelength (670 nm) produced by an LED, diode orlaser, etc., applied to the pathogens in a container, Petri dish todamage the viral DNA and/or viral RNA and parts of the capsular protein,etc. for a period of one second to 5 minutes or more and then theremaining dead components of the virus is stored in a refrigerator withor without Benzalkonium chloride (BAC) at a low temperature to be usedfor repeated vaccination as needed, e.g., by nasal self-administrationor intramuscular administration, or orally or as an adjuvant to anothervaccine, such as mRNA vaccines, etc. or after initial administration ofanother vaccine of the same organism, to stimulate an immune response tothe pathogen, thereby eliminating the need for the standard use offormalin, thimerosal, formaldehyde, glutaraldehyde, etc. for theproduction of vaccines, but are toxic and produce excessive and lastinginflammation at the site of the administration.

In yet a further embodiment, the vaccine is prepared from viruses orbacteria, fungi, etc. in a semifluorinated alkane and a saline, etc.solution containing, riboflavin or methylene Blue alone in combinationat a <5 microMolar or 0.25%-1% concentration in sodium phosphate bufferof pH 7.4 at 50 mM concentration or another photosensitizer, orβ-propiolactone (BPL), at low concentrations to prevent excessiveaggregation of the viral particles and addition of antivirals, killedviruses are separated, washed, and the remaining is combined with aphysiological solution or a semifluorinated alkane with an adjuvant withor without pathway inhibitors or another anti-inflammatory compound suchas Baricitinib or antivirals any desired antivirals affecting theattachment of the virus to the cell receptor, or preventing entrance inthe cells, or protease inhibitor or polymerase inhibitors, etc. orantivirals including valacyclovir, etc. or an antibiotic, antifungalwhere the organism is killed for vaccine production with or without UVradiation, such as UVA, UVB or UVC wavelengths, or another wavelength(670 nm) of a LED, diode, or laser, etc., applied to the entire pathogenin a container, for a period of one second to 5 minutes or more todamage viral capsid, etc. and the remaining dead viruses are stored in arefrigerator with or without Benzalkonium chloride (BAC) at a lowtemperature and used for repeated vaccination as needed by nasalinhalation, oral, or intramuscular administration, or as adjuvant toanother vaccine prepared by other means after the initial use of anothervaccine for the same organism, or another organism, thereby eliminatingthe need for the standard use of formalin, thimerosal, formaldehyde,glutaraldehyde, etc. which are toxic and produce excessive and lastinginflammation at the site of the administration.

In still a further embodiment, methylene Blue at a 1 mg/L concentrationadministered intravenously with LMWH or heparin mimetics or complementinhibitors or pathway inhibitors and at least one or more antivirals,such as remdesivir and valacyclovir with or without polyclonalantibodies cocktails and/or anti-inflammatory agents such asBaricitinib, etc. to kill the viral pathogens with or withoutsimultaneous light/laser radiation of the blood inflow tubing, for aperiod or 4, 8, 16, or 30 minutes followed by dialysis, hemodialysis,serum electrophoresis to remove dead viruses and unwanted toxins andmethylene Blue from the blood that is re-infused to the patient.

In yet a further embodiment, one administers a vaccine as a cocktail,etc. to boost the immune response of a person to specific viral,bacterial or fungal pathogens by administering a low dose of a vaccinethat is presently used for vaccination, the amount of this boostervaccine can be from 5%-99% of the original volume and its contents, orpreferably 10% or 20% or 40% or 60% volume, etc. with or without pathwayinhibitors such as Rock, Wnt, GSK or integrin inhibitors, or complementC1, C3, C5 inhibitors, etc. along with or without antivirals,antibiotics or antifungals or with or without an-anti-inflammatoryagent, such as a IL-7 inhibitor, DMF or Baricitinib, etc. or an immuneenhancer such as spermidine, etc. injected intramuscularly,subcutaneously, or orally or intravenously or preferably by nasalinhalation or by an inhaler etc. so the patients can eitherself-administer the vaccine in different doses at described intervalseither before the regular standard vaccination, during the sickness,shortly thereafter, or beyond the original vaccination or sickness toeither recognize an allergic response to the vaccine and/or to boostgradually the immune response of the patient who is old or too young oris an immunosuppressed patient, where the vaccine can be prepared thestandard way of killing the bacteria, or render them defenseless, orusing a specific protein part of the virus, or using mRNA, etc. of thevirus.

In still a further embodiment, the method further comprises the step of:delivery of oxygen to the patient by extracorporeal membrane oxygenationwhen the blood oxygenation level of the patient is low.

In accordance with still one or more embodiments of the presentinvention, there is provided a method of treating, reducing, oralleviating a medical condition in a patient. The method includesadministering to a patient in need thereof a biocompatible drugcomprising one or more antiviral medications together with one or morecell pathway inhibitors, the patient having at least one of arespiratory tract inflammatory disease, a central nervous systeminflammatory disease, and vasculitis, the one or more antiviralmedications preventing an attachment of viruses to cell walls, blockinga penetration of the viruses into cells, and/or inhibiting virusreplication by damaging nucleic acids of the viruses, and the one ormore cell pathway inhibitors blocking an inflammatory response ofinflamed tissue without inhibiting an immune response of the patient.The administration of the biocompatible drug to the patient treats theat least one of the respiratory tract inflammatory disease, the centralnervous system inflammatory disease, and the vasculitis, reduces thesymptoms associated with the at least one of the respiratory tractinflammatory disease, the central nervous system inflammatory disease,and the vasculitis, and/or alleviates the at least one of therespiratory tract inflammatory disease, the central nervous systeminflammatory disease, and the vasculitis.

In a further embodiment of the present invention, the patient has arespiratory tract inflammatory disease, and the respiratory tractinflammatory disease is selected from the group consisting of influenza,parainfluenza, severe acute respiratory syndrome, a coronavirus disease,an Epstein-bar virus disease, a herpes virus disease, a bacterialinfection, and combinations thereof.

In yet a further embodiment, the patient has a respiratory tractinflammatory disease, and the respiratory tract inflammatory diseasecomprises a coronavirus, the coronavirus being selected from the groupconsisting of COVID-19, mutations of COVID-19, mutations of the SARSCoV-2 virus, and combinations thereof.

In still a further embodiment, the biocompatible drug further comprisesa semifluorinated alkane and polymeric slow release nanoparticles ormicroparticles used as a carrier of the biocompatible drug; and thebiocompatible drug with the semifluorinated alkane and the polymericslow release nanoparticles or microparticles is administered byinhalation or as a topical ointment to the patient to treat the at leastone of the respiratory tract inflammatory disease, the central nervoussystem inflammatory disease, and the vasculitis, the semifluorinatedalkane evaporating quickly upon administration to the patient so as toleave the polymeric slow release nanoparticles or microparticles withthe biocompatible drug at a desired treatment location.

In yet a further embodiment, the polymeric slow release nanoparticles,lipid nanoparticles (LNP), or microparticles are conjugated with a viralspecific antibody while carrying at least two antiviral medications forintranasal inhalation or topically as an ointment to specifically targetone or more viruses, the viral specific antibody being obtained fromplasma/serum of patients who have recovered from a viral infection orthe viral specific antibody being produced in a tissue culture usingdead viruses cultured with T-cell lymphocytes or natural killers thatproduce the viral specific antibody in addition to producing exosomes orextracellular vesicles (ECV) that are both able to be harvested.

In still a further embodiment, the biocompatible drug is administeredthrough the nasal mucosa to reach branches of the trigeminal nerve orolfactory nerve for delivery of the biocompatible drug to the brain,brain vasculature, and the cerebrospinal fluid where the semifluorinatedalkane rapidly evaporates at body temperature in the tissue leaving thepolymeric slow release nanoparticles or microparticles with thebiocompatible drug at the desired treatment location.

In yet a further embodiment, the one or more antiviral medications areselected from the group consisting of amantadine, Lopinavir, linebackerand equivir, Arbidol, a nanoviricide, remdesivir a polymerase inhibitor,Favipiravir, Ebselen, oseltamivir, oseltamivir, indinavir, molnupiravira polymerase inhibitor, MK-4482/EIDD-2801, ribavirin, Oya1, Glidesivir,Xofluza, interferon, umifenovir, tamivir, baloxavir, and combinationsthereof; and the one or more cell pathway inhibitors are selected fromthe group consisting of Rock inhibitors, Wnt inhibitors, glycogensynthesis kinase 3 (GSK-3) inhibitors, integrin inhibitors, IL-1inhibitors, IL-6 inhibitors, TGF beta inhibitors, and combinationsthereof.

In still a further embodiment, the biocompatible drug further comprisesone or more protease inhibitors in combination with the one or moreantiviral medications and the one or more cell pathway inhibitors.

In yet a further embodiment, the at least one of the respiratory tractinflammatory disease, the central nervous system inflammatory disease,and the vasculitis comprises at least one of a viral infection of thelung, a viral brain encephalitis, and a brain vasculitis; and the methodfurther comprises administering tocilizumab or tamoxifen in combinationwith the one or more antiviral medications and the one or more cellpathway inhibitors to treat the viral infection of the lung, the viralbrain encephalitis, and/or the brain vasculitis; and administering theone or more cell pathway inhibitors through nose inhalation by spraying,aerosolization, or nebulization to reach both brain and lung tissue, andto reduce the inflammatory process and eliminate the side effects of theviral infection of the lung, the viral brain encephalitis, and/or thebrain vasculitis.

In still a further embodiment, the method further comprisesadministering interferon or pegylated interferon in combination with theone or more antiviral medications and the one or more cell pathwayinhibitors to the patient, where the interferon or pegylated interferonacts as an antiviral in the upper and lower respiratory tract, therebyblocking the replication of the RNA and DNA of the viruses at an earlystage of viral infection.

In yet a further embodiment, the method further comprises administeringa TMPRSS2 inhibitor, an ACE-2 inhibitor, and/or a neuropilin inhibitorin combination with the one or more cell pathway inhibitors to thepatient where the TMPRSS2 inhibitor, the ACE-2 inhibitor, and/or theneuropilin inhibitor inhibits entry of the virus into the cell.

In still a further embodiment, the method further comprisesadministering a low molecular weight heparin or synthetic heparinmimetics in combination with a macrolide to the patient to enhance nerverepair and prevent blood coagulation so as to combat an overactiveimmune response.

In yet a further embodiment, the macrolide comprises cyclosporine A.

In still a further embodiment, the method further comprisesadministering a polyphenol and/or a derivative of a polyphenol thatbinds to heparan sulfate, thereby preventing viral attachment to cellreceptors. In this further embodiment, the polyphenol and/or thederivatives of the polyphenol are selected from the group consisting ofEpigallocatechin gallate (EGCG), green tea, and catechin.

In yet a further embodiment, the method further comprises administeringa polyclonal antibody cocktail so as to effectively treat multipleproteins of a mutated virus.

In still a further embodiment, the method further comprisesadministering intravenously or by inhalation methylene blue, which actsas an antioxidant and converts methemoglobin to hemoglobin and acts asan antiviral at a concentration of 0.25-2 mg/L to 5 μg/ml or 4 mg/kg orless than 80 mg/L or 80 μM concentration, or 1 μg/ml for topicalapplications together with one or more antiviral medications, and theone or more cell pathway inhibitors; and further administering lowmolecular weight heparin to the patient to prevent blood coagulation;and performing dialysis, hemodialysis, or serum electrophoresis toremove unwanted toxins and creatinine and simultaneously acting toprevent blood clotting after administration of the methylene blue andthe low molecular weight heparin. However, the only side effects ofmethylene blue observed has been in patients with a glucose 6 phosphatedehydrogenase (G-6-PD) deficiency.

In yet a further embodiment, the methylene blue together with the one ormore antiviral medications and the one or more cell pathway inhibitorsare administered using ultra small pluralities of gold nanoparticles toenhance viral damage.

In still a further embodiment, the method further comprisesadministering methylene blue, which acts as antioxidant and convertsmethemoglobin to hemoglobin and acts as an antiviral at a concentrationof 0.25-2 mg/liter or less than 1 nM concentration, together with theone or more antiviral medications and the one or more cell pathwayinhibitors; administering low molecular weight heparin to the patient toprevent blood coagulation; and performing dialysis, hemodialysis, orserum electrophoresis to remove unwanted toxins and creatinine andsimultaneously acting to prevent blood clotting after administration ofthe methylene blue and the low molecular weight heparin.

In yet a further embodiment, the methylene blue together with the one ormore antiviral medications and the one or more cell pathway inhibitorsare administered using ultra small pluralities of gold nanoparticles toenhance viral damage, and initiate an immune response to the virus

In still a further embodiment, the method further comprisesadministering dimethyl fumarate orally, by injection, or by inhalationto prevent pyroptosis of cells resulting from an excessive immuneresponse.

In yet a further embodiment, the method further comprises administeringmycophenolic acid or metalloproteinase inhibitors to blocking anexcessive immune response of inflamed tissue.

In still a further embodiment, the method further comprisesadministering an anti-vascular endothelial growth factor medication incombination with the one or more antiviral medications, wherein theanti-vascular endothelial growth factor medication blocks the release ofthe vascular endothelial growth factor from affected capillaryendothelial cells or inflamed alveoli cells and prevents exhaustion of acellular immune response.

In yet a further embodiment, the method further comprises administeringprophylactically the one or more antiviral medications and methyleneblue as a nasal spray, in aerosolized or nebulized form, or as a vapor,together with zinc in a saline solution orally in aliginate, chitosanencapsulated beads, or polycaprolactone, or nasally in a salinesolution, to damage the invading viruses before entering the nasalmucosa along with an antibiotic or antiviral ointment applied to thenasal passages to kill the viruses in the nose and respiratory tract.

In still a further embodiment, the method further comprisesadministering prophylactically the one or more antiviral medications andmethylene blue as a nasal spray, in aerosolized or nebulized form, or asa vapor, together with zinc in a saline solution orally in alginate,chitosan encapsulated beads, or polycaprolactone, or nasally in a salinesolution, to damage the invading viruses before entering the nasalmucosa along with an antibiotic or antiviral ointment applied to thenasal passages to kill the viruses in the nose and respiratory tract.

In accordance with yet one or more embodiments of the present invention,there is provided a therapeutic vaccination method for a medicalcondition in a patient, the method comprising: (i) growing viruses,bacteria, fungi, parasites, or tumor cells on a cell culture or otherappropriate medium; (ii) harvesting the viruses, bacteria, fungi,parasites, or tumor cells from the cell culture or other appropriatemedium; (iii) killing the viruses, bacteria, fungi, parasites, or tumorcells in the cell culture or other appropriate medium with a dose ofmethylene blue that is greater than 2.0 micrograms per milliliter so asto damage the RNA and/or the DNA of the viruses, bacteria, fungi,parasites, or tumor cells, wherein the viruses, bacteria, fungi,parasites, or tumor cells remain in contact with the methylene blue fora period of time that is sufficient for the methylene blue to penetratethe viruses, bacteria, fungi, parasites, or tumor cells and attach toRNA or DNA of the viruses, bacteria, fungi, parasites, or tumor cellsand prevent multiplication of the viruses, bacteria, fungi, parasites,or tumor cells; (iv) separating the dead viruses, bacteria, fungi,parasites, or tumor cells from a remainder of the cell culture or otherappropriate medium using a filter and/or centrifuge; (v) depending onthe type of organism, adding antivirals, antibacterials, antifungals,antiparasitics, and/or anti-neoplastic medications at non-toxictherapeutic concentrations to the dead viruses, bacteria, fungi,parasites, or tumor cells so as to form a therapeutic vaccine; and (vi)administering the therapeutic vaccine to a patient in need thereof. Inthese one or more embodiments, the therapeutic vaccine simultaneouslyproduces a therapeutic response and a humoral and cellular immuneresponse to viruses, bacteria, fungi, parasites, or tumor cells in thebody of the patient without resulting in deleterious side effects to thepatient.

In a further embodiment of the present invention, the method furthercomprises the step of: (vii) adding one or more adjuvants and one ormore cell pathway inhibitors to the dead viruses, bacteria, fungi,parasites, or tumor cells to prevent an excessive immune response of thepatient.

In yet a further embodiment, the method further comprises the steps of:

(vii) administering metformin with GSK inhibitors to protect the kidneysof the patient; and(viii) performing kidney dialysis or electrophoresis to remove excesstoxins from the body of the patient.

In still a further embodiment, the method further comprises the step of:(vii) repeatedly administering the therapeutic vaccine to the patient asneeded until the viruses, bacteria, fungi, parasites, or tumor cells areeliminated and verified by polymerase chain reaction and/or imaging.

In yet a further embodiment, the step of killing the viruses, bacteria,fungi, parasites, or tumor cells in the cell culture or otherappropriate medium further comprises conjugating the methylene blue withgold nanoparticles so as to enhance a penetration of the methylene blueinto the viruses, bacteria, fungi, parasites, or tumor cells and attachto the RNA or DNA of the viruses, bacteria, fungi, parasites, or tumorcells and prevent multiplication of the viruses, bacteria, fungi,parasites, or tumor cells.

In still a further embodiment, the step of killing the viruses,bacteria, fungi, parasites, or tumor cells in the cell culture or otherappropriate medium further comprises adding a peptide nucleic acid(PNA), one or more anti-neoplastic medications, and/or one or moreantivirals to the cell culture or other appropriate medium so as toenhance the effect of the methylene blue on the RNA and/or the DNA ofthe viruses, bacteria, fungi, parasites, or tumor cells.

In yet a further embodiment, the step of administering the therapeuticvaccine to the patient further comprises administering the therapeuticvaccine together with antigens, gold nanoparticles, and a low non-toxicdose of at least two additional medications, the at least two additionalmedications comprising two or more antivirals, two or moreantibacterials, two or more antifungals, two or more antiparasitics,and/or two or more anti-neoplastic medications.

In still a further embodiment, the method further comprises the step of:

(vii) administering one or more immune stimulators, spermidine,anti-depressant agents, and/or diamidobenzimidazole (diABZI-4) totrigger the stimulator of interferon genes (STING), thereby enhancingthe immune response of the patient.

In yet a further embodiment, the method further comprises the step of:

(vii) administering Ceapin-A7 and KIRA8 to eliminate damaged cells,bacteria, viruses, fungi, parasites, or tumor cells in the patient.

In still a further embodiment, the step of administering the therapeuticvaccine to the patient further comprises administering the therapeuticvaccine together with an mRNA vaccine or a modified mRNA vaccine and alow non-toxic dose of at least one additional medication, the at leastone additional medication comprising one or more antivirals, one or moreantibacterials, one or more antifungals, one or more antiparasitics,and/or one or more anti-neoplastic medications.

In yet a further embodiment, the method further comprises the step of:

(vii) administering one or more inflammatory cell pathway inhibitors,one or more steroidal anti-inflammatory agents, one or morenon-steroidal anti-inflammatory drugs (NSAIDs), mycophenolate mofetil orother macrolides, methotrexate, an anti-TGF, at least two types ofantibody-coated nanoparticles, and/or one or more anticoagulants so asto create a therapeutic vaccine that can be administered duringinfection to kill the viruses, bacteria, fungi, parasites, or tumorcells in the patient, and to induce a humoral and cellular immuneresponse in the patient.

In still a further embodiment, the method further comprises the step of:

(vii) administering one or more inflammatory cell pathway inhibitors tothe patient together with the antivirals, antibacterials, antifungals,antiparasitics, and/or anti-neoplastic medications so that thetherapeutic vaccine is able to be used prophylactically or for treatmentof the patient as needed, thereby increasing an immune response of thepatient to the organism while simultaneously treating the organism.

In yet a further embodiment, the step of killing the viruses, bacteria,fungi, parasites, or tumor cells in the cell culture or otherappropriate medium further comprises killing the viruses, bacteria,fungi, parasites, or tumor cells with a high dose of at least twomedications that damage the RNA and/or DNA of the viruses, bacteria,fungi, parasites, or tumor cells; and the method further comprises thesteps of: (vii) filtering the dead viruses, bacteria, fungi, parasites,or tumor cells from the remainder of the cell culture or otherappropriate medium; (viii) extracting the antigens from the damagedviruses, bacteria, fungi, parasites, or tumor cells; and (ix) adding oneor more additional medications to the extracted antigens at a lownon-toxic dose to the patient, but at a dose that is still toxic to theorganisms.

In still a further embodiment, the method further comprises the stepsof: (vii) adding a poly (ADP-ribose) polymerase (PARP) inhibitor to thetherapeutic vaccine that blocks the RNA and/or DNA repair of theviruses, bacteria, fungi, parasites, or tumor cells; (viii) adding oneor more inflammatory pathway inhibitors to the therapeutic vaccine; and(ix) adding one or more immune stimulators to the therapeutic vaccine soas to enhance the immune response of the patient.

In yet a further embodiment, the step of administering the therapeuticvaccine further comprises repeatedly administering the therapeuticvaccine as needed to the patient at a low dose or a gradually increasingdose until a sufficient neutralizing antibody response is achieved inthe serum of the patient.

In still a further embodiment, the therapeutic vaccine is used fortherapy-resistant bacteria, fungi, parasites, or tumors.

In yet a further embodiment, a tumor of the patient has become resistantto checkpoint inhibitors and has created a milieu in which the newlygrown tumor cells are resistant to standard immune therapy; the methodfurther comprising the steps of: (vii) administering a combination oftwo different therapeutic vaccines, a first one of the two differenttherapeutic vaccines directed toward existing tumor cells and a secondone of the two different therapeutic vaccines directed toward anotherantigen from bacteria, viruses, or fungi to re-stimulate the cellularand humoral immune response of the body of the patient against thetherapy-resistant tumor cells; (viii) administering one or twoanti-neoplastic medications in combination with the first one or thesecond one of the two different therapeutic vaccines; and (ix)simultaneously administering one or more cell pathway inhibitors, immunestimulators, and/or anti-VEGFs to the patient as a cocktail.

In still a further embodiment, the method further comprises the step of:(vii) administering monoamine oxidase inhibitors, melatonin andspermidine to the patient so as to prevent exhaustion of the cellularimmune response of the patient.

In yet a further embodiment, the cell culture on which the viruses,bacteria, fungi, parasites, or tumor cells are grown and harvestedcomprises yeast culture media that permits the organisms to not onlygrow, but also mutate rapidly such that the therapeutic vaccine has apredictive value for mutation of the viruses, bacteria, fungi,parasites, or tumor cells even before the mutation occurs in thepatient; the therapeutic vaccine contains antigenic material from themutated and un-mutated organism such that the therapeutic vaccineinduces a humoral and cellular immune response against the past,present, and future mutations of the organism so as to kill theorganism; and the therapeutic vaccine is administered simultaneouslywith an anti-organism medication to effectively prevent viral,bacterial, fungal, parasitic, and tumor cell mutation in the patient.

In still a further embodiment, the method further comprises the step of:

(vii) administering light or electrical pulses to the viruses, bacteria,fungi, parasites, or tumor cells grown in the yeast culture media so asto encourage the mutation of the viruses, bacteria, fungi, parasites, ortumor cells to be harvested and killed for vaccination.

In yet a further embodiment, the method further comprises the step of:

(vii) administering a poly (ADP-ribose) polymerase (PARP) inhibitor withthe therapeutic vaccine so as to block the RNA and/or DNA repair of theviruses, bacteria, fungi, parasites, or tumor cells.

In still a further embodiment, the method further comprises the step of:

(vii) administering the therapeutic vaccine to the patient as topicaldrops, an ointment, spray for inhalation, in an inhaler, nasally byspraying powder, intravenously, by intramuscular injection,systemically, orally as a capsule, or locally inside a tumor.

In yet a further embodiment, the method further comprises the step of:

(vii) administering the therapeutic vaccine to the patient using aconical nasal drug delivery implant, the therapeutic vaccine beingdelivered to one or more nasal passageways of a patient.

In still a further embodiment, the conical nasal drug delivery implantis formed from a semi-flexible polymeric material by 3D printing theconical nasal drug delivery implant.

In yet a further embodiment, the conical nasal drug delivery implant isattached to a pair of glasses, an outer nose cover, an elastic headbandconfigured to be worn on the head of the patient, or is held in place byelastic components on the conical nasal drug delivery implant itself.

In still a further embodiment, the step of killing the viruses,bacteria, fungi, parasites, or tumor cells in the cell culture or otherappropriate medium further comprises adding at least one ofbeta-propiolactone (BPL), NSP13 inhibitors, bananin, and chromone-4c tothe cell culture or other appropriate medium so as to enhance the effectof the methylene blue on the RNA and/or the DNA of the viruses,bacteria, fungi, parasites, or tumor cells; and wherein the methodfurther comprises the step of: (vii) washing and filtering thetherapeutic vaccine to eliminate all unbound methylene blue,beta-propiolactone, NSP13 inhibitors, bananin, and/or chromone-4c priorto adding the antivirals, the antibacterials, the antifungals, theantiparasitics, and/or the anti-neoplastic medications.

In yet a further embodiment, the therapeutic vaccine is formed from aplurality of different virus types and/or mixed with other relatedvaccines for other virus types in order to treat both a coronavirus andanother latent virus of the patient.

In still a further embodiment, the therapeutic vaccine is mixed withanother vaccine made for bacteria, fungi, parasites, or tumor cells sothat both vaccines collectively stimulate cellular and humoral responseof the body of the patient.

In yet a further embodiment, the method further comprises the step of:(vii) adding synthetically produced peptoids to the tissue culture orother appropriate medium, the synthetically produced peptoidspenetrating the envelope of the viruses, bacteria, fungi, parasites, ortumor cells, and attaching to RNA and DNA of the viruses, bacteria,fungi, parasites, or tumor cells so as to prevent the RNA and DNA frombeing activated.

It is to be understood that the foregoing general description and thefollowing detailed description of the present invention are merelyexemplary and explanatory in nature. As such, the foregoing generaldescription and the following detailed description of the inventionshould not be construed to limit the scope of the appended claims in anysense.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described, by way of example, with referenceto the accompanying drawings, in which:

FIG. 1 illustrates a single nasal drug delivery implant, according toone embodiment of the invention, where the implant is conical in shapeand formed from a semi-flexible polymeric material;

FIG. 2 illustrates a double nasal drug delivery implant, according toanother embodiment of the invention, where the implant comprises a pairof conical portions connected to one another by a clip;

FIG. 3 illustrates a perforated nasal drug delivery implant, accordingto yet another embodiment of the invention, where the wall of theconical implant is perforated;

FIG. 4 illustrates a spring-loaded nasal drug delivery implant,according to still another embodiment of the invention;

FIG. 5 illustrates the double nasal drug delivery implant of FIG. 2disposed in the nose of a person;

FIG. 6 illustrates a double cone nasal drug delivery implant containingan N95 filter, according to yet another embodiment of the invention,where the N95 filter is configured to block small organisms, such asviruses;

FIG. 7A illustrates a nasal implant with an outer shell and an innerfilter shell that cooperates with the outer shell, according to anotherembodiment of the invention, wherein the inner filter shell is shownseparated from the outer shell; and

FIG. 7B illustrates the nasal implant of FIG. 7A with the outer shelland the inner filter shell, wherein the inner filter shell is showndisposed in the outer shell.

Throughout the figures, the same elements are always denoted using thesame reference characters so that, as a general rule, they will only bedescribed once.

DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION

In accordance with one or more embodiments, there is provided a methodof treating, reducing, or alleviating a medical condition in a patient.The method includes administering to a patient in need thereof abiocompatible drug comprising one or more antiviral medications togetherwith one or more cell pathway inhibitors dissolved in a non-toxicsemifluorinated alkane or other liquids, the patient having one or morerespiratory tract inflammatory diseases, the one or more cell pathwayinhibitors blocking an inflammatory response of inflamed tissue withoutinhibiting an immune response of the patient, and the semifluorinatedalkane evaporating quickly upon administration to the patient so as toleave the biocompatible drug at a desired treatment location. Theadministration of the biocompatible drug to the patient treats the oneor more respiratory tract inflammatory diseases, reduces the symptomsassociated with the one or more respiratory tract inflammatory diseases,and/or alleviates the one or more respiratory tract inflammatorydiseases.

In a further embodiment, the one or more respiratory tract inflammatorydiseases are selected from the group consisting of influenza,parainfluenza, severe acute respiratory syndrome, a coronavirus, anEpstein-bar virus, a herpes virus, an infection, and combinationsthereof.

In yet a further embodiment, the one or more respiratory tractinflammatory diseases comprise a coronavirus, the coronavirus selectedfrom the group consisting of COVID-2, COVID-19, or their mutations, andcombinations thereof.

In still a further embodiment, the biocompatible drug further comprisesnanoparticles or microparticles used as a carrier of the biocompatibledrug; and the biocompatible drug with the semifluorinated alkane and thenanoparticles or microparticles is administered by inhalation to thepatient to treat one or more respiratory tract inflammatory diseases.

In yet a further embodiment, wherein the nanoparticle or microparticlecarriers comprise slow release polymeric nanoparticles ormicroparticles; and the semifluorinated alkane is used to transport thebiocompatible drug with the slow release polymeric nanoparticles ormicroparticles.

In still a further embodiment, the slow release polymeric nanoparticlesor microparticles are conjugated with a viral specific antibody/antigen;glycoprotein, polysaccharides, etc. while carrying at least twoantiviral medications for intranasal inhalation to specifically targetone or more viruses, the viral specific antibody being obtained fromplasma/serum of patients who have recovered from a viral infection orthe viral specific antibody being produced in a tissue culture usingdead viruses cultured with T-cell lymphocytes or natural killers thatproduce the viral specific antibody in addition to producing exosomes orextracellular vesicles (ECV) that are both able to be harvested.

In yet a further embodiment, the one or more antiviral medications areselected from the group consisting of amantadine, Lopinavir, linebackerand equivir, Arbidol, a nanoviricide, remdesivir, oseltamivir,ribavirin, and combinations thereof

In still a further embodiment, the one or more cell pathway inhibitorsare selected from the group consisting of Rock inhibitors, Wntinhibitors, glycogen synthesis kinase 3 (GSK-3) inhibitors, integrininhibitors, IL-1 inhibitors, IL-6 inhibitors, and combinations thereof.

In yet a further embodiment, the biocompatible drug further comprisesone or more protease inhibitors in combination with the one or moreantiviral medications and the one or more cell pathway inhibitors.

In still a further embodiment, the method further comprises the step of,after treatment with the biocompatible drug, removing cytokines,enzymes, dead cells, from the circulation of the patient byplasmapheresis so as to prevent a cytokine storm.

In yet a further embodiment, the biocompatible drug is administered tothe patient by inhalation, orally, intravenously, or combinationsthereof.

In still a further embodiment, the biocompatible drug is administeredthrough the nasal mucosa to reach branches of the trigeminal nerve orolfactory nerve for delivery of the biocompatible drug to the brain,brain vasculature, and the cerebrospinal fluid where the semifluorinatedalkane rapidly evaporates at body temperature in the tissue leaving thebiocompatible drug at the desired treatment location.

In yet a further embodiment, the method further comprises administeringa stabilized hypochlorous acid, hypobromous acid (HOBr), bromamine, orchloramines, the stable N-chloro derivatives or chloramines, the stableN-chloro derivatives or N-chlorotaurine (NTC), dimethylated derivativesof NCT (N-chloro-2,2-dimethyltaurine [DM-NCT] andN,N-dichloro-2,2-dimethyltaurine [DM-NDCT] or Benzalkonium chloride andslow release polymeric nanoparticles, or LNP carrying at least two ofthe antiviral medications together with one or more cell pathwayinhibitors and heparin or low molecular weight heparin, or with polyphenols, such as catechin, found in fruit and vegetables, in asemifluorinated alkane or a suitable medium, the administration being inthe nose as inhalation, in spray or nebulized form to treat viralencephalitis or lung inflammation to kill one or more viruses andprevent the side effects of inflammation or as prophylaxis of viralinfection in the respiratory tract, encephalitis, vasculitis, dementia.

In still a further embodiment, the method further comprisesadministering tocilizumab in combination with at least one antiviralmedication to treat a viral infection of the lung, viral brainencephalitis, and/or brain vasculitis; and administering at least onecell pathway inhibitor, Wnt inhibitor, GSK inhibitor, or integrininhibitor with or without complement pathway inhibitors such as C3inhibitors—AMY-101 (NCT04395456) and APL-9 (NCT04402060); C5inhibitors—eculizumab (NCT04346797 and NCT04355494), C1 esteraseinhibitors, which block the classical complement pathway, through noseinhalation by spraying, aerosolization, or nebulization to reach bothbrain and lung tissue, and to reduce the inflammatory process andeliminate the side effects of the infection.

In yet a further embodiment, the method further comprises administeringinterferon or pegylated interferon and another antiviral medication incombination with the one or more cell pathway inhibitors, where theinterferon or pegylated interferon acts as an antiviral in the upper andlower respiratory tract, thereby blocking the replication of the RNA andDNA of the viruses at an early stage of viral infection.

In still a further embodiment, the method further comprisesadministering a TMPRSS2 inhibitor and an ACE-2 inhibitor in combinationwith the one or more cell pathway inhibitors, where the TMPRSS2inhibitor inhibits entry of the virus into the cell.

In accordance with one or more other embodiments of the presentinvention, there is provided a method of preventing a medical conditionin a patient. The method includes administering prophylactically atreatment compound or substance to prevent the occurrence of a viralinfection, the treatment compound or substance being selected from thegroup consisting of one or more antiviral medications, one or more cellpathway inhibitors, a type of mouthwash, hydrogen peroxide,povidone-iodine, ethanol, chlorhexidine, cetylpyridinium chloride, anIL-1 inhibitor, an IL-6 inhibitor, an IL-8 inhibitor, and combinationsthereof. The treatment compound or substance is administered topically,intranasally, or as a mouthwash.

In a further embodiment of the present invention, the viral infection isSARS-CoV-2, COVID-19, or a mutation thereof, and the treatment compoundor substance disrupts the SARS-CoV-2, COVID-19 or their mutations' lipidenvelope.

In yet a further embodiment, the method further comprises administeringa stabilized hypochlorous solution, or in chloramines, the stableN-chloro derivatives or chloramines, the stable N-chloro derivatives orN-chlorotaurine (NTC), dimethylated derivatives of NCT(N-chloro-2,2-dimethyltaurine [DM-NCT] andN,N-dichloro-2,2-dimethyltaurine [DM-NDCT], or Benzalkonium chloride ina semifluorinated alkane or liquid with slow release chitosanencapsulated nanoparticles in a saline solution or in oral form to passthrough the stomach to release a medication in the intestine to locallyprevent the intestinal side effect of the viral infection.

In still a further embodiment, the method further comprisesadministering prophylactically one or two antiviral medications as anasal spray, in aerosolized or nebulized form, or spray together withzinc in a saline solution orally in aliginate or chitosan encapsulatedbeads or nasally in polycaprolactone in a saline solution to damage theinvading viruses before entering the nasal mucosa.

In yet a further embodiment, the method further comprises administeringtamoxifen in combination with at least one antiviral medication to treata viral infection of the lung, viral brain encephalitis, and/or brainvasculitis; and administering at least one cell pathway inhibitor, Wntinhibitor, GSK inhibitor, and/or integrin inhibitor through the noseinhalation by spraying, aerosolization, or nebulization to reach bothbrain and lung tissue, and to reduce the inflammatory process andeliminate the side effects of the infection.

In accordance with yet one or more other embodiments of the presentinvention, there is provided a method of preventing a medical conditionin a patient. The method includes administering to a patient,experiencing a medical condition, one or more antiviral medicationstogether with one or more additional medications selected from the groupconsisting of one or more Wnt inhibitors, one or more Rock inhibitors,one or more GSK inhibitors, one or more integrin inhibitors, one or moreIL-6 inhibitors, one or more TGF beta inhibitors, one or moremacrolides, low molecular weight heparin, or with catechin in asemifluorinated alkane or a suitable medium and combinations thereof.The one or more antiviral medications and the one or more additionalmedications are administered orally, intranasally, intravenously,subcutaneously, topically, intraperitoneally, and/or by inhalation in asimultaneous, sequential, or separate manner.

In a further embodiment of the present invention, the medical conditionis selected from the group consisting of a lung viral infection, a brainviral infection, an intestinal viral infection, vasculitis, COVID-2,COVID-19, or their mutations, Alzheimer's disease, dementia, neuralgia,kidney disease, cardiac disease, encephalitis, and combinations thereof.

In yet a further embodiment, the medical condition is in a form of anend stage medical condition selected from the group consisting of an endstage lung infection, an end stage brain infection, encephalitis, andcombinations thereof; and wherein the one or more antiviral medicationscomprise a plurality of different antiviral medications to treat the endstage lung infection, the end stage brain infection, and/orencephalitis.

In still a further embodiment, the one or more additional medicationsadministered to the patient comprise low molecular weight heparin toenhance nerve repair and prevent blood coagulation so as to combat anoveractive immune response.

In yet a further embodiment, the one or more antiviral medicationsand/or the one or more additional medications are administered in aphysiological solution or semifluorinated alkane or a physiologicalliquid using polymeric slow release nanoparticles or microparticles,micelles, liposomes, and/or dendrimers as a drug carrier, the polymericslow release nanoparticles or microparticles comprising at least one ofpolylactic acid, polyglycolic acid, polycaprolactone, porous silicon,chitosan, and a polyethylene glycol-polylactic acid (PEG-PLA) blockcopolymer.

In still a further embodiment, the slow release polymeric nanoparticlesor microparticles, micelles, liposomes, lipid nanoparticles (LNP),and/or dendrimers are conjugated with a viral specific antibody so as toform antibody-coated slow release polymeric nanoparticles, LNP, ormicroparticles, antibody-coated micelles, antibody-coated liposomes,and/or antibody-coated dendrimers.

In yet a further embodiment, the one or more antiviral medications areselected from the group consisting of amantadine, Lopinavir, linebackerand equivir, Arbidol, a nanoviricide, remdesivir, oseltamivir,ribavirin, ritonavir and combinations thereof.

In still a further embodiment, the one or more additional medicationsadministered in a physiological solution or semifluorinated alkane or aphysiological liquid or any other suitable medium to the patientcomprise one or more Rock inhibitors in a form of botulinum toxin at apicogram concentration level.

In one embodiment, the semifluorinated alkane and medications areadministered preferably by nasal inhalation mouth inhalation, inhaler,as a spray, nanoparticles or microparticles, in a solution, or powder,or subcutaneous, or intramuscular, or intravenously, combined as acocktail or sequentially, orally etc.

In one embodiment to produce a vaccine, various methodologies can beemployed, such as a weakened virus is administered to the patient toproduce lasting antibodies, such as the use of polio vaccine developedinitially by Sabin and improved by Salk by using killed or inactivatedviruses.

In another embodiment, one can use a subunit of the virus, such as oneof a protein of the virus, such as in the hepatitis B vaccination madeby Novavax and similar vaccines used in Russia, where the geneticmaterial of one virus is inserted in another virus, such as Baculovirus,to build the spike protein by infecting other cells that grow and buildthe spike protein which is purified and used for vaccination of thepeople.

In one embodiment, the gene is implanted to a harmless virus, such asthe chimpanzee adenovirus producing flu-like symptoms, such as inSars-COVID-2, or engineered spike-protein. When the human adenovirus isused to carry a part of the gene that makes the spike-protein, itpotentially has the side effect of inflammation against the adenoproteinif the patient has been previously exposed to adenovirus.

In one embodiment, one can inject the genetic code with human RNA or DNAif needed by electroporation which is not very effective, but usingmessenger RNA or mRNA to carry the code letters that make a part of thevirus (S-Protein) can be administered to instruct the cell to make,e.g., the S-protein of the virus where the cell produces it andinitiates an immune response to the virus in the body. In order to bringmRNA inside the cells they are encapsulated in lipid nanoparticles(LNP), which penetrate the body's cell membrane, into its cytoplasm notin the nucleus and use the cells machinery to build the appropriateantigenic protein. This technology permits the immune cells to recognizethe antigen and attack the viruses or other organism.

In yet a further embodiment, despite the technological advances thereare some shortcomings that one does not know how long the mRNA vaccinesprovides an immune response to the patients, therefore there is still aneed for alternative technologies or improving the standardtechnologies, by further administering viral-like particles to inducehumoral and cellular immune response and interferon production fortherapy and/or for vaccination of the patient.

In one embodiment, the method comprises administering one to two or morevaccines such as, dead organisms, or their proteins or mRNA such asModerna vaccine and Pfizer vaccine, or AstraZeneca vaccine and withviral like particles (VLP) conjugated with the viral antigen withnanoparticles at a lower concentration of vaccine than normally is givenand if needed an adjuvant in a semifluorinated alkane or in a solutionwith or without a pathway inhibitor or complement C1-C3-C5 inhibitoreither nasally by inhalation or intramuscularly, or orally orintravenously separately or sequentially, or combined as a cocktail toreduce the side effects of the vaccines and increase the efficacy of thevaccination or to be repeated multiple times in an intervals of 3, 6, 9,or 12 months, etc. as needed, while the intranasal or inhalation orointment or oral as pills simplifies for the people storing the vaccineat a low temperature using a home refrigerator for self-administrationin different intervals as prescribed by a doctor.

In one embodiment, a vaccine is prepared from viruses or bacteria,fungi, etc. in a semifluorinated alkane and a saline, etc. solutioncontaining riboflavin or preferably another dye, such as methylene blue,with another adjuvant or viral like particles (VLP) conjugated with orwithout an antibody, or toll-like receptor 4, etc. with or withoutpathway inhibitors or another anti-inflammatory compound or antiviral orantibiotic, antifungal is administered where the organism is killedpreferably without radiation or with radiation exposure, such as x-rayor cobalt radiation etc. with or without or UV radiation such as UVA,UVB, or UVC wavelength or another wavelength of a LED, diode or laser,etc., applied to the entire pathogen in the container, Petri dish for aperiod of one second to 5 minutes or more and stored in a refrigeratorwith or without Benzalkonium chloride (BAC) at a low temperature and canbe used with nanoparticles/and antivirals for repeated vaccination asneeded by nasal or oral, or intramuscular administration, or as adjuvantto another vaccine prepared by other means or used after initial use ofanother vaccine for the same organism, eliminating the need for the useof formalin, thimerosal, formaldehyde, glutaraldehyde, etc. which aretoxic and produce excessive and lasting inflammation at the site of theadministration or because of unpleasant smell cannot be used for nasalspray or inhalation.

In one embodiment, a vaccine cocktail is prepared from viruses orbacteria, fungi, etc. in a semifluorinated alkane and a saline etc.solution containing methylene blue, with an adjuvant with or withoutviral like particles (VLP), etc., with or without pathway inhibitors oranother anti-inflammatory compound or antivirals or antibiotics,antifungals where the organism is killed with methylene blue and anantiviral applied to the entire pathogen in the container, Petri dishfor a period of one second to 5 minutes or more and the solution, etc.is collected, filtered, and stored in a refrigerator with or withoutBenzalkonium chloride (BAk) less than 0.01% or less at a low temperatureand can be used for repeated self-vaccination/administration as neededby nasal spray, inhalation, or oral pills or gummies or intraperitonealor intramuscular administration, or as adjuvant to another vaccineprepared by other means, such as mRNA vaccines or monoclonal orpolyclonal antibody coated nanoparticles, or LNP etc. or used afterinitial use of another vaccine for the same organism, butself-administered preferably by inhalation or orally, weekly for 1-2months or more intranasally as a spray or nebulization to eliminate allpotential pathogens, such as viruses that might remain in the nasalcavity, throat, pharynx, trachea, or in the alveoli and potentiallyreactivate and induce an epidemic or pandemic infection.

In one embodiment, the vaccines are distributed as a single dosage to bestored in refrigerator and administrated intranasally, orally, orsubcutaneously by people for 1 to 3 months, up to 5 months or longer,etc. as needed.

In one embodiment, the vaccines are distributed in older patients as asingle dosage with spermidine to enhance their immune response, to bestored in refrigerator and administrated intranasally, orally, orsubcutaneously by people for 1 to 3 months, up to 5 months or longer,etc. as needed.

In another embodiment, one or more anti-inflammatory agents, such asNSAIDs, combined with one or more vaccines along one or more pathwayinhibitors are administered to reduce a severe immune response tovaccines in patients with allergic history.

In one embodiment, vaccine is administered in a semifluorinated alkanecombined with pathway inhibitors as a spray simultaneously orsequentially, with or without antibody-coated nanoparticles, etc., thecombination therapy can include a vaccine such as dead viruses or mRNAor antibodies against viral proteins such as spike proteins, etc., thevaccination also include medications such as low molecular weightheparin, Ebselen, catechin, mycophenolic acid or pathway inhibitors orcomplement inhibitors that modify the severe immune response such asbone ache, fever, malaise, headache, etc. or side effect after a secondchallenge with repeated vaccinations, or observed immediately afteradministration of the vaccine combination preferably through the nose byinhalation though it can be given intramuscularly or subcutaneously byan injector nasally, by spray, or orally by pills and/or gummies, etc.as known in the art.

In still a further embodiment, the method further comprisesadministering one or more serum antibodies conjugated with theviral-like particles to induce an enhanced cellular immune response andinterferon production in the patient.

In yet a further embodiment, during treatment or after treatment withthe one or more antiviral medications and/or the one or more additionalmedications, the method further comprises the step of removingcytokines, enzymes, and/or dead cells from the circulation of thepatient by kidney dialysis, blood dialysis, and/or plasmapheresis so asto suppress a cytokine storm.

In still a further embodiment, a methylene Blue solution, a derivativeof phenothiazine, is prepared at a concentration of 0.25-4 mg/liter insemifluorinated alkanes or in a fluid for nasal inhalation, oral,topical or intravenous administration alone to act as an antioxidant, orwith one or two antivirals, such as Ebselen or remdesivir, valacyclovir,etc. and one or more Wnt inhibitors or anti-integrins, etc. and/or LMWHto treat viral respiratory tract infections and/or CNS viral involvementprophylactically or therapeutically.

In yet a further embodiment, when a patient has a severe viral kidney orliver disease, or viral respiratory disease, or viral brainencephalitis, an intravenous administration or oral or inhalation ortopical application of methylene blue, which acts as antioxidant andconverts methemoglobin to hemoglobin and acts as an antiviral at aconcentration of 0.25-4 mg/L or less than 4 muM concentration, with oneor two antivirals, such as Ebselen or remdesivir, Favipiravir,doxycycline, llopinavir, valacyclovir for inhalation or oraladministration, etc. with one or more Wnt inhibitors or ananti-integrin, Rock inhibitor or GSK inhibitor, etc. and LMWH in asemifluorinated alkane or in a fluid containing bile salt to kill theviruses including influenza, SARS-CoV-2, COVID-19, or their mutationsand reduce severe inflammatory processes followed with dialysis,hemodialysis, serum electrophoresis to remove unwanted toxins andcreatinine, etc. and simultaneously act to prevent blood clothing aftermethylene blue administration.

In still a further embodiment, a therapeutic vaccine is prepared fromviruses or bacteria, fungi, etc. or an adjuvant or a synthetic adjuvant,such as toll-like receptor 4 agonist in a semifluorinated alkane and asaline, such as a bile salt, etc. solution containing methylene bluewith or without antibody coated viral-like particles (VLP), etc., withor without pathway inhibitors or another anti-inflammatory compound orantiviral, such as remdesivir, Favipiravir, lopinavir, valacyclovir,etc. administered by inhalation or orally, and with or without anantibiotic, such as tetracycline derivatives and/or an antifungal, wherethe organism is killed preferably by medication without radiation wherethe viruses' RNA or DNA are damaged with methylene blue/medication whilethe S-antigen remains undamaged to induce a strong immune response tothe virus applied to the pathogens in a cell culture container to damagethe viral DNA and/or viral RNA and parts of the capsular protein, etc.for a period of one hours or a day or more, and then the remaining deadcomponents of the virus is stored in a refrigerator with or withoutBenzalkonium chloride (BAC) at a low temperature to be used for repeatedvaccination as needed, e.g., by nasal self-administration or oral aspills or in liposomes etc. or intramuscular administration, or as anadjuvant to another vaccine, such as mRNA vaccines, etc. or afterinitial administration of another vaccine of the same organism, tostimulate an immune response to the pathogen, thereby eliminating theneed for the standard use of formalin, thimerosal, formaldehyde,glutaraldehyde, etc. for the production of vaccines, but are toxic andproduce excessive and lasting inflammation at the site of theadministration.

In one embodiment, the RNA or DNA of the viruses are damaged withmethylene blue and or while the S-antigen or other viral proteins, etc.remain undamaged, and are administered along with antivirals orbenzalkonium chloride or another adjuvant, such as toll like receptor 4or VLP, etc. to induce a strong immune response to the virus in the bodykept with the pathogens that have grown in a container or cell cultureto damage the viral DNA and/or viral RNA and parts of the capsularprotein, of the virus etc. for a period of few hours or more dependingon the concentration of methylene blue, and then the remaining deadcomponents of the dead virus can be stored in a refrigerator with orwithout Benzalkonium chloride (BAC) at a low temperature to be used forrepeated vaccination with pathway inhibitor, such as Wnt, Rock, or GSKinhibitors or GSK beta inhibitors or another adjuvant such as toll-likereceptor agonists, etc. as needed, e.g., by nasal self-administration,or ointment or orally as encapsulated with vax or as gummy, etc. orintramuscular or subcutaneous, intraperitoneal, etc. administration, orused as an adjuvant to another vaccine by nasal or oralself-administration, such as mRNA vaccines, etc. or after initialadministration of another vaccine of the same organism, to stimulate animmune response to the pathogen, by measuring the neutralizingantibodies in the blood, thereby eliminating the need for the standarduse of formalin, thimerosal, formaldehyde, glutaraldehyde, etc. for theproduction of vaccines, that are toxic and produce excessive and lastinginflammation at the site of the administration.

In one embodiment, antivirals can be combined with methylene blue, aphenothiazine dye, a cationic compound to enhance damage to the viruses,bacteria's anionic RNA or DNA, and simultaneously acting as an in vivovaccine and therapeutically as anti-oxidant and anti-depressant whengiven in combination with of one of the pathway inhibitors, such as GSKinhibitors or GSK beta inhibitors and/or Wnt inhibitors, such asIvermectin or Niclosamide, in a solution or as polymeric slow releasenanoparticles or in semifluorinated alkanes to be administeredsystemically, or preferentially by inhalation, one or multiple timesdaily at below the toxic dose of methylene blue at 1-2 mg/L to reachboth the lung and the brain preventing or treating viral inflammatorydisease of the lung or the brain, etc. and preventing subsequent chronicAlzheimer's or Parkinson diseases and nerve damage and preventing ortreating the tangled tau neurofibriles and preventing Tau protein'stoxicity by activating plasma membrane calcium ATPase, thus preventingendoplasmic reticulum (ER) stress response and unfolding the protein.

In one embodiment, methylene blue, a tricyclic phenothiazine compoundapproved by the FDA for treatment of methemoglobinemia can block theviral interaction at concentrations of 3 μM-5 μM and more includingSAR-CoV-2 and COVID-19 or their mutations or other flaviviruses, etc.with the body's mucosa or respiratory cells or nerves, etc.

In one embodiment, methylene blue-photomediated viral RNA-proteincrosslinkage in presence of oxygen can be used for numerous therapy.However, methylene blue or in combination with one or more antiviralscan be used as therapy or vaccination either with or without VLP toenhance vaccination effect in any viral disease.

In one embodiment, methylene blue at a concentration of <4 μg/ml with orwithout light activation can inactivate most viruses, such as West NileVirus, a flavivirus, ebola or Marburg viruses, etc., coronavirus,alphavirus, myxovirus, filovirus, norovirus and flavivirus familymembers henipaviruses, bunyaviruses, arenaviruses, and other zoonoticRNA viruses.

In one embodiment, the combined use of methylene blue and an antiviral,such as Favipiravir inhibit the RDRP enzyme (RNA dependent RNA) totranscribe and permits incorporation of Favipiravir in the RNA of thevirus, thus the combination of methylene blue and an antiviral withoutlight or other combinations can be used to damage viral RNA whilepreserving the viral antigenic virus membrane, thus the preparation istherapeutic and simultaneously immune stimulating, such as a therapeuticvaccine, for the humoral or cellular response to specific virus'santigenic membranes, such as S-protein, etc. as used in vaccination,etc.

In one embodiment, methylene blue in combination with Remdesivirinhibits an enzyme that is important for replication of the RNA whilepreserving the antigenicity of the viral protein or S-protein or theirmutations that can be used for both therapy and vaccination ifadministered orally, such as pills, vax, or gummy etc. orintramuscularly, spraying nasally, by inhalation, by an inhaler, as anointment, as a powder, or inside a body cavity, etc.

In one embodiment, Lopinavir inhibits the protease needed forreplication of the virus. Thus, any combination of Lopinavir andmethylene blue at <5 μM or more concentrations damages the RNA of thevirus, while preserving the antigenecity of the cell membrane withoutthe use of light for vaccination. Many flaviviruses, including theDengue virus (DENY), Zika virus (ZIKV), West Nile virus, Yellow Fevervirus, and Japanese encephalitis virus are significant human pathogens,can be treated.

In one embodiment methylene blue, an FDA-approved drug, is abroad-spectrum and potent antiviral against Zika virus and Dengue virusboth in vitro and in vivo; methylene blue alone or in combination withone or more antivirals can considerably inhibit viral protease activity,inhibit viral growth, protect the brain organoids from ZIKV, methyleneblue works on the entry and post-entry in cell processes, inhibitingvirus replication alone or in combination with another antiviral orpathway inhibitors or in combination with LMWH preventing blood doting,etc.

In yet a further embodiment, the vaccine production uses a simple easyto produce methodology to be used anywhere, but specially in developingcountries, for any known or unknown viruses or bacteria or fungi wherethe incubation of the methylene blue with viruses or bacteria, or fungi,etc., where after the organism has grown on a cell culture media, etc.with or without a semifluorinated alkane or in cell culture media, aphysiological saline solution, etc., one adds a solution containingmethylene blue alone at a <5 microMolar or 0.25%4% or more concentrationin sodium phosphate buffer of pH 7.4 or at 50 mM concentration orpreferably more, for less than 2 days, in absence of light, etc. with orwithout another adjuvant, such as toll like receptor 4, with or withoutan antiviral, or with or without pathway inhibitors or anotheranti-inflammatory compound, such as Baricitinib or antivirals includingremdesivir, favipiravir, Lopanovir, valacyclovir, or Aplidin, etc. or anantibiotic, such as tetracycline derivatives, where the RNA or DNA ofthe organism is damaged without damaging the viral or bacterial membranecontaining the S-protein (antigen), etc. for vaccine production usingthe remaining dead viruses or proteins without crosslinking the viral orbacterial proteins, storing them in a refrigerator with or withoutBenzalkonium chloride (BAC) 0.004 to 0.01%, at a low temperature andused for repeated vaccination as needed by nasal inhalation, inhaler,spray, ointment, or orally as a pill or gummy, etc. for self vaccinationin different intervals, at a low volume that can be subsequentlyincreased until neutralizing antibodies are discovered in the body or asadjuvant to another vaccine prepared by other means, such as mRNAvaccines for nasal inhalation, ointment or orally or after the initialuse of another vaccine from the same organism, while eliminating theside effects of vaccines and the amount needed, thereby eliminating theneed for the standard use of formalin, thimerosal, formaldehyde,glutaraldehyde, etc., which are toxic and produce excessive and lastinginflammation at the site of the administration, while reducing the costof vaccination for a large population.

In still a further embodiment, methylene Blue at a <1 mg/L concentrationis administered intravenously, topically, nasally, orally,intramuscularly, intravenously, or intraperitoneally, with LMWH orheparin mimetics or complement inhibitors or pathway inhibitors and atleast one or more antivirals, such as Remdesivir, Favipiravir,monoclonal antibody-conjugated nanoparticles, and Acyclovir,valacyclovir, Lopinavir, linebacker and equivir, Arbidol, ananoviricide, oseltamivir, ribavirin, and combinations thereof with orwithout monoclonal or polyclonal antibody cocktails and/oranti-inflammatory agents, such as Baricitinib, or TGFbeta inhibitors,etc. to kill the viral pathogens with or without simultaneouslight/laser radiation of the blood inflow tubing, for a period or 4, 8,16, or 30 minutes or more followed by dialysis, hemodialysis, serumelectrophoresis to remove dead viruses and unwanted toxins and methyleneblue from the blood that is re-infused to the patient, and to preventlung fibrosis or myocardial damage or intestinal damage or brain damagein the patients.

In still a further embodiment, methylene Blue solution, a derivative ofphenothiazine, is prepared at a concentration of 0.25-2 mg/liter insemifluorinated alkanes or in a fluid for nasal inhalation, oral,topical or intravenous administration alone to act as an antioxidant, orwith one or two antivirals such as Ebselen or remdesivir, valacyclovir,etc. and one or more Wnt inhibitors or anti-integrins, etc. or LMWH totreat viral respiratory tract infections and/or CNS viral involvementprophylactically or therapeutically.

In yet a further embodiment, when a patient has a severe viral kidney orliver disease, or viral respiratory disease, or viral brainencephalitis, an intravenous administration or oral or inhalation ortopical application of methylene Blue, which acts as antioxidant andconverts methemoglobin to hemoglobin and acts as an antiviral at aconcentration of 0.25-2 mg/liter or less than 1 nM concentration, withone or two antivirals, such as Ebselen or remdesivir, Favipiravir,nitazoxanide, doxycycline, valacyclovir for inhalation or oraladministration, etc. with one or more Wnt inhibitors or ananti-integrin, Rock inhibitor or GSK inhibitor, etc. and LMWH in asemifluorinated alkane or in a fluid containing bile salt to kill theviruses including influenza, SARS-CoV-2, COVID-19, or their mutationsand reduce severe inflammatory processes followed with dialysis,hemodialysis, serum electrophoresis to remove unwanted toxins andcreatinine, etc. and simultaneously act to prevent blood clothing aftermethylene Blue administration.

In still a further embodiment, a vaccine is prepared from viruses orbacteria, fungi, etc. or an adjuvant or a synthetic adjuvant such astoll-like receptor 4 agonist in a semifluorinated alkane and a saline,such as a bile salt, etc. solution containing riboflavin or methyleneBlue or another photosensitizer, with or without viral-like particles(VLP), etc., with or without pathway inhibitors or anotheranti-inflammatory compound or antiviral, such as remdesivir,Favipiravir, valacyclovir, administered by inhalation or orally, andwith or without an antibiotic, such as tetracycline derivatives and/oran antifungal where the organism is killed with radiation exposure to UVradiation such as UVA, UVB, or UVC wavelengths or another wavelength(670 nm) produced by an LED, diode or laser, etc., or the viruses' RNAor DNA are damaged with methylene blue while the s antigen remainsundamaged to induce a strong immune response to the virus applied to thepathogens in a container, Petri dish to damage the viral DNA and/orviral RNA and parts of the capsular protein, etc. for a period of onesecond to 5 minutes or more and then the remaining dead components ofthe virus is stored in a refrigerator with or without Benzalkoniumchloride (BAC) at a low temperature to be used for repeated vaccinationas needed, e.g., by nasal self-administration or intramuscularadministration, or as an adjuvant to another vaccine, such as mRNAvaccines, etc. or after initial administration of another vaccine of thesame organism, to stimulate an immune response to the pathogen, therebyeliminating the need for the standard use of formalin, thimerosal,formaldehyde, glutaraldehyde, etc. for the production of vaccines, butare toxic and produce excessive and lasting inflammation at the site ofthe administration.

In one embodiment, the RNA or DNA of the viruses are damaged withmethylene blue while the S-antigen remains undamaged, and areadministered along with antivirals or benzalkonium chloride or anotheradjuvant to induce a strong immune response to the virus in the bodykept with the pathogens that has grown in a container, cell culture todamage the viral DNA and/or viral RNA and parts of the capsular protein,of the virus etc. for a period of few hours or more and then theremaining dead components of the dead virus can be irradiated once morewith a light of 670 nm wavelength for a few more minutes, stored in arefrigerator with or without Benzalkonium chloride (BAC) at a lowtemperature to be used for repeated vaccination with pathway inhibitorssuch as Wnt, Rock, or GSK inhibitors or GSK beta inhibitors or anotheradjuvant such as toll-like receptor agonists etc. as needed, e.g., bynasal self-administration or intramuscular or subcutaneous, etc.administration, or as an adjuvant to another vaccine, such as mRNAvaccines, etc. or after initial administration of another vaccine of thesame organism, to stimulate an immune response to the pathogen, therebyeliminating the need for the standard use of formalin, thimerosal,formaldehyde, glutaraldehyde, etc. for the production of vaccines, thatare toxic and produce excessive and lasting inflammation at the site ofthe administration.

In one embodiment, antivirals can be combined with Methylene blue, aphenothiazine dye, a cationic compound to enhance damage to the viruses,bacteria's anionic RNA or DNA, and simultaneously acting as anti-oxidantand anti-depressant when given in combination with of one of the pathwayinhibitors, such as GSK inhibitors or GSK beta inhibitors and/or Wntinhibitors, such as Ivermectin or Niclosamide, in a solution or aspolymeric slow release nanoparticles or in semifluorinated alkanes to beadministered systemically, or preferentially by inhalation, one ormultiple times daily at below the toxic dose of methylene blue at 1-2mg/L to reach both the lung and the brain preventing or treating viralinflammatory disease of the lung or the brain, etc. and preventingsubsequent chronic Alzheimer's or Parkinson diseases and nerve damageand preventing or treating the tangled tau neurofibriles and preventingTau protein's toxicity by activating plasma membrane calcium ATPase,thus preventing endoplasmic reticulum (ER) stress response and unfoldingthe protein (UPR).

In yet a further embodiment, the vaccine production uses a simple easyto produce methodology to be used anywhere, but specially in developingcountries, for any known or unknown viruses or bacteria where theincubation of the methylene blue with viruses or bacteria, or fungi,etc., after the organism has grown on a cell culture media, etc. with orwithout a semifluorinated alkane or in culture media, a physiologicalsaline solution, etc., one adds a solution containing methylene Bluealone at a <5 microMolar or 0.25%-1% or more concentration in sodiumphosphate buffer of pH 7.4 at 50 microM concentration or preferablymore, for less than 2 hours to days, etc. with or without anotheradjuvant, with or without pathway inhibitors or anotheranti-inflammatory compound, such as Baricitinib or antivirals includingvalacyclovir, etc. or an antibiotic if available, where the RNA or DNAof the organism is damaged without damaging the viral or bacterialmembrane containing the S-protein (antigen), etc. for vaccine productionusing the remaining dead viruses or proteins without crosslinking theviral or bacterial proteins, stored in a refrigerator with or withoutBenzalkonium chloride (BAC) at a low temperature and used for repeatedvaccination as needed by nasal inhalation, at a low volume that can besubsequently be increased until neutralizing antibodies are discoveredin the body or oral, or intramuscular administration, or as adjuvant toanother vaccine prepared by other means, such as mRNA vaccines for nasalinhalation or after the initial use of another vaccine from the sameorganism, thereby eliminating the need for the standard use of formalin,thimerosal, formaldehyde, glutaraldehyde, etc. which are toxic andproduce excessive and lasting inflammation at the site of theadministration.

In still a further embodiment, methylene Blue at a 1 mg/L concentrationis administered intravenously with LMWH or heparin mimetics orcomplement inhibitors or pathway inhibitors and at least one or moreantivirals, such as remdesivir and valacyclovir, and with or withoutpolyclonal antibodies cocktails and/or anti-inflammatory agents such asBaricitinib, etc. to kill the viral pathogens with or withoutsimultaneous light/laser radiation of the blood inflow tubing, for aperiod or 4, 8, 16, or 30 minutes followed by dialysis, hemodialysis,serum electrophoresis to remove dead viruses and unwanted toxins andmethylene Blue from the blood that is re-infused to the patient.

In yet a further embodiment, one administers a vaccine as a cocktail,etc. to boost the immune response of a person to specific viral,bacterial or fungal pathogens by administering a low dose of a vaccinethat is presently used for vaccination, the amount of this boostervaccine can be from 5%-99% of the original volume and its contents, orpreferably 10% or 20% or 40% or 60% volume, etc. with or without pathwayinhibitors such as Rock, Wnt, GSK or integrin inhibitors, or complementC1, C3, C5 inhibitors, etc. along with or without antivirals,antibiotics or antifungals or with or without an-anti-inflammatoryagent, such as a IL-7 inhibitor, DMF or Baricitinib, etc. or an immuneenhancer such as spermidine, etc. for inhalation or injectedintramuscularly, subcutaneously, or orally or intravenously orpreferably by nasal inhalation, as drops or spray, or by an inhaler etc.so the patients can either self-administer the vaccine in differentdoses at described intervals either before the regular standardvaccination, during the sickness, shortly thereafter, or beyond theoriginal vaccination or sickness to either recognize an allergicresponse to the vaccine and/or to boost gradually the immune response ofthe patient who is old or has cancer or is an immunosuppressed patient,where the vaccine can be prepared the standard way of killing thebacteria, or render them defenseless, or using a specific protein partof the virus, or using mRNA, etc. of the virus.

In still a further embodiment, the method further comprises the step of:delivery of oxygen to the patient by extracorporeal membrane oxygenationwhen the blood oxygenation level of the patient is low.

In another further embodiment, the treatment does not apply any meansthat provides 100% oxygen to the patient, since 100% oxygen is toxic tothe tissue and increases the inflammatory response that is not desirablein patients with COVID-19.

In one embodiment, the amount of oxygen for inhalation is 20-30% or30-40% or 40-50% or 50-80% best with standard C-Pap used for sleep apneacoupled with an oxygen tube supplying a certain amount of oxygen or withglutathione peroxidase to the air through the nose or mask.

In one embodiment, the treatment is divided into two or three stages,depending on the severity of the lung inflammation, at least one or twoantivirals, one to two Rock inhibitors or one to two Wnt inhibitors, oneor two GSK inhibitors, or one or two integrin inhibitors, at least oneor two protease inhibitors alone or at least one or two IL-1 or ILinhibitors or one to two known antivirals, such as amantadine,nucleoside analogues, such as AZT, aciclovir, ganciclovir, andvidarabine in combinations are used as inhalation where the medicationis dissolved in semifluorinated alkanes or combined as polymeric releasenanoparticles or one to two known antivirals such as amantadine,nucleoside analogues, such as AZT, aciclovir, ganciclovir, andvidarabine, or again depending on the severity of the disease, e.g., inend-stage disease, one can administer these combination of medications,orally, intravenously, semifluorinated alkanes with alkyl chains areharmless in the examined range from C₆ to C₁₀ but preferably C₆, inaddition to inhalation with simultaneous administration of macrolideimmune-suppressants, such as cyclosporine A, mycophenolic acid and withheparin or low molecular weight heparin (Lovenox) with or withoutcatechin in a semifluorinated alkane or a suitable medium, such as lowcarbon perfluorocarbon liquid C4-C6, to block viral receptors, heparansulfate and Sialic acid, and to enhance nerve repair and prevent bloodcoagulation, etc. to prevent overactive immune response and blood clotformation and to prevent vascular infarct, a side effect of the COVID-19infection. Furthermore plasmapheresis, kidney dialysis can be done toremove cytokines with or without extra-corporal oxygenation if bloodoxygenation remains low with the ventilator, or along with Glutathioneperoxidase, catalase, etc.

In the above-described treatment with two or three stages, the antiviralagents prevent either the attachment of viruses to the cell wall orblock their cell penetration or inhibit the virus replication bydamaging the nucleic acid (DNA or RNA) of the virus, etc. Theanti-inflammatory compounds affect the cell pathway of cell inflammationin response to various agents affecting the cells in a tissue or in anorgan. Among the most important anti-inflammatory compounds are Wntinhibitors that prevent early stage inflammation, Rock inhibitors thatprevent rock proteins activation, which blocks TGF beta that stimulatesscar formation after the inflammation is controlled. Similarly, integrininhibitors contribute to healing of the inflamed tissue preventing itfrom becoming overactive producing over active scarring, and GSK-3 areactive in intracellular signaling pathways, involved in cellularproliferation, migration, and apoptosis. Inhibition of GSK-3 contributesto the healing process. GSK-3 inhibitors increase the CD8(+) OT-I CTLfunction and the clearance of viral infections. Interleukins (ILs) are agroup of cytokines produced by cells and participate in a number ofinflammatory processes. There are a number of interleukins from IL-1 toIL-17, inhibition of these cytokines significantly reduces aninflammatory response in the tissue produced after a number of diseases,such as bacterial and viral infections, etc. Azidothymidine (AZT) orZidovudine (ZDV) is an antiretroviral used to prevent and treat HIV/AIDSinfection along with Acyclovir, ganciclovir and Vidarabine are activeagainst a broad spectrum of viral infection in patients with AIDS oracquired immunodeficiency syndrome, etc. Semifluorinated alkanes arenon-toxic and do not cause irritation, and can carry oxygen usedpreviously as a blood substitute. However, no one has used thischaracteristic to deliver simultaneously oxygen in the lungsimultaneously with other medications by loading them also with oxygenprior to its administration as aerosolized nanodrops or microdrops inthe spray system. Semifluorinated alkanes dissolve numerous hydrophilicor hydrophobic compounds. Their temperature transition from liquid tovapor is low, so they can evaporate easily. They can be formed as aliquid compound or can be aerosolized for inhalation through the nose ormouth along with various medications. Their applications are best forsurfaces of the skin or mucosa or aerosolized for inhalation to reachthe alveoli of the lung, etc. They may not be approved yet forintravenous application. For the latter application, one can use aphysiologic solution with a pH of 7-7.5 and osmolality of about 300mosmol having 0.9% or more saline, to administer the medicationsintravenously or as spray for inhalation. The anti-inflammatory agentsdescribed above, including the anti-virals can be taken orally, such asZidovudine and Acyclovir, ganciclovir and Vidarabine, etc. However, aformulation of these and others antivirals can be given intravenously orintramuscularly in solution or can be dissolved in semifluorinatedalkanes for inhalation.

In one embodiment, a method of drug delivery is described for treatmentof respiratory tract inflammatory diseases or encephalitis caused byvarious viruses, such as influenza, parainfluenza, SAR or coronaviruses,COVID-2 or COVID-19, or their mutations, etc., EBV, Herpes virus, etc.,or a bacterial infection, etc., where the anti-viral medications areadministered along with cell pathway inhibitors to block an inflammatoryresponse of the tissue which does not inhibit an immune response, suchas a Rock inhibitor, Wnt inhibitor, GSK inhibitor, integrin inhibitors,with or without complement pathway inhibitors such as C3inhibitors—AMY-101 (NCT04395456) and APL-9 (NCT04402060); C5inhibitors—eculizumab (NCT04346797 and NCT04355494), eculizumab,Ultomiris, and C1 esterase inhibitors, which block the classicalcomplement pathway or in combination, dissolved in a non-toxic ornon-irritative semifluorinated alkanes liquid, or other liquids, whichare amphiphilic liquids dissolving both hydrophilic and hydrophobicdrugs, or as polymeric slow release nanoparticles carrying themedication applied as a spray or evaporative solution or in aevaporative aerosolized drops during the inhalation passing through thenose or mouth or olfactory or trigeminal nerves, etc. to the brain orthe lung alveoli, while on the way the nano- or micro-droplets attach tothe nerve receptors, fibers of olfactory nerve reaching the olfactorybulb and the brain or attach to the mucosa, epithelia or endothelialcells of the nose pharynx, larynx, epiglottis, trachea, bronchi and lungalveoli. The semifluorinated alkanes rapidly evaporates at bodytemperature leaving the medication(s) or slow release nanoparticle onthe surface of the tissue in the brain or the lung, thus releasing themedication over a time period of one day to one week to 3 weeks ormonths depending on the composite of the polymer.

In one embodiment, the semifluorinated alkanes or perfluorocarbon liquidwhich are non-toxic fluidics, and serve as solvents alone or incombination with other solvents, such as polyethylene glycol (PEG) orethanol, etc., dissolve hydrophobic and hydrophilic medications withease and thereby enhancing the penetration of the medication in thetissue therefore are best suitable for inhalation, spray or nebulizationdelivery of medications both to the lung and brain through therespiratory pathway or through the olfactory and trigeminal nerves tothe brain.

In one embodiment, the semifluorinated alkanes or perfluorocarbon liquidwith low carbon chains evaporate faster in one day to a week, and highercarbon chain forms evaporate in a few weeks to months.

In one embodiment, the low density semifluorinated alkane orperfluorocarbon liquid or another solution are used by mixing them withviral or bacterial or fungi antigens or modified mRNA, for vaccination,or combined with antibodies or other medications, etc. to beadministered by injection intramuscular or inside a body cavity orpreferably to be applied locally or topically or as an ointment or as anspray or nebulized as micro-droplets or nano-droplets or the vaccinationis combined with therapeutic medications such as pathway inhibitors,Rock, Wnt, GSK, or integrin inhibitors or complement inhibitors C1, C3,C5 inhibitors alone or as slow release polymeric nanoparticles for nasalspray or inhaler where the nanodroplets or microdroplets afterinhalation locate themselves over the mucosal surfaces of the nose,pharynx, and deliver medication to the mucosal cells or to the blood,etc. and the nanoparticles continue releasing the medications for weeks,or months depending on their compositions to prevent excessiveinflammatory or anaphylactic response to the vaccination.

In one embodiment, a low density semifluorinated alkane orperfluorocarbon liquids or another solution are used by mixing them withcombinations with various slow release PEGylated polymeric slow releasepolymeric nanoparticles or microparticles, such as lactic acid, glycolicacid, or in combination or polycaprolactone, porous silicon, anhydride,micelles, liposomes, solid lipids, etc. conjugated with antibodies orother medications, such as antivirals, antibacterials, antifungals, oranti-parasites, etc. to be administered by injection intravenously orinside a body cavity as an emulsion or to be applied locally ortopically or injectable emulsion or ointment or as spray or nebulized asmicro-droplets or nano-droplets for therapeutic medication for nasalinhalation as a spray or inhaler where the nano-drops or micro-dropsafter inhalation locate themselves over the mucosal surfaces of thenose, pharynx, larynx, bronchi, and alveoli to be positioned between thefluid on the surface of the mucosal cells and the air and preventdryness of the alveoli mucosa and deliver medication to the cells or tothe blood, etc. and the nanoparticles continue releasing the medicationsfor weeks, months or years depending on the compositions.

In one embodiment, oxygenated or non-oxygenated semifluorinated alkanesor perfluorocarbon liquid with carbon chain of 3-10 C withantibody-coated viral-like particles and/or viral-like particles areconjugated with viral antigens administered nasally as a spray orinhalation or repeated in another time interval from one month to oneyear, etc. as needed to create an immune response to the viral antigenor viral protein or proteins or to the combination of VLP and antigensenhancing the immune response and, since the spray or the inhaler can bestored in the refrigerator, the patient can be instructed to performrepeated self-vaccination as prescribed by the doctor depending on thepresence or absence of the neutralizing antibody in the blood of thepatient.

In another embodiment, oxygenated or non-oxygenated low densitysemifluorinated alkanes or a perfluorocarbon liquid with antibody-coatedviral-like particles in combination with complement inhibitorsadministered nasally as a spray or inhalation and repeated in anothertime of one month to one year as needed to create an immune response tothe viral antigens or viral proteins while complement inhibitors reducethe allergic response to the antigens or VLPs, the spray or the inhalercan be stored in the refrigerator, and the patient can be instructed toperform repeated self-vaccination as prescribed by the doctor dependingon the presence or absence of neutralizing antibody in the blood of thepatient.

In one embodiment, the antibody-coated PEGylated polymeric slow releasenanoparticles with desired medications are mixed with a low densityoxygenated or non-oxygenated semifluorinated alkanes (SFA) having 4-8carbons and 100% oxygen in the container that is capable of delivering apuff of oxygen and nebulized SFA or perfluorocarbon liquids at a lowcarbon chain of 4-8 carbons that evaporate within one week to a month orlonger depending on the carbon chain.

In one embodiment, the oxygenated semifluorinated alkanes (SFA) carriesPEGylated nanoparticles that carry the needed gene(s) along with CRISPRwith a cationic compound and thiol where the gene delivery is donethrough the nasal delivery or with an inhaler to the lung to modifygenetic defect of the alveolar cells, etc. such as pulmonary fibrosis,the nanoparticles are conjugated with thiol or cell penetrating peptidesto enhance their penetration in the cells.

In one embodiment, the oxygenated or non-oxygenated semifluorinatedalkanes/nanoparticle emulsions evaporate and leave the slow releasepolymeric nanoparticles on the cell surface to release the medicationfor a long time to the lung, or brain, or in the circulation.

In one embodiment, the oxygenated or non-oxygenated semifluorinatedalkanes or perfluorocarbon liquids are administered by spraying,nebulization or an inhaler along with medications where the droplets ofSFA or PFCL pass through the nasal pathways to the lung alveoli wherethey can pick up oxygen from the air or blood and release them when theblood oxygen concentration drops below 94%.

In another embodiment, the semifluorinated alkane with an emulsion ofpolymeric release nanoparticles and genes penetrate or are picked upthrough the cell membrane where the medication is released or they maypicked up by the endothelial cells and enter the circulation to continuebeing active and release the medication elsewhere in the body such aslung, heart, and brain, etc.

In one embodiment, a low density semifluorinated emulsion withantibody-coated particles carrying the medication are picked up by theneuronal cells in the mucosal cells of the nose and elsewhere, andtravel to the brain through the olfactory nerve and bulb or through thetrigeminal nerves brought to the brain and are released to treat viralbacterial, or fungal encephalitis.

In one embodiment, the semifluorinated emulsion with antibody-coatedslow release polymeric nanoparticles carrying the medication such asantivirals, antibiotics, or antifungals alone or in combination withpathway inhibitors or complement inhibitors where the nanoparticles arepicked up by the neuronal cells, in the mucosal lining of the nose andelsewhere and travel to the brain through the olfactory nerve and bulbor through the trigeminal nerves brought to the brain and are releasedto treat viral bacterial, or fungal encephalitis, or chronicinflammatory diseases, such as Alzheimer's disease or Parkinson'sdisease.

In one embodiment, the inhaled semifluorinated alkanes withnano-droplets and/or micro-droplets work as lubricants in therespiratory tract after their inhalation by nasal spray or nebulizationor through an inhaler reducing the dryness of the respiratory pathways.

In one embodiment, the oxygenated semifluorinated alkanes and polymericslow release nanoparticles can enhance medication penetration in thetissue such as antiviral, protease inhibitors, or polymerase inhibitorsor transcriptase inhibitors (NRTIs) and since they are not nutrientswill prevent bacterial growth on them and the oxygen damages thebacteria and viruses enhancing the effect of antivirals and antibioticsor antifungal medication on these organisms.

In one embodiment, a method of drug delivery is described for treatmentof respiratory tract inflammatory diseases caused by various viruses,such as influenza, parainfluenza, SAR or coronaviruses, COVID-2 orCOVID-19, or their mutations, etc., EBV, Herpes virus, etc., orbacterial infections, etc. where the anti-viral medication isadministered in a physiological solution or semifluorinated alkane or aphysiological liquid or a suitable medium along with cell pathwayinhibitors to block an inflammatory response of the tissue which doesnot inhibit immune response, such as Rock inhibitors such as Fasudilhydrochloride, or ROCK2, Fasudil1-(5-Isoquinolinesulfonyl)-2Methylpiperazine Calcium Channel Blockers, or as SAR407899, or Inhibitorof cyclic nucleotide dependent- and Rho-kinases GSK 269962, potent andselective ROCK inhibitor GSK 429286, selective Rho-kinase (ROCK)inhibitor H1152 dihydrochloride, selective Rho-kinase (ROCK) inhibitorGlycyl H 1152 dihydrochloride, selective Rho-kinase (ROCK) inhibitor;more selective analogue of H1152, cell-permeable, selective Rho-kinaseinhibitor OXA 06 dihydrochloride, potent ROCK inhibitor PKI1447dihydrochloride, potent and selective ROCK inhibitor; antitumor SB772077B, potent Rho-kinase inhibitor; vasodilator SR 3677dihydrochloride, potent, selective Rho-kinase (ROCK) inhibitor TC-S7001,potent and highly selective ROCK inhibitor Y-27632 dihydrochloride,Botox or botulinum toxin in conjunction with at least two antivirals,such as Glidesivir, Favipiravir, Remdesivir, nanoviricides, GS-6207(Lenacapavir/Gilead) in picomolar concentration, or GS-CA1, Oya1,umifenovir, tamivir ribavirin dissolved in a liquid semifluorinatedalkanes, or other liquids, or as polymeric slow release nanoparticlesapplied as drops or spray or evaporative solution or in a evaporativeaerosolized nano- to micro-drops that travels through the nasal mucosato reach the lung alveoli, while on the way, attaches to the mucosa,epithelia or endothelial cells or nose pharynx, larynx, epiglottis,trachea, bronchi and lung alveoli. The semifluorinated alkanes rapidlyevaporate at body temperature leaving the medication(s) or slow releasenanoparticles of polylactic, polyglycolic acid or combination thereof,or combination of polycaprolactone, anhydrides, porous silicone,micelles, and/or liposomes on the surface of the tissue or slow releasenanoparticles on the surface of the tissue, releasing the medicationover a time period of one day to one week to 3 weeks or months dependingon the composite of the polymer.

In one embodiment, a method of drug delivery described for treatment ofrespiratory tract inflammatory diseases caused by various viruses, suchas influenza, parainfluenza, SAR or coronaviruses, COVID-2 or COVID-19,or their mutations, etc., EBV, Herpes virus, etc., or bacterialinfections, etc. where the anti-viral medications are administered in aphysiological solution or semifluorinated alkane or a physiologicalliquid or a suitable medium with a cell pathway inhibitor to block aninflammatory response of the tissue which does not inhibit an immuneresponse, such as in a physiologic pH adjusted to 7-7.5 pH andosmolarity of 280-300 mOsm or slow release polymeric nanoparticles fromthe Wnt compound, such as FH535, IWP-2, PNU-74654, IWR-lendo, IWR-exo,Demethoxycurcumin, CCTO36477, KY02111, WAY-316606, SFRP, IWP, LGK974,C59, Ant1.4Br/Ant 1.4Cl, Ivermectin, Niclosamide, apicularen andbafilomycin, XAV939, XAV939, G007-LK and G244-LM, NSC668036, SB-216763,gemtuzumab, etc., small molecule Wnt inhibitor PKF118-310, theWnt/β-catenin pathway inhibitor dissolved in a liquid semifluorinatedalkane, or other liquids, or as polymeric slow release nanoparticlesapplied as a spray or evaporative solution or in evaporative aerosolizeddrops that travel through the nasal mucosa to reach the lung alveoliwhile on the way attaches to the mucosal, epithelial, or endothelialcells of nose pharynx, larynx, epiglottis, trachea, bronchi and lungalveoli. The semifluorinated alkane rapidly evaporates at bodytemperature, thereby leaving the medication(s) or slow releasenanoparticles on the surface of the tissue, releasing the medicationover a time period of one day to one week to 3 weeks or months dependingon the composite of the polymer.

In one embodiment, a method of drug delivery described for treatment ofrespiratory tract inflammatory diseases caused by various viruses, suchas influenza, parainfluenza, SAR or coronaviruses, COVID-2 or COVID-19,or their mutations, etc., EBV, Herpes virus, etc., or bacterialinfections, etc. where the anti-viral medication is administered in aphysiological solution or semifluorinated alkane or a physiologicalliquid or a suitable medium with a cell pathway inhibitor to block aninflammatory response of the tissue which does not inhibit an immuneresponse like steroids, the cell pathway inhibitor being, for example, aGSK 269962 inhibitor or GSK inhibitors, such as synthetic small-moleculeATP-competitive inhibitors, and substrate-competitive inhibitors,non-ATP-competitive inhibitors, where FRAT/GBP competes with Axininhibiting GSK-3 activity or anti-integrins such as Risuteganib,vedolizumab, anti-integrins, such as abciximab, Eptifibatide, Tirofiban,αIIbβ3 antagonists, Natalizumab, 3 mg to ±52 μg/mL, MLN-00002,Firategrast, IVL745, antagonists of αvβ3 and/or αvβ5 integrins, LM609,Vitaxin, Abegrin, CNTO95, Cilengitide. MLD-based disintegrins,L000845704, SB273005, Volociximab, JSM6427 or dissolved in a liquidsemifluorinated alkanes or other liquids with other medications or aspolymeric slow release nanoparticles applied as a spray or evaporativesolution or in evaporative aerosolized drops that travels through thenasal mucosa to reach the lung alveoli while on the way attaching to themucosal, epithelial or endothelial cells or nose pharynx, larynx,epiglottis, trachea, bronchi and lung alveoli where the semifluorinatedalkane/medication(s) rapidly evaporates leaving the medication(s) orslow release nanoparticles on the surface of these organs after inhalingone time to 10 times as needed, thereby releasing the medication over atime from one day to 2 weeks or more. However, the dose applied throughthis methodology is <30 times in concentration compared to systemicmedication given intravenously, etc. and it is more effective locally,to combat the viruses and their complications.

In one embodiment, a method of drug delivery described for treatment ofrespiratory tract inflammatory diseases caused by various viruses, suchas influenza, parainfluenza, SAR or coronaviruses, COVID-2 or COVID-19or their mutations, etc., EBV, Herpes virus, etc., or bacterialinfections, etc. where the anti-viral medications are administered in aphysiological solution or semifluorinated alkane or a physiologicalliquid or a suitable medium with IL-1 and/or IL-6 inhibitors, such asKevzara (sarilumab) or nitric oxide (NO) donor (NONOate), interleukinantagonists, or in combination with Rock inhibitors, etc. to blockinflammatory response IL-6 of the tissue which does not inhibit immuneresponse (as steroids do), dissolved in liquid semifluorinated alkanesor other liquids with other medications or as polymeric slow releasenanoparticles applied as a spray or an evaporative solution or inevaporative aerosolized drops that travel through the nasal mucosa toreach the lung alveoli while on the way attaching to the mucosal,epithelial or endothelial cells or nose pharynx, larynx, epiglottis,trachea, bronchi and lung alveoli where dissolved medication in thesemifluorinated alkanes rapidly evaporates from the lung leaving themedication(s) and/or slow release nanoparticles on the surface of theseorgans after inhaling, one time to 10 times or more as needed releasingthe medication over a time period from one day to 2 weeks or more.

In one embodiment, a method of drug delivery described for treatment ofrespiratory tract inflammatory diseases caused by various viruses, suchas influenza, parainfluenza, SAR or coronaviruses, COVID-2 or COVID-19,or their mutations, etc., EBV, Herpes virus, etc., or bacterialinfections, etc. where the anti-viral medication is administered in aphysiological solution or semifluorinated alkane or a physiologicalliquid or a suitable medium with a protease inhibitor, such as Ebselen,an inhibitor to target SARS-CoV-2, COVID-19, or their mutations, Mpro orGanovo to block the entry of the virus in the cell dissolved in a liquidsemifluorinated alkane or other liquids which does not cause irritation,with other medications, or as polymeric slow release nanoparticlesapplied as a spray or evaporative solution or in a evaporativeaerosolized drops that travel through the nasal mucosa to reach the lungalveoli while on the way attaching to the mucosal, epithelial orendothelial cells or nose pharynx, larynx, epiglottis, trachea, bronchiand lung alveoli where the semifluorinated alkane rapidly evaporatesleaving the medication(s) or slow release nanoparticles on the surfaceof these organs after inhaling one time to 10 times as needed, therebyreleasing the medication over a time from one day to 2 weeks to monthsor years.

In one embodiment, a method of drug delivery described for treatment ofrespiratory tract inflammatory diseases caused by various viruses, suchas influenza, parainfluenza, SAR or coronaviruses, COVID-2 or COVID-19,or their mutations, etc., EBV, Herpes virus etc., or bacterialinfections, etc. where the anti-viral medication such as Lopinavir, orlinebacker and equivir, or HIV protease inhibitor darunavir, isadministered in a physiological solution or semifluorinated alkane or aphysiological liquid or a suitable medium with a protease inhibitor suchas Ganovo or INO-4800 to block the entry of the virus into the cell andAPNO1 an angiotensin converting enzyme 2 to block the virus adhesion tothe cells, or in combination with a Rock inhibitor, Wnt inhibitor, GSKinhibitor, or integrin inhibitor or IL-1 or IL-6 inhibitor Kevzara ornitric oxide (NO) donor (NONOate) or interleukin antagonists, such asanakinra, dissolved in a liquid semifluorinated alkane or other liquidswith other medications as a nanoparticle compound or as polymeric slowrelease nanoparticles applied as spray or evaporative solution or inevaporative aerosolized drops that travel through the nasal mucosa toreach the lung alveoli while on the way attaching to the mucosal,epithelial or endothelial cells or nose pharynx, larynx, epiglottis,trachea, bronchi and lung alveoli where the semifluorinated alkanerapidly evaporates because of high body temperature, leaving themedication(s) or slow release nanoparticles on the surface of theseorgans after inhaling one time to 10 times or more as needed, releasingthe medication over a time from one day to 2 weeks to months or years inthe chronic disease of the lung.

In one embodiment, a method of drug delivery described for treatment ofrespiratory tract inflammatory diseases caused by various viruses, suchas influenza, parainfluenza, SAR or coronaviruses, COVID-2 or COVID-19,or their mutations, etc., EBV, Herpes virus, etc., or bacterial orfungal infections, etc. where the anti-viral medication such asLopinavir, or linebacker and equivir, Arbidol, NanoViricide and/or anHIV protease inhibitor darunavir, is administered in a physiologicalsolution or semifluorinated alkane or a physiological liquid or asuitable medium with a protease inhibitor such as Ganovo or INO-4800 toblock the entry of the virus to the cell and APNO1 an angiotensinconverting enzyme 2 to block the virus adhesion to the cells, or incombination with PolyTop mAb therapy or cocktail of antibody therapy byRegeneron Velochimmune or Vir's antibody platform or VAAST platformhuman monoclonal antibody or TZLS-501 an IL 6 inhibitor or Kevzara orActems Tocilizumab with Rock inhibitors, Wnt inhibitors, GSK inhibitorsor integrin inhibitors or anti-bacteria or antifungal or IL-1 inhibitorsdissolved in a liquid semifluorinated alkane or other liquids and othermedications and polymeric slow release nanoparticles are applied as aspray or evaporative solution or in evaporative aerosolized drops thattravel through the nasal mucosa or mouth to reach the lung alveoli whileon the way attaching to the mucosal, epithelial or endothelial cells ornose pharynx, larynx, epiglottis, trachea, bronchi and lung alveoliwhere the semifluorinated alkane/medication(s) rapidly evaporatesleaving the medication(s) or slow release nanoparticles on the surfaceof these organs after inhaling one time to 10 times or more as neededreleasing the medication over a time from one day to 2 weeks, months, oryears.

In one embodiment, after inhalation or systemic treatment of viralinflammation with antivirals, a severe inflammatory response is treatedwith Rock, Wnt, GSK, or integrin inhibitors alone or in conjunction withother therapeutic immunosuppressant agents dissolved in thesemifluorinated alkanes or other liquids with other medications, such asa macrolide, cyclosporine A, mycophenolic acid, ascomycin Immunomycin,FR-900520, FK520, is an ethyl analogue of tacrolimus (FK506) forinhalation, can reduce the overt inflammatory response of the diseaseprocess; while MPA inhibits inosine monophosphate dehydrogenase.Mycophenolate mofetil alone, or in combination with a proteaseinhibitor, and reverse transcriptase inhibitor abacavir, and polymeraseinhibitor, remdesivir, prevents most viral replications by depletion ofGuanine, depletion of guanosine in substrate guanine triphosphate (GTP),while simultaneously preventing endoplasmic stress induced by viralinfections in the neuronal cells, thereby preventing neurofibrillary andmisfolding of proteins such as amyloid, however, in a later stage of thedisease, steroids can be used even though steroids have their unwantedside effects and also can be replaced with NSAIDs that are moredesirable, however, inhalation, or by an inhaler would be preferable tosystemic therapy, except in desperate end stage cases where systemicsteroids, such as prednisone, dexamethasone, fluoroquinolone, etc. mightbe useful in combination with antivirals and antibacterials, such asTetracycline derivative medications, a metalloproteinase inhibitor,demeclocycline, doxycycline, Adoxa, Vibramycin, Minocycline, Minocin,etc. to treat inflammatory viral lung or brain infections through thenasal inhalation, etc.

In one embodiment, in an immunosuppressed individual after organtransplantation, for viral infection prophylaxis or therapeutically inaddition to inhalation therapy, systemic administration of naturalkiller cells or modified killer T-cells systemically along with Wnt,Rock, GSK inhibitors and integrin inhibitors, antibiotics such as,Tetracycline derivative medications a metalloproteinase inhibitor,include Demeclocycline, Doxycycline, Adoxa, Vibramycin, Minocycline,Minocin, antifungals, both as inhalation dissolved in semifluorinatedalkanes or other liquids, or systemically can be given to combat aninflammation or any superinfection with bacteria and fungi which requireadditional antibacterial and/or antifungal medications can beadministered in a physiological solution or semifluorinated alkane or aphysiological liquid or a suitable medium both systemically, inside abody cavity, or by inhalation dissolved in semifluorinated alkanes orother liquids as needed.

In one embodiment, a method of drug delivery described for treatment ofrespiratory tract inflammatory diseases caused by various viruses, suchas influenza, parainfluenza, SAR or coronaviruses, COVID-2 or COVID-19,or their mutations, etc., EBV, Herpes virus, etc., or bacterialinfections, etc. where the anti-viral medication such as Lopinavir,favipiravir or linebacker and equivir, unifenovir and a vaccine, such aslipid-encapsulated mRNA 1273, COVID-19 S-Timer, or SARS-COVID-2,viral-like particles (VLP) or an adjuvant or viral Lily vaccine etc.with antibody-coated nanoparticles administered simultaneously orsequentially with a Rock inhibitor, Wnt inhibitor, GSK inhibitor, orintegrin inhibitor in a solution or dissolved in a liquidsemifluorinated alkane or other liquids with other medications or aspolymeric slow release nanoparticles applied as a spray or evaporativesolution or in evaporative aerosolized drops that travel through thenasal mucosa to reach the lung alveoli while on the way attaching to themucosal, epithelial, or endothelial cells or nose, pharynx, larynx,epiglottis, trachea, bronchi and lung alveoli where the semifluorinatedalkane rapidly evaporates leaving the medication(s) or slow releasenanoparticles on the surface of these organs after one or more times ofinhalation as needed.

In one embodiment, a vaccine prepared as described with methylene blueis administered prophylactically or therapeutically alone or with one ormore antivirals in a physiological solution or semifluorinated alkane ora physiological liquid with or without LMWH in a suitable mediumadministered by inhalation, or intranasally, by ointment, orally aspills to a patient every 2-4 months or at a lower quantity to preventre-infection by a coronavirus that causes COVID-19 or its mutations,etc.

In one embodiment, the described medications can be supported byfrequent inhalation and oral administration of Glutathione peroxidase,catalase, flavonoid, containing polyphenyls, epigallocatechin gallatecatechins (EGCG) having antioxidants compounds found in black tea,coffee, oolong, white tea, Pu-reh, Chamomile tea, the vegetable, such asfruits or coco, Mpro enzyme inhibitors and antioxidant, antimicrobial,antidiabetic, antiallergic, anticancer, hypocholesterolemic, statins andimmunomodulatory mangiferin, genistein, estradiol, berberine andbaicalein, sulforaphane, vitamin D and high doses of vitamin C, vitaminE, D, or quercetin, curcumin, resveratrol, Alpha-lipoic acid,tocopherols and tocotrienols, carotenoids, glutathione tocopherols,carotenoids, and other plant based Wnt inhibitors, ivermectin,niclosamide, etc. reducing excessive glutamate that can cause neuronaldeath, and Alzheimer's disease.

In one embodiment, a patient is treated with a combination ofremdesivir, a Wnt inhibitor (e.g., Ivermectin), and a proteaseinhibitor, such as ritonavir or Ganovo, dissolved in a semifluorinatedalkane or other liquids used for inhalation 4 times along withsupportive therapy for 3 weeks to produce a gradual recovery.

In one embodiment, in early coronavirus infection, it is treated with acombination of an antiviral medication such as Remdesivir, oseltamivirribavirin at non-toxic concentrations or Rock inhibitor or Wntinhibitor, or GSK inhibitor or integrin inhibitor at non-toxicconcentrations in a liquid of semifluorinated alkanes or other liquidswhich does not cause irritation, sprayed in the nose or through themouth or nebulized for deep breathing through the mouth 1-10 times ormore as needed.

In one embodiment, a patient who tests positive for an influenza virustest is treated with a combination of fasudil, a Rock inhibitor andoseltamivir (Tamiflu) in a semifluorinated alkane for inhalation 4 timesdaily dissolved in semifluorinated alkane or other liquids and oralTylenol, and baby aspirin 2-3 times daily as needed, and his symptomsimprove gradually within 3 days while he is on therapy, and he isfollowed for 5 weeks until the symptoms completely subside and he isable to return to work.

In one embodiment, in early coronavirus infection without history ofhypertension or known cardiac disease, QTC prolongation or failure,stent or infarct, it is treated with a combination of an antiviralmedication such as Remdesivir, tamivir, ribavirin at non-toxicconcentrations and/or Rock inhibitor or Wnt inhibitor, or GSK inhibitoror integrin inhibitor, TGF beta inhibitors or in combinations, atnon-toxic low concentration of Hydroxychloroquine/chloroquine andamodiaquine which has shown some efficacy against viruses such as HIV,Zika virus, even SARS-CoV, by oral administration high doses of 400 mgto 600 mg with the side effect of heart and kidney disease, but lowconcentrations of 6 mg or less were used in a liquid semifluorinatedalkane which does not cause irritation, sprayed in the nose, or throughthe mouth, or nebulized for inhalation, deep breathing through the mouth1-4 times or more as needed to block intracellular penetration of thevirus. Of note is that previously high oral doses of 600 mgHydroxychloroquine/chloroquine and amodiaquine had been given orally andnot by inhalation at 1/100 of the oral dose. The oral dailyadministration can have serious systemic complications.

In one embodiment, antivirals alone or combined with proteaseinhibitors, such as Ganovo, or with convalescent plasma, antibodyagainst COVID-19, Baricitinib, etc. can be administered when dissolvedin semifluorinated alkanes or other liquids which does not causeirritation, sprayed in the nose or through the mouth or nebulized forinhalation, with C-Puff for deep breathing through the mouth 1-4 timesdaily or as slow release polymeric nanoparticles once for prophylacticviral upper respiratory tract prior to the start of the infection or insituations that one suspects that he or she might come or have come incontact with a person carrying viral diseases wherein the antiviral canbe chosen depending on the expectation of specific viruses and thetreatment can continue for a period of time until the danger passes,e.g., in traveling by plane to certain areas with reported cases.

In one embodiment, a person prophylactically self-administers a dailyapplication of combination therapy with oseltamivir (Tamiflu) andBaricitinib, and a GSK inhibitor, intra-nasally followed with deepbreathing 3-4 times daily in a semifluorinated alkane for 3 days untilhe returns from a trip. The person is then examined for signs ofCOVID-19 disease. The person feels that the medication is well toleratedand no side effects are produced, his repeat examination shows he isnormal with no fever, cough, or running nose, etc.

In one embodiment, a method of drug delivery described for treatment ofrespiratory tract inflammatory diseases caused by various viruses,bacteria, etc. or chronic smoking or exposure to toxic aerosolizednanoparticles and air pollution or asthma and allergens and pathogens,where the inflammation or its consequences are treated with aninflammatory cell pathway inhibitor to block the inflammatory responseof the tissue while it does not inhibit an immune response, such as aRock inhibitor, Wnt inhibitor, GSK inhibitor, or integrin inhibitorsIL-1 and IL-6 inhibitors dissolved in liquid semifluorinated alkanes orother liquids as the drug, or in polymeric slow release nanoparticlesapplied locally as a spray or evaporative solution or in evaporativeaerosolized drops that travels through the nasal cavity or mouth toreach the lung alveoli and while on the way attaching to the mucosa,epithelial or endothelial cells of the mouth, nose throat, pharynx,larynx, epiglottis, trachea, bronchi and lung alveoli where thesemifluorinated alkanes which is non-toxic or causes irritation to thetissue, rapidly evaporates leaving the medication(s) or slow releasenanoparticles, such as polymeric lactic, glycolic acid, or incombination, or porous silicon or polycaprolactone, etc. on the surfaceof these tissues, releasing the medications over a time of dailyinhalation, daily for one week to 3 weeks, then the release of themedication from the nanoparticles continues for months or years toinhibit chronic inflammatory lung diseases.

In one embodiment, the disease process affects many other organs andcreates an inflammatory response that can damage these organs, such asin bacterial or viral infections or immune or autoimmune response,chronic inflammation of the prostate, gastro-intestinal tract, joints,one applies a similar strategy for treatment combining anti-bacterialand antiviral with Rock inhibitors, Wnt inhibitors, GSK inhibitors, andintegrin inhibitors, IL-6 inhibitors, Baricitinib interleukinantagonists (anakinra), in a known non-toxic dose administered locally,systematically, or orally either with semifluorinated alkane or thestandard way in a physiological solution, or in the form of polymericfunctionalized nanoparticles for slow release of the medication.

In one embodiment, the patient having a cytokine storm as a result of aviral infection and body's cellular immune/humoral response receivingthe inventive therapy, undergoes plasmapheresis to remove, e.g., suchcytokines, enzymes, dead cells, etc. from the circulation.Plasmapheresis is a known method to remove unwanted toxic componentsfrom blood plasma. Because the patient's plasma is treatedextracorporeal, then reinfused, in contrast to reinfusing only cellularcomponents of the patient's blood, plasmapheresis also beneficiallydetoxifies the patient's plasma without compromising blood volume andwith minimal or no fluid loss. This technique avoids the seriouscomplications and side effects of simply returning the cellularcomponents of the blood to the patient. Additionally, all precautionsare observed to avoid hypotension and loss of calcium ions in theprocess of citrate anticoagulation that this procedure requires. Thepatient can be treated initially with presently available anticoagulantssuch as heparin, or low molecular weight heparin, polyphenols, such ascatechins, coumadin, etc., which can be immediately neutralizedpost-procedure. Neutralization uses standard techniques known in theart, such as calcium, etc. Hemofiltration treatment is performed withactivated carbon, treatment on non-ionic exchange resins, etc. forremoving free toxins and also toxin bound with plasma proteins, etc. asin renal dialysis methods. The process may be instituted or repeated asneeded. The addition of Rock inhibitors or Wnt inhibitors, GSKinhibitors, integrin inhibitors, IL-1 inhibitors, or IL-6 inhibitorsalong with other therapeutic agents, such as disulfiram, anakinra, ormacrolide immune suppressants such as cyclosporine, Tacrolimus,mycophenolic acid, Ascomycin, Immunomycin, FR-900520, FK520, is an ethylanalogue of tacrolimus (FK506) which can be administered in aphysiological solution or semifluorinated alkane or a physiologicalliquid or a suitable medium, systemically or for inhalation dissolved insemifluorinated alkanes or a suitable medium can reduce the overtinflammatory response seen in immune therapy or an autoimmune disease.In some cases with kidney involvement or its protection, kidneydialysis, hemodialysis and or serum electrophoresis is done to removeunwanted toxins and creatinine, etc.

The viral and microbial pathogens can gain access to the brain passingthrough the damaged endothelial cells of the brain or spinal cordvessels through the circulation or alternatively through the olfactoryor trigeminal nerves directly bypassing all barriers of the brain. Inone embodiment, a similar route through the nasal mucosa can be utilizedto deliver medications such as antivirals or antibiotics such asrifampin and Rock inhibitors to fight the pathogens or providemedications needed to enhance brain nerve survival such as inAlzheimer's disease or Parkinson's disease, etc.

In one embodiment, the viruses are transmitted to brain via circulationusing transcellular penetration of the brain capillaries with infectedleukocytes.

In one embodiment, the virus gains access to the tissue by using theACE2 cell receptors of the nasal epithelial cells with the assistance ofTMPRSS2 and Purine protein that are found in the mucosa lining of thenose where they reside and multiply before moving toward the respiratoryairways and the lung or use the existing channels that lead to the brainthrough the olfactory nerve or trigeminal nerves. In one embodiment, onecan block these enzymes using Rock inhibitors or other proteaseinhibitors at microgram to milligram concentrations of Rock inhibitors,Wnt inhibitors, GSK inhibitors, or integrin inhibitors, or lowconcentrations of hydroxychloroquine and amodiaquine at 1-6 milligramsin solubilized or aerosolized formulation for inhalation, etc. or blocksthe viruses by at least two antivirals such as Tamiflu, Baricitinib,Glidesivir, Tonofovir Disproxil fumarate, lamivudine, efavirenz,Delutegravir and maraviroc, or Velpatasvir, JFD00244, etc. a SIRT2inhibitor affecting nsp16 protein, or in combinations, Favipiravir,nitazoxanide, Xofluza, Remdesivir, nanoviricides, Oya1, umifenovir,tamivir ribavirin dissolved in liquid semifluorinated alkanes or otherphysiological liquids in combination or sequentially.

In one embodiment, one or at least two antivirals are used with Rockinhibitors, Wnt inhibitors, GSK inhibitors, or integrin inhibitors aspolymeric slow release nanoparticles applied as drops or spray or anevaporative solution or dissolved in liquid semifluorinated alkanes orother physiological liquids, in an evaporative aerosolized nano- tomicro-drops that travels through the nasal mucosa to reach the branchesof trigeminal nerve or olfactory nerve to the brain, brain vasculature,and cerebrospinal fluid where the semifluorinated alkanes rapidlyevaporate at body temperature in the tissue leaving the medication(s) orslow release nanoparticles of polylactic, polyglycolic acid,polycaprolactone, porous silicon, micelles or liposomes combinationthereof, or the medications move in the respiratory tract, through thenose, throat, and bronchi to the lung alveoli, and release slowly themedications from the nanoparticles over a time period of one day or oneweek to 3 weeks or months depending on the composition of thenanoparticles.

In one embodiment, the slow release polymeric pluralities ofnanoparticles are conjugated with a viral specific antibody whilecarrying at least one or two antivirals to specifically target theviruses.

In one embodiment, the viral antibody can be obtained from plasma/serumof the patients who have recovered from the infection or the antibodycan be produced in the tissue culture against the dead viruses which iscultured with T-cell lymphocytes or natural killers that produce theantibody in addition to producing exosomes or extracellular vesicles(ECV) that can both be harvested to be conjugated with the slow releasepolymeric nanoparticles or alone to be used for intranasaladministration to travel to the brain and lung and kill viruses and theECV contribute to recovery of the brain and its vasculature by theiranti-inflammatory effect.

In one embodiment, the viral antibody coated polymeric nanoparticles areconjugated with antivirals and pluralities of antibodies coatednanoparticles combined with cellular pathway inhibitors or IL-1 and/orIL-6 inhibitors, such as kevzara or nitric oxide (NO) donor (NONOate),interleukin antagonists or rituximab, tocilizumab, etc. administeredintra-nasally by inhalation and the same delivery system ofsemifluorinated alkane or a physiological saline solution with slowrelease polymeric nanoparticles to seek the viruses, release themedication and block their entry to the endothelial cells, brain, etc.or kill the viruses while releasing the medications and protecting thenose, lung, or brain tissue from further invasion of viruses andreducing the inflammation of the brain and the nerves involved thatcause neuralgia and pain.

In one embodiment, pluralities of viral or a fragment of the viral Sprotein antibody(s) coated polymeric nanoparticles are conjugated withCPP, or ACPP and one or two antivirals with semifluorinated alkanes or asolution is administered intra-nasally, intravenously intramuscularly,topically to enhance cell penetration of the nanoparticle inside thecells to damage the viruses outside the cells and those which havepenetrated the cells

In one embodiment, pluralities of ACE-2 or neuropilin receptorsantibody(s) coated polymeric nanoparticles or LNP are conjugated withCPP, or ACPP, or heparin or catechins or linoleic acid and one or twoantivirals to block the viruses to enter the cells via ACE-receptors orneuropilin receptors inside the cells by nasal or topical, or systemicadministration.

In one embodiment, after inhalation of antivirals, and cellular pathwayinhibitors or IL-1 and/or IL 6 inhibitors, such as kevzara of rituximab,tocilizumab, etc. are absorbed through the lung capillaries in the bloodand travel to the heart and brain via circulation first, before they arediluted as is the case with intravenous administration, since in brainvasculitis, the blood brain barrier (BBB) is broken, the medication andnanoparticles or LNP gain access rapidly to the inflamed areas of thebrain where the medication is released over a long time protecting thebrain substance and preventing fibrin induced beta amyloid oligomersproduction and microglial proliferation that encourages a chronicinflammation leading to Alzheimer disease, dementia or neuralgia, etc.

In one embodiment, the intranasal administration and inhalation reducesthe side effects or systemic administration of medications, such ascellular pathway inhibitors or IL-1 and/or IL 6 inhibitors such askevzara of rituximab, tocilizumab, or antivirals, etc. because themedication reaches directly to the source of inflammation and it isapplied at a significantly lower dose than the systemic administrationof these medications.

In one embodiment, the medications can be simultaneously administered ina physiological solution or semifluorinated alkane or a physiologicalliquid or a suitable medium orally, intravenously and nasally as spray,ointment with or without methylene blue with or without tetracycline ordoxycycline with heparin as a prophylactic with LMWH to prevent entry ofthe virus inside the cell by blocking the Furin endoprotease ormetalloproteinase inhibitors or heparim mimetics with metalloproteinaseinhibitors, such as doxycycline, etc., as needed for therapy and/or asprophylaxis of the viral infection when traveling, or flying byairplane, etc.

In one embodiment, Hypochlorous acid (HOCL) is produced by myeloid cellssuch as neutrophils, immune cells, eosinophils, mononuclear phagocytes,and B lymphocytes. The non-myeloid cells such as fibrocytes, etc. canalso generate Hypochlorous acid (HOC1) in the presence of a solution ofsodium chloride (NaCl) in the tissue.

In one embodiment, the stabilized Hypochlorous acid is in generalprepared in a physiological saline solution of 0.9%-1.5%, preferably 1%,with Hypochlorous acid at 0.01%, 0.03%, and 0.1% w/v at pH of 3.0-5.0and the concentration of 0.1 to 2.8 μg/ml. In the cell, the primaryenzyme responsible for production of the Hypochlorous acid in presenceof NaCl is myeloperoxidase found in phagosomes. In one embodiment,hypochlorous acid is conjugated with taurine that is an antioxidantreducing to toxicity of Hypochlorous acid when it is used in combinationof other medications to treat respiratory disease or medication isintended to reach brain through the nasal administration.

In one embodiment, stabilized Hypochlorous acid or chloramines, thestable N-chloro derivatives or N-chlorotaurine (NTC), dimethylatedderivatives of NCT (N-chloro-2,2-dimethyltaurine [DM-NCT] andN,N-dichloro-2,2-dimethyltaurine [DM-NDCT] and slow release polymericnanoparticles carrying at least two antivirals and Rock inhibitors orGSK inhibitors or Wnt inhibitors and IL-6 inhibitors, interleukinantagonists, etc. are administered in a physiological solution of orBenzalkonium chloride or semifluorinated alkane or a physiologicalliquid or a suitable solution in the nose as inhalation in spray ornebulized form in viral encephalitis or lung inflammation in SARS-CoV-2,COVID-19, or their mutations to kill the viruses and prevent the sideeffects of inflammation in the brain and lung.

In one embodiment, stabilized Hypochlorous acid or chloramines, thestable N-chloro derivatives and slow release polymeric nanoparticlescarrying at least two antivirals and Rock inhibitors or GSK inhibitorsand IL-6 inhibitors, etc. are administered in a physiological solutionor semifluorinated alkane or a physiological liquid along with heparinor low molecular weight heparin, or heparin mimetics or syntheticheparin, such as PG500 and PG545, or polyphenols such as catechins orEbselen and/or glutathione peroxidase, and superoxide dismutase(SOD)—metabolize oxidative toxic intermediates requiring zinc, selenium,manganese iron, copper, and for ideal catalytic activity applied in thenose as inhalation, in spray or nebulized form to treat viralencephalitis or lung inflammation in SARS-CoV-2, COVID-19, or theirmutations to kill the viruses, etc., such as coronaviruses and preventthe side effects of inflammation or as prophylaxis of viral infection inthe respiratory tract, encephalitis, vasculitis, dementia, andneuralgia, etc.

In one embodiment, one can administer prophylactically, one or twoantivirals as nasal spray, aerosolized or nebulized form, or oral zinclozenges, or zinc orally at about 15 mg/day, vitamin D<than 4000 IU/day,atrovastatin or other statins oral 10-50 mg/day more and/or gargle withsalt and lukewarm water at a salt concentration of >0.9% to 1.5% or moreNa Cl or spray it as aerosolized or nebulized for nasal inhalation, etc.to damage the invading viruses before entering the nasal mucosa, etc.

In one embodiment, increasing the salt concentration enhances the actionof the myeloperoxidase to create Hypochlorous acid or chloramines, thestable N-chloro derivatives to fight viruses.

In one embodiment, one can administer prophylactically, antiviral nasalspray, aerosolized or nebulized form of zinc or oral zinc lozenges, orzinc at about 15 mg, vitamin D<than 4000 IU/day and/or with salt andlukewarm water or as spray it as aerosolized or nebulized for nasalinhalation, or hydrogen peroxide at <3% concentration mouthwash orgargle in a short time.

In one embodiment, the mouthwash Listerine in low concentrations ordiluted form can be applied to the nose, mouth, or throat mucosa toeliminate viruses.

In one embodiment, povidone iodine toxicity to the eye was tested afterinjection in the eye 0.1 mL of 50, 100, 200, or 400 micrograms (microg)of PVP-I in 1 eye without toxic effect; higher concentrations of 100milligrams to 1000 milligrams or more has been used routinely tosterilize the skin prior to surgery.

In one embodiment, povidone iodine at 400 micrograms to 10 milligrams ormore can be used as inhalation/day, inhalation through both nostrils for1-14 days or using Q-tipped applicator with a mixture of 1-20% ethanoland 0.1-1% or more povidone iodide or other iodine preparations, such ascadexomer, Inadine, tincture of iodine iodophor, lugol iodine, etc. canbe administered with or without Ebselen and/or glutathione peroxidase,and superoxide dismutase (SOD)—metabolize oxidative toxic intermediatesrequiring zinc, selenium, manganese iron, copper, and for idealcatalytic activity applied in the nose in a physiological solution orsemifluorinated alkane or a physiological liquid or another medium toeliminate viruses and bacteria in the nose respiratory tract.

In one embodiment, Povidone iodine 0.1% is combined with zinc <15 mg ina solution or ointment, etc. applied to the skin of the upper lip, nasalskin, and nose mucosa entrance to damage the invading viruses/bacteriabefore entering the nasal mucosal cells, etc. reducing the chance of theinfection during traveling by plane, etc.

In one embodiment, squalene nanoparticles combined with riboflavinapplied to the nose and exposed to a low level of UV radiation of 3mW/cm2 for one minute damage the viral particles in the nose withoutcrosslinking the nasal proteins.

In one embodiment, the hypochlorous acid (HOCL) is stabilized at PH 5and less can be applied as drops or spray or nebulized form locally orby inhalation to the nose and its surrounding tissue to eliminateviruses.

In one embodiment, the stabilized hypochlorous solution is acid at a pH3 to pH 9 and the concentration of 0.01% to about 0.05% or in asemifluorinated alkane or liquid as a slow release nanoparticles oflactic acid, polyglycolic acid, polycaprolactone, or as micelles or inliposomes for nasal or inhalation as spray or aerosolized form.

In one embodiment, the purpose of the invention is to block the viruses,such as SARS-CoV-2, COVID-19, or their mutations, influenza, herpes,zoster, Zika, Epstein-bar, HIV etc. at different levels of entry in thecell or block the mechanisms involved in its replication and release ofthe virus including the virucidal activity by preventing attachment orof the viruses' glycoprotein with the glycosylated host protein on thecell membrane surface or inside the cell preventing its capsid formationby inhibiting viral reverse transcriptase, preventing the DNA or RNAtransport to the nucleus, or the viral integrase and viral integrationin the chromosome, or preventing viral protease to breakdown the cellprotein to build viral capsid, or by inducing an innate immune response,such as stimulation of complement C1, C3, C5, toll-like receptors and NKcells and cytotoxic T cells. Other approaches are the use of venompeptides affecting the viral replication cycle, inhibiting viralattachment glycoprotein to the cells, such as ChTx and Scyllatoxin-basedmimetics or cecropin A, Magainin or by preventing attachment of virusglycoprotein to CXCR4 and CCR5 co-receptors or disintegration of viralcapsid or interfering with the reverse transcription using melittinpeptides or preventing the viral assembly of the viral capsid usingpeptide hecate and interfering in the assembly of the viral capsid andin the organization of the polymerase complex or using peptides derivedfrom Wasp venom to affect Zika virus, chikungunya, dengue, and HIVvirus.

In one embodiment, the stabilized hypochlorous or chloramines, thestable N-chloro derivatives or chloramines, the stable N-chloroderivatives or N-chlorotaurine (NTC), dimethylated derivatives of NCT(N-chloro-2,2-dimethyltaurine [DM-NCT] andN,N-dichloro-2,2-dimethyltaurine [DM-NDCT] solution is acid at a pH 3 topH 9 and the concentration of 0.01% to about 0.05% or with mimeticheparin with or without Benzalkonium chloride in or with catechincombined with LMWH in a semifluorinated alkane or a suitable medium toblock viral receptors, heparan sulfate and Sialic acid, present in themucosa cells, endothelial cells or neuronal cells, or olfactory bulb andthe thiol bound of the viruses, etc., as a slow release nanoparticles oflactic acid, polyglycolic acid, polycaprolactone, or as micelles or inliposomes and chitosan and encapsulated in a non-dissolvable compoundgiven orally to pass through the stomach and is released by enzymaticaction in the intestinal tract to release the medication and getabsorbed in the intestine to kill the viruses such as SARS-CoV-2,COVID-19, or their mutations locally preventing the intestinal sideeffect of viral infection.

In one embodiment, certain compounds can be used prophylactically asmouthwash or hand cleansing, nasal spray, such as hydrogen peroxide,povidone-iodine, ethanol, chlorhexidine, cetylpyridinium chloride, todisrupt the SARS-CoV-2 lipid envelope, COVID-19 lipid envelope, or theirmutations, etc.

In one embodiment, for prophylaxis such as traveling by airplane, onecan combine two or more antivirals with zinc, or povidone iodine, etc.or in a semifluorinated alkane or in a physiologic fluid in the form ofslow release polymeric pluralities of nanoparticles, micelles liposomes,polyglycolic acid, or lactic acid, etc. administered through the nose ororally to last one week or more and release medication afteradministration in the form of spraying or nebulization by an intranasalroute and inhalation to prevent viral attachment to the surface of thenose, throat, mucosa or lung alveoli or kill the incoming viruses orprevent their multiplication before reaching the brain and prevent theirmigration to the brain via the olfactory nerve.

In one embodiment, certain compounds can be used prophylactically asmouthwash or hand cleansing, such as hydrogen peroxide, povidone-iodine,ethanol, chlorhexidine, cetylpyridinium chloride, Hypochlorous acid, orchloramines, the stable N-chloro derivatives, or chloramines, the stableN-chloro derivatives or N-chlorotaurine (NTC), dimethylated derivativesof NCT (N-chloro-2,2-dimethyltaurine [DM-NCT] andN,N-dichloro-2,2-dimethyltaurine [DM-NDCT] alone or in combination todisrupt the SARS-CoV-2, COVID-19, or their mutations lipid envelope.

In one embodiment, the damage to the capillary endothelial cells causesaccumulation of platelets and other blood cells causing vascularocclusion, pain, stroke, paralysis, etc.; therefore, in one embodiment,any treatment to combat viral or bacterial central nervous system (CNS)vasculitis or vasculitis in an autoimmune response, such as lupus or inimmunotherapy of cancer, etc. should be treated also with oral orsystemic anticoagulants, such as aspirin in low molecular weightheparin, and/or in severe conditions, anticoagulants, such as Coumadin,or heparin, low molecular weight heparin (Lovenox), without or withcatechin in a semifluorinated alkane or a suitable medium as slowrelease nanoparticles of lactic acid, polyglycolic acid,polycaprolactone, or as micelles or in liposomes and chitosan with orwithout Benzalkonium chloride or to block viral receptors, heparansulfate and Sialic acid, in the mucosa, endothelial cells or neuronalcells, or olfactory bulb, etc., as slow release nanoparticles of lacticacid (LA), polyglycolic acid (PGLA), polycaprolactone, or as micelles,or in liposomes and chitosan to prevent cellular damage by virus and toenhance nerve repair and prevent blood coagulation or TPA to dissolvethe blood clot, etc. followed by plasmapheresis, and/or kidney dialysisto remove excessive cytokines.

In one embodiment, the cytokines can be measured by using either thesaliva, expectorations, tear, urine, or nasal secretion, cerebrospinalfluid or aqueous fluid of the eye, or blood circulation, etc., theconcentrations of cytokines, such as IL-1 and/or IL-6, IL-8 are higherin the inflammatory diseases, etc., and the increase or decrease oftheir concentrations are indicative of the progression of viralinfection or its prognosis.

In the brain and spinal cord, microglial cells act as immune cells, suchas macrophages and respond to any pathogen encountered.

In one embodiment, several viruses can affect the upper respiratorysystem and brain simultaneously, such as influenza viruses orSARS-CoV-2, COVID-19 viruses, or their mutations, and herpes simplex,mumps, or measles, EBV etc.

In one embodiment, the patient with early cases of viral CNS vasculitiscan be treated with one or two or more anti-virals or IL-6 inhibitors,interleukin antagonists via inhalation using aerosolized or nebulizedmedication, in semifluorinated alkane, as polymeric slow releasenanoparticles to cover the nasal passages to the brain from theolfactory epithelium to olfactory bulb, and subsequently to theposterior gyms rectus and the cerebrospinal fluid and simultaneouslylower respiratory tract infection is treated as described here, whilethe presence of the virus and cytokines, such as IL-6, before and aftertherapy can be verified through the nasal secretion or cerebrospinalfluid (CSF), blood, etc. as prognostic indication of the diseaseprocess.

In one embodiment, the persistence of headache is a sign of brainvasculitis and increase in the intracranial pressure associated damageto pericytes of small brain capillaries leading to leakage of the bloodenriched fibrinogen and accumulation and activation of microglial cellsleading to loss of myelin and white matter and buildup of tau andamyloid oligomers, fibrils, and plaque and Alzheimer's disease orParkinson's disease, dementia; in one embodiment, the nasal applicationor inhalation of one or more antivirals and anti-inflammatory agents,such as Rock inhibitors, Wnt inhibitors, GSK inhibitors, and integrininhibitors with or without complement pathway inhibitors, such as C3inhibitors—AMY-101 (NCT04395456) and APL-9 (NCT04402060); C5inhibitors—eculizumab (NCT04346797 and NCT04355494), C1 esteraseinhibitors, which block the classical complement pathway with anti-IL6medication, such as Kevzara, tocilizumab, rituximab, etc., or antiviral,baloxavir marboxil, and antibiotics such as tetracycline derivatives ametalloproteinase inhibitor and/or low molecular weight heparin(Levonox) with or without catechin and LMWH in a semifluorinated alkaneor a suitable medium to block viral receptors, heparan sulfate, andSialic acid, as a slow release nanoparticles of lactic acid,polyglycolic acid, polycaprolactone, or as micelles, or in liposomes andchitosan or tissue plasminogen activator (tpa) in the form of nasalspray or aerosolized medication or nebulized medication to reduce theinflammatory process and low molecular weight heparin assists inclearing the fibrinogen and oligodendrocyte loss preventing future sideeffects of viral encephalitis, such as dementia, Alzheimer's disease,neuralgia, etc.

In one embodiment, viral infection of the lung and brain vasculitis,produce anoxia and ischemia through HIF-1 factor that inducesangiogenesis. TiPARP is activated in the cell nucleus that eliminatesthe HIF-1alpha and TiPARP. Tamoxifen works similarly for the breasttumor and degrades HIF-1 and prevent ischemia and anoxia. In oneembodiment, Tamoxifen is combined with an antiviral in a viral infectionof the lung and viral brain encephalitis and brain vasculitis and cellpathway inhibitors, Wnt inhibitor, GSK inhibitors, and integrininhibitors administered in a physiological solution or semifluorinatedalkane or a physiological liquid or a suitable medium combined orsequentially through the nose inhalation by spraying, aerosolization, ornebulization to reach both brain and the lung tissue, reduce theinflammatory process and eliminate the side effects of the infection.

In one embodiment, in respiratory viral infection of the upper or lowerrespiratory system or brain is associated with significant fibrinformation, the treatment is given as nasal application or inhalation ofone or more antivirals and anti-inflammatory agents, such as Rockinhibitors, Wnt inhibitors, GSK inhibitors, and integrin inhibitors withanti-IL6 medication, such as Kevzara, or nitric oxide (NO) donor(NONOate), tocilizumab, etc., or tPA tissue plasminogen activator innanogram to microgram concentrations in the form of nasal spray oraerosolized medication or nebulized medication to reduce theinflammatory process and tPA assists in clearing the fibrinogen/fibrinpreventing future side effects of viral encephalitis, or enhancing theclearing the lung from the fibrinous exudates initiated by the viralinflammatory disease. In one embodiment, Mucinex given orally will worksynergistically to cleanse the lung alveoli, or a mucomyst is deliveredby inhalation which contains acetylcysteine, n-acethylsystein, or itsderivatives, which have an anti-inflammatory and antithrombotic effectwhen combined with antivirals and call pathway inhibitors fortherapeutic vaccines, etc.

In one embodiment, the TPA can be administered in a physiologicalsolution or semifluorinated alkane or a physiological liquid or asuitable medium intravenously either to dissolve the blood clot in thevessels or prevent coronary stent clot formation.

In one embodiment, the brain vasculitis and viral infection producesheadache as a sign of cranial vasculitis and increased intracranialpressure, in addition to other symptoms of fever, shiver, and neckstiffness, or nerve palsy, etc., release of viral cytokines and cellularand humoral immune response enhance the inflammatory process in thebrain. In one embodiment, one treats the viral brain and upperrespiratory infection by simultaneous administration of antiviralagents, with one or more anti-inflammatory cell pathway inhibitors toblock the excessive inflammatory response of the brain tissue and itsvasculature while maintaining a normal immune response, with one or moreRock inhibitors antitumor SB 772077B, potent Rho-kinase inhibitor;vasodilator SR 3677 dihydrochloride, potent, selective Rho-kinase (ROCK)inhibitor TC-S7001, potent and highly selective ROCK inhibitor Y-27632dihydrochloride, Botox or botulinum toxin, ROCK2 inhibitor, KD025,Netarsudil, Fasudil, and its derivatives, and/or Wnt inhibitors, GSKinhibitors, integrin inhibitors, or IL-1 and/or IL-6, IL-8 inhibitorsdissolved in liquid semifluorinated alkanes or other liquids as thedrug, or in a polymeric slow release nanoparticles administered locallyas a spray or evaporative solution or in evaporative aerosolized dropsor nebulization that travels through the nasal cavity where thesemifluorinated alkanes which is non-toxic or causes irritation to thetissue, rapidly evaporates leaving the medication(s) or slow releasenanoparticles, such as polymeric lactic, glycolic acid, or incombination, or porous silicon or polycaprolactone, liposomes, micelles,etc. on the surface of these tissues, or travel to the brain through theolfactory or trigeminal nerves releasing the medications over time tothe brain, or simultaneously to the mouth to reach the lung alveoli, andwhile on the way attaching to the mucosa, epithelial or endothelialcells of the trachea, bronchi and lung alveoli and its vasculature andsimultaneous absorption of the medication through the nasal capillaries,and lung capillaries provide the delivery of the medication through thecirculation to the heart, and brain to their inflamed vasculature bydaily inhalation, for one week to three weeks, or the release of themedication from the nanoparticles continues for months or years toinhibit chronic inflammatory processes in the brain that is associatedwith silent dementia and Alzheimer's disease, Neuralgia, or Parkinson'sdisease depending on the location of the inflammation.

In one embodiment, the antiviral delivery and pathway inhibitors areconjugated with antibody coated nanoparticles made of pluralities ofdimethyl fumarate (DMF), squalene, lanosterol or squalamine or theirderivatives that per se are antibiotic/anti-inflammatory compounds,tetracycline and doxycycline, a metalloproteinase inhibitor, to reducethe excessive inflammatory immune response, combined withsemifluorinated alkanes or a physiological solution as aerosolized dropsor spray for intranasal administration to the lung, brain, and heart.

In one embodiment, the antiviral delivery and pathway inhibitors areconjugated with antibody coated nanoparticles made of pluralities ofheparin or synthetic heparin mimetics or synthetic heparin, such asPG500 and polyphenols, such as catechins or hyaluronic acid or theirderivatives that per se are anti-inflammatory compounds to reduce theexcessive fibrin release or breakdown the fibrinogen and inflammatoryimmune response, combined with semifluorinated alkanes or aphysiological solution as aerosolized drops or spray for intranasaladministration to prevent blood clotting, closure of vasculature orcoronary stent, etc.

In one embodiment, the nasal approach to the delivery of antivirals,pathway inhibitors or IL-6 inhibitors, etc. using a semifluorinatedalkane compound or in physiologic fluid combined with slow releasepolymeric nanoparticles or antibody-coated nanoparticles can beconsidered as a systemic application of the drug delivery in viraldiseases involving the lung, heart, and brain or their generalizedvascular involvement (vasculitis) of the intestinal tract, brain orincreased coagulopathy, a single disease complex that is best treatedthrough judicious intranasal route or inhalation, since the major organs(e.g., heart, lung, intestine, and brain) are reached very fast and thelung absorption provide the circulation route to reach the rest ofbody's vasculature to be treated immediately and also long term withslow release polymeric nanoparticles.

In one embodiment, the administration of the inflammatory pathwayinhibitors, such as a Rock inhibitor, Wnt inhibitor, GSK inhibitor, suchas synthetic small-molecule ATP-competitive inhibitors, andsubstrate-competitive inhibitors, non-ATP-competitive inhibitors, whereFRAT/GBP competes with Axin inhibiting GSK-3 activity or integrininhibitors or IL-1 and/or IL-6 inhibitors via nasal administration andinhalation using a semifluorinated alkane compound or in physiologicfluid with polymeric slow release nanoparticles, block the severeinflammatory response of the brain tissue caused by the invasion of thepathogens, which stimulate glial cells proliferation and migrationproducing oligomers of amyloid that coalesce building fibrils, tau andamyloid plaques, and the medication over time prevents the consequencesof the brain vasculitis and encephalopathy in viral diseases of thebrain.

In one embodiment, the viral encephalitis, if not treated in time,causes slow simmering or sui generous inflammatory process that may notbecome recognized, in time, to be treated leading to glial response,production of oligomers of beta amyloid and to self-sustainedprogressive Alzheimer's disease years or decades later.

In one embodiment, one or two antivirals, such as Tamiflu, Baricitinib,Glidesivir, Favipiravir, Xofluza Remdesivir, nanoviricides,Lenacapavir/Gilead in picomolar concentrations or GS-CA1, Oya1,interferon, umifenovir, tamivir ribavirin, baloxavir can be used orally,systemically or with or without IL-6 inhibitors, etc. Intranasal andorally as prophylaxis of the viral infection in the winter season orwhen traveling, or flying etc.

In one embodiment, at least one antiviral is combined with one pathwayinhibitor, such as Wnt inhibitor FH535, IWP-2, PNU-74654, IWR-lendo,IWR-exo, Demethoxycurcumin, CCTO36477, KY02111, WAY-316606, SFRP, IWP,LGK974, C59, Ant1.4Br/Ant 1.4Cl, Ivermectin, Niclosamide, apicularen andbafilomycin, XAV939, XAV939, G007-LK and G244-LM, NSC668036, SB-216763,gemtuzumab, etc., small molecule Wnt inhibitor PKF118-310, Niclosamidewith both antiviral and anti-inflammatory effect, Fasudil, Netarsudil,the Wnt/β-catenin pathway inhibitor or Rock inhibitors with an IL-6inhibitor or Kevzara, or nitric oxide (NO) donor (NONOate), or Actemsare used in combination with interferon which is normally produced bynatural killer cells in the body to excite cellular immune response inthe body where interferons or pegylated interferon act as antivirals inthe upper and lower respiratory tract blocking the replication of theRNA and DNA of the viruses at an early stage of viral infection.

The interferons are released in the body as cytokines to exciteprotective immune such as natural killers, macrophages, majorHistocompatibility complex, etc. The interferons act as an antiviralpreventing the virus growth in the cells. Interferon or pegylatedinterferon attaches to the cell receptors of the nasal or throat of theairway system and brain vasculatures, etc. and prevents DNA or RNA ofthe virus from replicating, the medication is administered in aphysiological solution or semifluorinated alkane or a physiologicalliquid or a suitable medium as a spray of aerosolized liquid ornebulized liquid with or without semifluorinated alkanes preferably atan early stage in the disease process and not if a cytokine storm iseminent.

In one embodiment, antivirals and pathway inhibitors, such as Wntinhibitors, such as Ivermectin, Niclosamide, etc. can be given orallyspecially in children or when intestinal involvement is predicted orintranasal inhalation as slow release polymeric nanoparticles or LNP orgold nanoparticles at a significantly lower concentration than systemicadministration for both viral infection of the lung and brainvasculitis, etc.

In one embodiment, interferon enhances cellular response while cellpathway inhibitors such as Rock, Wnt, GSK, or integrin inhibitors suchas such as abegrin, cilengitide, abciximab, tirofiban, natalizumab,eptifibatide, or risuteganib in a low concentration of 1 microgram to 10micrograms as a solution and IL-6 inhibitor or Kevzara, and/or nitricoxide (NO) donor (NONOate) or Actems to inhibitors, retuaximab,tocilizumab, control the inflammatory process preventing a cytokineresponse.

In one embodiment, viruses may affect upper or lower respiratory systemfollowed by a bacterial infection with pathogens such as Streptococcuspneumonia, Haemophilus influenza, Staphylococcus aureus, or E. Coli,etc. However, the bacterial encephalitis, or meningitis is caused morecommonly through the circulation. In these cases, a combination use ofan antibacterial and one or two antivirals and one pathway inhibitorwith or without complement pathway inhibitors, such as C3inhibitors—AMY-101 (NCT04395456) and APL-9 (NCT04402060); C5inhibitors—eculizumab (NCT04346797 and NCT04355494); C1 esteraseinhibitors, which block the classical complement pathway can beadministered in a physiological solution or semifluorinated alkane or aphysiological liquid or a suitable medium by inhalation and systemicadministration of a non-toxic dose of the antibacterial, antibiotics, orrefabutin, etc. medications.

In one embodiment, the TMPRSS2 inhibitor Camostat inhibits entry of thevirus in the cells and one or two antivirals nasal combined with Rockinhibitors or GSK inhibitors, or integrin inhibitors, such as abegrincilengitide, abciximab, tirofiban, natalizumab, eptifibatide, orrisuteganib in a low concentration of 1 microgram to 10 micrograms as asolution with or without semifluorinated alkanes or as polymericnanoparticles can be administered in a physiological solution orsemifluorinated alkane or a physiological liquid, simultaneously orsequentially by inhalation for prophylactic as well and treatment ofviral infection affecting the brain and its vasculature or the lung.

In one embodiment of viral encephalitis, one can combine intranasaladmiration of two antivirals such as lopinavir and ritonavir orBaricitinib, Glidesivir, Favipiravir, Xofluza, Remdesivir, nitazoxanide,nanoviricides, Oya1, interferon, or pegylated interferon, umifenovir,tamivir, lopinavir, etc. with protease inhibitors such as NSAIDS, orcox-2 inhibitors celecoxib, propanoic acid derivatives, etc. that blockthe main protease of the virus (M-Pro) essential for virus replicationor MicroRNAs or atovaquone with its antiviral effect against RNAviruses, or antisense molecule fomivirsen, antiherpes drugs inhibitviral replication with a Rock inhibitor, or Wnt inhibitor, GSKinhibitor, integrin inhibitor or an IL-6 inhibitor such as kevzara,rituximab, Melatonin, etc. in a semifluorinated alkane or a physiologicsolution as polymeric slow release delivery as nasal spray ofaerosolized, or nebulized drops to treat or use it as prophylaxis insusceptible patients or those who are exposed, such as health careworkers etc., or first responders.

In one embodiment, in end stage viral encephalitis or lung infection,one can combine antivirals with Wnt inhibitors, or integrin inhibitorsor Rock inhibitors with IL-6 inhibitors, a macrolide such as tacrolimus,mycophenolic acid, or cyclosporine administered in a physiologicalsolution or semifluorinated alkane or a physiological liquid or asuitable medium intranasal with intravenous administration or orally tosuppress cytokine storm with simultaneous kidney dialysis and blooddialysis or plasma electrophoresis.

In one embodiment, antivirals are administered in combination with MPA,an antiviral and TNF inhibitor, and LMWH, catechins, and a Wntinhibitor, such as niclosamide or ivermectin, or melatonin in polymericslow release nanoparticles with or without semifluorinated alkanes as anasal spray or by inhaler to prevent or treat viral encephalitis orprevent the side effect of the viral infection of the brain or aftertraumatic brain injuries, such as Alzheimer's disease or Parkinson'sdisease, by eliminating the infection and reducing the endoplasmicreticulum stress in the neuronal cells.

In one embodiment, one administer intranasal antivirals along withmedications that block the ACE-2 receptor to which viral particlesattach as the compound hydroxyquinoline at low concentration of micro tomilligrams, Rock inhibitors where rock inhibition reduces the bloodpressure, and while reducing the angiotensin II and increases Ang (1-9)plasma levels and inhibiting the NOX4-Derived ROS-Mediated RhoA/RhoKinase Pathway, or follicle stimulating hormone or finistride to inhibittestosterone production, along with IL-6 inhibitors or tocilizumabdissolved in a semifluorinated alkane or in a physiologic solution aspolymeric slow release antibody coated polymeric nanoparticles asaerosolized delivery system, etc.

In one embodiment, the two viruses such as SARS-CoV-2, COVID-19, ortheir mutations and a herpes virus is involved simultaneously orsequentially one can add two antivirals with ganciclovir or acyclovir orvalacyclovir, Cidofovir, Vidarabine, Penciclovir, Foscarnet FomivirsenFamciclovir or Oseltamivir phosphate, Rimantadine, Amantadine,Zanamivir, Telbivudine, Lamivudine, Entecavir, Emtricitabine, Adefovirand heparin mimics containing glucosamine saccharides/acrylamide to bindto 13-Secretase (BACE-1) involved in Alzheimer's disease (AD)administered with or without polyphenols, such as catechins, with orwithout fluvoxamine, selective serotonin reuptake inhibitors (SSRIs), ortetracycline derivatives, a metalloproteinase inhibitor, or doxycycline,etc., as an antibacterial such as rifampin with Rock inhibitors or otheranti-inflammatory compounds in a physiological solution orsemifluorinated alkane or a physiological liquid or a suitable mediumintranasally as slow release polymeric nanoparticles with or withoutsemifluorinated alkanes with a Rock inhibitor and IL-6 inhibitor, ornitric oxide (NO), donor (NONOate) as antiviral and anti-cytokines suchas or nitric oxide (NO) donor (NONOate), interleukin antagonists or DMFby inhalation, systemic, oral, topical locally to halt spread of thevirus to the brain or its reactivation or to prevent continuation ofinflammation as nasal inhalation, etc. in the brain leading toAlzheimer's disease, dementia, and neuralgia, etc.

In one embodiment, two or more antivirals that can be used with thedescribed therapeutic vaccine as a cocktail, in the semifluorinatedalkane as a cocktail of antivirals and with pathway inhibitors orcomplement inhibitors, such as: Fosfonet Sodium; RimantadineHydrochloride; Saquinavir Mesylate; Somantadine Hydrochloride;Sorivudine; Statolon; Stavudine; Tilorone Hydrochloride; Trifluridine;Valacyclovir Hydrochloride; Vidarabine; Vidarabine Phosphate; VidarabineSodium Phosphate; Viroxime; Zalcitabine; Zidovudine; Zinviroxime, zinc,heparin, anionic polymers. Ganciclovir; Ganciclovir Sodium; Idoxuridine;Kethoxal; Lamivudine; Lobucavir; Memotine Hydrochloride; Methisazone,Adefovir; Alovudine; Alvircept Sudotox; Amantadine Hydrochloride;Aranotin; Arildone; Atevirdine Mesylate; Avridine, Acyclovir; AcyclovirSodium; Desciclovir; Didanosine; Disoxaril; Edoxudine; Enviradene;Acemannan; Nevirapine; Penciclovir; Pirodavir; Ribavirin; RimantadineHydrochloride; Saquinavir Mesylate; Somantadine Hydrochloride;Sorivudine; Statolon; Stavudine; Enviroxime; Famciclovir; FamotineHydrochloride; Fiacitabine; Fialuridine; Fosarilate; Foscarnet Sodium,Cidofovir; Cipamfylline; Cytarabine Hydrochloride; Delavirdine Mesylate,zanamivir, amantadine, and Palivizumab. Other examples of anti-viralagents include, but are not limited to Acemannan; Nevirapine;Penciclovir; Pirodavir; Ribavirin; Rimantadine Hydrochloride; SaquinavirMesylate; Somantadine Hydrochloride; Sorivudine; Statolon; Stavudine,etc.

In one embodiment, with a viral infection, the antiviral can be givenwith an anti-inflammatory compound such as naltrexone, or disulfiram,combined with cox-2 inhibitors or Rock or Wnt or GSK inhibitors oranti-integrin intranasal with a semifluorinated or liquid solution withslow release nanoparticles or polylactic, polyglycolic,polycaprolactone, or porous silicon, micelles, or liposomes, etc. withor without IL-6 inhibitors.

In one embodiment of viral infection, the virus induces a storm cytokineresponse causing generalized vasculitis and thrombus formation, ontreating this condition in addition to the antivirals such as theinhibitor Sofosbuvir, a polymerase inhibitor and ribavirin, umifenovir,tamivir, lopinavir etc., pathway inhibitors, such as Rock inhibitors,with inhibition of cytokine IL-6 with an inhibitor such as Kevzara ornitric oxide (NO), donor (NONOate), or rituximab intranasaladministration with semifluorinated or liquid solution with slow releasenanoparticles or polylactic, polyglycolic, polycaprolactone, or poroussilicon, micelles, or liposomes, etc.

In one embodiment, the medications can be simultaneously administered ina physiological solution or semifluorinated alkane or a physiologicalliquid or medium orally, intravenously, and nasally as needed fortherapy and/or as prophylaxis of the viral infection or when traveling,or flying by airplane, etc.

In one embodiment, one can administer prophylactically, antivirals nasalspray, aerosolized or nebulized form of zinc or oral zinc lozenges, orzinc at about 15 mg, vitamin D<than 4000 IU/day and/or with salt andlukewarm water or spray it as aerosolized or nebulized for nasalinhalation, or hydrogen peroxide at <3% concentration in combinationwith Listerine mouthwash at low concentration or gargle in a short time.

In one embodiment, the mouthwash Listerine in low concentration ordiluted form can be applied to the nose, mouth or throat mucosa withsalt water to eliminate viruses.

In one embodiment, povidone iodine toxicity to the eye was tested afterinjection in the eye 0.1 mL of 50, 100, 200, or 400 micrograms (microg)of PVP-I in one eye without toxic effect; higher concentrations of 100milligram to 1000 milligram or more has been used routinely to sterilizethe skin prior to surgery.

In one embodiment, povidone iodine at 400 micrograms to 10 milligrams ormore can be used as inhalation/day through both nostrils for 1-14 daysor using Q-tipped applicator with a mixture of 1-20% ethanol and 0.1-1%or more povidone iodide or other iodine preparations such as cadexomer,Inadine, tincture of iodine iodophor, lugol, iodine, with or withoutLMWH, etc. can be administered in a physiological solution orsemifluorinated alkane or a physiological liquid or salt water toeliminate viruses and bacteria in the nose or respiratory tract.

In one embodiment, Povidone iodine 0.1% in salt water is combined withzinc <15 mg in a solution or ointment, etc. applied to the skin of theupper lip, nasal skin, and nose mucosa entrance to damage the invadingviruses/bacteria before entering the nasal mucosal cells, etc. reducingthe chance of the infection during traveling by plane, etc.

In one embodiment, nanoparticles of squalene nanoparticles combine withriboflavin in salt water 0.9% NaCl applied to the nose and exposure to alow level of UV radiation of 3 mW/cm2 for one minute damage the viralparticles in the nose without crosslinking the nasal proteins.

In one embodiment, hypochlorous acid (HOCL) is stabilized at PH 5 andleas in salt water >0.9% NaCl can be applied as drops or spray ornebulized form locally or by inhalation to the nose and its surroundingtissue to eliminate viruses.

In one embodiment, certain compounds can be used prophylactically asmouthwash or hand cleansing, nasal spray, such as hydrogen peroxide,povidone-iodine, ethanol, chlorhexidine, cetylpyridinium chloride todisrupt the COVID-19 lipid envelope.

In one embodiment, for prophylaxis such as traveling by airplane orvisiting a patient, or in the office, one can combine two or moreantivirals with zinc, or povidone iodine, or another antiseptics, etc.or in semifluorinated alkane or in a physiologic fluid in form of slowrelease polymeric pluralities of nanoparticles, micelles, liposomes,polyglycolic acid, or lactic acid, etc. administered in form of sprayingor nebulization by intranasal route and inhalation to last one week ormore and release medication to prevent viral attachment to the surfaceof the nose, throat, mucosa, or lung alveoli, etc. or kill the incomingviruses or preventing their multiplication before reaching the brain andprevent their migration to the brain via olfactory nerve.

In one embodiment, the stabilized hypochlorous acid or chloramines, thestable N-chloro derivatives or chloramines, the stable N-chloroderivatives or N-chlorotaurine (NTC), dimethylated derivatives of NCT(N-chloro-2,2-dimethyltaurine [DM-NCT] andN,N-dichloro-2,2-dimethyltaurine [DM-NDCT] solution has a pH 3 to pH 9and a concentration of 0.02% to about 0.05% or in a semifluorinatedalkane or liquid such as 1% or more NaCl solution as a slow releasenanoparticles of lactic acid, polyglycolic acid, polycaprolactone or asmicelles or in liposomes for nasal administration or inhalation as aspray or aerosolized form with or without antivirals.

In one embodiment, the stabilized hypochlorous acid or chloramines, thestable N-chloro derivatives or chloramines, the stable N-chloroderivatives or N-chlorotaurine (NTC), dimethylated derivatives of NCT(N-chloro-2,2-dimethyltaurine [DM-NCT] andN,N-dichloro-2,2-dimethyltaurine [DM-NDCT] at a concentration of 0.025%in 1% sodium chloride with electrolyzed water is obtained fromEcoloxTech, Envirolite®, etc. without phosphates, or Phosphate BufferedSaline (PBS) and sodium Hypochloride, phosphate with or without a Rockinhibitor, at 1-20 microgram/ml or more, Wnt inhibitor atpico-nanogram/ml concentrations or more, GSK 50 microgram/ml inhibitoror statins at <100 microgram/ml concentration or integrin inhibitors at25-200 microgram/ml or more concentration with one or more antivirals orbronchodilators.

In one embodiment, 60 milligrams of iron oxide administered in aphysiological solution or semifluorinated alkane or a physiologicalliquid once every two days enhances the production of hemoglobin.

In one embodiment, the nose can be disinfected with intra-nasalMiramistin solution, an old non-toxic disinfectant that kills thebacteria and viruses without affecting the normal cells.

In one embodiment, one or more convalescent plasma's antibodies are usedto coat or conjugate with slow release polymeric nanoparticles whichseek and attach to the viruses; where the nanoparticles are made fromlactic, polyglycolic acid, polycaprolactone, anhydrides, porous silicon,micelles, liposomes, etc. carrying medications, such as antivirals orpluralities of nanoparticles are used carrying two or more antivirals ina physiological solution or administered in a physiological solution orsemifluorinated alkane or a physiological liquid or a suitable mediumintra-nasally as spray or drops or nebulization for inhalation to treatthe early stage viral infection and reduce both viral infection sideeffects of the infection in the brain or the lung.

In one embodiment, pluralities of one or more antibody-coated slowrelease polymeric nanoparticles, such as polylactic acid, polyglycolicacid, porous silicon, micelles, liposomes, polyanhydrides, polyesters,polycaprolactone with cell penetrating peptides carry antivirals, suchas nelfinavir, or Remdesivir, etc. along with bronchodilators such as,emetine, hydroxychloroquine and amodiaquine or its derivatives,salbutamol, obatoclax, albuterol, with or without Rock inhibitors, Wntinhibitors, GSK inhibitors or integrin inhibitors, intra-nasally orthrough the mouth as inhalation, to enhance relaxation of the bronchithat bring air in the lung alveoli by relaxing the smooth muscles of thevessels of the lung and brain.

In one embodiment, a combination of antivirals and salbutamol, and IL-6inhibitors, Rock inhibitors, Wnt inhibitors, GSK inhibitors, or integrininhibitors, or nitric oxide (NO), donor (NONOate) with or without DMF toinhibit inflammatory processes of the brain or lung vessels leading toleakage of fibrinogen stimulating production of oligomeric beta-amyloidin the brain or fibrin in the lung and can slow down or inhibitformation of Alzheimer's plaques, tau and tangled fibrils or dementia,etc. or reduce oxygen absorption by the lung capillaries and hemoglobin.

In one embodiment, the combination of antivirals with or withouttetracycline derivatives, a metalloproteinase inhibitor whichantibacterial and an anti-inflammatory and/or nitric oxide (NO), donor(NONOate), with antibody-coated polymeric slow release nanoparticles,such as polylactic acid, polyglycolic acid, porous silicon, micelles,liposomes, polyanhydrides, polyesters, polycaprolactone and antiviralswith pathway inhibitors to reduce the inflammation and with cellpenetrating peptides or activatable cell penetrating peptides (ACPPs) orcyclodextrin or low-molecular-weight (2-5 kDa) polyethylene glycol, orlow molecular weight heparin, synthetic heparin mimetics heparin mimicscontaining glucosamine saccharides/acrylamide to bind to 13-Secretase(BACE-1) involved in Alzheimer's disease (AD), or synthetic heparin,such as PG500, etc. or Epigallocatechin gallate (EGCG), a green teacatechin, that binds to heparan sulfate or in combination with lowmolecular weight heparin or heparin mimetics to bind to heparan sulfateand sialic acid preventing the viral attachment to viral cell receptors,such as Neuroplin-1 and ACE-2 receptors of the mucosa, endothelial cellsor neuronal cells, or olfactory bulb, etc. as slow release nanoparticlesof lactic acid, polyglycolic acid, polycaprolactone, or as micelles orin liposomes and chitosan administered in semifluorinated alkane or asuitable medium through inhalation or vapor, nasal spray or nebulizationto reach the brain directly and lung endothelial cells and cells ofalveoli directly to inhibit the intracellular viral replication, in thebrain, and lung and kill them with minimal amount of antiviralmedication compared to the systemic administration of the antiviral thatrequires production of a large amount of medication with its associatedexpenses and complications.

In one embodiment of a method of treating, reducing, or alleviating amedical condition in a patient, the method comprising administering to apatient in need thereof a biocompatible drug comprising one or moreantiviral medications together with one or more green tee, oolong,cinnamon, or orange with or without linoleic acid in the warm to boilingwater or a nebulizer creating vapor containing the active ingredient ofthe cocktail for simultaneous inhalation of the vapor's components toinhibit attachment of viruses to ACE-2 receptors or neuropilins'sreceptors in the nasal pathway to the lung to through the olfactorynerve and trigeminal nerve to brain thereby preventing the viralattachment to enter the nasal or respiratory pathway to the alveolicells and olfactory nerve or sensory trigeminal nerves, to gain accessto the brain cell producing viral encephalitis, or lung infection, wherethe cocktail can be consumed orally after it is cooled down to beabsorbed through the gut preventing damage to the intestine, liver,kidney and the brain through the blood circulation.

In one embodiment of a method of treating, reducing, or alleviating amedical condition in a patient, the method comprises administering to apatient in need thereof a biocompatible drug cocktail comprising one ormore antiviral medications together with or without one or more greentee, oolong, Cinnamon, or orange with or without linoleic acidpolyphenyls, epigallocatechin gallate catechins (EGCG) havingantioxidants compounds cocktail also and catechins etc. found in blacktea, or coffee, oolong, white tea, Pu-reh, Chamomile tea, the vegetable,such as fruits or coco, alone or in combinations as a cocktail, or inaddition to it one or more antioxidants, antimicrobial, statins andimmunomodulatory mangiferin, genistein, estradiol, berberine andbaicalein, sulforaphane, with or without vitamin D and high doses ofvitamin C, vitamin E, D, or with or without quercetin, curcumin,resveratrol, Alpha-lipoic acid, tocopherols and tocotrienols,carotenoids, glutathione tocopherols, carotenoids alone or with orwithout linoleic acid mixed in the warm to boiling water or a nebulizerto create a vapor containing the active ingredients for nasal inhalationof the components of the cocktail which are inhibiting attachment ofviruses to ACE-2 receptors or neuropilins's receptors etc. therebypreventing the viral attachment or entering the nasal or respiratorypathway to the alveoli cells and olfactory nerve or sensory trigeminalnerves, to gain access to the brain cell producing viral encephalitis,where the cocktail can also be consumed orally after it is cooled down.

In one embodiment, phosphorylation of endoplasmic reticulum residentkinase (PERK) and increased eIF-2a phosphorylation is a marker ofendoplasmic reticulum (ER) stress response. The intranasal applicationof inhibitors of phosphorylation with medications, such as Baricitinib,a Janus kinases inhibitor as anti-TNF and/or cycloheximide at lowconcentrations of nanogram/ml to 1-4 microgram/ml, with methylene blueat a concentration of 1 μg/ml for inhalation multiple times a day asneeded, or naproxen prevents/treats not only the viral growth andinfection/inflammation in the lung and brain (encephalitis/Alzheimerdisease) but also prevent ER stress induced protein misfolding, such asbeta amyloid tangles or plaques, chronic inflammation and neuropathy.

In one embodiment, inhibitors of phosphorylation of endoplasmicreticulum resident kinase (PERK) a marker of endoplasmic reticulum (ER)stress response, and prevention of hyperphosphorylation of eIF-2a, suchas with a short lasting cycloheximide in DMSO in nanogram/ml to1-microgram/ml concentration or Baricitinib, a Janus kinases inhibitoras anti-TNF, or naproxen that interacts with the viral nucleocapsid andanti-inflammatory and an antiviral, such as remdesivir or favipiravir ornitazoxanide, in semifluorinated alkanes is administered in combinationwith nitric oxide (NO), donor (NONOate), pathway inhibitors and LMWHwith antivirals as a topical application or nebulization, spray in thenose to prevent or treat viral replication and protein misfolding in thebrain diseases caused by viral encephalitis including influenza viruses,coronaviruses, e.g., SARS-CoV-2, COVID-19, or their mutations herpesviruses, herpes zoster, Epstein Barr virus, cytomegalovirus andsubsequent Alzheimer's disease formation, etc., the medications are usedsequentially or combined or at different time of the day preferentiallyas a nasal inhalation, etc.

In one embodiment, other viruses that can be treated with the describedtherapeutic vaccine are certain RNA viruses that are antigens invertebrate animals which include, but are not limited to, the following:members of the family Retroviridae, the genus Orbivirus Colorado TickFever virus), the genus Rotavirus (human rotavirus); the familyPicomaviridae, including the genus Enterovirus, poliovirus, Coxsackievirus A and B, enteric cytopathic human orphan (ECHO) viruses, hepatitisA virus, Porcine enteroviruses, the genus Cardiovirus(Encephalomyocarditis virus) the genus Rhinovirus (Human rhinovirusesthe genus Apthovirus; the family Calciviridae, Feline picornavirus andNorwalk virus; the family Togaviridae, including the genus Alphavirus,Ross river virus, Venezuelan equine encephalitis virus, Western equineencephalitis virus, the genus Flavirius, yellow fever virus; Denguevirus, Japanese encephalitis virus, St. Louis encephalitis virus, MurrayValley encephalitis virus, West Nile virus, Central European tick bornevirus, Far Eastern tick borne virus, Omsk hemorrhagic fever virus), thegenus Rubivirus (Rubella virus), the genus Pestivirus (Mucosal diseasevirus, the family Bunyaviridae, including the genus Bunyvirus(Bunyamwera and related viruses, California encephalitis group viruses),the genus Phlebovirus, Sandfly fever Sicilian virus, Rift Valley fevervirus, the genus Nairovirus, hemorrhagic fever virus, and the genusUukuvirus\the family Orthomyxoviridae, including the genus influenzavirus (influenza virus type A, many human subtypes; Swine influenzavirus, and Avian and Equine Influenza viruses; influenza type B manyhuman subtypes, and influenza type C, the family paramyxoviridae,including the genus Paramyxovirus, Parainfluenza virus type I,Parainfluenza viruses types 2 to 5, Newcastle Disease Virus, Mumpsvirus, the genus Morbillivirus, Measles virus, subacute sclerosingpanencephalitis virus, distemper virus, Rinderpest virus, the genusPneumovirus respiratory syncytial virus (RSV), Bovine respiratorysyncytial virus, forest virus, Sindbis virus, Chikungunya virus,O'Nyong-Nyong virus, Ross river virus, Venezuelan equine encephalitisvirus, Western equine encephalitis virus, the genus Flavirius (Mosquitoborne yellow fever virus, Dengue virus, Japanese encephalitis virus, St.Louis encephalitis virus, Murray Valley encephalitis virus, West Nilevirus, Kunjin virus, Central European tick borne virus, Far Eastern tickborne virus, Kyasanur forest virus, Louping III virus, Powassan virus,Omsk hemorrhagic fever virus), the genus Rubivirus (Rubella virus), thegenus Pestivirus (Mucosal disease virus, Hog cholera virus, Borderdisease virus); the family Bunyaviridae, related viruses, Californiaencephalitis group viruses, the genus Phlebovirus Sandfly fever Sicilianvirus, Rift Valley fever, virus, the genus Nairovirus, Crimean-Congohemorrhagic fever virus, Nairobi sheep disease virus), and the genusUukuvirus (Uukuniemi and related viruses); the family Orthomyxoviridae,including the genus Influenza virus, Influenza virus type A, many humansubtypes; Swine influenza virus, and Avian and Equine Influenza viruses;influenza type B and influenza type C the family paramyxoviridae,including the genus Paramyxovirus, Parainfluenza virus type I, Sendaivirus, Hemadsorption virus, Parainfluenza viruses types 2 to 5,Newcastle Disease Virus, Mumps virus, the genus Morbillivirus, Measlesvirus, subacute sclerosing panencephalitis virus, distemper virus,Rinderpest virus, the genus Pneumovirus, respiratory syncytial virus(RSV), Bovine respiratory syncytial virus and Pneumonia virus of mic);the family Rhabdoviridae, including the genus Vesiculovirus (VSV),Chandipura virus, Flanders-Hart Park virus), the genus Lyssavirus(Rabies virus) (Marburg virus and Ebola virus); the family Arenaviridae,including Lymphocytic choriomeningitis virus (LCM), Tacaribe viruscomplex, and Lassa virus; the family Coronoaviridae, includingInfectious Bronchitis Virus (IBV), the infectious bronchitis virus (IBV)in chickens, picornavirus, and/or hepeviridae virus infection,betacoronaviruses gama, sarbecoviruses (SARS-like viruses includingSARS-CoV-2) and merbecoviruses, Mouse Hepatitis virus, Human entericcoronavirus, and Feline infectious peritonitis (Feline coronavirus). Inaddition, other viruses that can be treated with the describedtherapeutic vaccine are certain DNA viruses that are antigens invertebrate animals which include, but are not limited to: the familyPoxviridae, including the genus Orthopoxvirus (Variola major, Variolaminor, Monkey pox Vaccinia, Cowpox, the family Herpesviridae, includingthe alpha-Herpesviruses, Herpes Simplex Types 1 and 2, Varicella-Zoster,Equine abortion virus, Equine herpes virus 2 and 3, pseudorabies virus,infectious bovine keratoconjunctivitis virus, infectious bovinerhinotracheitis virus, feline rhinotracheitis virus, infectiouslaryngotracheitis virus, the Beta-herpesviruses Human cytomegalovirusand cytomegaloviruses of swine, monkeys and rodents; the gamma-herpesviruses, Epstein-Barr virus (EBV), Marek's disease virus, Herpessaimiri, Herpesvirus ateles, the family Adenoviridae, including thegenus Mastadenovirus, Human subgroups A, B, C, D, E and ungrouped;simian adenoviruses, infectious canine hepatitis, (Avian adenoviruses);and non-cultivatable adenoviruses; the family Papoviridae, including thegenus Papillomavirus, Human papilloma viruses, human immunodeficiencyvirus (HIV), bovine papilloma viruses, bovine coronavirus, variouspathogenic papilloma viruses of other species), the genus Polyomavirus);the family Parvoviridae including the genus Adeno-associated viruses,the genus Parvovirus, bovine parvovirus, canine parvovirus, Aleutianmink disease virus, DNA viruses may include viruses that do not fit intothe above families such as Creutzfeldt-Jacob disease viruses and chronicinfectious neuropathic agents, animals include porcine FelineCoronavirus: two forms, Feline enteric coronavirus, feline infectiousperitonitis (FIP), canine coronavirus (CCoV), and Mouse hepatitis virus(MHV).

In one embodiment, one can administer antivirals with pathway inhibitorsin combination with TNF alpha inhibitors, such as baricitinib, and Rafinhibitors, such as sorafenib, regorafenib, dabrafenib, with or withoutanti-VGEFs, aerosolized or in slow release polymeric nanoparticles withor without semifluorinated alkanes by nasal application, inhalation,etc. at low concentrations to inhibit inflammatory processes andexcessive activation of glial cell stimulation in viral encephalitis ortraumatic brain injuries while protecting the existing neuronal cellsand preventing side effects, such as Alzheimer's disease or Parkinson'sdisease, etc.

In one embodiment, the combination of antivirals and salbutamol withantibody-coated nanoparticles, such as polylactic acid, polyglycolicacid, porous silicon, micelles, liposomes, polyanhydrides, polyesters,polycaprolactone with cell penetrating peptides or activatable cellpenetrating peptides (ACPPs) or cyclodextrin or low molecular weightheparin, synthetic heparin mimetics, or synthetic heparin, such as PG500and semifluorinated alkane or catechins alone or combined with lowmolecular weight heparin or heparin mimetics that bind to heparansulfate or to sialic acid which are the component of ACE-2 andneuropilin-1 receptors of the mucosa, endothelial cells or neuronalcells, or olfactory bulb, etc. as slow release nanoparticles of lacticacid, polyglycolic acid, polycaprolactone, or as micelles or inliposomes and chitosan that the site where the influenza, SARS-CoV-2,COVID-19, or their mutations and other viruses enter the cells, etc. ina hyaluronic acid solution at <1% concentration or LMWH are administeredin a physiological solution or semifluorinated alkane or a physiologicalliquid through inhalation, or by an inhaler or through the nose to reachthe brain directly and lung endothelial cells and remain there for aperiod of time before the semifluorinated alkane evaporates, leaving theantibody-coated polymeric slow release nanoparticles in place topenetrate the alveoli cells or brain vessels cells directly to inhibitthe intracellular viral particles, and kill them with a minimal amountof antiviral medication compared to the systemic administration whilethe nanoparticles can deliver the medication for a long period of time,reducing the need for a production or availability of medication in apandemic viral infection, while salbutamol and low molecular weightheparin or synthetic heparin mimetics and polyphenols, such as catechinsand/or Probenecid inhibits Panex-1 and prevent formation of fibrin andbeta-amyloid that encourages tau plaque and neurofibrillary formation asa precursor of dementia or Alzheimer's disease occurring afterinflammatory processes of the brain.

In another embodiment, where the disease has progressed, the combinationof inhalation and intravenous administration of antibody-coatedpolymeric slow release nanoparticles/antivirals with cell penetratingpeptides or activatable cell penetrating peptides (ACPPs) orcyclodextrin, or polyethylene glycol, or low molecular weight heparin,micelles, etc. is given simultaneously intravenously or orally thatenhances also the cellular immune response of the body directly in thegut, lung, or brain directly which clears the dead viruses or deadcells, etc. that can produce toxins and multi-system inflammatorydisease in adults or children after viral infection.

In one embodiment, the combination of antivirals and salbutamol,adrenaline, Albuterol bronchodilator, hyaluronic acid, withantibody-coated polymeric slow release nanoparticles, such as polylacticacid, polyglycolic acid, porous silicon, PEG-PLA, micelles, liposomes,polyanhydrides, polyesters, polycaprolactone with cell penetratingpeptides or activatable cell penetrating peptides (ACPPs) orcyclodextrin or epigallocatechin gallate (EGCG), that bind to heparansulfate or to sialic acid preventing the viral attachment to its cellreceptors or pegylated heparin or synthetic heparin mimetics, orsynthetic heparin, such as PG500, or catechins alone or combined withlow molecular weight heparin, or low molecular weight heparin (LMWH), orheparin mimetics that bind to heparan sulfate or to sialic acid whichare the component of ACE-2 and neuropilin-1 receptors of the mucosa,endothelial cells or neuronal cells, or olfactory bulb etc. as a slowrelease nanoparticles of lactic acid, polyglycolic acid,polycaprolactone, or as micelles or in liposomes and chitosan that thesite where the influenza, SARS-CoV-2, COVID-19, or their mutations andother viruses enter the cells, etc. in nanoparticles, micelles, orliposomes are administered with protease (PLpro or Mpro, etc.) blockingagents, such as Ebselen, Ebseleno, or Ebselenum, and or glutathioneperoxidase, GPx and superoxide dismutase (SOD)—metabolize oxidativetoxic intermediates requiring zinc, selenium, manganese iron, copper,and for ideal catalytic activity applied in the nose etc., which also isan antiviral, antibacterial, anti-inflammatory, anti-prostaglandin, andneuroprotective effect, administered in a physiological solution orsemifluorinated alkane or a physiological liquid or as vapor byinhalation through the nose, or through the mouth by an inhaler to reachthe brain directly in lung, brain blood vessel endothelial cells, andremain in the nose, alveoli, brain endothelial cells, and to inhibit thereplication of intracellular viruses, and kill them with minimal amountof antiviral medications compared to the systemic administration of themedications while improving breathing through the relaxation of bronchismooth vessels and in the brain enhancing neuronal regeneration andprevention of amyloid plaque formation.

In one embodiment, the combination of antivirals with antibody-coatedpolymeric slow release nanoparticles, such as polylactic acid,polyglycolic acid, porous silicon, micelles, liposomes, polyanhydrides,polyesters, polycaprolactone with cell penetrating peptides oractivatable cell penetrating peptides (ACPPs) or pegylatedlow-molecular-weight heparin or synthetic heparin mimetics or syntheticheparin, such as PG500, or epigallocatechin gallate (EGCG), that bindsto sialic acid, combined low molecular weight heparin (LMWH) or heparinmimetics that bind to heparan sulfate or to sialic acid preventing theviral attachment to its cell receptors in slow release nanoparticles oflactic acid, polyglycolic acid, polycaprolactone, or as micelles or inliposomes and chitosan or cyclodextrin are administered with naturallyor synthetically produced compounds to inhibit protease (PLpro or Mpro),such as Ebselen, and/or glutathione peroxidase and superoxide dismutase(SOD)—metabolize oxidative toxic intermediates requiring zinc, selenium,manganese iron, copper, and for ideal catalytic activity applied in thenose, blocking proteases, which also has an antiviral, antibacterial,anti-inflammatory, anti-prostaglandin, and neuroprotective effect, orpreventing the SARS-CoV-2, COVID-19, or their mutations spikesattachment to the cells, by administration in a semifluorinated alkaneor a suitable medium through inhalation or through the mouth by aninhaler to reach the brain directly through the nose, lung, brain bloodvessel endothelial cells and to remain in the nose, alveoli, brainendothelial cells for a longer period of time to inhibit the cell entrythrough the ACE-2 or preventing replication of intracellular viruses,and kill them with minimal amount of antiviral medications compared tothe systemic administration for a long period of time for the patient torecover.

In one embodiment, one can examine and assess the degree of vascular andbrain involvement or damage after viral brain involvement using anelectroencephalogram prior and after administration of the antiviral andRock inhibitors, etc. medications through the nose or orally orintravenously, with the administration of polymeric slow releasenanoparticles carrying antivirals with or without Rock inhibitors, Wntinhibitors, GSK inhibitors, or integrin inhibitors, etc. or salbutamolwhich indicates the functional recovery of the affected brain cells ortreating seizure, sleep difficulty, etc.

In one embodiment, the combination of antivirals with antibody-coatedpolymeric slow release nanoparticles, such as polylactic acid,polyglycolic acid, porous silicon, PEG-PLA, micelles, liposomes,polyanhydrides, polyesters, polycaprolactone with cell penetratingpeptides or activatable cell penetrating peptides (ACPPs) orcyclodextrin or pegylated nanoparticles or PEG-PLA or PGG-PGLA orPEG-Heparin, or synthetic heparin mimetics, or synthetic heparin, suchas PG500, nanoparticles with polyphenols, such as catechins alone thatbind to sialic acid or combined with low molecular weight heparin thatbind to both heparan sulfate and to sialic acid which are the componentof ACE-2 and neuropilin-1 receptors of the mucosa, endothelial cells orneuronal cells, or olfactory bulb, etc. that the site where theinfluenza, COVID-19 and other viruses enter the cells, etc. as slowrelease antibody-coated nanoparticles of lactic acid, polyglycolic acid,polycaprolactone, or as micelles or in liposomes and chitosan, etc. areadministered in a physiological solution or semifluorinated alkane or aphysiological liquid by spray or inhalation or through the nose, mouthby an inhaler in combination with bronchodilators, such as xanthinebronchodilators terbutaline, non-selective beta.-stimulants,isoprenaline, adrenaline, Sudafed, beta.sub.2-agonist fenoterol,formoterol, pirbuterol, reproterol, salbutamol, indacaterol,aminophylline and choline theophyllinate and anti-allergic agents, suchas ketotifen, cromoglycate, and anti-inflammatory agents, such asDexamethasone, fluticasone, betamethasone, budesonide, flunisolide,beclomethasone, dipropionate, ciclesonide, triamcinolone acetonide,etc., anticholinergic agents, ipratropium bromide, oxitropium bromideand tiotropiumetc, alone or in combinations as needed to treat viralbrain infection, encephalitis or lung viral infections, such asinfluenza viruses or SARS-CoV-2, COVID-19, or their mutations, etc.

In one embodiment, with encephalitis viral infection, the vasculitiscauses severe migraines, which are treated with the combination ofantivirals with antibody-coated nanoparticles such as polylactic acid,polyglycolic acid, porous silicon, PEG-PLA, micelles, liposomes,polyanhydrides, polyesters, polycaprolactone with cell penetratingpeptides or activatable cell penetrating peptides (ACPPs) or pegylatednanoparticles or PEG-PLA or PGG-PGLA or PEG-Heparin or synthetic heparinmimetics or synthetic heparin, such as PG500, or catechins alone orcombined with low molecular weight heparin that bind to heparan sulfateor to sialic acid which are the component of ACE-2 and neuropilin-1receptors of the mucosa, endothelial cells or neuronal cells, orolfactory bulb, etc. the site where the influenza, SARS-CoV-2, COVID-19,or their mutations and other viruses enter the cells, etc. as slowrelease antibody-coated nanoparticles of lactic acid, polyglycolic acid,polycaprolactone, LNP or gold nanoparticles or as micelles or inliposomes and chitosan or nanoparticles or cyclodextrin administered ina physiological solution or semifluorinated alkane or a physiologicalliquid by spray or inhalation or through the mouth by an inhaler, incombination with bronchodilators, such as isoprenaline, adrenaline,Sudafed, salbutamol, albuterol, indacaterol, glycopyrrolate, formoterol,aminophylline or in combinations and choline theophylline andanti-inflammatory agents, such as Dexamethasone, fluticasone,betamethasone, Rock inhibitors, Wnt inhibitors, GSK inhibitors, orintegrin inhibitors or in combinations, anticholinergic agents,ipratropium bromide, oxitropium bromide and tiotropiumetc, alone or incombinations with anti-migraine medications, such as almotriptan,rizatriptan, triptan through inhalation, or orally or NSAIDs, such aspropionic acid derived non-steroidal agents.

In one embodiment, the combination of antivirals such as Remdesivir,zanamivir, ribavirin, flumist, ruprintrivir and pleconaril, Favipiravir,etc. and protease inhibitors, such as Ganovo, with antibody-coatedpolymeric nanoparticles, such as polylactic acid, polyglycolic acid,porous silicon, PEG-PLA, micelles, liposomes, polyanhydrides,polyesters, polycaprolactone conjugated with or without cell penetratingpeptides or activatable cell penetrating peptides (ACPPs) orcyclodextrin, or low-molecular-weight (2-5 kDa) polyethylene glycol orPEG-modified NPs densely coated by low MW PEG or Pluronic F-127 modifiedNPs, as PEG-polyacrylic acid, or papain or pegylated nanoparticles orPEG-PLA or PGG-PGLA or PEG-Heparin or synthetic heparin mimetics orsynthetic heparin, such as PG500, or catechins alone or combined withlow molecular weight heparin that bind to heparan sulfate or to sialicacid which are the component of ACE-2 and neuropilin-1 receptors of themucosa, endothelial cells or neuronal cells, or olfactory bulb, etc.that the site where the influenza, COVID-19 and other viruses enter thecells, etc., as nanoparticles, PEG-LA, polysorbates are administered ina physiological solution or semifluorinated alkane or a physiologicalliquid as drops or spray, orally or intravenously in combination withanti-allergic agents, such as ketotifen, cromoglycate, andanti-inflammatory agents, such as Dexamethasone, fluticasone,budesonide, flunisolide, ciclesonide, beclomethasone, dipropionate,triamcinolone acetonide, fluorocinolone, betamethasone, etc.,anticholinergic agents, ipratropium bromide, oxitropium bromide andtiotropiumetc, melatonin, alone or GABA inhibitors such as KDS2010, lowmolecular weight heparin (Lovenox) to simultaneously act as an antiviral(e.g., SARS-CoV-2 and COVID-19) or their mutations or anti-bacterial andto enhance nerve repair and prevent blood coagulation, NSAIDS incombinations with polyphenols, such as catechins as needed to treatintestinal viral infections (e.g., COVID-19) as inhalation therapy orthrough the mouth by an inhaler, with or without semifluorinatedalkanes.

In one embodiment, end stage viral brain and lung infection antiviralsare administered in a physiological solution or semifluorinated alkaneor a physiological liquid or a suitable medium by inhalation orintravenously or orally in combination with anticoagulants, aspirin,Coumadin, non-coagulative low molecular weight heparin, or syntheticheparin mimetics or synthetic heparin, such as PG500, etc., andimmunomodulators, Rock inhibitors, Wnt inhibitors, integrin inhibitors,cyclosporine, macrolide, mycophenolic acid, ascomycin, tacrolimus, etc.with GABA inhibitors, such as KDS2010, or melatonin that regulates thesleep-wake cycle or low molecular weight heparin (Lovenox) andpolyphenols, such as catechins that bind to heparan sulfate or to sialicacid which are the component of ACE-2 and neuropilin-1 receptors of themucosa, endothelial cells or neuronal cells, or olfactory bulb cells,etc. the site where the influenza, SARS-CoV-2, COVID-19, or theirmutations and other viruses enter the cells, etc. as a polymeric slowrelease nanoparticles of lactic acid, polyglycolic acid,polycaprolactone, or as micelles or in liposomes and chitosan to enhancenerve repair and prevent blood coagulation in antibody-coated polymericslow release nanoparticles to combat an overactive immune response.

In one embodiment, when the viral infection is associated with acytokine storm or multi-organ disease, blood electrophoresis, kidneydialysis, and/or dielectrophoresis are needed to remove excessivecytokine and killed cells and viruses, etc.

In the cells, TRIM proteins are generated by the interferon. A number ofTRIMs are needed to block viral infections. Trim2 binds to the antibodyconjugated non-enveloped virions in the infected cells and directs thevirions to the proteasomes where the virions are degraded.

In one embodiment, since there are no antivirals for newly geneticallymodified viruses, the body's immune response including cellular responsewith killer cells is the only way to overcome a viral infection; theimmune stimulation is beneficial at the early diseases process butexcessive response damages the vital organs of the patient the so calledmulti-organ disease.

In one embodiment, to stimulate the immune response, one can useviral-like particles along with serum antibody(s) obtained fromconvalescent person or an animal to conjugate with viral-like particles(VLP) that naturally produce a strong cellular immune response andinterferon against any invading organism in this case the viral antigenthat VLPs are conjugated with the viral antigen, e.g., COVID-19 or theirmutations, spike protein or multiple antigens, etc. to initiate humoraland cellular response against the recently propagated epidemic viralinfection. In one embodiment, this methodology using methylene blue canbe used to produce a vaccine in antibody-coated polymeric slow releasenanoparticles to produce or enhance the immune system to fight the viral(e.g., COVID-19) infection in general or SARS-CoV-2, COVID-19, or theirmutations or other specific viruses, by inhalation or nasal drops orspray or aerosolized drops.

In one embodiment, using the antibody(s) coated VLPs used with themethylene blue vaccine production technology produces a strong cellularimmune response by stimulating interferon production against anyinvading organism in this case the viral antigen, VLPs are conjugatedwith the viral antigen e.g., SARS-CoV-2, COVID-19, or their mutationsspike protein or RNA or multiple antigens, etc. to initiate humoral andcellular response against the recently propagated epidemic viralinfection and natural killer cells that are culture grown withSARS-CoV-2, COVID-19, or their mutations, antigen(s) or protein(s) areadministered in a physiological solution or semifluorinated alkane or aphysiological liquid with or without antivirals simultaneously with orwithout Rock inhibitors, or Wnt inhibitors as ivermectin, niclosamide orintegrin inhibitors, simultaneously or sequentially by inhalation,subcutaneously, intraperitoneally, intramuscularly or intravenously toinitiate a cellular and humoral immune response against the SARS-CoV-2,COVID-19 virus, or their mutations, or in immunosuppressed patient,where the natural killer cells attack the viruses to eliminate theinfected cells and viruses.

In one embodiment, antibody-coated VLP that induces interferonproduction conjugated with spike protein of the virus is prepared withthe known technology in the art for vaccination in antibody and CPP orMucus penetrating agents coated polymeric slow release nanoparticles,with or without antivirals, and administered in a physiological solutionor semifluorinated alkane or a physiological liquid intra-nasally,subcutaneously, or orally or systemically at low concentrations whichcan be repeated initially monthly, every three months, or six months oryearly by measuring the antibody or neutralizing antibody in a person.

In one embodiment, antibody-coated VLP that induces interferonproduction conjugated with fragments of RNA of the virus is prepared orafter irradiation with UV light to crosslink it to lose its activity,but maintaining its antigenicity for vaccination in antibody (s), ACPPor MPP-coated polymeric slow release polymeric nanoparticles with orwithout antivirals simultaneously or sequentially and administered in aphysiological solution or semifluorinated alkane or a physiologicalliquid intra-nasally, subcutaneously, or orally or systemically at lowconcentrations which can be repeated initially monthly, every threemonths, or six months or yearly by measuring the antibody orneutralizing antibody present in a person.

In one embodiment, using the spike protein or crosslinked DNA or RNAfragments of a number of viruses can be used with an antibody, CPP orMPP-coated VLP that enhance interferon production and to induce ahumoral and cellular response against any viruses or other pathogensadministered, in a physiological solution or semifluorinated alkane or aphysiological liquid initially at very low but gradually increasingconcentrations to render immune response against any organism.

In one embodiment, vaccination is performed with multiple viralantibodies, and CPP coated VLPs that induces interferon productionconjugated with slow release polymeric nanoparticles with or withoutantivirals simultaneously or sequentially and administered in aphysiological solution or semifluorinated alkane or a physiologicalliquid, etc. intra-nasally, subcutaneously, or orally or systemically atlow concentrations which can be repeated initially monthly, every threemonths, or six months or yearly by measuring the antibody orneutralizing antibody present in a person.

In one embodiment, the VLPs can be coated with one or more viral(COVID-19) antibodies and another adjuvant, such as acrylic-acid-basedadjuvant (ADJ) in antibody-coated polymeric slow release nanoparticleswith or without antivirals, or catechins or Lovenox such as Remdesivir,favipiravir, etc. used in vaccine with and or an adjuvant production tocreate an incremental increase in immune response to the viruses,bacteria, etc. intramuscularly, by inhalation, intranasally withoutinducing a cytokine storm.

In one embodiment, the VLP or an adjuvant/antigen/antibody/Rockinhibitors, etc. vaccination is done with or without an antibody andACPP-coated polymeric slow release of viral antibody, orantiviral-coated pluralities of nanoparticles alone or in an oxygenatedsemifluorinated alkane with adjuvants, such as Analgesic adjuvants,calcium phosphate hydroxide, saponin-based adjuvants (SBAs) aluminumphosphate, alum, aluminum hydroxide, paraffin oil, Mycobacterium bovis,squalene detergents, antivirals, catechins and/or Lovenox, antibiotics,such as tetracycline, a metalloproteinase inhibitor which areantibacterial and anti-inflammatory or doxycycline, Egg proteins, yeastproteins, Acidity regulators, or modified sugar molecules againstviruses, such as Tamiflu, etc. in a semifluorinated alkane or a liquidfor inhalation or intramuscularly, etc.

In one embodiment, the VLP/antigen/antibody/Rock inhibitors, etc.vaccination is done with or without antibody and ACPP, or MPP-coatedpolymeric slow release nanoparticles having dexamethasone or Rockinhibitors, Wnt inhibitors, integrin inhibitors, or GSK inhibitors withadjuvants such as Analgesic adjuvants, calcium phosphate hydroxide,aluminum phosphate, alum, aluminum hydroxide, paraffin oil,Mycobacterium bovis, squalene detergents, antiviral, antibiotics,Saponin-based adjuvants (SBAs), antivirals with Tetracycline derivativemedications, a metalloproteinase inhibitor which is antibacterial andanti-inflammatory include demeclocycline, doxycycline, Minocycline,Minocin, etc. to treat inflammatory viral lung or brain infectionthrough the nasal inhalation, etc., Egg proteins, yeast proteins,acidity regulators, or modified sugar molecules against viruses, such asTamiflu, green tee extracts etc. or other antivirals, such as baloxavirmarboxil, combined with nanoparticles or polymeric slow releaseantibody-coated pluralities of nanoparticles coated with a virus,SARS-CoV-2, COVID-19, or their mutations or influenza or other virusesin combination with LMWH/catechins, LMWH, heparin mimetics or viral-likeor antibody coated viral like nanoparticles and an adjuvant such asacrylic-acid-based adjuvant (ADJ) to induce an immunity against thespecific virus or treat specific viruses, etc. or vaccination forinhalation, or subcutaneous, intraperitoneal, or intramuscular orintravenous injection monthly, every three months, or six months oryearly by measuring the antibody or neutralizing antibody present in aperson.

In one embodiment of viral lung or brain involvement the antibody, CPPor low-molecular-weight (2-5 kDa) polyethylene glycol or poloxamer,Lovenox-coated, VLP that induces interferon production is combined withor without polyphenols such as catechins with LMWH that block ACE-2 andneuropilin-1 receptors for the virus cell entry, and one of Rockinhibitors, Wnt inhibitors, GSK and/or integrin inhibitors, or withtherapeutic medications, such an antiviral in a semifluorinated alkaneor suitable medium administered by inhalation, with such as salbutamol,fenoterol, adrenalin, dobutamine, in antibody-coated polymeric slowrelease nanoparticles to reduce the side effect of vaccination andenhance recovery regardless of its application, intranasal,intramuscular, inhalation, or through the mouth by an inhaler, orintraperitoneal or intravenously.

In one embodiment, antivirals combined with antibody (monoclonal orpolyclonal antibodies) coated or aptamer or mRNA or in combinationsconjugated pluralities of nanoparticles or polymeric slow releasenanoparticles coated against a virus, SARS-CoV-2, COVID-19, or theirmutations or influenza or other viruses in combination with LMWH,heparin mimetics/catechins, or a metalloproteinase inhibitortetracycline derivatives which antibacterial and anti-inflammatory andantibody-coated viral-like nanoparticles or an adjuvant as a vaccine toinduce interferon and an immune response to the antigens and a pathwayinhibitor, with or without additional adjuvants to induce an immunityagainst the specific virus/bacteria, etc. or treat specific viruseswhile blocking excessive type 2 immune response.

In one embodiment, an adjuvant can be used or added to a vaccine toenhance the immune response including amorphous aluminumhydroxyphosphate sulfate (AAHS), aluminum hydroxide, aluminum phosphate,potassium aluminum sulfate (Alum), Oil in water emulsion made ofsqualene, Monophosphoryl lipid A (MPL), QS-21, extracted from theChilean soapbark tree in liposomes, Cytosine phosphoguanine (CpG) asynthetic DNA mimicking viral bacteria genetic material, GlucopyranosylLipid Adjuvant-Stable Emulsion (GLA-SE), synthetic Toll-like receptor(TLR)4 agonist, adjuvant Fluzone®. The GLA-SE adjuvant Fluzone vaccine,or saponins, etc.

In one embodiment, one can start with VLP antigen/antibodies vaccinationthrough the inhalation or variation of vaccines repeatedly combined withpathway inhibitors.

In one embodiment, one can start with one mRNA vaccine and move tosecond application of the same or another vaccine, one such as VLPantigen/antibodies or synthetic toll-like receptor agonist in asemifluorinated alkane or perfluorocarbon liquid through the inhalationor variation of vaccines repeatedly combined with pathway inhibitors inslow release polymeric nanoparticles.

In one embodiment to prevent vasculitis, one can administer two or moreantivirals, combined with cell inflammatory pathway inhibitors, withLMWH, or heparin mimetic, linoleic acid etc. complement inhibitors,anti-inflammatory compounds, by inhalation, orally, systemically,intravenously, subcutaneously, intramuscularly, etc.

In one embodiment of viral encephalitis, one prevents Alzheimer's andParkinson's disease and other viral-related CNS infections with anantiviral in combination with cell inflammatory pathway inhibitors andwith LMWH, or a heparin mimetic, complement inhibitors and specificmedications such as Bariticinib, Kezara, and with LMWH, or heparinmimetics, complement inhibitors, etc. and GSK inhibitors by inhalation,orally, systemically, intravenously, subcutaneously, intramuscularly,etc.

In one embodiment, the endoplasmic reticulum stress of the neuronal cellin viral diseases and also traumatic brain injuries, etc. is treated byadding anti-inflammatory medications, such as such as Bariticinib,Kezara, to pathway inhibitors and combining ACE-2 inhibitors, neuropilinreceptor blockage, catechins and linoleic acid, etc.

In one embodiment, as described with the use of methylene blue, forself-vaccination with a single dose unit or vaccine for nasal inhalationwith one or multiple vaccines produced for numerous viruses that isobtained or ordered for home delivery from the pharmacists by doctor'sprescription by inhalation, orally, systemically, intravenously,subcutaneously, intramuscularly, etc.

In one embodiment, two healthy laboratory animals with a bodytemperature of 37° C. are vaccinated, one by nasal inhalation/jetinjector, and the other one by intramuscular injection of a vaccine madeof treated (damaged) COVID-19 viruses grown in the cell culture media,with a solution of methylene blue at a concentration of 30 μg/ml in thedark environment for about two days. The samples of these treatedviruses are placed in a cell culture and do not show any sign of growth.EM microscopy of the samples show these viruses have damaged RNA geneticmaterial with some breaks in the single stranded RNA. The animalstolerate the vaccination well without showing much of a malaise, theirtemperature rises less than one degree C. by the second day. Bothanimals develop neutralizing antibodies in their blood after two tothree weeks. The animals are challenged one month after vaccinationthrough nasal inhalation of the COVID-19. Except for a mild rise in thebody temperature and an increase in neutralizing antibodies in theirblood, which last for few months that followed, the animals do not showany other signs of infection.

In another embodiment, two healthy laboratory animals with a bodytemperature of 37° C. are inoculated with 105 COVID-19 plaque formingunits of the virus through the nose. The animals' temperatures aremonitored regularly for any sign of increase. As soon as the animals'temperature rise one degree C. above the normal temperature to 38degrees C., and the animals appear reluctant to play, a nose swab istaken from the animals and evaluated by PCR which becomes positive andthe viruses are also grown on cell culture simultaneously. One animalimmediately receives an intravenous dose of 3 mg/Kg of a solution ofmethylene blue in a normal physiological solution intravenously dailyafter a short intramuscular anesthesia, if the temperature remains highand is allowed to recover with monitoring his temperature for anotherday. A nasal swab is done daily for verification of the virus. The otheranimal having an increased body temperature and positive nasal swab,etc. is treated both by nasal inhalation with a methylene blue solutionhaving 5 μg/ml methylene blue, by a jet injector/nebulizer two timesdaily and intravenous injection of the methylene blue at <3 mg/Kg dose.By three days, their body temperatures are dropped to 37.3 degree C.,and gradually normalize though the animal with combination therapy withnasal inhalation is less affected.

In one embodiment, the vaccine is produced by a combination of VLP, deadbacteria, or viruses and methylene blue, in combination with pathwayinhibitors, etc. for self-administration by nasal inhalation orsubcutaneously or intramuscularly as needed and single dose vaccines useor add this vaccine to other existing mRNA vaccines.

In one embodiment, pluralities of viral or a fragment of the viral Sprotein antibody(s) coated polymeric nanoparticles are conjugated withCPP, or ACPP and one or two antivirals to enhance cell penetration ofthe nanoparticle inside the cells to damage the viruses which havepenetrated the cells by nasal or topical, or systemic administration.

In one embodiment, pluralities of ACE-2 or neuropilin receptorsantibody(s) coated polymeric nanoparticles are conjugated with CPP, orACPP, or heparin or catechins or linoleic acid and one or two antiviralsto block the viruses to enter the cells via ACE-receptors or neuropilinreceptors inside the cells by nasal or topical, or systemicadministration.

In one embodiment, antivirals can be combined with or without methyleneblue, a phenothiazine dye, a cationic compound to enhance damage to theviruses, bacteria anionic RNA or DNA, and simultaneously acting asanti-oxidant and anti-depressant when given in combination with one ofthe pathway inhibitors, such as GSK inhibitors or GSK beta inhibitorsand/or antivirals in a solution or as polymeric slow releasenanoparticles or in semifluorinated alkanes to be administered bysystemic or preferentially by inhalation one or multiple times dailybelow the toxic dose of 1-2 mg/L to reach both the lung and the brainpreventing or treating viral inflammatory disease of the lung or thebrain, and preventing subsequent Alzheimer's or Parkinson's diseases andnerve damage and preventing or treating the tangled tau neurofibrilesand preventing Tau protein's toxicity by activating plasma membranecalcium ATPase, thus preventing endoplasmic reticulum (ER) stressresponse and unfolding the protein.

In one embodiment of vaccine preparation, to avoid the use offormaldehyde or glutaraldehyde, which are toxic and crosslink the viraland bacterial membranes which are harvested from the viruses orbacterial for their proteins for vaccine production and or autovaccination to be used as prophylaxis or treatment of the viral orbacterial diseases such as SAR-Cov-2 or COVID-19, MCV, EBV, papillomavirus, Zoster or Hopes viruses, coronavirus, Zika, EBV, Zoster, etc. andtheir mutations, these organisms are grown in cell culture and harvestedby centrifuge and filtration, then exposed to concentrations ofmethylene blue with or without cell penetrating peptides (CPP) orcyclodextrin or in combination with cysteine, etc., to enhance membranepenetration at concentration of above 1 mg/L to 50 mg/L or more with anantiviral at low concentrations for a period of about <30 minutes to 24hours or more depending on the concentration of methylene blue alone orthe antiviral without external light radiation to damage RNA or DNA ofthe virus, e.g., flaviviruses including the Dengue virus (DENY), EbolaZaire, West Nile virus, Zika virus (ZIKV), Japanese encephalitis virus,Yellow Fever virus, influenza viruses, coronaviruses, herpes viruses,EBV, hepatitis A, B, and C viruses, or papilloma virus, while protectingthe viral protein membranes and S-proteins of the viruses forvaccination; since methylene blue passes easily through viral orbacterial membrane because of its cationic charge to attach to RNA andDNA with its anionic charge and oxidizes the Guanine in presence ofoxygen, thereby damaging the RNA or DNA and creating single-strandbreaks (ssb) in the RNA of the viruses or bacteria. The presence ofantivirals and antibacterials enhances the process, while leaving theviral capsid membrane or bacterial membrane intact to be used lateralone or with other synthetic adjuvants such as Toll-like receptor 4,Saponin-based adjuvants (SBAs), etc. for vaccination alone, preferablyin combination with LMWH or heparin mimetic to prevent simultaneousblood clotting induced by methylene blue. While methylene blue actstherapeutic by activating PI3-Akt and inhibiting GSK3β reducing edema ofthe brain produced by breakdown of blood brain barrier at the site orthe endothelial cells and reduce inflammatory cytokines production, suchas tumor necrosis factor (TNF)-α, (IL-6), interleukin (IL)-1β, andreduces the neutrophil cell infiltration in the brain and reducesmicroglial cell activation in encephalitis, while methylene blue and/orcatechins or lineolic acid, and LMWH, etc. inhibit the entrance of thevirus inside a cell through the ACE-2 receptor inhibition afterinhalation, nasally, spray, ointment or orally as a solution, liposomes,pills, or gummy, polycaprolactone, intravenous, etc. administration withor without pathway inhibitors to reduce inflammatory response to thetoxins at different sites in the brain and lung or intestinal tract orin brain infarct or in ischemic reperfusion syndrome or as in traumaticbrain injuries, etc. preventing subsequent Alzheimer's or Parkinson'sdiseases.

In one embodiment, administration of this vaccine with or withoutantivirals, or LMWH or pathway inhibitors, nasally by spray ornebulization one can apply a light source of 670 nm for a short periodof time through a fiber optic, the nasal cavity or oral cavity, throat,or through pharynx to kill the viruses directly.

In one embodiment, one administers stabilized hypochlorous acid, thestable N-chloro derivative, or chloramines, the stable N-chloroderivatives or N-chlorotaurine (NTC), dimethylated derivatives of NCT(N-chloro-2,2-dimethyltaurine [DM-NCT] andN,N-dichloro-2,2-dimethyltaurine [DM-NDCT], glutathione peroxidase, andslow release polymeric nanoparticles that carry at least two of theantiviral medications together with one or more cell pathway inhibitorsand heparin or low molecular weight heparin, synthetic heparin mimetics,or in combination with polyphenols and its derivatives that bind toheparan sulfate, linoleic acid, catechins and/or to sialic acid, therebypreventing the viral attachment to its cell receptors in the respiratorysystem or intestinal tract or brain as slow release nanoparticles orantibody-coated nanoparticles of lactic acid, polyglycolic acid,polycaprolactone, or as micelles, or in liposomes and chitosan; or asantibody-coated antiviral nanoparticles, such as gold or silver or zincnanoparticles of 1-100 nm, preferably 1-10 nm in diameter, which act asantivirals and can penetrate the virus with or without methylene blue todamage the RNA or DNA of the virus and kill them with or without LMWHfor vaccine production or therapeutic.

In one embodiment, this preparation is used for administration in thenose as inhalation, in spray, or by an inhaler, or nebulized form ororally to treat viral encephalitis or lung inflammation or orally forintestinal tract involvement for treatment of the virus to kill one ormore viruses that remain in the nose/pharynx/throat or in the intestineafter vaccination, or after having recovered from a virus infection, andprevent their reactivation, or further virus transmission to the healthypeople, or it can be used as prophylaxis.

In one embodiment, antibody-coated slow release polymeric nanoparticlesthat carry at least two of the antiviral medications together with oneor more cell pathway inhibitors and heparin or low molecular weightheparin, synthetic heparin mimetics, or in combination with polyphenolsand its derivatives that bind to heparan sulfate, linoleic acid,catechins and/or to sialic acid, thereby preventing the viral attachmentto its cell receptors as a slow release nanoparticles or antibody coatednanoparticles of lactic acid, polyglycolic acid, polycaprolactone, or asmicelles, or in liposomes and chitosan; or as antibody-coated antiviralnanoparticles, such as gold or silver or zinc nanoparticles of 1-100 nm,preferably 1-10 nm in diameter, which act as antivirals and canpenetrate the virus with or without methylene blue to damage the RNA orDNA of the virus, and kill them or after they are heated with lightradiation in the nose, etc. after inhalation.

In another embodiment, the method further comprises the steps ofadministering a stabilized hypochlorous acid, the stable N-chloroderivative, or chloramines, the stable N-chloro derivatives orN-chlorotaurine (NTC), dimethylated derivatives of NCT(N-chloro-2,2-dimethyltaurine [DM-NCT] andN,N-dichloro-2,2-dimethyltaurine [DM-NDCT], with antiviral medicationstogether with pathway inhibitors and low molecular weight heparin orlinoleic acid, and catechins conjugated with antibody-coated gold orsilver or zinc nanoparticle of 1-100 nm preferably 1-10 nm in diameterwhich act as antivirals and can penetrate the virus conjugated with orwithout methylene blue for administration in the nose as inhalation, inspray or nebulized form, or orally to treat viral encephalitis or lunginflammation to kill one or more viruses that remain in thenose/pharynx/throat or in pills or gummy for oral delivery, aftervaccination or after having recovered from a virus infection toeliminate remaining of resistant viruses by the above combinations toprevent reactivation or further virus transmission to healthy people oras prophylaxis.

In one embodiment of vaccine production, the viruses are grown byincubating them in the cell culture, after the viruses invade the cells,using the cell machinery they grow to the degree that they can exit orburst the cell wall, at this stage the viruses are separated from thecells by filtration by passing them through the pores of less than 200micron by centrifugation. The intact viruses with their intact membranesand capsid containing the genetic component of the virus are incubatedwith a solution of methylene blue or combined with cell penetratingpeptides or cyclodextrin, etc. at a desired concentration of 1microgram/ml to 50 micrograms or more; the methylene blue with itspositive charge and partially lipophilic action penetrates the outermembrane of the virus entering the virus with or without an antiviral,passing through the viral capsid and tightly attaches to the negativelycharged RNA or DNA of the virus that in presence of the oxygen damagesthe Guanine of the RNA of DNA, which occurs rapidly at this stage orsimultaneously one adds metallic nanoparticles of gold or silver, orzinc with the size of preferably <10 nm to one nanometer in diameterwhich has an antiviral effect with or without CPP or ACPP, which becauseof their size they penetrate the virus and attach to the DNA or RNA ofthe virus then entire viral culture is passed through a beam of laserradiation at a wavelength that is absorbed by the metallic nanoparticlesattached to RNA or DNA of the virus, while it does not damage the outermembrane proteins or S-antigen, etc. of the virus by creating onlylocally an increased temperature at the site of the nanoparticlesdamaging the RNA or DNA to which the positively charged nanoparticlesare attached, this process might take less than few seconds to a fewminutes or more depending on the laser power and the spot size of thelaser. At this stage, the DNA or RNA of the viruses are severely damagedwhile the viruses' membranes and their S-proteins and capsid proteinsremain intact with their antigenic properties that can be harvested andutilized as a vaccine to be administered by inhalation,self-administration, injection intramuscularly, orally, in solution,ointment, in pills, in gummy, etc., alone or in combination with otherantivirals and cell pathway inhibitors, such as Rock, GSK, integrin, andWnt inhibitors, such as ivermectin or niclosamide, or LMWH, etc.

In one embodiment, the viral protein can also be combined with asynthetic adjuvants such as toll like receptor 4 or non-syntheticadjuvants, etc., to enhance the immune response of the patient oranimals to the vaccine which can be used as nasal inhalation at repeatedintervals as needed to induce sufficient immune response that can bechecked for presence of neutralizing antibodies in the patient or thevaccine can be added to other vaccines such as mRNA vaccine, etc. toboost their effect or if the virus has mutated, and administered whenneeded as self-administration by inhalation through the nose, mouth andto vaccinate a large number of the population fast or the vaccine can bealso injected initially as ordered by the physician, where the methodsimplifies the production and application of the vaccine application ina large population everywhere, specifically in developing countries,etc. the components can be premade to be used for any potential virus,etc. or the vaccine can be stored by freezing it in a regularrefrigerator.

In one embodiment, the vaccines can be prepared from circulating tumorcells or tumor tissue from the cancerous circulating tumor cells orobtained by biopsy from any part of the body to be grown in the tissueculture and treated the same way with methylene blue, etc. or otherappropriate dye and antibody-conjugated gold, silver or zincnanoparticles of smaller than 10 microns, magnetic, paramagnetic ornonmagnetic, nanoparticles and can be killed in vitro with or withoutradiation for vaccine production with or without pathway inhibitors andantitumor medication, etc. with or without external laser, or othersource of energy if needed such as alternating magnetic field, thevaccine can be administered with or without LMWH to the patient locallyor intra-arterially or intravenously, by inhalation, etc.

In one embodiment, in patients with viral infections, etc., such asCOVID-19, there is an increased inflammatory process in the blood withrelease of cytokines causing a cytokine storm, etc. in these conditionsanti-inflammatory compounds or inflammatory pathway inhibitors, such asRock inhibitors, Wnt inhibitors, integrin inhibitors, and GSK inhibitorin antibody and CPP or PEG-coated polymeric slow release nanoparticlesalong with antiviral with or without DMF can be therapeutic orprophylactic if used by inhalation, orally, subcutaneously orintravenously or injected locally.

In one embodiment, anti-inflammatory compounds or inflammatory pathwayinhibitors such as Rock inhibitors, Wnt inhibitors, integrin inhibitors,and GSK inhibitors along with antivirals can be combined with IL-1,IL-2, IL-6, and/or IL-17 inhibitors in antibody-coated and CPP or PEGconjugated polymeric slow release nanoparticles with LMWH/catechins astherapeutic or prophylactic if used by inhalation, orally,subcutaneously, intravenously, injected locally, or topically.

In one embodiment, anti-inflammatory compounds or inflammatory pathwayinhibitors such as Rock inhibitors, Wnt inhibitors, integrin inhibitorsand GSK inhibitors along with antivirals and/or GABA inhibitors such asKDS2010, low molecular weight heparin (Lovenox) to simultaneously act asantiviral (e.g., COVID-19) and other RNA viruses or anti-bacterialand/or synthetic heparin mimetics/catechins to block virus entry in thecells and probenecid Panex-1 inhibitor to enhance nerve repair andprevent blood coagulation and has an antiviral effect, with or withoutCPP-conjugated with pluralities of polymeric slow releaseantibody-coated pluralities of nanoparticles can be combined with IL-1IL-2, IL-6, IL-17 inhibitors or a metalloproteinase inhibitor which areantibacterial, antiviral, and anti-inflammatory as therapeutic orprophylactic with extended release of the medication, if used byinhalation, orally, subcutaneously, or intravenously or injected locallyor intraperitoneally.

In one embodiment, anti-inflammatory compounds or inflammatory pathwayinhibitors, such as Rock inhibitors, Wnt inhibitors, integrin inhibitorsand GSK inhibitors along TGF beta inhibitors, such as botulinum toxin atpictogram concentrations, with antiviral and/or protease inhibitors,such as indinavir, ritonavir, nelfinavir, darunavir, amprenavir,favipiravir, fosamprenavir, lopinavir, atazanavir, saquinavir,tipranavir, nitazoxanide, Apilimod or vacuolin-1 in polymeric slowrelease antibody-conjugated polymeric nanoparticles/CPP conjugated canbe combined with IL-6, Kevzara, or Baricitinib, IL-17 inhibitors,antiviral mycophenolic acid as therapeutic or prophylactic with extendedrelease of the medication if used by inhalation, or by an inhaler,orally, topically, subcutaneously, intravenously, or injected locally.

In one embodiment, anti-inflammatory compounds or inflammatory pathwayinhibitors such as Rock inhibitors, Wnt inhibitors, integrin inhibitorsand GSK inhibitors along with antiviral and/or protease inhibitors, suchas Ganovo, in ACPP conjugated polymeric slow release antibody-conjugatednanoparticles can be combined with IL-6 Kevzara, IL-17 inhibitors,antivirals, mycophenolic acid, as therapeutic or prophylactic withextended release of the medication if used by inhalation, or by aninhaler, orally, subcutaneously or intravenously or injected locally.

In one embodiment, anti-inflammatory compounds or inflammatory pathwayinhibitors, such as Rock inhibitors, Wnt inhibitors, integrininhibitors, and GSK inhibitors along with an antiviral, such as,favipiravir, ritonavir, Remdesivir, Burton tyrosine kinase inhibitor(BTK) ibrutinib, zanubritinib, acalabrutinib, or JAK-STAT, or JAK1/JAK2inhibitor ruxolitinib, baricitinib, Pacritinib or inhibition ofoxidative stress with Thalidomide and lenalidomide, PI3K/AKT/mTORpathway inhibitors, Duvelisib, inhibitors of phosphorylation ofendoplasmic reticulum resident kinase (PERK), Rapamycin, with or withoutcomplement pathway inhibitors, such as C3 inhibitors—AMY-101(NCT04395456) and APL-9 (NCT04402060); C5 inhibitors—eculizumab(NCT04346797 and NCT04355494); C1 esterase inhibitors, which block theclassical complement pathway and antiandrogen bicalutamide or anti-VEGFsavastin, dexamethasone, or tetracycline derivatives, metalloproteinaseinhibitors which are antibacterial, antiviral, and anti-inflammatory ornitric oxide (NO) or donor (NONOate) in antibody-coated polymeric slowrelease pluralities of nanoparticles as a nasal spray or inhalationtherapy in viral lung infection or viral encephalitis asanti-inflammatory agents to release the medication slowly withoutaffecting other organs and treat or prevent an autoimmune response invarious organs, such as type 1 diabetes, autoimmune encephalitis thatbecomes chronic leading to Alzheimer's disease and dementia, Bechetdisease, temporal arteritis, Crohn's disease, unknown causes of uveitisand many chronic diseases.

In one embodiment, generalized damage to the brain, lung, retina bloodvessels, and/or endothelial cells that caused blood clot formationand/or leakage of the capillaries is seen in fluorescein retinalangiography, etc. or large veins and arteries are reported. In oneembodiment, anti-inflammatory compounds or inflammatory pathwayinhibitors such as Rock inhibitors, Wnt inhibitors, integrin inhibitors,and GSK inhibitor along with an antiviral, such as ritonavir,Remdesivir, favipiravir, nitazoxanide, etc. are combined withantibody-coated polymeric slow release pluralities of nanoparticles areconjugated with dipyridamole, to treat endothelial cell damage orsimultaneously or sequentially with GABA inhibitors such as KDS2010,probenecid a panx-1 inhibitor, low molecular weight heparin(Lovenox)/polyphenols, such as catechins, epicatechin (EC),epigallocatechin (EGC), epicatechin gallate (ECG), and epigallocatechingallate (EGCG), to simultaneously prevent viral cell entry, act as anantiviral (e.g., COVID-19) and other viruses or anti-bacterial ifpresent, such as a metalloproteinase inhibitor which is an antibacterialand an anti-inflammatory in a semifluorinated alkane or other medium,and to enhance nerve repair and prevent blood coagulation as a nasalspray or inhalation, or by an inhaler, or intravenous applications alongwith anti-blood coagulants, such as aspirin, Coumadin, low molecularweight heparin (Lovenox), or synthetic heparin mimetics, or syntheticheparin, such as PG500, non-anticoagulant low molecular weight pegylatedheparin or non-anticoagulant low molecular weight heparin and to enhancenerve repair and prevent blood coagulation, etc.

In one embodiment, Protease inhibitors, such as Ulinastatin, leupeptinepsilon-aminocaproic acid, Aprotinin Camostat mesilate, etc., indinavir,fosamprenavir, Artemisinin, ritonavir, nelfinavir, amprenavir,lopinavir, saquinavir atazanavir, tipranavir, and darunavir, etc., blockthe viral attachment and entry in the cell, such as combined with aviral polymerase inhibitor, such as Remdesivir, favipiravir, Ribavirin(RIB), nitazoxanide, etc. with or without α(1)-antitrypsin (AA T),Stachyflin, acetylstachyflin, Thiobenzamide, and an anti-inflammatoryagent, such as dexamethasone and/or pathway inhibitor, such as Rockinhibitor (e.g., Fasudil) and/or Wnt inhibitors (e.g., Niclosamide) withboth an antiviral and anti-inflammatory effect, ivermectin, etc., GSKinhibitor, or integrin inhibitor conjugated with antibody-coatedpolymeric slow release nanoparticles with a physiological solution orsemifluorinated alkane or low molecular weight heparin (Lovenox), orsynthetic heparin mimetics, non-anticoagulant low molecular weight,pegylated heparin, or non-anticoagulant low molecular weight heparinadministered as a spray, aerosolized through the nose, mouth or injectedsubcutaneously, intravenously in a non-toxic dose, as topical ointmentfor intranasal application, or as a dry powder or liquid formulations tobe used for inhalation as aerosolized preparation.

In one embodiment, one or more antivirals are used with pluralities ofheparin or anti-coagulative or low molecular weight heparin tosimultaneously act as antiviral, e.g., SARS-CoV-2, COVID-19, or theirmutations or other RNA or DNA viruses and anti-bacterials, such astetracycline derivatives, a metalloproteinase inhibitor which areantibacterial and anti-inflammatory or synthetic heparin mimetics orunfractionated heparins or synthetic heparin, such as PG500, conjugatedwith antibody-coated slow release polymeric pluralities of nanoparticleswith or without and anti-VEGF (e.g., Avastin or Eylea) and areadministered in a physiological solution or semifluorinated alkane or aphysiological liquid as an aerosolized formulation for inhalation, or byan inhaler, subcutaneously, intramuscularly, or intravenously to treatearly stage SARS-CoV-2, COVID virus, or other influenza viruses, orinjected subcutaneously for treatment of Zika and or dengue viruses,Epstein Barr virus, viral encephalitis, etc., and reduce inflammatoryprocesses in the body, eliminate the viruses in brain, in encephalitisor multi-organ disease after coronavirus infection, etc.

In one embodiment, a polymerase inhibitor, such as favipiravir(Faviflu), moroxydine, Azaindole VX-787, an inhibitor of PB2 and one ormore protease inhibitors, such as Stachyflin, Doxycycline,acetylstachyflin, Thiobenzamide or darunavir, saquinavir, ritonavir,nelfinavir, Artemisinin, fosamprenavir, lopinavir, Faviflu, amprenavir,atazanavir, tipranavir, and one or more anti-inflammatory agents, suchas dexamethasone and/or pathway inhibitor, such as a Rock inhibitor(Fasudil) and/or Wnt inhibitor (Niclosamide), ivermectin, etc., GSKinhibitor, or integrin inhibitor conjugated with antibody-coatedpolymeric slow release nanoparticles with a physiological solution orsemifluorinated alkane administered in a physiological solution orsemifluorinated alkane or a physiological liquid as a spray, aerosolizedthrough the nose, mouth, or injected subcutaneously, intravenously in anon-toxic dose, or as topical ointment for intranasal application.

In one embodiment, a nuclear pathway inhibitor such as Leptomycin B iscombined with an antiviral (including SARS-CoV-2 and COVID-19) or theirmutations, such as Remdesivir, favipiravir and dexamethasone or Kevzara,or a pathway inhibitor such as a Wnt inhibitor such as Niclosamide withboth an antiviral and anti-inflammatory effect, or synthetic heparinmimetics, or synthetic heparin, such as PG500, and GABA inhibitors suchas KDS2010, low molecular weight heparin (Lovenox) or othernon-anticoagulant low molecular weight heparin/catechins tosimultaneously act as antiviral (e.g., against Covid-19), etc. andtetracycline derivatives, a metalloproteinase inhibitor which areantibacterial, antiviral, and anti-inflammatory or anti-bacterial byinhibiting the proteases and/or mycophenolic acid, an immunomodulator,with potent antiviral activity to enhance nerve repair and prevent bloodcoagulation, etc. conjugated with multiple antibody-coated slow releasenanoparticles with a physiological solution or semifluorinated alkane ora physiological liquid administered as a spray, aerosolized through thenose, mouth or injected subcutaneously, intravenously, or orally in anon-toxic dose.

In one embodiment, a viral RNA and protein synthesis inhibitor such asNucleozin or Cycloheximide or Naproxen and a polymerase inhibitor suchas moroxydine are combined with an antiviral, such as remdesivir,Faviflu, Baricitinib, a Janus kinases inhibitor as anti-TNF anddexamethasone or a pathway inhibitor such as Wnt inhibitor such asniclosamide, etc. conjugated with multiple antibody-coated slow releaseslow release nanoparticles with a physiological solution orsemifluorinated alkane administered as spray, aerosolized through thenose, mouth, or injected subcutaneously, intravenously in a non-toxicdose or as dry powder or liquid formulations to be used for inhalationas aerosolized preparation or ointment.

In one embodiment, a compound such as an influenza virus inhibitor suchas sialidase is combined with a viral inhibitor such as Remdesivir,Favipiravir, Ribavirin (RIB), histone deacetylases (HDACs), such asSodium Phenylbutyrate (PB) and Valproic Acid (VPA), etc. with or withoutα(1)-antitrypsin (AA T), Stachyflin, acetylstachyflin, Thiobenzamide,and an anti-inflammatory agent such as dexamethasone and/or a pathwayinhibitor, such as a Rock inhibitor (Fasudil) and/or Wnt inhibitor(Niclosamide), ivermectin, etc., GSK inhibitor, or integrin inhibitorconjugated with antibody-coated polymeric slow release nanoparticleswith a physiological solution or semifluorinated alkane, or lowmolecular weight heparin (Lovenox), or synthetic heparin mimetics,non-anticoagulant low molecular weight pegylated heparin, ornon-anticoagulant low molecular weight heparin/catechins administered asa spray, aerosolized through the nose, mouth, orally or injectedsubcutaneously, intravenously in a non-toxic dose for lung, brain ormulti-organ diseases after coronavirus infection or other viralinfections or Multisystem Inflammatory Syndrome in Children (MIS-C).

In one embodiment, a compound such as an influenza virus inhibitor, suchas indinavir, fosamprenavir, Artemisinin, ritonavir, nelfinavir,amprenavir, lopinavir, saquinavir atazanavir, tipranavir, and darunavir,etc., block the viral attachment and entry in the cell, such as combinedwith a viral inhibitor such as Remdesivir, favipiravir, Ribavirin, GS-2067, GS-CA1, polyphenol and its derivatives such as catechins and ananti-inflammatory agent, such as dexamethasone and/or a pathwayinhibitor, such as a Rock inhibitor (Fasudil), etc. and/or Wnt inhibitor(Niclosamide), ivermectin, etc., GSK inhibitor, or integrin inhibitorsconjugated with antibody-coated polymeric slow release pluralities ofnanoparticles with a physiological solution or semifluorinated alkane,with or without spironolactone against prions EBV, or other viruses bynasal application, reduces pulmonary edema at a lower dose than systemicadministration and reduces the transmembrane serine protease 2 (TMPRSS2)action and as an antioxidant or low molecular weight heparin (Lovenox),or synthetic heparin mimetics, non-anticoagulant low molecular weightpegylated heparin, or non-anticoagulant low molecular weight heparinadministered as a spray, aerosolized through the nose, mouth, orally orinjected subcutaneously, intramuscularly, intravenously, by inhalationand/or combined with a known anti-inflammatory agent that can preventpyroptosis of cells, such as dimethyl fumarate (DMF), administeredorally, by injection or by inhalation in a slow release polymericpluralities of nanoparticle format for a short period or time of 1-2weeks as needed in a non-toxic dose of 100-1000 mg as needed for lung,brain, or multi-organ diseases after coronavirus infection, such asSARS-CoV-2, COVID-19, or their mutations or other severe viralinfections or with mycophenolic acid, an immunomodulator, with potentantiviral activity in Multisystem Inflammatory Syndrome in Children(MIS-C), DMF or Fumaric acid esters (FAEs) inhibit the activity of thetranscription factor NF-κB and proinflammatory cytokines by T cells byits immunomodulatory mechanisms.

In another embodiment, in a systemic multisystem disease, where there isa genetic flaw in alpha-interferon, one administers syntheticinterferons made by recombinant DNA technology with anti-inflammatoryagents, such as doxycycline, a metalloproteinase inhibitor, which has anantibacterial and anti-inflammatory effect along with LMWH, polyphenoland its derivatives, such as catechins, NSAIDS or dexamethasone, with orwithout an anti-VEGF (e.g., Avastin or Eylea), one or more pathwayinhibitors, such as Wnt, Rock, GSK, integrin inhibitors with TGF-alphainhibitors with or without an anti-VEGF (e.g., Avastin or Eylea), withone or more antiviral agents, such as indinavir, molnupiravir, orMK-4482/EIDD-2801, and mycophenolic acid, an immunomodulator, withpotent antiviral activity in a semifluorinated alkane of other suitablemedium for inhalation, intramuscular, or intravenously.

In one embodiment of virals or COVID-19 disease or in multisystemdisease, one administers LMWH, polyphenol and its derivatives, such ascatechins, NSAIDS, doxycycline, one or more pathway inhibitors, such asWnt, Rock, GSK, integrin inhibitors with TGF-alpha inhibitors, inaddition to Pegaptanib sodium, with or without an anti-VEGF (e.g.,Avastin or Eylea), a nucleotide polyethylene glycol RNA aptamer thatinhibits angiogenesis that binds to VEGF₁₆₅, or another anti-VEGF withone or more antiviral agents or with ebselen and orglutathioneperoxidase and superoxide dismutase (SOD)—requiringadditional zinc, or manganese, or heparin for ideal catalytic activityapplied to the nasal passages, in a semifluorinated alkane or othersuitable medium for inhalation, intramuscular, intravenously or inside abody cavity injection.

In one embodiment, one or more antivirals, such as Remdesivir, Ribavirin(RIB), histone deacetylases (HDACs), such as Sodium Phenylbutyrate (PB)and Valproic Acid (VPA) as an antiviral and protection of the liver andkidney, etc. are combined with NS1 inhibitors combined with MEK1 andMEK2, NFKB inhibitors, such as Bortezomib and glycosylation inhibitors,such as L-fructose and L-xylulose and one or more Rock inhibitors or Wntinhibitors are combined with GSK inhibitors or integrin inhibitorsconjugated with antibody-coated polymeric slow release nanoparticleswith a physiological solution or semifluorinated alkane administered asa spray, aerosolized through the nose, mouth, at a non-toxic dose or asa dry powder or liquid formulations to be used for inhalation asaerosolized preparation.

In one embodiment, one or more antivirals, such as Remdesivir,Favipiravir, Ribavirin (RIB), oseltamivir, cyclosporine, etc. and ananti-oxidants or immunomodulators, such as calcitrol, Rolipram, aselective phosphodiesterase-4 (PDE-4) inhibitor to reduce bronchospasm,anti TNF alpha inhibitor Baricitinib, a Janus kinase inhibitor,interleukin antagonists, low molecular weight heparin, or syntheticheparin mimetics, an antiviral used in HIV infection, such as GS-6207, along acting HIV capsid inhibitor, IL-6, Kevzara, PDE5 inhibitorssildenafil and tadalafil, enhance the level and action of cGMP, relaxthe smooth muscles of the lung or brain etc. improve tissue oxygenationand remove toxic proteins such as beta amyloid etc., IL10 inhibitorssuch as Canakinumab (Ilaris), GABA inhibitors such as KDS2010, lowmolecular weight heparin (Lovenox) to enhance nerve repair and preventblood coagulation, NSAIDs ibuprofen, Dexamethasone, and one or more Rockinhibitors or Wnt inhibitors are combined with a GSK inhibitor orintegrin inhibitor conjugated with antibody-coated polymeric slowrelease nanoparticles, where the antibody prevents the virus fromentering the cells is administered with a physiological solution orsemifluorinated alkane administered at a non-toxic dose in aphysiological solution or semifluorinated alkane or a physiologicalliquid as a spray, aerosolized through the nose, mouth, intravenously orintramuscular or subcutaneously as needed in lung, brain or multi-organdiseases after coronavirus infection or other viral infections.

In one embodiment, the inflammatory viral diseases of the lung, brain,and other organs are treated as described in this application inaddition with high oral doses of antioxidants such as ascorbic acid,Octyl gallate (octyl 3,4,5-trihydroxybenzoate), gallate (propyl3,4,5-trihydroxybenzoate), Calcium 1-ascorbate Propyl6-O-Palmitoyl-l-ascorbic acid (ascorbyl palmitate, natural ortocopherols, Synthetic α-tocopherol Synthetic γ-tocopherol Synthetic6-tocopherol, tetracycline and/or mycophenolic acid, an immunomodulator,has potent antiviral activity or Baricitinib, etc. or ananti-inflammatory agent such as dimethyl fumarate (DMF), used orally orwith or without and anti-VEGF by inhalation at low concentrations,inhibit pore formation and pyroptosis with its indiscriminate cellulardestruction in the lung, brain, or multi-organ diseases aftercoronavirus infection or viral or SARS-CoV-2, COVID-19 infections, etc.or severe inflammation of the lung or brain or intestinal tractinflammation, the so-called Multisystem Inflammatory Syndrome inChildren (MIS-C) diseases, etc.

In one embodiment, a compound such as an influenza virus inhibitor suchas sialidase is combined with a viral inhibitor such as Remdesivir,Favipiravir, Thiobenzamide, and an anti-inflammatory agent such asdexamethasone and/or a pathway inhibitor, such as Rock inhibitor(Fasudil) and/or Wnt inhibitor (Niclosamide), ivermectin, etc., GSKinhibitor, or integrin inhibitor conjugated with antibody-coatedpolymeric slow release nanoparticles, or conjugated with antibody-coatedliposomes filled with low molecular weight heparin (Lovenox) orsynthetic heparin mimetics or synthetic heparin, such as PG500, ornon-anticoagulant low molecular weight pegylated heparin filledliposomes or PEG-PLA, micelles or non-anticoagulant low molecular weightheparins administered in a physiological solution or semifluorinatedalkane or a physiological liquid as a spray, aerosolized through thenose, mouth, orally or injected subcutaneously, intravenously in anon-toxic dose or dry powder and liquid formulations is used forinhalation as a aerosolized preparation.

In one embodiment, one or two antivirals such as Remdesivir,Favipiravir, Ribavirin (RIB), oseltamivir, cyclosporine, and/orNiclosamide are combined with another antiviral heparin or low moleculeweight heparin such as Lovenox or synthetic heparin mimetics which actsin blocking virus attachment and entrance to the cells or endothelialcells used with a Rock inhibitor (Fasudil) and/or Wnt inhibitor(Niclosamide), ivermectin, etc., GSK inhibitor, or integrin inhibitorconjugated with antibody-coated polymeric slow release nanoparticles, orconjugated with antibody-coated liposomes filled with low molecularweight heparin (Lovenox) or synthetic heparin mimetics ornon-anticoagulant low molecular weight pegylated heparin-filledliposomes or micelles or non-anticoagulant low molecular weight heparins<600KD or other heparins, such as recombinant heparin, high molecularweight heparin, low molecular weight heparin, unfractionated heparin,heparin fragments, heparin analogue, low-molecular-weightheparin-taurocholate 7 (LHT7) and sulfonated polysaccharides containingheparin activity, heparan sulfate. In one embodiment, heparin, sulfatedheparin, or synthetic heparin, such as PG500, can be combined withcatechins or cyclodextrin or conjugated with chitosan andpoly(lactide-co-glycolide) complexes with or without other antivirals,such as faviflu, remdesivir, etc., to be used as nasal spray or combinedwith 0-pamitoyol to treat various viral infections, such as herpessimplex viruses of types 1 and 2), and the respiratory syncytial virus(SRV), influenza viruses, SARS-CoV-2, COVID-19, or their mutations humanpapilloma virus 16 (HVP-16), etc. administered in a physiologicalsolution or semifluorinated alkane or a solvent such as polyethyleneglycol or ethanol or a physiological liquid as a spray, aerosolizedthrough the nose, mouth, orally, or injected subcutaneously,intravenously in a non-toxic dose, or as a dry powder and liquidformulations used for inhalation as a aerosolized preparation to inhibitviral invasion in the cell or its proliferation.

In one embodiment, giant papillary conjunctivitis (GPC) is treated withartificial tears while avoiding the use of a contact lens oradministration of topical with an NSAID, such as Ketorolac 0.4%, etc.combined with low molecular weight heparin, e.g., enoxaparin or heparinmimetics.

In one embodiment, the viral infection, such as SARS-CoV-2, COVID-19, ortheir mutations etc. is treated with a topical application of lowmolecular weight heparin, such as lovenox, etc. with cyclosporine A asan anti-inflammatory and antiviral agent and anti-fungal at0.0000001%-5% concentration with or without antivirals such as Faviflu,Remdesivir, Favipiravir, etc. with or without Wnt inhibitors, such asivermectin or niclosamide which work synergistically with heparin orheparin mimetics or heparin nanoparticles and Ebselen and/or glutathioneperoxidase, and superoxide dismutase (SOD)—metabolize oxidative toxicintermediates requiring zinc, selenium, manganese iron, copper, and forideal catalytic activity and LMWH to treat viral conjunctivitis and/orscleritis, vasculitis, retinitis, loss of the smell, cerebralvasculitis, or lung infection caused by SARS-CoV-2, COVID-19, or theirmutations virus, etc.

In one embodiment, the viral infection, such as SARS-CoV-2, COVID-19, ortheir mutations, etc. is treated with a topical, intranasal, inhalation,etc. application of low molecular weight heparin or heparinnanoparticles, such as Lovenox, etc., with cyclosporine A or Tacrolimus,or a mycophenolic acid, an immunomodulator, has potent antiviralactivity and an anti-inflammatory and antiviral agents at 0,0000001%-5%concentration with or without other anti-inflammatory agents, such ascolchicine or in combination with Panx1 inhibitor probenecid in viralvasculitis to protect neurons from damage in the brain or afterrefractive corneal surgery.

In one embodiment, low molecular weight heparin, synthetic heparinmimetics, or synthetic heparin, such as PG500, work synergistically withcyclosporine A, antiviral and antifungal, synergistically to treattopically blepharitis, and dry eye with or without Wnt inhibitors at anon-toxic concentration.

In one embodiment, low molecular weight heparin or heparin nanoparticlesor antibody conjugated nanoparticles and/or microparticles of heparinmimetics, or synthetic heparin, such as PG500, PG 545, worksynergistically with catechins or with cyclosporine A, and anti-fungaland/or mycophenolic acid an immunomodulator, with potent antiviralactivity and an anti-inflammatory and antiviral agent where the antibodyprevents the virus from entering the cells with or without a solution ofstabilized hypochlorous acid at pH 6-8 or another medium in bacterialand viral infections of the lid and conjunctiva, etc.

In one embodiment, a topical application of low molecular weightheparin, such as Lovenox, or synthetic heparins, such as PG500, PG 545,etc. with cyclosporine A antiviral and anti-fungal at 0.0000001%-5%concentration with or without antivirals such as Faviflu, remdesivir,etc. with or without Wnt inhibitors such as ivermectin or niclosamidework synergistically to treat conjunctivitis and or scleritis caused byCOVID-19 virus.

In one embodiment, one or two antivirals, such as Remdesivir,Favipiravir, Ribavirin (RIB), oseltamivir, histone deacetylases (HDACs),such as Sodium Phenylbutyrate (PB) and Valproic Acid (VPA),cyclosporine, mycophenolic acid as an anti-inflammatory and antiviralanti-fungal agent, and/or Niclosamide are combined with anotherantiviral heparin or heparin mimetics, such as PG500, or PG 545, orheparin nanoparticles or low molecule weight heparin, such as Lovenox,which acts in blocking numerous viruses attachment and entrance to thecells or endothelial cells used with a Rock inhibitor (Fasudil), TGFbeta inhibitors, and/or Wnt inhibitor (Niclosamide), ivermectin, etc.,GSK inhibitor, or integrin inhibitor conjugated with antibody-coatedpolymeric slow release nanoparticles, such as polylactic, polyglycolicor a combination or polycaprolactone, polyanhydride, etc., or conjugatedwith antibody-coated liposomes filled with low molecular weight heparin(LMWH), such as (Lovenox) or non-anticoagulant low molecular weightpegylated heparin-filled liposomes or micelles, heparin nanoparticleswhere antibody prevents the virus from entering the cells ornon-anticoagulant low molecular weight heparins <6000KD, other heparinsfor use such as recombinant heparin, high molecular weight heparin, lowmolecular weight heparin, unfractionated heparin, heparin fragments,heparin analogue, low-molecular-weight heparin-taurocholate 7 (LHT7) andsulfonated polysaccharides containing heparin activity, heparan sulfate.or heparin mimetics/catechins administered in a physiological solutionor semifluorinated alkane or a physiological liquid as a spray,aerosolized through the nose, mouth, orally, or injected subcutaneously,intravenously in a non-toxic dose, or as a dry powder and liquidformulations is used for topical application, on the conjunctiva,intranasal inhalation as a aerosolized preparation to inhibit viralinvasion in the cell or its proliferation in conjunctivitis, nasal,throat, pharynx, lung, or through the nasal sensory nerves to brain andbrain vessel to prevent or treat vasculitis.

In one embodiment, LMWH or heparin nanoparticles or synthetic heparin orheparin mimetics, such as PG500, or PG 545, at 0.01 mg/ml to 30 mg/ml isused in combination with or without catechins and/or doxycycline with pHadjusted to 7.5 and a concentration of 0.1% to 2% is inblepharoconjunctivitis caused by bacterial infection, or antivirals inblepharoconjunctivitis as topical drops or spray.

In one embodiment, LMWH or heparin nanoparticles at 0.01 mg/ml to 30mg/ml concentration is used topically in combination with one or twoantivirals in blepharoconjunctivitis, such as in viral conjunctivitis,such as SARS-CoV-2, COVID-19, etc.

In one embodiment, LMWH or heparin nanoparticles or synthetic heparin,such as PG500, PG 545, etc. at 0.01 mg/ml to 30 mg/ml concentrationand/or as a combination with or without catechins and doxycycline orwith doxycycline with pH adjusted to 7.5 and concentration of 0.1% to 2%and/or triamcinolone at 400 microgram/0.1 ml are used topically inscleritis caused by a viral infection or in an autoimmune response to apathogen.

In one embodiment, LMWH or pegylated heparin or heparin mimetics, suchas PG500, PG 545 etc., nanoparticles is used topically in combinationwith a solution of sodium hypochlorite at concentrations 0.01-10%,stabilized to a pH of 5-10 preferably 7.5 to treat bacterial or viralconjunctivitis or viral keratoconjunctivitis, such as SARS-CoV-2,COVID-19 or their mutations, HSV1-2, VZV or intranasally for upper orlower respiratory viral infection or viral encephalitis as prophylaxisor therapeutic.

In one embodiment, LMWH or heparin mimetic, such as PG500, PG 545, etc.is used topically for inhalation, intranasally, etc. in combination withhypochlorous acid or sodium hypochlorite or chloramines, the stableN-chloro derivatives or N-chlorotaurine (NTC), dimethylated derivativesof NCT (N-chloro-2,2-dimethyltaurine [DM-NCT] andN,N-dichloro-2,2-dimethyltaurine [DM-NDCT] or their nanoparticlessequentially in viral upper respiratory infection, such as SARS-CoV-2,COVID-19, or their mutations, influenza, HSV 1-2 or Epstein Bar virus orVZV, etc. infection or viral encephalitis, vasculitis with or withoutprobenecid or histone deacetylases (HDACs), such as SodiumPhenylbutyrate (PB) and Valproic Acid (VPA).

In one embodiment, LMWH or pegylated heparin antibody-coated pluralitiesof nanoparticles or heparin mimetics, such as PG500, PG 545, etc., isused topically or for inhalation, intranasally, etc. in combination withanti-virals, such as Baricitinib, Glidesivir, Favipiravir, XofluzaRemdesivir, nanoviricides, Oya1, interferon, umifenovir, tamivirribavirin, baloxavir in viral upper respiratory infection, such asSARS-CoV-2, COVID-19, or their mutations, influenza, HSV 1-2 or EpsteinBar virus or VZV, etc. infection or viral encephalitis or vasculitis.

In one embodiment, heparin, or sulfated heparin, or heparin mimeticswith or without polyphenols with and without TGF beta inhibitors can becombined with cyclodextrin or conjugated with chitosan andpoly(lactide-co-glycolide) complexes with or without other antivirals,such as faviflu, remdesivir, Baricitinib, Glidesivir, Favipiravir,Xofluza Remdesivir, nanoviricides, Oya1, interferon, Artemisinin,umifenovir, tamivir. ribavirin, baloxavir, etc., to be used as nasalspray or combined with 0-pamitoyol to treat various viral infections tothe eye, nose, or respiratory tract, such as herpes simplex viruses oftypes 1 and 2), and the respiratory syncytial virus (SRV), influenzaviruses, SARS-CoV-2, COVID-19, or their mutations, human papilloma virus16 (HVP16), etc.

In one embodiment, when internal eye structures are involved inSARS-CoV-2, COVID-19, or their mutations or other viruses, oneadministers non-toxic concentrations of Baricitinib, Glidesivir,Favipiravir, remdesivir, Artemisinin, etc. topically or injected insidein uveitis, retinitis and vasculitis with or without low molecularweight heparin.

In one embodiment, the GPC is treated with administering slow releasepolymeric nanoparticles carrying one or more cell pathway inhibitors,such as the Rock inhibitor Fasudil, wmt.IL6 or TGF-beta inhibitor suchas Kavzara, Ivermectin or antiviral PLpro or Mpro inhibitors, such asEbselen, Ebseleno, or Ebselen, and/or glutathione peroxidase andsuperoxide dismutase (SOD)—metabolize oxidative toxic intermediatesrequiring zinc, selenium, manganese iron, copper, and for idealcatalytic activity applied in the nose, conjunctiva and/or with NSAIDsor low molecular weight heparin or pegylated heparin antibody-coatedpluralities of nanoparticles, such as Lovenox, Fragmin, dalteparin ornon-anti-thrombotic heparin, or heparin mimetic such as PG500, PG 545,etc., unfractionated heparin, an antibiotic, such as tetracyclinederivatives doxycycline, etc. or antiviral combinations.

In one embodiment, an intranasal application of low molecular weightheparin or heparin is administered with pluralities of nanoparticles andvasoconstricting agent, and Wnt inhibitors or mast cell stabilizercontrol itching and Astemizole an antihistaminic agent, at 0.1-0.5microgram/ml for as inhalation or spray running nose and allergicresponse, in lid, conjunctiva, nose and throat, etc.

In one embodiment, a topical application of low molecular weightheparin, such as Lovenox or synthetic heparin, such as PG500, PG 545,etc., with cyclosporine or mycophenolic acid or Baricitinib as ananti-inflammatory and antiviral agent at a 0.0000001%-5% concentrationor with Ebselen or doxycycline which also has an antiviral,antibacterial, anti-inflammatory, anti-prostaglandin, andneuroprotective effect, with or without antivirals, such as Faviflu,remdesivir, etc. and, vidarabine ointment, and trifluridine solution(Viroptic) or idoxuridine solution and ointment, work synergistic totreat conjunctivitis caused by bacteria and viruses or COVID-19 virus orits mutations and dry eye.

In one embodiment, a topical application in the conjunctiva or nasal oflow molecular weight heparin, such as Lovenox, or heparinantibody-coated pluralities of nanoparticles, etc. with probenecid orprobenecid nanoparticles and/or with Ebselen and/or glutathioneperoxidase and superoxide dismutase (SOD)—metabolize oxidative toxicintermediates requiring zinc, selenium, manganese iron, copper, and forideal catalytic activity applied with mycophenolic acid/Doxycyclinewhich acts as an antiviral, antibacterial, anti-inflammatory,anti-prostaglandin and neuroprotective as solution or ointment, worksynergistically to treat ocular inflammation caused by bacteria andviruses or SARS-CoV-2, COVID-19 virus, or their mutations, and dry eyeor after corneal refractive surgery.

In one embodiment, a topical application of low molecular weight heparinor antibody-coated heparin nanoparticles, or LMWH as Lovenox, etc., withadministration of topical with an NASID, such as Ketorolac 0.4% in dryeye and blepharoconjunctivitis.

In one embodiment, a topical application of low molecular weight heparinor with or without antivirals or pegylated heparin antibody-coatedpluralities of nanoparticles, such as Lovenox from 0.1 mg to 10 mg, etc.with mycophenolic acid, etc. at 0.0000001%-5% concentration worksynergistically to treat dry eye, allergic blepharoconjunctivitis orGiant papillary conjunctivitis, and scleritis, etc.

In one embodiment, a topical application of low molecular weight heparinor pegylated heparin nanoparticles, such as Lovenox, or heparinmimetics, such as PG500, PG 545, etc., with or without antivirals, withivermectin or niclosamide at picogram to microgram concentrations withor without antivirals, work synergistically to treat conjunctivitiscaused by bacteria and viruses.

In one embodiment, a topical application of low molecular weightheparin, such as Lovenox or catechins of pegylated heparin orantibody-coated pluralities of nanoparticles or othernon-anticoagulative heparins, where antibody, aptamer or mRNA conjugatedwith nanoparticles prevents the virus from entering the cells from 0.1mg to 10 mg and Ebselen which also has an antiviral, antibacterial,anti-inflammatory, anti-prostaglandin and neuroprotective effect at a0.00000001%-5% concentration with or without antivirals such asFavipiravir or an antibiotic, work synergistic to treat conjunctivitiscaused by bacteria and viruses.

In one embodiment, a topical application of low molecular weightheparin, such as Lovenox, etc., from 0.01 mg to 10 mg with apilimod orvacuolin-1, or Wnt inhibitor or Rock inhibitor or probenecid atmicrogram to nanogram concentrations, work synergistically for neuronalgrowth of the cornea after refractive surgery, such as LASIK, Smile, orcataract surgery, etc.

In one embodiment, the conjunctivitis is treated initially withnon-specific artificial tear drops and cold compress while more severecases of bacterial infections are managed with antibiotic drops orointments, such as Sulfacetamide, or ofloxacin or Polytrim, or Ciloxan(ciprofloxacin), combined or sequentially as anti-inflammatory agents,are useful except for steroid which requires exclusion of viralinfection, anti-integrins or GSK-inhibitors, etc. Preference is given ifviral infections, such as COVID-19 is suspected, to Wnt inhibitors,ivermectin, and an antiviral, such as acyclovir or valcyclovir orebselen and to low molecular weight heparin or antibody-coated heparinnanoparticles if other viruses are involved.

In one embodiment of bacterial or viral conjunctivitis, Lovenox or lowmolecular weight heparin or non-anti-coagulant heparin can be usedcombined or sequentially as, from 0.1 mg to 10 mg or more daily alonebecause of its antiviral effect or in addition to other antivirals totreat diseases, such as the SARS-CoV-2, COVID-19, or their mutationsvirus or herpes virus and other viruses, with antivirals such asBaricitinib, a Janus kinases inhibitor as an anti-TNF, Glidesivir,Favipiravir, Xofluza Remdesivir that blocks virus replication,nanoviricides, Oya1, interferon, umifenovir, tamivir ribavirin,baloxavir, histone deacetylases (HDACs), such as Sodium Phenylbutyrate(PB) and Valproic Acid (VPA), melatonin, can be used orally, as pills orgummy or liposomes or with semifluorinated alkanes or as a spray,intranasally, topically, by inhalation, or systemically with or withoutIL-6 inhibitors, etc. or Ebselen and or Ivermectin or other antiviralssuch as saquinavir, indinavir, ritonavir, nelfinavir, amprenavir,fosamprenavir, lopinavir, atazanavir, tipranavir, darunavir, etc.

In one embodiment of bacterial or viral conjunctivitis, Lovenox alone orin combination or sequentially as with ivermectin, or Ebselen and/orglutathione peroxidase and superoxide dismutase (SOD)—metabolizeoxidative toxic intermediates requiring zinc, selenium, manganese iron,copper, and for ideal catalytic activity applied to the eye withmycophenolic acid, an immunomodulator, potent antiviral activity or anantibiotic, doxycycline or a capsid inhibitor GS-6207 (Lenacapavir), canbe used in bacterial conjunctivitis or blepharoconjunctivitis because oftheir antibacterial effect, anti-viral effect, and its anti-inflammatoryaction or can be used in combination with an antibiotic or adisinfectant solution, such as hypochlorous acid or sodium hypochloriteor N-chlorotaurine (NTC), dimethylated derivatives of NCT(N-chloro-2,2-dimethyltaurine [DM-NCT] andN,N-dichloro-2,2-dimethyltaurine or their nanoparticles, which has alsosynergistic effect with low molecular weight heparin which as soothingeffect in addition to antiviral or bacterial, and anti-inflammatoryaction in the nose, lung, or brain.

Hypochlorous acid (HCLO) and its anion hypochlorite (OCl⁻) is naturallyproduced compound by the white blood cells by the enzyme myeloperoxidaseto eliminate invading bacteria, viruses, or fungi in the body. Itpenetrates the cell wall of the bacteria, protein, and nucleic acids todenature and deactivate them.

In one embodiment, stable Hypochlorous acid can be produced by eitheradding chlorine to the water to form hypochlorite, and ClO⁻ (HClO andClO⁻ are oxidizers). Hypochlorous acid can also be made by electrolysisof salt (Na Cl) in water (H₂O) producing hypochlorous acid and sodiumhydroxide (NAOH). Stable hypochlorous acid has a pH of 5-6. At pH 11-13,the chlorine is mostly in the form of hypochlorite solution, whereas atpH 5, most of the chlorine is present as hypochlorous acid (HOCl). Thehypochlorous acid with a long shelf life can be produced.

In one embodiment, Hypochlorous acid at concentrations of <500-50 orless, parts per million is not toxic and can be used as topical drops orspray for conjunctivitis blepharitis keratitis, or intranasally asinhalation at a concentration of <50 parts per million.

In one embodiment, the viral conjunctivitis is treated combined orsequentially with topical administration of liquid or ointment ofBaricitinib, a Janus kinase inhibitor as an anti-TNF, Glidesivir,Favipiravir, Xofluza Remdesivir, nitazoxanide, Artemisinin,nanoviricides, Oya1, interferon, umifenovir, tamivir ribavirin,baloxavir can be used topically, orally, systemically, or with orwithout IL-6 inhibitors, etc. and Lovenox and/or Ivermectin, and Ebselennanoparticles with or without or N-chlorotaurine (NTC), dimethylatedderivatives of NCT (N-chloro-2,2-dimethyltaurine [DM-NCT] andN,N-dichloro-2,2-dimethyltaurine nanoparticles.

In one embodiment, the viruses causing conjunctivitis can also bedrained in the nose through the nasolacrimal duct and infect the nose,through and pharynx. In one embodiment, the conjunctival and the nasalcavities are treated combined or sequentially by drops using thedescribed antivirals with antibody-coated pluralities of nanoparticlesof low molecular with heparin as spray drops or inhalation simultaneouswith the treatment of the conjunctiva with or without dimethylatedderivatives of NCT (N-chloro-2,2-dimethyltaurine [DM-NCT] andN,N-dichloro-2,2-dimethyltaurine nanoparticles.

In one embodiment, all forms of Heparins, such as high molecular weightheparin or heparin nanoparticles, low molecular weight heparin,unfractionated heparin, heparin analogues, heparin mimics containingglucosamine saccharides and acrylamide, and sulfated polysaccharidescontaining heparin activity heparin fragments, recombinant heparin orpegylated heparin nanoparticles or heparin mimetics have similarblocking effect on the viruses, such as SARS-CoV-2, COVID-19, or theirmutations, etc., bacteria and inflammation.

In one embodiment of bacterial or viral conjunctivitis, Lovenox can beused in bacterial conjunctivitis or blepharoconjunctivitis, because ofits antibacterial effect, anti-viral effect, and its anti-inflammatoryaction or in combination or sequentially with NSAIDs such as Ketorolac0.4% in allergic conjunctivitis as topical medication ointment or spray.

In one embodiment of bacterial or viral conjunctivitis, Lovenox can beused in bacterial conjunctivitis or blepharoconjunctivitis because ofits antibacterial effect, anti-viral effect, and its anti-inflammatoryaction or dimethyl fumarate (DMF), or a Janus kinase inhibitor as ananti-TNF alpha with Ebselen and tetracyclines and its derivatives, orglutathione peroxidase and superoxide dismutase (SOD)—requiringadditional zinc, or manganese, for ideal catalytic activity applied tothe conjunctiva, nasal passages or used orally or by injection or asinhalation in severe inflammatory conditions, such as multiplesclerosis, psoriasis, to inhibit protein Gasdermin D pore formation, anduncontrolled cellular damage or pyroptosis, in combination orsequentially with one or more antivirals, Favipiravir, nitazoxanide,Remdesivir, and/or molnupiravir or MK-4482/EIDD-2801 and/or a proteaseinhibitor, such as ritonavir, saquinavir, and indinavir administered ina physiological solution or semifluorinated alkane or a physiologicalliquid for inhalation with or without an inhaler in a COVID-19 upper orlower respiratory infection of its vasculitis in brain vasculitis, ormultisystemic inflammatory disease or orally or intravenously orsubcutaneously, etc., where the low molecular heparin attaches to theSARS-CoV-2, COVID-19, or their mutations, ACE-2 receptor and prevents ortreats the infection.

In one embodiment of bacterial or viral conjunctivitis, Lovenox orDalteparin can be used in bacterial conjunctivitis orblepharoconjunctivitis because of its antibacterial effect, anti-viraleffect, and its anti-inflammatory action or in combination orsequentially with one or more antivirals Remdesivir, Favipiravir, or aprotease inhibitor, such as ritonavir, saquinavir, and indinavir,molnupiravir or MK-4482/EIDD-2801 or nitazoxanide administered in aphysiological solution or semifluorinated alkane with an additionalsolvent, such as polyethylene glycol (PEG) or ethanol, or aphysiological liquid applied topically in the conjunctiva to treat aviral blepharoconjunctivitis or a viral keratitis, where the lowmolecular heparin or heparin mimetics attaches to the SARS-CoV-2,COVID-19, or their mutations, ACE-2 receptor and prevents or treats theinfection applied topically or using an inhaler.

In one embodiment, Lovenox or enoxaparin sodium solution is prepared at10-100 mg/ml at pH of 5.5-7.5 administered in a physiological solutionor semifluorinated alkane or a physiological liquid intra-nasally with aRock inhibitor and or TGF beta inhibitors as slow release polymericnanoparticles alone or in combination or sequentially with 1-2antivirals and a decongestant administered in a physiological solutionor semifluorinated alkane or a physiological liquid intra-nasally or byan inhaler to treat SARS-CoV-2, COVID-19 or their mutations asprophylaxis or therapy.

In one embodiment, Lovenox or enoxaparin sodium solution or heparinnanoparticles or pegylated heparin nanoparticles, or heparin mimetics isprepared at 1-100 mg/ml at pH of 5.5-7.5 alone as powder, inhalationdose from 0.1 mg to 20 mg or more daily solution or polymericnanoparticles for slow release poly (lactic glycolic) acid or incombination or sequentially with 1-2 antivirals and a decongestantadministered in a physiological solution or semifluorinated alkane or aphysiological liquid intra-nasally or by an inhaler to treat COVID-19 asprophylaxis or therapy.

In one embodiment, Lovenox or enoxaparin sodium solution or pegylatedemoxaparin nanoparticles, or heparin mimetics, such as PG-500 or PG-545,are prepared at 1-100 mg/ml at pH of 5.5-7.5 alone as powder, or sprayfor Inhalation dose from 0.1 mg to 20 mg or more daily solution orpolymeric nanoparticles for slow release or in combination orsequentially with 1-2 or more antivirals, Wnt inhibitor ivermectin orniclosamide, GSK inhibitor or anti-integrins and a decongestantadministered in a physiological solution or semifluorinated alkane withan additional solvent, such as polyethylene glycol (PEG) or ethanol or aphysiological liquid intra-nasally or by an inhaler, such as a deliverydevice selected from the group consisting of a nebulizer, an inhaler, oran aerolizer, ultrasonic nebulizer, jet nebulizer, to treat SARS-CoV-2,COVID-19, or their mutations and other viral respiratory diseases asprophylaxis or therapy.

In one embodiment, Lovenox or enoxaparin sodium or pegylated enoxaparinnanoparticles or heparin mimetics solution is prepared at 1-100 mg/ml atpH of 5.5-7.5 alone as powder, inhalation dose from 0.1 mg to 20 mg ormore daily solution or polymeric antibody-coated pluralities ofnanoparticles for slow release or in combination or sequentially with1-2 or more antivirals, Wnt inhibitor ivermectin or niclosamide, GSKinhibitor or anti-integrins or TNF alpha inhibitors Baricitinib, a Januskinases inhibitor, and/or IL-1β inhibitors, such as canakinumab or DMF,and a decongestant with or without stabilized hypochlorous acid solutionat pH 5-7 or sodium hypochlorite solution or administered in aphysiological solution or semifluorinated alkane with an additionalsolvent such as polyethylene glycol (PEG) or alcohol or a physiologicalliquid intra-nasally with or without an antibiotic ointment applied tothe nasal passages or by an inhaler, ultrasonic nebulizer, jet nebulizerto treat SARS-CoV-2, COVID-19, or their mutations or other viruses asprophylaxis or therapy of respiratory viral infection or viralencephalitis or severe vasculitis.

In one embodiment, Lovenox or enoxaparin sodium solution or antherAnticoagulants heparin is prepared at 1-100 mg/ml at a pH of 5.5-7.5alone or in combination or sequentially with 1-2 antivirals such asremdesivir and one protease inhibitor or other anti-virals, such asganciclovir or acyclovir or valacyclovir, Cidofovir, Vidarabine,Penciclovir, Foscamet Fomivirsen Famciclovir or Oseltamivir phosphate,Rimantadine, Amantadine, Zanamivir, Telbivudine, Lamivudine, Entecavir,Emtricitabine, capsid inhibitor GS-6207 (Lenacapavir), Adefovir, IL6inhibitor, administered in a physiological solution or semifluorinatedalkane or a physiological liquid intranasally as slow release polymericnanoparticles for topical application in viral keratitis as topicaldrops, spray or inhalation in inflammatory vasculitis of the brain orthe lung or topical application in the eye.

In one embodiment, Lovenox or enoxaparin sodium solution or anotheranticoagulant, heparin or heparin nanoparticles is prepared at 10-100mg/ml at a pH of 5.5-7.5 as powder, solution or polymeric nanoparticlesfor slow release, alone or in combination or sequentially with 1-2antivirals and remdesivir that blocks virus replication and one proteaseinhibitor or other anti-virals with or without stabilized hypochlorousacid, NCT of up to 0.5 mM concentration or sodium hypochlorite forinhalation or topic intranasal application, in treatment of viraldiseases of the eye, nose, upper and lower respiratory disease and viralcerebral vasculitis or orally with or without DMF for intestinalcomplication of COVID-19.

In one embodiment, Lovenox or enoxaparin sodium solution or anotheranticoagulant, heparin or heparin or heparin mimics containingglucosamine saccharides and acrylamide antibody-coated nanoparticles isprepared at 10-100 mg/ml at a pH of 5.5-7.5 as powder, solution or incombination or sequentially with 1-2 or more antivirals and remdesivirthat blocks virus replication and one protease inhibitor or otheranti-virals with or without stabilized hypochlorous acid (NaCLO),N-chlorotaurine (NTC), dimethylated derivatives of NCT(N-chloro-2,2-dimethyltaurine [DM-NCT] andN,N-dichloro-2,2-dimethyltaurine [DM-NDCT] nanoparticles or sodiumhypochlorite at 0.05-1.5 wt %; or more or hypochlorous acid (HCLO) incombination with water or semifluorinated alkanes at similarconcentrations or stabilized hypochlorous acid 0.10% for inhalation orfor topic intranasal application along with an antibiotic ointmentapplied with or without Ebselen and or glutathione peroxidase andsuperoxide dismutase (SOD)—requiring additional zinc, or manganese, forideal catalytic activity applied to the nasal passages, in treatment ofviral. bacterial diseases of the eye, nose, upper and lower respiratorydisease and viral cerebral vasculitis where endothelial cell of thevessels are damaged by the released cytokine, or orally for intestinalcomplication of SARS-CoV-2, COVID-19, or their mutations in MultisystemInflammatory Syndrome in Children (MIS-C).

In one embodiment, low molecular weight heparin or pegylated heparinnanoparticles at 0.01 mg to 300 mg·ml solution, preferably 0.05-0.1 wt %or 1-10 mg/ml is used alone or in combination with DMF at microgram tomilligram concentrations, doxycycline at concentrations of 0.5%-10%doxycycline alone or in combination with sodium hypochlorite of 0.001-2wt % or hypochlorous acid, N-chlorotaurine (NTC), dimethylatedderivatives of NCT (N-chloro-2,2-dimethyltaurine [DM-NCT] andN,N-dichloro-2,2-dimethyltaurine [DM-NDCT] nanoparticles, or with orwithout probenecid in water or semifluorinated alkanes with additionalsolvents, such as polyethylene glycol (PEG) or ethanol as topical,mucosal, oral, intranasal, inhalation, etc. an antibiotic ointment, suchas doxycycline, applied to the nasal passages to treat bacterial orviral conjunctivitis or nasal and respiratory tract, influenza,COVID-19, etc., viral, RNA or DNA viruses including prions or bacterialrespiratory infection or cerebral vasculitis, necrotizing scleritis,encephalitis, intestinal multisystem disease in SARS-CoV-2, COVID-19, ortheir mutations.

In one embodiment, low molecular weight heparin or heparinantibody-coated pluralities of nanoparticles at 0.01 mg to 300 mg·mlsolution, preferably 0.05-0.1 wt % or 1-10 mg/ml is used alone or incombination with doxycycline at concentrations of 0.5%-10% doxycyclinealone or with dexamethasone 400-2000 mg/ml in combination orsequentially in water of semifluorinated alkanes with or withoutprobenecid as topical, mucosal, oral, intranasal, tetracyclinederivatives, an antibiotic ointment etc. applied to the nasal passagesby inhalation, etc. act simultaneously as an antiviral, antibacterial,and an anti-inflammatory in respiratory viral infections,anti-inflammatory or as topical drops in the eye for ocular and adnexalinflammation or uveitis or scleritis.

In one embodiment, low molecular weight heparin or heparin mimicscontaining glucosamine saccharides and acrylamide to bind to13-Secretase (BACE-1) involved in Alzheimer's disease (AD) or pegylatedheparin nanoparticles at 0.01 mg to 300 mg·ml solution, preferably0.05-0.1 wt % or 1-10 mg/ml is used as spray or aerosolized forinhalation alone or in combination with doxycycline at concentrations of0.5%-10% doxycycline alone or rifampin 0.1 mg to 5 mg/ml and Rockinhibitors with dexamethasone 400-2000 mg/ml in water or semifluorinatedalkanes with an additional solvent, such as polyethylene glycol (PEG) oralcohol as topical, mucosal, oral, intranasal, inhalation, or the use ofinhalator to treat vascular endothelial cell damage in the lung or inthe brain, etc. by preventing COVID-19 or other viruses to attach to theendothelial cell wall, prevent complement factors activation, andcausing damage and subsequent attachment of the platelets and blood clotformation.

In one embodiment, one administers subcutaneously or intravenously, etc.low molecular weight heparin or heparin mimetics combined with LY6E, anaturally occurring protein in the body, to prevent the virus attachmentto the ACE-2 receptors and inhibition of virus to enter the endothelialcells and damage them in respiratory viral infection or viral brainencephalitis through an inhalation preparation or intravenously orsubcutaneously.

In one embodiment of a case of conjunctivitis or viral or bacterialrespiratory or brain infection, one can administer topically or sprayfor inhalation a combination or sequentially with mycophenolic acid anIL-17 inhibitor or cyclosporine as antiviral and anti-inflammatory andan antiviral agent in a 0.5-1 mg/ml physiological solution orsemifluorinated alkanes, as emulsion or micelles or nano-micelles,liposomes, or oil in water, with 0.001-20 or more mg/ml of low molecularweight heparin or heparin mimetics, or heparin antibody-coatedpluralities of nanoparticles and at least one or more antivirals, incombination or sequentially topically or for inhalation or withLifitegrast at concentration of 1 mg/ml or dexamethasone, at 10microgram/ml to 4 mg/ml one-three times to five times a day or more or1-2 drops a day, with doxycycline and minocycline to reduce bacterialspread, and act as anti-inflammatory agents, etc.

In one embodiment, all accessible body cavities involved with a viral orbacterial infection, such as the bladder, uterus, abdominal cavity, eye,or CNS cavities or in the joint or subcutaneously can be treated withnon-toxic doses of the above described preparations in a non-toxic dosealong with TNF alpha inhibitor Baricitinib, a Janus kinase inhibitor orIL-beta inhibitors or DMF in a physiological solution or semifluorinatedalkane or a physiological liquid by intracavity administration orinjection or intravenously or intraarterial as is needed and preventpost encephalitis induced dementia.

In one embodiment using intranasal delivery to the brain takes a shorterand faster route than the systemic administration. Since the bloodvessel are separated from the brain by the presence of the blood brainbarrier. In addition, the nasal delivery bypasses the generalcirculation that brings polymeric slow release nanoparticles to theliver where they are taken up from circulation and never reach thebrain.

In one embodiment, at least two antivirals used in an appropriate mediumat a lower concentration that is administered alone to increaseeffectiveness of the preparation against the viral infection whilereducing their toxicity and treat a viral infection.

In one embodiment, at least two antivirals PEGylated or non-PEGylatedare combined with one or more protease inhibitors or polymeraseinhibitors with LMWH, or mycophenolic acid to increase effectiveness ofthe preparation against the viral infection while reducing theirtoxicity and treat a viral infection.

In one embodiment, at least two antivirals are combined withanti-inflammatory agents such as Baricitinib, DMF, complement inhibitors(C1, C3, C5) and one pathway inhibitor sequentially or as a cocktail atreduced concentrations to increase their efficacy and reduced their sideeffects.

In one embodiment, the vaccine is created to act simultaneouslytherapeutically and as vaccine by killing the viruses or bacteria orfungi after they have grown in the cell culture media or other culturemedia, using at least one antiviral or one antibiotic, a tetracycline orantifungals and methylene blue at concentrations of <5 μg/ml or more,this remaining mixture will have an antiviral, methylene blue and/or anantibiotic, such as tetracycline or antifungal that can be administeredto a person as a therapeutic medication/vaccine while after itsabsorption in the body through inhalation, nose or orally in theintestinal tract or administration intramuscularly or intravenously orintraperitoneally acts as vaccine because, it is made of a composite ofmedications, such as methylene blue and at least one antiviral and/orantibacterial or antifungal plus antigenic material from the virusessuch as antigenic membrane protein or bacterial protein, etc.Stimulating the body's immune response to produce neutralizingantibodies against viruses or bacteria or fungi, etc. This vaccinationcocktail is made of a non-toxic dose of methylene blue that penetratesthe membrane wall of the bacteria and virus, etc. to attach itself tothe RNA and DNA of the organism and corrupts their genetic material, orin conjunction with one or more antivirals or one more antibiotics,etc., such as tetracycline derivative, etc., or antifungals, such asvorcanazol, etc. that enter now with ease the viral and bacterialmembranes or fungi to enter the cytoplasm of the viruses or bacteria orfungi and attach to their RNA and DNA, thus damaging it and killingthese organisms, while the remaining membranes of the virus and/orbacteria still remains antigenic producing an immune response to theorganism.

In one embodiment, this above-mentioned mixture can be made in a largequantities to act also now therapeutic, i.e., they can kill the organismlocally. However, when they are absorbed inside the body, the deadmembranes of these organisms maintain their antigenic characteristic andinduce a humoral or cellular immune response as a vaccine does byenhancing the immune response. Therefore, the vaccine acts now boththerapeutically by killing the viruses or bacterias or fungi, etc. andsimultaneously acts as vaccine since it contains also the antigenicmaterial of the organism, plus antivirals and or antibiotics orantifungals or antiparasites that it carries.

In another embodiment, the antigen of the viruses or bacteria, etc.,obtained as above, is added to one or more antivirals or one or moreantibiotics to build this mixture that acts both therapeutically or asvaccine after administration, nasally, orally, intramuscularly orintravenously killing the viruses or bacteria, etc. and simultaneouslyacting as a vaccine enhancing the immune response to the specific virusor bacteria or fungi.

In another embodiment, the antigen of the viruses or bacteria, etc. isadded to one or more antivirals or one or more antibiotics with orwithout methylene blue at less than 4 microgram/ml concentration tobuild this mixture that acts both therapeutically to which a pathwayinhibitor and/or LMWH is added in order to act as anti-inflammatoryreducing the inflammatory response to the mixture while acting as avaccine simultaneously because it carries the antigen of the specificvirus and bacteria or fungi along with the appropriate medications.

In one embodiment, the antigen/medication of the viruses or bacteria,etc. obtained as above is added to one or more antivirals or one or moreantibiotics to build this mixture that acts both therapeutically towhich other compound are added, such as LMWH or heparin mimetic, toprevent side effects of blood coagulation, or in addition to catechinsor linoleic acid etc.

In one embodiment, the approach to therapy of moderate to severe viralinflammatory disease or persistent viruses after therapy, etc. is to usemessenger RNA coated CRISPR (crRNA) directed to a specific region of thevirus where Cas-9 or Cas-13, etc. conjugated via thiol, not a modifiedvirus, with antibody-coated very small 1-20 nm in size or preferably1-10 nm nanoparticles of gold, silver or zinc which penetrate themembranes of the viruses with ease and have an antiviral activitycombined with an mRNA inhibitor, such as plitidepsin or Aplidin, alongwith one or more antivirals, such as Remdesivir, Favipiravir ornitazoxanide or Lopinavir or methylene blue, etc. or with or withoutpathway inhibitors and with LMWH or heparin mimetic in a solution or ina semifluorinated alkane or with or without linoleic acid, andadministered as intranasal spray or by inhalation, orally, etc. todamage the mRNA viruses, such as SARS-CoV-2 or COVID-19 or otherrespiratory viruses or HIV virus, etc.

In one embodiment, the approach to therapy of moderate to severe viralinflammatory disease or persistent viruses after therapy, is to usemessenger RNA conjugated CRISPR interference (CRISPRi) or using acatalytically dead (dCas9 protein), which does not have endonucleaseactivity for genes regulation (i.e. cutting or replacing it) whiledirected to specific region of the virus where dCas 9 or dCas 13, etc.conjugated with an antibody coating, not with a modified virus, but withvery small 1-20 nm in size or preferably 1-10 nm antiviral nanoparticlesof gold, silver or zinc with an mRNA inhibitor, such as remdesivir orplitidepsin or Aplidin, via thiol in a cationic milieu.

In one embodiment of therapeutic vaccination, a combination of methyleneblue with dead or without dead viruses or an mRNA virus vaccine, etc.plus antivirals, e.g. polymerase inhibitor such as remdesivir, orplitidepsin or Aplidin, or lopinavir, a protease inhibitor, and pathwayinhibitors and LMWH and/or heparin mimetic are prepared for inhalationusing a mixed micelle system where two or more medications can be mixedfor multiple inhalation using an inhaler or with a mucomyst byinhalation, which contains acetylcysteine, n-acethylsystein or itsderivatives, which act as an anti-inflammatory and antithrombotic whencombined with antivirals and cell pathway inhibitors for therapeuticvaccines, etc., or by spraying through the nose or mouth all atnon-toxic concentrations the micelles can be administered with orwithout PEG for ease of penetration through the mucosa covering thenasal mucosa, reaching the brain through the olfactory or trigeminalnerves or through the throat, trachea, bronchi and lung alveoli to reachthe alveoli of the lung capillaries with ease.

In one embodiment, the antigens of multiple viruses or mRNAs, ormutations the same virus, bacteria, etc. is added to one or moreantivirals or one or more antibiotics, such as tetracycline derivativeswith or without methylene blue at about a 4 microgram/ml concentrationwith antibody-conjugated gold, silver, or zinc, etc. small nanoparticlesof less than 20 nm preferably 1-10 nm in diameter to build this mixturethat acts both therapeutically to many viruses, the so-called universaltherapeutic vaccine against viruses or bacteria or fungi, etc. to whicha pathway inhibitor is added in order to act as anti-inflammatoryreducing the inflammatory response to the mixture, while acting as avaccine simultaneously because it carries the antigen of the specificvirus and bacteria or fungi along with the appropriate medications,forming a cocktail for vaccination against, e.g., numerous strains ofviruses or bacteria or fungi etc.

In another embodiment, the antigen of the viruses or bacteria, etc. isadded to one or more antivirals or one or more antibiotics with orwithout methylene blue at less than a 4 microgram/ml concentration tobuild this mixture that acts both therapeutically to which a pathwayinhibitor is added in order to act as anti-inflammatory reducing theinflammatory response to the mixture while acting as a vaccinesimultaneously because it carries the antigen of the specific virus andbacteria or fungi along with the appropriate medications forming acocktail for vaccination against, e.g., numerous viruses to bacteria forimmunization of children or adults.

In one embodiment this above-mentioned mixture, can be made in a largequantities to act also now therapeutic, i.e., they can kill the organismlocally, however when they are absorbed inside the body the deadmembranes of these organism maintain their antigenic characteristic andinduce a humoral or cellular immune response as a vaccine does enhancingthe immune response. Therefore, the vaccine acts now boththerapeutically by killing the viruses or bacteria or fungi etc. andsimultaneously acts as vaccine since it contains also the antigenicmaterial of the organism, plus antivirals and/or antibiotics,anti-fungals, or antiparasites that it carries.

In one embodiment to reduce an inflammatory response, one can deliverthe therapeutic combination of an antiviral incrementally orencapsulated in wax, gelatin, polycaprolactone, or as a capsule, pill,or dry powder for inhalation by combining one antiviral such as proteaseinhibitor, such as Ebselen and/or a polymerase inhibitor, such asremdesivir, faviravir, and/or with a transcription inhibitor, such asabacavir combined with Mpro or Ganovo to block the entry of the virus inthe cell and/or antibody coated nanoparticles or LNP or goldnanoparticles etc. with one or more cell pathway inhibitors, such asRock inhibitor Fasudil or ROCK2, Fasudil1-(5-Isoquinolinesulfonyl)-2Methylpiperazine Calcium Channel Blockers, and/or Molnupiravir apolymerase inhibitor polymerase inhibitor, AT-527. orally or with RBDinhibitor, heparin mimetic, LMWH, lenolic acid, or with oneanticoagulant, such as rivaroxaban (Xarelto), dabigatran (Pradaxa),apixaban (Eliquis) or edoxaban (Lixiana), etc. or orally orintramuscularly, subcutaneously, etc., by injection, or by inhalation,or with a mucomyst by inhalation or intravenously which containsacetylcysteine, n-acethylsystein, or its derivatives, where they act asan anti-inflammatory and antithrombotic, or by inhalation at very lowdoses that can be increased incrementally by the doctor/patient untilneutralizing antibodies are measured in the serum of the patient andprevent a severe immune response that can produce blood clots in themain vessels or dissolving blood clot if they have formed.

In one embodiment, in cell culture of viruses including SARS-CoV-2 or 19or Omicron etc. or their mutations or any other viruses, the methyleneblue can be combined with one or more DNA or RNA damaging agents withoutdamaging or crosslinking the viral proteins, such as an antiviral, anantimetabolite, such as Floxuridine, 5-Fluorouracil, 6 Mercaptopurine,cytarabine, flurabine, or para-aminobenzoic acid (PABA), or sulfonamide,the antimetabolite antibiotics preventing replication of DNA or RNA oractinomycine-D, etc., ribavirin, a nucleoside reverse transcriptaseinhibitor (NRTI) targets enzymes, including inosinate dehydrogenase,thymidylate synthase, cytidine-5′-triphosphate synthetase, etc. thatblock RNA and DNA of viruses or other antivirals, such as achemotherapeutic agent, salvianolic acid A & B, an antiviral agent, oran antineoplastic agent, or an antitumorgenic agent, or animmunotherapeutic agent such as mycophenolic acid or antimitotic agentor their analogues or a prodrug that are activated by viral proteases,such as paclitaxel, combretastatin, bryostatin, colchicine, ordiscodermolide at low non-toxic concentrations to kill the organism inthe cell culture or to be administered after preparation as a vaccinesubsequently locally, nasally, orally, intravenously, orintramuscularly, etc. or administered to the patient combined with oneor more inflammatory pathway inhibitors and/or LMWH or anotheranticoagulant absorbed inside the body through various routes ofadministrations, such as the nose, orally, intravenously,intra-arterially, locally, etc. where the dead membrane of theseorganisms are sieved out and they maintain their antigeniccharacteristics and induce both a humoral and/or cellular immuneresponse as a vaccine, thereby enhancing the immune response while themedications kill the viruses, therefore this vaccine acts now boththerapeutically and prophylactically, while the pathway inhibitors, etc.prevent severe inflammatory processes, or radiotherapeutic agents and/orchemotherapeutic agents are provided.

In one embodiment, lipid nanoparticles combined with one or moreantivirals or a vaccine, such as an mRNA vaccine, etc., is deliveredthrough inhalation to avoid systemic absorption of the nanoparticlesthrough the reticuloendothelial cells, or in the liver or spleen, whilereducing the amount of medication that is given alone or in combinationwith one or more pathway inhibitors to prevent post vaccinationinflammatory processes, and the therapeutic vaccine can beself-administered by the patient at any frequency or concentration asprescribed by the physician with or without LMWH or anotheranticoagulant, such as a mucomyst by inhalation, which containsacetylcysteine, n-acethylsystein, or its derivatives that act as ananti-inflammatory, Entyvio (vedolizumab), ustekinumab and IL-12/23Xeljanz and antithrombotic when combined with antivirals and cellpathway inhibitors for therapeutic vaccines, etc. with or withoutlineolic acid.

In another embodiment, the therapeutic vaccine uses lipid nanoparticlescombined with antivirals or an existing vaccine, and is deliveredthrough inhalation to avoid systemic absorption of the nanoparticlesthrough the reticuloendothelial cells, or in the liver or spleen, whilereducing the amount of medication when it is given alone or incombination with one or more pathway inhibitors to prevent postvaccination excessive inflammatory processes, and the therapeuticvaccine can be self-administered by the patient at any frequency orconcentration as prescribed by the physician with or without LMWH oranother anticoagulant or with a mucomyst by inhalation, which containsacetylcysteine, n-acethylsystein, or its derivatives that act as ananti-inflammatory and antithrombotic when combined with antivirals andcell pathway inhibitors for therapeutic vaccines, etc., or lineolicacid, or catechins, etc. self-administered by inhalation to treat viralencephalitis with or without methylene blue boosting other vaccines whenadministered together as adjuvant.

In one embodiment, the gold, silver, zinc, or other metallic ornon-metallic antibody-coated nanoparticles combined with antivirals,antibacterials, or antitumorals as a vaccine is delivered throughinhalation to avoid systemic absorption of the nanoparticles through thereticuloendothelial cells, or in the liver or spleen, while reducing theamount of medication given alone or in combination with one or morepathway inhibitors to prevent post vaccination inflammatory processesand the therapeutic vaccine can be self-administered by the patient atany frequency or concentration as prescribed by the physician with orwithout LMWH or another anticoagulant or lineolic acid. The samecombination can be given through other routes to the body as needed.

In one embodiment, metallic or non-metallic antibody-coatednanoparticles, such as gold, silver, or zinc oxide with or without PEG,etc. are conjugated with an mRNA in which the nucleoside is modified tocarry the vaccine inside the cell eliminating the use of polymer hydridnanoparticles (LPNs) or can carry any other gene to the organ as needed,by either local injection, inhalation, intra-arterially, intravenously,orally, in the eye, inside other body cavities, or in the circulationetc. as needed.

In one embodiment, the antibody-coated polyethylene glycol coatedmetallic nanoparticles, such as gold, silver, or zinc oxide at 1-10 nmdiameter or more can be conjugated with a Dcr, a catalytically dead(dCas9 protein), CRISPR, or CRISPRi via thiol in a cationic milieu totemporarily or permanently cut or modify the desired gene(s) in the bodyor selectively in the desired organs, etc.

In one embodiment, involving the in vitro culture of bacteria, fungi orparasites, or a malignant or benign tumor, the methylene blue can becombined with one or more DNA or RNA damaging agents without damaging orcrosslinking the bacteria, fungi, or parasites, or a tumor's proteins,such as an antiviral, an antimetabolite, such as Floxuridine,5-Fluorouracil, 6-Mercaptopurine, cytarabine, flurabine, tacrolimus,para-aminobenzoic acid (PABA), or sulfonamide, the antimetaboliteantibiotics preventing replication of DNA or RNA or actinomycine-D,etc., ribavirin, a nucleoside reverse transcriptase inhibitor (NRTI)target enzymes, including inosinate dehydrogenase, thymidylate synthase,cytidine-5′-triphosphate synthetase, etc. that block RNA and DNA virusesor bacteria, fungi, or the tumor cells, a chemotherapeutic agent,salvianolic acid A & B, an antiviral agent, an antineoplastic agent, anantitumorgenic agent, or an immunotherapeutic agent, such asmycophenolic acid or an antimitotic agent or their analogues or prodrugthat are activated by viral proteases, such as paclitaxel,combretastatin, bryostatin, colchicine, or discodermolide at lownon-toxic concentrations to kill the organism in the cell culture or thetumor cells and to be used as a vaccine locally, intravenously, nasally,by inhalation, or administered to the patient combined with one or moreinflammatory pathway inhibitors and/or LMWH absorbed inside the bodythrough various routes of administration, where the dead membranes orcytoplasmic proteins of these dead organisms, viral, bacteria, fungi, ora patient's tumor cell maintain their antigenic characteristics withoutbeing crosslinked and induce a humoral and/or cellular immune responseas a vaccine, thereby enhancing the immune response with or withoutnatural killer cells, while the medications kills the bacteria, fungi,parasites, or a patient's tumor cells. As such, the vaccine acts both ina therapeutical and prophylactical manner by eliminating the causativeagents, while the pathway inhibitors, etc. prevent severe inflammatoryprocesses or provided with a combination of radiotherapeutic agents orchemotherapeutic agents at a low non-toxic level with or without othermedications, such as LMWH, or another anticoagulant, etc.

In one embodiment, the patients, after recovery from the respiratoryviral infection, such as the SARS-CoV-2 infection, COVID-19, or otherviral diseases, such as EBV, etc., have prolonged symptoms of thedisease, these include severe fatigue, neuropathy, shortness of breathand dizziness, weakness and hypoxemia, headaches or confusion, increaseddepression and anxiety, gastrointestinal symptoms, coronary plaquerupture, a heart attack, chronic inflammation, myocarditis, simmeringencephalitis, or bronchitis, etc. that translates into hundreds orthousands of patients, considering the millions or people affected justfrom the COVID-19 virus.

In one embodiment, the cause of the chronic disease is due to stillliving viruses in the respiratory tract or elsewhere that create chronicinfections, and are treated with repeat full doses or ½, ⅓, ¼, or alower percentage dose of an existing vaccine alone or combined with oneor more pathway inhibitors, such as Wnt, GSK, Rock inhibitors, oranti-integrins injected intramuscularly, or preferably, by inhalation ororally.

In one embodiment, the cause of the chronic disease is due to stillliving viruses in the respiratory tract or elsewhere or persistence ofviral antigens in the tissue, e.g., in the lung, heart, or brain, etc.that create chronic infections, are treated with repeat full doses or ½,⅓, ¼, or a lower percentage dose of a therapeutic vaccine which has anantiviral effect and a vaccine effect to activate the immune systemalone, or preferably combined with one or more pathway inhibitors, suchas Wnt, GSK, Rock inhibitors, or anti-integrins injectedintramuscularly, or preferably, by inhalation or orally, and/or combinedfor a period of time with anticoagulants to prevent blood clotting suchas an LMWH, or heparin mimetics, or another anticoagulant, complement C3or C5 inhibitors, or steroids or DMF or Tocilizumab, intravenously,intramuscularly, or by inhalation, etc.

In one embodiment, the therapeutic vaccine can be made in a viral cellculture for the growth of the virus prior to preparation as a vaccine,as described above, or the virus is grown in egg as is known in the art,where the eggs produce numerous copies of the viruses, the virus isextracted and killed or weakened with a combination of methylene blue atdoses of <4 μg/ml or more, and one or more antiviral medications,antineoplastics, and/or anticytotoxic medications, etc. are used todamage the RNA or DNA without crosslinking the membrane proteins, suchas the S-protein of the virus or affecting the cytoplasmic proteins thatinduce antigenic response, and with or without pathway inhibitors orother agents for reducing the inflammatory response of the host, and areprepared as known in the art prior to filtration and conjugation oflipid nanoparticles, nano-emulsions, micelles, solid lipidnanoparticles, or gold, zinc, or silver antibody coated nanoparticleswith thiol binding for the vaccination without using a viral vector thathas the potential of an immune response to the viral antigen, such asseen with Adenovirus 5, or AAD virus or Adenovirus 26 or the use ofother viruses from chimpanzees, birds, etc. In one embodiment, to reducethe immune response to egg proteins, one can deliver the vaccineencapsulated in vax or gelatin, by measuring the viral physical titer,thermal and colloidal stability, molar mass and size, and nucleic acidcontent aggregation, etc. combined with pathway inhibitors such asivermectin or niclosamide etc. orally that are released in theintestine, in low doses that can be increased incrementally untilneutralizing antibodies are measured in the serum of the patient andprevent a severe immune response that can produce blood clots in themain vessels.

In one embodiment, where the patient has an egg allergy, mRNA vaccinesare made as known in the art and/or combined with therapeutic vaccineshaving one or more antivirals, but delivered by inhalation or orallyalong with pathway inhibitors that the patient can administer to himselfor herself by inhalation or orally incrementally as prescribed by adoctor or administered intramuscularly by a health professional. Thecombination of pathway inhibitors with a vaccine with or without LMWH oranother anticoagulant reduces or eliminates the side effects ofvaccinations.

In one embodiment, recombinant virus-like particles are used to elicitan immune response to viral proteins with or without polysaccharides orproteins, with combined or separate administration of pathwayinhibitors, such as Wnt inhibitors (e.g., ivermectin or niclosamide) byinhalation or orally, and/or combined with 4-phenylchalcone oxide atconcentrations of <400 mg/kg, an inhibitor of soluble epoxide hydrolasethat produces leucotoxine and leucotoxine-diol given by inhalation ororally, etc. to combat post vaccination side effects of fluid leakage inthe lung, brain, intestine, or kidney.

In one embodiment with children, the immune response to the invadingviruses or SAR-CoV-2 and its mutations, such as COVID-19, etc. or inbacterial infections, such as tuberculosis (TB), is not strong enough tokill viruses or bacteria by antivirals and antibiotics, etc. ormonoclonal antibodies, thereby it may not be recognized while thechildren can carry the virus to others. In these situations, managementof the disease should be different than adults by administering acombination of immune stimulation (i.e., a vaccine), adjuvants andtreatment medication(s) as described above to eradicate the diseaseprocess, rather than just one medication.

In one embodiment, the therapeutic vaccine (i.e., vaccine plusmedications) can be used as a booster to stimulate the immune responsewith other vaccines and subsequent to the vaccination using any othervaccine.

In one embodiment, the therapeutic vaccine (i.e., vaccine plusmedications) can be used as a booster to stimulate immune response withother vaccines and subsequent to the vaccination using any other vaccinein combination with oral administration of microbiome to enhance theeffect of gut microbiome and its anti-inflammatory effect on thediseases processes by producing short chain fatty acid in the gut thatare absorbed by the gut blood vessels.

In one embodiment, the vaccine alone or with heparin, such as theJohnson & Johnson (J&J) COVID-19 vaccine, carrying an antigen such as anadenovirus protein or another viral protein used as a vector, etc. inaddition to SAR-CoV-2 or Covid 19 or their mutations' protein, such asan s-protein can initiate a so-called generalized heparin inducedthrombosis which is manifested by fatigue, headache, and simultaneousthrombosis and thrombocytopenia about 5 to 14 days after vaccination ora side effect of the use of heparin or LMWH immune response or viralantigen building an immunocomplex on the platelets and monocytes againstplatelet factor (4 PF4), where activation of monocyte and plateletproduces blood clots. In one embodiment, the heparin is replaced withanother anticoagulant, such as rivaroxaban (Xarelto), dabigatran(Pradaxa), apixaban (Eliquis) or edoxaban (Lixiana) administration incombination or sequential administration of a Wnt inhibitors, such asivermectin or niclosamide, or with Rock inhibitors or integrininhibitors or GSK inhibitors, and/or an immunosuppressant such asmycophenolic acid, cyclosporine, etc., Bariticinib, with or withoutplasmapheresis, or kidney dialysis to remove the antigens and cytokinesfrom the blood and to stop the autoimmune response of the body, and thestandard dose of vaccination is reduced to ½ or ¼th of the standard doseto avoid an excessive immune response.

In one embodiment, one can grow many different viruses in different thecell culture media or in egg and produce numerous copies of the viruses.The viruses are then extracted and killed or weakened with a combinationof methylene blue at doses of <4 mg/liter or more and one or moreantivirals medications and one or more antineoplastic or anticytotoxicmedications, etc. to damage the RNA or DNA without crosslinking themembrane proteins, such the S-protein of the COVID-19 virus or thecytoplasmic and capsid membrane proteins or glycoprotein of any otherviruses that have been grown without crosslinking them or affecting thecytoplasmic protein or their capsid membrane that induce an antigenicresponse with or without pathway inhibitors or other agents reducing theinflammatory response of the host and prepared as known in the art priorto filtration and conjugated with lipid nanoparticles, nano-emulsions,micelles, solid lipid nanoparticles and/or antibody coated nanoparticlesof gold, zinc, silver, etc. with thiol binding, thereby producing avaccine that simultaneously acts against many known or unknown viruseswithout using a viral vector that has the potential of an immuneresponse to the viral antigen, such as seen with Adenovirus 5, AADvirus, or Adenovirus 26 or the use of other viruses, from chimpanzees,birds, etc. In one embodiment to reduce immune response, one can deliverthe vaccine incrementally or encapsulated in vax or gelatin, bymeasuring the viral physical titer, thermal, and colloidal stability,molar mass and size, and nucleic acid content aggregation, etc. combinedwith pathway inhibitors, such as ivermectin or niclosamide with oneanticoagulant, such as rivaroxaban (Xarelto), dabigatran (Pradaxa),apixaban (Eliquis) or edoxaban (Lixiana), etc. orally that are releasedin the intestine, or by intramuscular, subcutaneous, etc. injection, orby inhalation at very low doses that can be increased incrementally bythe doctor/patient until neutralizing antibodies are measured in theserum of the patient and prevent severe immune response that can produceblood clot in the main vessels.

In one embodiment, the therapeutic vaccine has multiple antivirals andthe viral envelope or capsid protein or glycoprotein is combined with atoll-like receptor 2 or TLR4 or VLP to stimulate simultaneously T-Cellresponse in addition to the humoral response produced by B-cells againstviral antigens, conjugated with antibody coated metallic or non-metallicnanoparticles where the combination therapy cannot only vaccinate aperson, but simultaneously attack the viruses including variouscoronaviruses after its administration with pathway inhibitors with orwithout apixaban (Eliquis) anticoagulant, administered intramuscularly,orally, or by inhalation at a very low concentration dose that can besubsequently repeated in different intervals, using higher concentrationor volume doses, until the neutralizing antibodies are discovered in theblood of the patient.

In one embodiment, to reduce immune response, one can deliver thetherapeutic vaccine incrementally or encapsulated in wax, gelatin, orpolycaprolactone, or the therapeutic vaccine can be freeze-dried to bethawed with a physiologic solution before administration combined withone or more antivirals such as a protease inhibitor, and/or a polymeraseinhibitor, remdesivir and/or with a transcription inhibitor combinedwith cell pathway inhibitors, such as a Rock inhibitor, Fasudil orROCK2, 1-(5-Isoquinolinesulfonyl)-2 Methylpiperazine Calcium ChannelBlockers, with one anticoagulant, such as rivaroxaban (Xarelto),dabigatran (Pradaxa), apixaban (Eliquis) or edoxaban (Lixiana), etc. ororally that are released in the intestine, or administered byintramuscular or subcutaneous injection, or by inhalation, or with amucomyst, which contains acetylcysteine, n-acethylsystein, or itsderivatives by inhalation or intravenously, where they act as ananti-inflammatory and antithrombotic or by inhalation at very low dosesthat can be increased incrementally by the doctor/patient untilneutralizing antibodies are measured in the serum of the patient andprevent a severe immune response that can produce a blood clot in themain vessels.

In one embodiment, in patients with a severe coronavirus infection orits mutations, one can prevent the kidney damage by administering a lowdose of metformin or Klotho that strengthens the heart muscle andskeletal muscles and enhances the recovery from the infection.

In another embodiment, in patients with a severe coronavirus infectionor its mutations that affects the liver, there is an increase ofinsoluble bilirubin in the plasma that can affect among others the brainfunction, and in these situations, whole body radiation is administeredusing a strong light, e.g., ultraviolet A (UVA) radiation (460-490 nm)to convert the bilirubin to soluble bilirubin that now can be excretedthrough the gallbladder as bile. In addition, the UVA radiation may beapplied as needed hourly that simultaneously kills the viruses on thesurface area of the skin and just beneath the skin, contributing tofaster recovery of the patients or the persons. The UVA radiation may beapplied night for sterilization. To protect the eyes of the patient, UVblocking glasses may be worn by the patient.

In one embodiment, at least two antivirals are combined or appliedsequentially with LMWH or a heparin mimetic with catechins to preventattachment of the virus to the cell membrane receptors, the medicationis administered intravenous or inside a body cavity or preferably as aspray, inhalation through an inhaler, through the nose such asnebulizer, a dry powder inhaler, liquid or suspension inhaler, breathactuated nebulizer, injector, topically, orally, intramuscularly,locally, or as described by Peyman U.S. Pat. Nos. 7,678,078 and10,272,035, where the container is filled with a defined amount ofsemifluorinated alkane and nanoparticle emulsion and appropriatemedication using compressed oxygen instead of air to spray thesemifluorinated/medication as a fine spray or in nebulized form in thenasal cavity or mouth while the person inhales.

In one embodiment, if the patient cannot tolerate methylene blue, or isallergic to it, methylene blue can be replaced in the first step towardthe vaccine production after the growth of the organism in cell cultureor another suitable medium by administration of higher than normal dosesof antimetabolite, such as Floxuridine, 5-Fluorouracil, 6Mercaptopurine, cytarabine, flurabine, or para-aminobenzoic acid (PABA),or sulfonamide, the antimetabolite antibiotics preventing replication ofDNA or RNA or actinomycine-D, etc., ribavirin, a nucleoside reversetranscriptase inhibitor (NRTI) targets enzymes, including inosinatedehydrogenase, thymidylate synthase, cytidine-5′-triphosphatesynthetase, etc. that block RNA and DNA of viruses or an antiviralagent, an antineoplastic agent, an antitumorigenic agent, or animmunotherapeutic agent, such as mycophenolic acid or an antimitoticagent or their analogues or prodrug that are activated by viralproteases, such as paclitaxel, combretastatin, bryostatin, colchicine,or discodermolide at low non-toxic concentrations to kill the organismin the cell culture, or platinum anti-cancer medication and itsderivatives or combination thereof, followed in combination with secondstep of administration of one or more non-toxic doses of antivirals orantibacterials or antiparasites anti-tumoral agents (in tumortherapeutic vaccine) to the dead organism or tumor cells prior to theadministration to the patient and with one or more cell inflammatorypathway inhibitors, baricitinib, LMWH, heparin mimetics at a non-toxicconcentration, etc. as second step of therapeutic vaccines formulation.

In one embodiment, the antiviral medication can be a polymeraseinhibitor, such as remdesivir and an additional compound can be anotherantiviral or any other medication that modifies the side effects ofviruses, such as inflammation or inhibition of cellular response to thevirus, etc. with or without cell pathway inhibitors, etc.

In one embodiment, in the past, one has concentrated efforts to producea vaccine that produces neutralizing antibody to the S-antigen which isthe receptor protein on the SARS-CoV-2, and COVID-19 and their variants,such as the UK's B.1.1.7 variants, South Africa's B.1.351 variants,Brazil's P.1 variants and India's B.1.617. In contrast, the presenttherapeutic vaccine produces neutralizing antibodies against allantigenic proteins or glycoproteins of the viruses, and other related,future coronaviruses, covering other vulnerable areas of the viruses,etc., thus there is less chance for the virus to mutate and escape thetherapeutic vaccine and the addition of medication in these cases withtwo antivirals, enhances the vaccination effect by the body's immunehumoral and cellular response and covers practically all viruses,including those that have survived the initial vaccination using astandard vaccination processes, such as mRNA vaccine etc. to prevent newmutations. This methodology applies also to other coronaviruses alpha,beta, and gamma coronaviruses, though so far humans are affected onlywith beta coronaviruses, while the others have affected various animals.

In one embodiment, a nasal or sublingual implant is 3D-printed usingknown 3D printing technology controlled by software of a computer formultiple drug delivery in a slow release manner or nanoparticles, usedfor prophylactic, therapeutic, or therapeutic vaccination (see FIGS.1-6). Creating one or two intranasal degradable implants containingnanoparticles or antibody-coated nanoparticles of gold nanoparticles orslow release medications as a therapeutic vaccine or therapeutic aftervaccination having a cone structure with or without a centrally locatedfilter that can block organisms smaller than viruses, etc. and can beremoved after a period of time or replaced for repeated therapeuticvaccination and treatment.

In FIG. 1, an illustrative nasal delivery implant 10 is depicted. FIG. 2depicts a pair of nasal delivery implants 10 connected to one anothervia a clip member 12 so that the implants 10 are able to be insertedinto the nostrils of a person 18 (see FIG. 5). In FIG. 3, anillustrative nasal delivery implant 14 with a perforated wall is shown.In FIG. 4, an illustrative nasal delivery implant 16 with aspring-shaped wall is shown.

In one embodiment, the degradable nasal delivery implant may have or nothave a filter. For example, in FIGS. 7A and 7B, a nasal implant with anouter shell 10 and an inner filter shell 20 that cooperates with theouter shell 10 is shown. The nasal implant of FIGS. 7A and 7B may bebiodegradable or non-biodegradable. The outer shell 10 of the implant inFIGS. 7A and 7B may be formed from a flexible or semi-flexible material(e.g., a flexible or semi-flexible polymeric material, such assilicone). The inner filter shell 20 of the implant in FIGS. 7A and 7Bmay be formed from an N95 filter material or any filter material thatblocks particles having a size larger than 0.06 microns. The filteringimplant of FIGS. 7A and 7B can be formed as a single unit for eachnostril or comprise two connected nostril portions that are attached toone another via a bridge, as previously described.

In one embodiment, the therapeutic vaccine delivery systems are 3-Dprinted to provide a nasal slow release, or sublingual release or as acapsule with medication(s) for oral delivery, or as an example, thenasal delivery device covers the medication to the nasal pathway,pharynx, larynx, trachea, bronchi, and lung alveoli, having a polymericbase such as a hydrogel or any polymer organic or synthetic compoundsuch as beeswax, cellulose derivatives, poly(ethylene glycol) PEG, andpoly(N-vinyl pyrrolidone), polylactic acid, polyglycolic acid, or PGLA,poly(β-amino esters, or polymeric nanoparticles, PEI, dextran, dextrin,poly(glutamic acid), poly(aspartamides), chitosans, poly(l-lysine), etc.PNIPAAm, crosslinked gels, PNIPAAm copolymers, and various Pluronics ora mixture of two block copolymers, poly(l-histidine)-b-PEG(polyHis-b-PEG) and poly(l-lactic acid)-b-PEG-b-polyHis-ligand(pLLA-b-PEG-b-polyHisligand), antibody coated gold nanoparticles capableof endosomal disruption, escape, or beeswax are used in a drug capsuleas a binding agent, or the use of porous silicon or other semiflexiblepolymers or plastics carrier of medications made in shape of cylinder orsemicylinder, a flexible tube with a wider base leading to a narrowertop, for insertion in the nostrils of any size that fits comfortably inthe entrance of the nose or having a connected base that holds thedividing wall of nose tighter like a clip (see FIGS. 1-3), whichreleases medication/therapeutic vaccine over a day to a week or can bereplaced as needed with a fresh one, having the same function, asdelivering the medication or the therapeutic vaccines by other routes ofadministration having at least two antivirals, antibacterials,antiparasitics or antifungals medication, etc. or medication with one ormore dead viruses, bacteria, parasites, including malaria, etc. wherethe organisms are killed in the process of producing a vaccine orweakened organisms with a high dose of methylene blue, i.e., >5 mg/L,and antiviral, antibacterial, antiparasites, antifungals, such asanti-malaria parasites, etc. depending on the infection, combined withat least one inflammatory cell inhibitor, such as Wnt, Rock, GSK orintegrin inhibitors where the medication is slowly released when thepolymer dissolves in nasal fluid and is inhaled or administered orally,intramuscularly, intravenously etc. or by inhalation to treat one ormore respiratory viral/bacterial/fungal infection(s), parasiticinfection or it works as a prophylaxis for the viral infection,bacterial infection, fungal infection or parasitic infection etc. orduring the infection as a therapeutic vaccination stimulatingsimultaneously the humoral and cellular response to one or more virusesor bacteria, fungi or parasites affecting the lung, brain, heart, liver,kidney, or intestinal tract, etc.

In one embodiment, the therapeutic vaccine is administered with aninhaler.

In one embodiment, the therapeutic vaccine is injected with or withoutconjugation with gold nanoparticles via thiol for cellular absorption orpenetration, subcutaneously, intramuscularly, intravenously forinhalation or orally, or intramuscularly etc. in a physiologic salinesolution, or dissolved in semifluorinated alkanes.

In one embodiment, creating a therapeutic vaccine against malaria wherethe organism such as Plasmodium falciparum (P0 malaria parasites or P.vivax, P. ovale, and P. malariae genus with over hundred species aretransmitted by Anopheles mosquitos. The malaria parasites have twodifferent lifestyles: (1) initially ingested by the mosquitoes from aninfected victim where they grow in the insect's stomach and producesporozoites (sporogonic style) before (2) infecting another subject,where the sporocytes grow in the host liver cells before entering thered blood cells, then regrow and multiply as merozoites and burst thered blood cells. Circulating infected parasites in humans produce thesymptoms of chill and fever. The parasites can again be picked up bymosquitos to undergo sporogonic cycle generating zygots, oocyst, andsporocytes.

In one embodiment, the malaria parasites are cultivated in variousstages in vitro as known in the art (described by Frederick L. Schusterin Clin Microbiol Rev. 2002 July; 15(3): 355-364. Cultivation ofPlasmodium spp.).

In one embodiment, the principle of therapeutic vaccine is by harvestingviruses, or bacteria, or fungi or parasites, or tumor cells, etc. formthe cell culture or appropriate medium, then the viruses, bacteria,fungi, or parasites, etc. are killed with a high dose of methyleneblue >4 mg/L with or without gold nanoparticles for cell penetration anddamaging the RNA or the DNA of the organism along with methylene blueand kept for a period of time for penetration of the methylene blue inthe viruses, bacteria, or fungi, or parasites, of tumor cells etc.,other substances can be added to the medium, such as peptide nucleicacid or anti-neoplastics to enhance the effect of the methylene blue onthe RNA or DNA, then the dead viruses, bacteria, fungi, or parasites,etc. are separated from the rest of the medium to which, depending onthe organism, antivirals, antibacterials, or antifungals, orantiparasites, etc. at a non-toxic therapeutic concentration of theappropriate medication is added, depending on the volume or themedication needed, route of administration to create simultaneously animmune and a therapeutic response in the body without inducing the sideeffects of medication, in general at low doses so that the combinationcocktail initiates an immune response (humoral and cellular) to viruses,bacteria, fungi, parasites, or tumor cells, etc. and to which one addscell pathway inhibitors such as Wnt, Rock, GSK, or integrin inhibitorsto prevent an excessive immune response, or additional medications, suchas low molecular weight heparin, Mucomyst, or pluralities ofantibody-coated nanoparticles, anti-TGFs or baricitinib, tocilizumab,steroid etc. is needed or metformin to protect the kidneys with GSKinhibitors or kidney dialysis or electrophoresis is done to removeexcessive toxins, the treatment can be repeated as needed until theviruses, bacteria, fungi, or parasites are eliminated and verified byPCR, etc.

In one embodiment, the therapeutic vaccine with methylene blue can bereplaced with another medication with a similar toxic effect on RNA orDNA of viruses, or bacteria, or fungi or parasites and the rest of themedications described above are added to enhance the therapeutic vaccineeffect for a needed period of time in the post-operative period or intherapy resistant organisms.

In one embodiment, an intravenous administration of a therapeuticvaccine is done to maintain a non-toxic amount of the medication in thecirculation, this volume is significantly reduced if therapeutic vaccineis injected subcutaneously or intramuscularly or by inhalation so itdoes not cause a localized toxicity to the tissue exposed while stillthe immune response is maintained, in fact might be used therapeuticallywhen there is a localized response to the originally administeredvaccine.

In one embodiment of providing an antimalarial vaccine, adding thePlasmodium-specific kinase PfCRK4 inhibitor such as citric acid or aquinine derivative to the medium enhances the killing effect ofmethylene blue (MB) with or without gold nanoparticles, etc.

In one embodiment, one adds to the methylene blue at least twoadditional antimalarial medications at a non-toxic dose, such as one ofchloroquine, amodiaquine, quinine, quinidine, mefloquine, primaquine,lumefantrine (see the table below) and halofantrine, etc., which areactive against the erythrocytic stage of parasites and one of primaquineto kill intrahepatic forms of the parasites or gametocytes to which oneadds one of gold or silver or zinc nanoparticles (with or withoutantibodies), preferably 1-10 nm in diameter in size that are capable ofentering into live parasites damaging it RNA or DNA of the organism orwith cell penetrating peptides providing an antigenic deadparasites/medication(s) the so called therapeutic vaccine which arecapable of inducing an antigenic response from the host, e.g., apatient, or an animal etc. when administered to a patient/animal, andthe patient/animal is immunized against the future infection by malariaspecies.

In one embodiment of a therapeutic vaccine, one adds an inflammatorycell pathway inhibitor, such as Wnt, Rock, integrin or GSK inhibitors orpreferably Ivermectin at a non-toxic concentration which also acts as anantimalarial agent and anti-inflammatory compound to prevent overactivation of a patient's immune response, the therapeutic vaccine canbe administered orally to be absorbed by the intestinal tract to reachliver directly. In one embodiment, the compound, such as baricitinib orTGF beta inhibitors or compliment C3 or C5 inhibitors, or metformin atlow doses as long as needed etc. are added.

In one embodiment, various components of the therapeutic vaccine can beadministered in therapy resistant bacterial, viral, fungal or parasiticinfections, to stimulate humoral or cellular immune response such askiller cells, in combination or separately to the patient by inhalation,intramuscular, subcutaneous, or intravenous injection or locally atnon-toxic dose or preferably orally to be absorbed by the gut and itscirculation reaching the liver more directly to damage the liverparasites that are growing in the liver, whereas intravenousadministration reaches the erythrocytes phase of infection to treat itdirectly repeatedly as needed.

In one embodiment, after administration of an antimalarial therapeuticvaccine by nasal inhalation, orally as a capsule or hydrogel in beeswax,etc., an excessive immune response is treated by kidney dialysis,electrophoresis, hemodialysis to remove the dead parasites, cytokines,etc. and prevent a cytokine storm in cases of a multi-systeminflammatory response (MIS-C) in children that may also treated with Wntinhibitors, such as ivermectin or niclosamide orally or by inhalation,etc. in one embodiment with lung infection nasal inhalation oftherapeutic vaccine is preferred.

In one embodiment of an already infected person, a therapeuticvaccination of the patient can be continued with repeated therapeuticvaccination administration to the patient for 3-4 times in an intervalof 6 days to kill new parasites that can be released from the livercells that are treated and simultaneously an immune response is createdin the patient.

In one embodiment, after the treatment with a therapeutic vaccine, onecontinues the therapy with methylene blue at a lower concentration of1-2 mg/L to inhibit selectively the glutathione reductase of Plasmodiumfalciparum, or in combination with a lower dose of an antimalarialagent, such as chloroquine, at lower nontoxic concentrations to maintaina medication level in the plasma of the patient that can damage theparasite, but not the patient and treat methemoglobinemia if it ispresent, the only contraindication for use of methylene blue is if it isgiven systemically to a patient lacking glucose-6-phosphatedehydrogenase (G6PD enzyme which can be evaluated rapidly in anylaboratory with an on-site screening testing for G6PD enzyme deficiencyusing a finger prick to obtain blood samples.

In one embodiment, the therapeutic vaccine is produced, in the lab, withhigh toxic doses of >5 m/L, however, after its preparation one uses anantimalarial medication, and the dead parasites at a non-toxic dose ofmethylene blue at <4 mg/l in combination with a non-toxic concentrationof antimalarial medication and a non-toxic dose of gold, silver, or zincnanoparticles are used as desired repeatedly as needed in combined withcell pathway inhibitors or complement inhibitors until the parasites areeliminated.

In one embodiment, the therapeutic vaccine is combined with a non-toxicdoses of methylene blue or other medications and an immunosuppressants,such as mycophenolic acid, Rapamycin, or an antiviral agent, anantibacterial or antifungal or an antineoplastic agent, anantitumorigenic agent, or an immunotherapeutic agent, TLR 4 or anantimitotic agent or their analogues or prodrugs or Monoclonalantibodies or polyclonal antibodies conjugated with or withoutnanoparticles for the treatment of each disease.

In one embodiment for treatment of malaria parasites, the patient istreated with a non-toxic dose of immunosuppressant(s), or after initialtreatment with a therapeutic vaccine, the patient can be treated for aperiod of time with non-toxic doses of immunosuppressant agents, such asmycophenolic acid at 19 μmol/L of Rapamycin at 13.7 μmol/L.

In one embodiment, the therapeutic vaccine is administeredsimultaneously or sequentially by intravenous administration of culturegrown killer cells, or engineered cytotoxic T-cells using gene editingtechnologies to change the DNA of the T-cells to overcome the tumor'sbarriers and to kill the parasites with or without adjuvants or atherapy resistant infection.

In one embodiment, a vaccine cocktail is prepared from viruses orbacteria, fungi, or parasites, etc. in a semifluorinated alkane, aphysiological saline solution, the organism is killed with high doses ofmethylene blue (>5 mg/L) or another medication that damages RNA or DNAof the organism and filtered to obtain the dead viruses or bacteria,fungi, or parasites transferred in a solution containing methylene blueat a non-toxic concentrations of 2 mg/L MB having an adjuvant, such asthe toll-like receptor 4, 7 and 8, with Alum or another adjuvant with orwithout viral like particles (VLPs), etc., with or without one or moreinflammatory cell pathway inhibitors or another anti-inflammatorycompound, such as Ivermectin, or one or two antivirals, antibiotics,antifungals, or antiparasites where the dead organisms or at least oneor more parts of its proteins such as an S-antigen or glycoprotein orBispecific antibodies, protein, glycoprotein saccharide etc. areconjugated with gold, silver, zinc, or organic nanoparticles and thecocktail, is collected, and prepared and stored in a refrigerator withor without a Benzalkonium chloride (BAk) solution of 0.01% or lessconcentration at a low temperature and can be used for repeatedself-vaccination/administration as needed by nasal spray, inhalation, ororal pills or gummies or intraperitoneal, intramuscular, subcutaneous,or intravenous or local administration, or can be used as adjuvant toanother vaccine prepared by other means, such as mRNA vaccines ormonoclonal or polyclonal antibody-coated nanoparticles, or LNP, etc. orafter administration of another vaccine for the same organism, butself-administered is preferred by inhalation or orally, weekly, ormonthly as needed to eliminate the organism or self-administrationintranasal as a spray or nebulization, or injected by professionalsintravenously or intramuscularly, etc. to eliminate all potentialpathogens, such as viruses that might remain in the nasal cavity,throat, pharynx, trachea, or in the alveoli and potentially reactivateand induce an epidemic or pandemic infection or therapy resistantbacteria and fungi or parasites that hide in the liver cells, etc.

In one embodiment, the therapeutic vaccine can be freeze dried forstorage, then thawed with water prior to it being administered.

TABLE 1 List of antimalarial medications and their combinations. Highfirst dose quinine, Primaquine, halofantrine, Ivermectin, Primaquine ingametocyte development, Tafenoquine in preventing relapse, Cycloguaniland proguanil, Amodiaquine, Amodiaquine plus sulfadoxine-pyrimethamine,dihydroartemisinin-piperaquine, Doxycycline, Atovaquone proguanil(Malarone) in chemoprophylaxis, and Antimicrobial, Atovaquone-proguanilcombination, Artesunate-Mefloquine combination, Artesunate Artemisinin,oral pyronaridine, Pyronaridine-artesunate,Dihydroartemisinin-piperaquine KAE609 (cipargamin; formerly NITD609, anew synthetic antimalarial spiroindolone analogue against asexual andsexual stages of Plasmodium falciparum, synthetic trioxolane drug.Arterolane Maleate-Piperaquine Phosphate, dispersible tablet ofarterolane, maleate (AM) Piperaquine phosphate (PQP), ArterolaneMaleate-Piperaquine Phosphate, Artemether-Lumefantrine, e4-aminoquinoline drug hydroxychloroquine (HCQ), Halofantrine, Cysteineand aspartic protease inhibitors, Lead compounds at nanomolarconcentrations, Ferroquine combination with Artesunate, Malariaantibodies coated nanoparticles or lipid nanoparticles (LNP).

TABLE 2 List of immunosuppressants and antimalarials. Mycophenolic acid,Rapamycine, cyclosporine A, etc. Plant toxins cytotoxic agents, etc.reactive oxygen species (ROS), radiation (UV, X- ray, gamma), cisplatin,oxaliplatin, and carboplatin), cyclophosphamide, chlorambucil, andtemozolomide. Imatinib has antimalarial activity by inhibition of theerythrocyte tyrosine kinase that causes parasite entrapment andtermination of the infection or in addition to inflammatory pathwayinhibitors, Lenzilumab and an antimalarial monoclonal antibody.

In one embodiment, one uses the therapeutic vaccine (i.e., medicationand simultaneous or sequential vaccination) in respiratory viraldiseases, drug resistant bacteria, drug resistant fungi, or drugresistant parasites, or a tumor where the initial steps are similar by:(1) growing the organism or tumor cells or fungi in appropriate culture;(2) then killing the organism by using one or two medications thataffect DNA or RNA of the organism or tumor cells in an above non-toxicconcentration (e.g., methylene blue at a concentration >4 mgL or anyother cytotoxic or antineoplastic, etc. medication at a above non-toxicconcentration/L, filtering out the organisms protein or antigens; (3)combining the proteins, glycoproteins, or antigens with at least one ortwo anti-organism drugs (i.e., drug resistant or not resistant) at anon-toxic concentration of the medication e.g., 2 mg/L methylene blueand/or other antivirals, antibacterials, antifungals, anti-neoplastics,or anti-parasites, (4) addition of an immune stimulator, such as one ormore toll-like receptors 2, 4, saponin, or VLP, etc. or complement(s)after in vitro and in vivo animal experimentation to find out theireffect at a tolerable volume locally, intramuscularly, intranasally byinhalation, or orally, etc. at known non-toxic doses, or intravenouslyat a non-toxic dose and volume combined with anti-inflammatorymedications or cell pathway inhibitors, such as Wnt, Rock, GSK, orintegrin inhibitors or in combination as needed with other medications,such as anticoagulants (e.g., LMWH, n-acethylsystein, etc.), DMF,Baricitinib, etc. or anti-VEGF agents, such as bevasizumab (Avastin,etc.) to revive an exhausted cellular immune response and thetherapeutic vaccine can be administered repeatedly as needed to killpotential existing pathogens and induce simultaneously a humoral orcellular response by measuring the neutralizing serum antibodies and ifthe patient is immunosuppressed, one administers simultaneously orsequentially culture-grown natural killer cells, etc. with or withoutcheckpoint inhibitors and TGF beta inhibitors, and if the immuneresponse creates a cytokine storm response (LDH level above 300 value asan inflammatory signature in the body), the patient is treated withkidney dialysis plus metformin administration or serum electrophoresisto remove the cytokines, etc. The treatment is repeated for eachorganism until they are dead, or repeated treatment is performed usingthe therapeutic vaccine with another medication.

In one embodiment, one uses the therapeutic vaccine (i.e., medicationand simultaneous or sequential vaccination) by utilizing any existingvaccine, such as those using mRNA, viral S-protein, or using anothercarrier instead of LPN, such as modified adeno-associated viral vector,etc. and combine it with appropriate antivirals, antibacterials,antifungals, antiparasites, antitumors, and/or antibody-coatednanoparticles, etc. collecting the polysaccharides, proteins,glycoproteins, glycan, or antigens, or part of the proteins orbispecific antibodies, with at least one anti-“organism” drug (i.e.,regardless of being drug resistant or not resistant) at a non-toxicconcentration or addition of an immune stimulator, such as one or moretoll-like receptors 2, 4, etc. or VLPs or complement(s) after in vitroand in vivo animal experimentation to find out their effect at atolerable volume locally, intramuscularly, intranasally, by inhalation,orally, subcutaneously, intramuscularly, intravenously, etc. at knownnon-toxic doses, or intravenously at a non-toxic dose and volume withanti-inflammatory medications or cell pathway inhibitors, such as Wnt,Rock, GSK, or integrin inhibitors added alone or in combination asneeded with other medications, such as anticoagulants (e.g., LMWH,mucomyst, DMF, Baricitinib, etc.) or anti-VEGF agents, such asbevacizumab (Avastin, etc.) and the therapeutic vaccine can beadministered repeatedly as needed to induce simultaneously a humoral orcellular response by measuring the neutralizing serum antibodies, and ifthe patient is immunosuppressed, one administers simultaneously orsequentially culture-grown natural killer cells, etc. with or withoutcheckpoint inhibitors and TGF beta inhibitors, and if the immuneresponse creates a cytokine response, the patient is treated with kidneydialysis plus metformin administration or serum electrophoresis toremove the cytokines, etc. The treatment is repeated for each organismuntil they are dead, or the treatment is repeated using the therapeuticvaccine with other medications.

In Table 3 below, most of the drug resistance organisms that can betreated with the described therapeutic vaccine are listed. It should beunderstood that medications or method can be modified but the basicmethodology remains the same (i.e., the multipronged attack on theorganism and strengthening simultaneously the immune response of thepatient).

It is estimated that >2.4 million of therapy resistance infectionsoccur, not counting the malignant or benign tumors and about 3,000 casesof Clostridioides difficile occurs each year as a result of therapyresistant bacteria etc.

TABLE 3 List of drug resistant organisms. Carbapenem-resistantAcinetobacter, Clostridioides difficile, Candida auris,Enterobacterales, Neisseria gonorrhoeae, and drug-resistantCampylobacter. Candida, ESBL-producing Enterobacterales,Vancomycin-resistant Enterococci (VRE) ontyphoidal Salmonella,multidrug-resistant Pseudomonas aeruginosa, Shigella, Salmonellaserotype Typhi, Methicillin-resistant Staphylococcus aureus (MRSA),Drug-resistant Tuberculosis, Streptococcus pneumoniae,Erythromycin-Resistant Group A Streptococcus, Clindamycin-resistantGroup B Streptococcus, Drug-resistant Mycoplasma genitalium,Azole-resistant Aspergillus fumigatus, Drug-resistant Bordetellapertussis, Carbapenem-resistant Acinetobacter, Drug-resistant Candidaauris (C. auris). Drug-resistant C. auris, Clostridioides difficile (C.difficile), C. difficile or C. diff, previously Clostridium difficile,Carbapenem-resistant Enterobacterales (CRE), Drug- resistant Neisseriagonorrhoeae, Drug-resistant gonorrhea, Drug-resistant N. gonorrhoeae,Drug-resistant Campylobacter, Drug-resistant Campylobacter, Drug-resistant Candida Species, Dozens of Candida species-a group of fungi-:Drug- resistant Candida species Pathogen. ESBL-producingEnterobacterales, Extended-spectrum β-lactamase, ESBL-producingEnterobacterales Pathogen, Vancomycin-resistant Enterococcus (VRE),Multidrug- resistant Pseudomonas aeruginosa, Multidrug-resistant P.aeruginosa, Drug-resistant nontyphoidal Salmonella, Drug-resistantSalmonella serotype Typhi, Typhoid fever, Drug-resistant Salmonellaserotype Typhi Pathogen, Drug-resistant Shigella, Methicillin-resistantStaphylococcus aureus (S. aureus) (MRSA), Resistant staph (short forStaphylococcus), Drug-resistant Streptococcus pneumoniae (S. pneumoniae)Bacteria Pneumococcus, Drug-resistant S. pneumoniae. Drug-resistantTuberculosis (TB), multidrug-resistant TB (MDR TB), or extensivelydrug-resistant TB (XDR TB), Mycobacterium tuberculosis (M.tuberculosis), Erythromycin-resistant Group A Streptococcus,Clindamycin-resistant Group B Streptococcus.: Resistant group B strep,GBS, Azole-resistant Aspergillus fumigatu, Drug-resistant Mycoplasmagenitalium, Drug-resistant Bordetella pertussis, lyme disease caused bybacterium Borrelia burgdorfeior parasite Babesia, Bacteria Ehrlichiosis,Anaplasmosis, Bacteria Borrelia miyamotoi, Powassan virus, BacteriaTularemia and Borrelia lonestari, or single cell organism protozoa,mycobacterum leprae causing Leprosis, etc.

In one embodiment, chemotherapeutic agents are used instead of methyleneblue, or with a combination of methylene blue with or without gold zincnanoparticles etc. to damage the RNA or DNA of the organism.

Anti-tumor chemotherapeutic agents can be used in the process oftherapeutic vaccine formation (e.g., if the patient is allergic tomethylene blue), usually initially at least two drugs at higher thannon-toxic concentrations and subsequently when the protein antigens (orproteoglycans) is separated from the organism, and co-administered withthe same medications at below the toxic concentration, e.g. thechemotherapeutic agents, that are approved by the FDA as describedbelow. The therapeutic vaccine is combined with one of the cellinflammatory pathway inhibitors, such as Wnt inhibitors, Rock, GSK,integrin inhibitors, or one of the TGF beta inhibitors, or otheranti-inflammatory agents.

Anticancer chemotherapy agents mostly affect RNA or DNA of the cells fortreatment of certain types of cancer, and can have their side effects.Therefore, when used in combination with a vaccine as therapeuticvaccines, their concentrations are reduced below the approvedtherapeutic levels, and at least two or more chemotherapeutic agents areused in combination to create a 1-2 punch, and are more effective sincethey affect the organisms in different way. In one embodiment, not allmedicines and drugs used to treat cancer work the same way, such astargeted therapy, hormone therapy, and immunotherapy.

In one embodiment, chemotherapy affects the cell cycle. Interestingly,most normal cells will recover from the therapy, but cancer cells aremutated cells and usually do not recover after therapy.

In one embodiment, two drugs act in a different way on the cells or theorganisms, such as alkylating agents act by damaging its DNA, such asAltretamine, Dacarbazine, Cyclophosphamide. Ifosfamide, Lomustine,Mechlorethamine Bendamustine, Busulfan, Carboplatin, CarmustineChlorambucil, Cisplatin, Melphalan, Oxaliplatin, Temozolomide, Thiotepa,Trabectedin. Nitrosoureas are alkylating agents that pass theblood-brain barrier to reach brain tumors, such as CarmustineStreptozocin, and Lomustine.

TABLE 4 List of chemotherapeutic drugs. Antimetabolites: interfere withDNA and RNA by acting as a substitute to the DNA, but cannot reproduceitself for the building blocks of RNA and DNA. These are: 5-fluorouracil (5-FU), 6-mercaptopurine (6-MP), Capecitabine (Xeloda),Cladribine, Clofarabine, Cytarabine (Ara-C)Floxuridine, Decitabine,Fludarabine, Gemcitabine (Gemzar), Hydroxyurea, Methotrexate,Thioguanine, Nelarabine, Trifluridine/tipiracil combination,Pentostatin, Pralatrexate,, Pemetrexed (Alimta), Anti-tumor antibiotics:these work by changing the DNA inside cancer cells prevent them to growand multiply, Anthracyclines: interfere with enzymes involved in copyingDNA and the cell cannot reproduce. Daunorubicin, Doxorubicin liposomal,Epirubicin, Doxorubicin (Adriamycin), Idarubicin, Valrubicin canpermanently damage the heart at high doses, Bleomycin Mitoxantrone,Mitomycin-C, Dactinomycin, Topoisomerase inhibitors: are plant alkaloidswhich interfere with enzymes called topoisomerases that separate thestrands of DNA. Topoisomerase inhibitors block different enzymes andprevent the production of their copies such as Topoisomerase Iinhibitors: Topotecan Irinotecan liposoma, Irinotecan, Topoisomerase IIinhibitors include: Teniposide, Etoposide (VP- 16), Mitoxantrone (alsoacts as an anti-tumor antibiotic), mitotic inhibitors; such as plantalkaloids work by stopping cells from dividing, mitotic inhibitorsinclude the taxanes and vinca alkaloids, Taxanes include:Nab-paclitaxel, Paclitaxel, Cabazitaxel, Docetaxel; Vinca alkaloidsinclude: Vincristine Vinorelbine, Vincristine liposomal, Vinblastine,other chemotherapy drugs Eribulin, Hydroxyurea, Ixabepilone, Mitotane,All-trans-retinoic acid, Arsenic trioxide, Asparaginase, Omacetaxine,Procarbazine, Pegaspargase, Romidepsin, Vorinostat.

In one embodiment, one utilizes targeted therapies of proteins,glycoproteins or receptors (e.g., on the cancer cells, etc.) withimmunotherapy drugs to boost or alter the patient's immune system, byeither blocking the activity of the enzyme acyl-CoA:cholesterolacyltransferase (ACAT) or administering toll-like receptor 4 boostingT-cells that can fight cancer cells or the viruses etc.

In one embodiment, a therapeutic vaccine can be prepared by obtaining atumor cell biopsy as known in the art, growing the cell in a culturemedium damaging the DNA of the tumor, by administering to the cellculture at least one of methylene blue at a toxic concentration with oneor more chemotherapeutic agents at a toxic level obtaining antigenicproteins, glycoproteins, or proteoglycans as known in the art,administering the antigens with at least two chemotherapeutic agents ormethylene blue at or below the non-toxic concentration to damage thetumor cells' DNA and its metastatic cells and combining the cocktailwith one or more cell pathway inhibitors to a prevent cytokine storm andan Anti-VEGF, and/or a checkpoint inhibitor and or an anticoagulant,such as LMWH, or mucomyst, or immunoglobin is delivered to prevent bloodclotting, either by inhalation or intravenously or orally which containsacetylcysteine, n-acethylsystein, etc. and/or resveratrol and culturegrown killer cells intravenously, intra-arterially, in the desiredplace, or by inhalation, or orally, as capsule etc.

TABLE 5 List of most frequent cancers for which therapeutic vaccine canbe used. Bladder cancer, colon and rectal cancer, breast cancer, kidneycancer, leukemia, lung cancer, liver cancer, melanoma, endometriacancer, non-Hodgkin's lymphoma, pancreatic cancer, thyroid cancerprostate cancer, retinoblastoma, Adrenocortical carcinoma, anal cancer,astrocytoma, Kaposi's Sarcoma, Basal Cell Carcinoma of the Skin, otherskin cancers, bone cancer, Brain tumors Bronchial tumors, Carinoidtumors, Meduloblastoma, cervical cancer, hairy cell lumphoma, Esophagealcancer Ewing Sarcoma, eye cancers, Gallbladder cancer, gastric cancer,gastrointestinal cancer, ovarian cancer, testicular cancer, metastaticcancer, hypopharyngeal cancer, head and neck cancer, lip and oral cavitycancer, throat cancer, lung cancer. Mesothelioma, squamatous cancer,Meyeloproliferative neoplasm, nasal cavity cancer, neuroblastoma,Non-small cell lung cancer, parathyroid cancer, pharyngeal cancer,pheochromocytoma, pituitatry tumors, Multiple Myeloma, Primary CNSlymphoma, peritoneal cancer, vaginal cancer, penile cancer, vulvarcancer, osteosarcoma, soft tissue sarcoma, uterine sarcoma, wilms'tumor, etc.

In one or more embodiment, the steps of therapeutic vaccines aresimilar, namely: (1) growing the organism, (2) killing the organism witha high dose of at least two medications, (3) retrieving the antigenicprotein/proteoglycans from the dead organism, (4) combining the antigen(proteoglycans) with or without gold nanoparticles at low non-toxic doseof at least two appropriate medications depending on the organism (e.g.,for viruses one uses two antiviral polymerase inhibitor and a proteaseinhibitor, etc. and adds immune stimulators such as toll-like receptor 4to the cocktail and/or monoamine oxidase inhibitors, and spermidine),(5) add one of anti-inflammatory cell pathway inhibitors to preventimmune over reaction, (6) if needed, use culture-grown killer cells toenhance the killing of the organisms, (7) add anticoagulant to preventblood clotting, etc., and (8) use kidney dialysis or hemodialysis orelectrophoresis to remove toxins in case of a cytokine storm combinedwith Bariticinib or DMF metformin at low dose etc. to reduceinflammatory response. The steps can be administered simultaneously orsequentially.

In one or more embodiments, the steps of the therapeutic vaccines aresimilar, namely: (1) growing the organism, and (2) killing the organismwith a high dose of at least two medications that damage RNA and DNA.

In one embodiment, the medications used to kill the organism areconjugated with cell penetrating peptides (CPPs) or ACPPs orcyclodextrin etc. and the nucleoside transporter ENT2 enabling targetedcell-penetrating anti-DNA autoantibody which penetrates the organism'smembrane and localizes itself in the nuclei or the DNA or RNA anddamages them, in addition to ENT2 which is a bispecific antibody, suchas Deoxymab-1 (DX1) prevents repair of damaged DNA or RNA with orwithout Ceapin-A7 and KIRA8 to remove the damaged cells, bacteria,viruses, fungi, or parasites.

In one embodiment, one retrieves the antigenic protein/glycoproteinsfrom the organisms with damaged RNA/DNA, and includes proteins,glycoproteins, or saccharides to be used for vaccination alone orcollectively.

In one embodiment, one combines the antigen (proteoglycans, etc.) withor without gold nanoparticles at a low non-toxic dose of at least twoappropriate medications depending on the organism, e.g., for viruses oneuses of one an antiviral polymerase inhibitor and a protease inhibitor,etc. to which one adds immune stimulators such as toll-like receptor 4and spermidine to the cocktail or anti-depressant agents, such asmonoamine oxidase inhibitors, or use with an mRNA vaccine, ordiamidobenzimidazole (diABZI-4), to trigger the stimulator of interferongenes (STING), thereby enhancing the immune response, and with orwithout Ceapin-A7 and KIRA8 to eliminate the damaged cells, bacteria,viruses, fungi, or parasites.

In one embodiment, an mRNA vaccine is prepared for vaccination of humanor animal against viral, bacterial, fungal, or parasitic infections andit is combined with one or more medications against the organism, at orbelow the toxic levels of the medication and combine them withinflammatory cell pathway inhibitors or the anti-inflammatory agents,such as steroids or non-steroidal anti-inflammatory drugs (NSAIDs) withor without anticoagulants n-acetylcysteine to create a therapeuticvaccine and administer it during the infection to kill the organism(e.g., viruses, bacteria, fungi, or parasites) and enhance immunehumoral and cellular response.

In one embodiment, one administers a therapeutic vaccine with at leasttwo types of antibody-coated nanoparticles, and anti-inflammatory cellpathway inhibitors or mycophenolate mofetil or other macrolides andabatacept, combined with methotrexate, with an TGF beta inhibitor givenorally or intranasally, as a spray or powder, intramuscularly, etc. toprevent immune over reaction, to prevent fibrosis and scar formation ofthe affected organ and to treat the disease.

In one embodiment, the therapeutic vaccine stimulates the person's oranimal's immune system, which is not limited to B cells activation, butalso T-cells that destroy the infected cells and the organisms (e.g.viruses, bacteria, fungi, parasites, or tumor cells) since the proteinthat induces the antigenic response in the host is not limited to justfew proteins or glycoproteins of the organism, but therapeutic vaccinehas a mixture of hundreds of proteins glycoproteins, saccharides, etc.,thereby creating a killer cell response of the immune system toeliminate the organism and create the immune memory to hundreds ofantigens present in an organism, thus the immune response is broad andthe immune memory covers the present and potentially future mutation oforganisms. In addition, the therapeutic vaccine is administered withantivirals, antifungals, antiparasitics, antibacterials, or anti-tumormedications depending on the organism and contain anti-inflammatorycompounds, or in immune suppressed individuals is given along withculture grown killer cells and an anticoagulant, such as mucomyst,n-acetylcysteine, immunoglobulin, or in combination with othermedications that reduce the van willebrand factor in the patient toreduce blood clot formation, with or without metalloproteinaseinhibitors such as doxycycline or tetracycline, etc. to preventexcessive tissue damage or scarring after an infection in the lung orbrain, etc.

In one embodiment, the medications and adjuvants can be administeredsimultaneously or sequentially by oral, intramuscular, intravenous,transdermal, inhalation or by nasal spray as needed, or potentiallyadministered in low doses, but more frequently while judging the immuneresponse of the person or animal by measuring the neutralizingantibodies in the blood, etc.

In one embodiment, a therapeutic vaccine is formed from one or moreknown antivirals, such as methylene blue, etc. or an mRNA vaccine or oneor more antiviral nucleotide analogues or mimetics, such as sofosbuvir(tenofovir) that are synthetic, chemically modified nucleoside andinhibit the viral metabolism and also damage the RNA or DNA of the virus(see below), etc., such as in HIV, herpes virus, hepatitis Blamivudine/entecavir or hepatitis C virus, etc. or herpes infections(acyclovir) or arthropod-borne viruses or flavivirus, producinghemorrhagic fevers, encephalitis/myelitis, neuropathic or teratogenicmanifestations (ZIKV), where a nucleoside can inhibit RNA dependentpolymerases, helicase, NTPase, methyltransferase to produce atherapeutic vaccine that is then added to non-toxic doses of anothermedication (antiviral, antibacterial, antifungal, antiparasitic, etc.)with Deoxymab-1 (DX1) preventing repair of damaged DNA or RNA, orcombined with anti-inflammatory pathway inhibitors and medications thatinhibit blood coagulation such as mucomyst or n-acetylcysteine, orimmunoglobulin, etc.

In one embodiment, at least one or more nuclease analogue or mimeticsare used with or without methylene blue with or withoutbeta-propiolactone to damage the DNA or RNA of the virus in preparationfor a therapeutic vaccine in vitro in which the nuclease mimetic entersthe cells to inhibit viral enzyme such as DNA or RNA polymerases or oneuses anti-flavivirus nucleosides, or an antimetabolite, etc. to damagethe RNA or DNA of the organism in combination with inhibitors offlavivirus RdRp, such as GS-441524, GS-5734, 2′-C-methyladenosine,2′-C-methylguanosine, 2′-C-methylcytidine, Sofosbuvir,2′-C-ethynyladenosine, NITD449, TD008, NITD20, NITD203,4′-C-azidocytidine, 4′-C-azidocytidine, RO-9187, T-1106,6-Methyl-7-deazaadenosine, N6-(9-antranylmethyl) adenosine,N6-benzyl-5′-O-triisopropylsilyl, N6-benzyl-5′-O-triisopropylsilyladenosine, N6-benzyl-5′-O-trityladenosineN6-benzyl-5′-O-tert-butyldimethylsilyl-adenosine,N6-benzyl-5′-O-tert-butyldimethylsilyl-adenosine,2′,5′Di-O-trityluridine, 3′,5′Di-O-trityluridine with or without theinhibitors of flaviviral methyltransferase, such as Ribavirin and othernucleoside synthesis inhibitors, ETAR, IM18, 6-Azauridine, or incombination with rigid amphipathic nucleosides,5-(Perylen-3-yl)ethynyl-arabino-uridine,5-(Perylen-3-yl)ethynyl-2′-deoxy-uridine, or5-(Pyren-1-yl)ethynyl-2′-deoxy-uridine in a concentration that damagesthe RNA or DNA of the organism, but does not crosslink the proteins, orglycoproteins of the virus to be used at a non-toxic level and volumewhen administered in animals or humans with cellular inflammatorypathway inhibitors, such as Wnt inhibitors, Rock inhibitors, GSKinhibitors, or integrin inhibitors, etc. to control the immune responseand a non-toxic concentration of nuclease analogue or mimetics as atherapeutic vaccine with or without Ceapin-A7 and KIRA8 and spermidineto enhance removal of the damaged cells and organisms with or withoutimmunoglobulin to prevent potential chronic inflammation and Alzheimer'sdisease or pulmonary fibrosis, when administered by nasal inhalation forbrain/lung involvement in viral pneumonia or encephalitis, or byintramuscular administration, etc.

In one embodiment, the therapeutic vaccine is used as prophylaxis ortherapy of ongoing infection, etc.

In one embodiment, one or more nucleoside analogue are used for in vitroand in vivo antiflaviviral activities, e.g., to damage the RNA/DNA ofthe organism or to kill the viruses (organism) in vitro with a toxicconcentration, but administer them at below the non-toxicconcentrations, and with anti-inflammatory cell pathway inhibitors to beused as a therapeutic vaccine, in vivo in combination with one or moreantivirals and Ceapin A7 or KIRA-8 to remove damaged cells or deadorganisms, with or without spermidine or toll like receptor 4 to enhancean immune response by nasal application or combined with immunoglobulinto prevent blood clot formation after vaccination of a patient.

In one embodiment, other viral inhibitors of flaviviral nucleosideanalogue can be used alone or with one or more nucleoside analogueadditions, such as NS5 RdRp, or other antivirals, such as7-Deza-2′-methyladenosine, Sofosbuvir, NITD008, T-1106, BCX4430, orinhibitors of flaviviral NS5 RdRp and/or heterobase substitutions andribose modifications flaviviral RdRp nucleoside inhibitors or 1′-Cyanosubstituted nucleosides, or GS-441524, a 1′-cyano substitutedC-nucleoside derived from 4-aza-7,9-dideazaadenosine, in combinationwith a phosphoramidate prodrug of GS-441524, referred to as GS-5734, or2′-C-methyl substituted nucleosides or 2′-Fluoro-2′-C-methyl substitutednucleosides, or 2′-C-Methyl-nucleoside, C7 carbamoyl moiety to NITD008molecule or another 2′-ethynyl modified derivative, referred to asNITD449, and 3′-C- and 3′-O-substituted nucleosides, or 4′-Azidosubstituted nucleosides, 4′-azido modified nucleoside analogue,4′-azidocytidine (R-1479) and 4′-azido-aracytidine, or prodrug of4′-azidocytidine, called balapiravir, or imino-C-nucleoside analogueBCX4430, or heterocyclic base-modified nucleosides, including T-1106,93-95 6-methyl-7-deazaadenosine, and numerous N6-alkyl or arylsubstituted nucleosides, or in combination with T-1106 or ribavirin or6-Methyl-7-deazaadenosine or N6-Alkyl or aryl substituted nucleosides,or tritylated nucleosides, or alkylated, silylated, or acylatedpyrimidine nucleosides, or 2′,5′di-O-trityluridine and3′,5′di-0-trytiluridine or tritylated nucleosides, or nucleosideinhibitors of flaviviral MTase, methylation reactions byS-adenosyl-1-methionine is the nucleoside analogueS-adenosyl-1-homocysteine (SAH) or flexible nucleoside analogues knownas “fleximers”, or nucleoside inhibitors of flaviviral NTPase/helicase,or nucleoside inhibitors of flaviviral NTPase/helicaseRibavirin or itsderivatives or other nucleoside synthesis inhibitors or 6-azauridine and5-aza-7-deazaguanosine, 6-Azauridine and its derivatives are inhibitorsof orotidine monophosphate decarboxylase, blocking cellular de novopyrimidine biosynthesis, or 6-azauridine and 5-aza-7-deazaguanosine, or6-Azauridine and its derivatives.

In one embodiment, the therapeutic vaccine is produced with nucleosideanalogue in combination with another antiviral, such as favipiravir, tobe used as booster shots with the existing vaccines such as mRNA vaccinewith or without nanobodies obtained from llamas and alpacas to attach tothe RBD-ACE2, or multiple antibodies to spike proteins or the use ofACE2 decoys or administered together with a known antiviral such asremdesivir, etc. and anti-inflammatory pathway inhibitors and Ceapin-A7and KIRA8 or spermidine to strengthen the immune response.

In one embodiment of a therapeutic vaccine (TVac), the antibody includesviral, bacterial, or fungal nuclear components/proteins or with orwithout lipids/proteins or with polysaccharides/protein, or an mRNAvaccine (where a single stranded RNA carries the gene's genetic sequencethat is read by the ribosome) for synthesis of an antigenic protein,stimulating the antibody production by the immune cells, the antibody isproduced after exposure of a person by contact with an antigen throughthe skin, mucosa, by inhalation, digestion, or if it is injected in theperson in combination with or without gold nanoparticles conjugated withthiol along with a low non-toxic dose of at least two appropriatemedications against the organism, e.g., for viruses one uses one of anantiviral polymerase inhibitor and a protease inhibitor, etc. with orwithout immune stimulators, such as toll-like receptor 4 and spermidineand one of the anti-inflammatory pathway inhibitors, e.g., a Wntinhibitor, Rock inhibitor, GSK-3 inhibitor, or integrin inhibitor.

In one embodiment, the nuclear components DNA or RNA is obtained andisolated with standard methodology using kits with TRIzol, magneticbeads, centrifugation, then combined with the proteins of the organismto enhance the immune response with or without gold nanoparticles of 1-5nanometers in diameter at a low non-toxic dose of at least twoappropriate medications depending on the organism, e.g., for viruses oneuses of one antiviral polymerase inhibitor and a protease inhibitornucleoside analogues, etc. to which one adds immune stimulators, such astoll-like receptor 4 and spermidine and a pathway inhibitor.

In one embodiment, the therapeutic vaccine (TVac) is administered asneeded repeatedly by measuring the neutralizing antibodies in serum as abooster vaccine alone or in combination with other vaccines such as anmRNA vaccine or DNA/protein vaccine, or polysaccharide/protein vaccineor glycoprotein vaccine, or anti-tumor vaccine or anti-venom vaccine,etc. with one of cell inflammatory pathway inhibitor andn-acetylcysteine for treatment or prophylaxis of a disease.

In one embodiment, the cell pathway inhibitors or complement inhibitors,or caspases inhibitors, are used in a therapeutic vaccine to reduce theinitiation of apoptosis and severe inflammatory response in the tissue,when administered with a therapeutic vaccine as a prophylaxis ortherapeutic with appropriate antivirals, antiparasitics, orantineoplastics with a pathway inhibitor and an immune stimulatorcombined or separately as prescribed intervals by the physician.

In one embodiment, the therapeutic vaccine (TVac) is administered asneeded repeatedly by measuring the neutralizing antibodies in a serum orused as a booster vaccine alone or in combination with other vaccines,such as an mRNA vaccine or DNA/protein/vaccine or polysaccharide/proteinvaccine or glycoprotein/vaccine, or anti-tumor vaccine or anti-venomvaccine, with antivirals, antibacterials, antiparasitics, orantineoplastic medication, etc. with one of cell inflammatory pathwayinhibitor and or caspases inhibitors, such as VX-765 a novel Caspase-1inhibitor, which is an enzyme regulating the generation of IL-1b andIL-18 or Ivachtin or Caspase-6 inhibitor Z-VEID-FMK or Caspase-3inhibitor Z-DQMD-FMK or caspase inhibitor Boc-D-FMK or Z-VEID-FMK etc.or a pan-caspase inhibitor and or toll-like receptor 4, etc. or VLP toenhance an immune response and complement inhibitors andn-acetylcysteine to prevent blood clot formation for treatment orprophylaxis of a disease, whereas the antivirals, antifungals,antineoplastic medication, or antiparasitics are given as a cocktail orseparately as needed daily or as ordered by a physician.

In one embodiment, using therapeutic vaccines which is a cocktail ofantigens obtained from the viruses or fungi, or bacteria or parasites ora tumor plus appropriate non-toxic doses of antifungal, antivirals,antiparasitics, or antineoplastic medication with non-toxic doses ofanti-inflammatory cell pathway inhibitors, such as Wnt, Rock, or GSK-3inhibitors or antiparasitics, and/or complement inhibitors, and or pancaspase inhibitors, or Toll-like receptor 4, etc. to enhance immuneresponse or antibody-coated nanoparticles or slow releaseantibody-coated nanoparticles administered by inhalation, digestion,injection, or intravenous intramuscular or nasal inhalation or throughthe skin and mucosa, etc. as a cocktail or cocktails or separatelyduring the vaccination which can be given initially by at least twice inan interval of two weeks or more or as needed prophylactically ortherapeutically at intervals of 2 weeks as needed, whereas theantivirals, antifungals, or antineoplastic medication are administeredas needed daily, or as ordered by a physician.

In one embodiment, using therapeutic vaccines which is a cocktail ofantigens obtained from the viruses or fungi, or parasites or a tumorconjugated with polymeric nanoparticles or microparticles with orwithout antibody-coated nanoparticles that can be an organic materialsuch as hydrogel, silicon, or porous hydrogel or porous silicon or slowrelease polymeric nanoparticles of polylactic acid, polyglycolic acid orin combinations of nanoparticles of hydrogel and alginate, etc. or aremetallic nanoparticles, such as gold, silver, zinc, etc. or non-metallicnanoparticles, etc. where the pluralities of nanoparticles can carry onetype of antigen, e.g., viral protein or carry many viral proteins plusviral glycoproteins or viral polysaccharides, or DNA or mRNA of anorganism, etc. in different nanoparticles or different nanoparticles cancarry the antigen of one virus or more viruses and some nanoparticlescarry the antigen of a mutated virus etc., plus appropriate non-toxicdoses of antivirals, antifungals, antiparasitics, or antineoplasticmedications with non-toxic doses of anti-inflammatory cell pathwayinhibitors, such as Wnt or Rock, or GSK-3 or anti-TGF beta, and/orcomplement inhibitors 3, 6 etc., and or a pan caspase inhibitors, suchas MX1013 that inhibits caspase-1, 3, 6, 7, 8, and 9, or Toll-likereceptor 4, etc. to enhance an immune response or the variousnanoparticles can be administered sequentially alone or in combinations,where the antibody-coated pluralities of nanoparticles or slow releaseantibody nanoparticles are administered by inhalation, digestion, orintravenous injection or nasal inhalation, etc., or through the skin andmucosa, intramuscular injection, or orally etc., depending on the organinvolved or given in many forms of combinations sequentially etc. or asa cocktail or cocktails which can be give initially at least twice in aninterval of two weeks or more or as needed prophylactically as neededthereafter or therapeutically at intervals of two weeks or more, asneeded whereas and the antivirals, antifungals, antineoplasticmedications, etc. can be administered as needed daily or as ordered by aphysician.

In one embodiment, the therapeutic vaccine is given with pluralities ofnanoparticles with, e.g., antivirals etc. administered to animmunosuppressed person to cover multiple organisms simultaneously, suchas viruses and bacteria or parasites and fungi, or a tumor, etc. incombination with at least one or more antivirals and/or one or moreantibacterials or one or more antiparasitics and one or more antifungalsor one or more antineoplastic medications, in a non-toxic dose with cellpathway inhibitors, and immune stimulators or caspase inhibitor, etc. oran anticoagulant as a cocktail of pluralities of nanoparticles.

In one embodiment, the patient has a therapy-resistant virus, for whichhe or she had received antiviral medication without success, the patientis administered a therapeutic vaccine (a vaccine and antiviral), and ifthe virus does not respond to the therapy, a combination of antiviraltherapeutic vaccine and an antibacterial vaccine (or therapeuticantibacterial vaccine) is given, by nasal inhalation, orally,intramuscularly, or intravenously, to enhance the stimulation of thecellular and humoral response that now acts strongly against theoriginal therapy-resistant virus and eliminates it, the combination ofthe antiviral and antibacterial therapeutic vaccine is givensimultaneously or sequentially with one of the cell inflammatory pathwayinhibitors, one of the complement inhibitors and Ceapin-A7 and KIRA8 orone of the caspase inhibitors to reduce over reaction of the immuneresponse and an antiviral for a longer time until the infection iseliminated.

In one embodiment, the patient has a therapy-resistant bacteria, forwhich he or she had received antibacterial medication without success,the patient is administered a therapeutic vaccine (a vaccine andantibiotic), and if the bacteria does not respond to the therapy, acombination of an antibacterial therapeutic vaccine and an antiviralvaccine (or therapeutic antiviral vaccine) is given, by nasalinhalation, orally, intramuscularly, or intravenously, to enhance thestimulation of the cellular and humoral immune response that now actsstrongly against the original therapy-resistant bacteria and eliminatesit, the combination of the antibacterial and antiviral therapeuticvaccine is given simultaneously or sequentially with one of the cellinflammatory pathway inhibitors, one of the complement inhibitors andCeapin-A7 and KIRA8 or one of the caspase inhibitors to reduceoverreaction of the immune response and an antibacterial for a longertime as needed until the infection is eliminated.

In one embodiment, the patient has a therapy-resistant tumor, for whichhe or she had received antineoplastic medication without success, thepatient is administered a therapeutic vaccine (a vaccine andantineoplastic), and if the tumor does not respond to the therapy, acombination of an antineoplastic therapeutic vaccine and anantibacterial vaccine (or antibacterial therapeutic vaccine) is given,by nasal inhalation, orally, intramuscularly, or intravenously, toenhance the stimulation of the cellular and humoral immune response thatnow acts strongly against the original therapy-resistant tumor andeliminates it, the combination of the antineoplastic and antibacterialtherapeutic vaccine is given simultaneously or sequentially with one ofthe cell inflammatory pathway inhibitors, one of the complementinhibitors and Ceapin-A7 and KIRA8 or one of the caspase inhibitors toreduce overreaction of the immune response and an antiviral for a longertime until the infection is eliminated.

In one embodiment, the patient has a therapy-resistant fungi, for whichhe or she had received antifungal medication without success, thepatient is administered a therapeutic vaccine (a vaccine andantifungal), and if the fungi does not respond to the therapy, acombination of an antifungal therapeutic vaccine and an antibacterialvaccine (or therapeutic antibacterial vaccine) is given, by nasalinhalation, orally, intramuscularly or intravenously, or locally toenhance the stimulation of the cellular and humoral immune response thatnow acts strongly against the original therapy-resistant fungi andeliminates it, the combination of the antibacterial and antifungaltherapeutic vaccine is given simultaneously or sequentially with one ofthe cell inflammatory pathway inhibitors, one of the complementinhibitors and Ceapin-A7 and KIRA8 or one of the caspase inhibitors toreduce overreaction of the immune response and an antiviral for a longertime until the infection is eliminated.

In one embodiment, the patient has a therapy-resistant parasite, forwhich he or she had received anti-parasitic medication without success,the patient is administered a therapeutic vaccine (a vaccine andanti-parasitic medication), an if the parasite does not respond to thetherapy, a combination of antiviral (or antibacterial) vaccine (ortherapeutic vaccine) and an anti-parasitic therapeutic vaccine is given,by nasal inhalation, orally, intramuscularly, intravenously, or locallyto enhance the stimulation of the cellular and humoral response that nowacts strongly against the original therapy-resistant parasite andeliminates it, the combination of anti-parasitic and antibacterialtherapeutic vaccine is given simultaneously or sequentially with one ofthe cell inflammatory pathway inhibitors, one of the complementinhibitors and Ceapin-A7 and KIRA8 or one of the caspase inhibitors toreduce overreaction of the immune response and an anti-parasiticmedication for a longer time as needed until the infection iseliminated.

In the embodiments described above, the therapeutic vaccination can beused for vaccination and therapy of humans, wild animals, farm animals,pets, birds, fish or any other living being that can be infected withany organism or in a neoplastic disease, such as cancer of any organs.

In one embodiment, two or more antivirals are combined at non-toxicdoses, and are administered intranasally, intravenously orsubcutaneously, intramuscularly, orally, etc. for preventing viralattachment to the cells, entry into cells, and viral assembly, etc.

In one embodiment, the TMPRSS2 inhibitor, camostat and/or heparin, LMWH,or heparin mimetics, etc. inhibit entry of the virus into the cells. Inthis embodiment, one, two, or more antivirals are used in a nasalapplication to: (1) prevent virus attachment to the cells; (2) uncoatthe virus inside the cell using, e.g., the antiviral Amantadine, etc. toprevent the virus from using the cell mechanism to replicate; (3) theseare combined with prevention of the proteins for assembly by the virus,using a protease inhibitors, such as Darunavir, ebselon, or ritonavir,saquinavir, and indinavir, etc.; (4) addition of transcriptioninhibitors, such as nucleoside reverse transcriptase inhibitor (NRTI),etc.; (5) prevention of assembly of the viral protein with a polymeraseinhibitor, such as remdesivir, Acyclovir, or valcyclovir, etc.; (6)blocking the RNA or DNA with methylene blue or the use of nucleosideanalogues, such as Foscarnet, Fomivirsen, Famciclovir or Oseltamivir,etc.; and (7) prevention of release of viral particles from the infectedcells with antiviral Zanamivir.

In one embodiment, temporary nasal implants are used for drug deliveryin combination with slow release nanoparticles, or the addition ofantibody-coated pluralities of polymeric nanoparticles with or withoutlow molecular weight heparin, and linoleic acid with or withoutanti-inflammatory pathway inhibitors to prevent reinfection and toreduce an inflammatory response in the nose and respiratory pathway orbrain inflammation and reduce viral loads in vaccinated, reinfected,and/or unvaccinated patients or the temporary nasal implant can be usedafter its nostril implantation for analysis through the mail sent to alaboratory, etc. after one or more days or nights to measure the viralload in the nose.

In one embodiment, the temporary nasal implant is used to delivertherapeutic vaccines for respiratory inflammation or infection orcentral nervous system infection, etc.

In one embodiment, the nasal swab or implant is used for measurement ofthe viral load in the nose alone, or in a patient with chronic or“long-covid”, the persistence of the virus is proven, also by obtainingaqueous fluid from the eye by taking a small volume liquid biopsy fromthe anterior chamber of the eye as described in U.S. Pat. No.10,278,920, the entire disclosure of which is incorporated herein byreference, for lab analysis or administration of antivirals, etc.

In one or more embodiments, the steps of the therapeutic vaccines aresimilar, namely: (1) growing the organism in the cell culture, etc.; (2)killing the organism with a high dose of at least two medications thatdamage RNA and DNA; (3) obtaining the antigens from the dead RNA and/orDNA of the damaged viruses and adding medications at a low non-toxicdose to the patient, but still toxic enough to the viruses, with orwithout inflammatory pathway inhibitors and a PARP inhibitor that blocksthe RNA and/or DNA repair; and (4) with or without toll-like receptor 4,etc. to enhance an immune response, the therapeutic vaccine that can beused both prophylactically, or for treatment if the patient or animal isinfected since it still kills the viruses while stimulating body'simmune response to the virus as often as needed by administrationnasally, orally, intramuscularly, intravenously, locally, or inside anorgan, e.g., inside an eye or the brain where the blood brain barrierprevents medications, etc. from penetrating the brain or the eye.

In one embodiment, the initial steps of growing viruses, bacteria,fungi, parasites or tumor cells are performed, then the second step ofdamaging the RNA and/or DNA is done either with a toxic dose ofmethylene blue >4 mg/liter alone or combined with peptide nucleic acids(PNAs) that damage specific RNA by attaching tightly to the organism'sDNA/RNA, thus inhibiting, e.g., bacterial, viral, fungal, parasitic, ortumor cell's protein production for the organism's survival, eithermethylene blue or PNA can be used in vitro with or without toxic dosesof antivirals, antibacterials, antifungals, antiparasitics, oranti-neoplastic medications as needed to kill the organisms, then afterfiltering the medications, the dead viruses, bacteria, fungi, parasites,or tumor cells are used as vaccine antigens including their proteins,glycoproteins, saccharides, etc. combined with nontoxic doses ofantivirals, antibacterials, antifungals, antiparasitics, orantineoplastic medications alone depending on the organism with orwithout a PARP inhibitor to prevent RNA and/or DNA from regenerating andpreventing future mutations, and other anti-inflammatory pathwayinhibitors, such as Wnt, Rock, GSK, and/or integrin inhibitors areadministered at non-toxic concentrations and volumes to preventexcessive an immune response, or with toll-like receptors or otheradjuvants, etc., to enhance immune response administeredintramuscularly, or by nasal inhalation, spray, etc., or orally as acapsule or injected subcutaneously or injected inside a body cavity todamage the viruses, bacteria, fungi, parasites, or tumors and inducing acellular and humoral immune response, with or without an anticoagulant,such as low molecular weight heparin, a heparin mimetic,n-acethylsystein, Abelacimab, etc., to prevent blood clotting and thetherapeutic vaccine can be repeatedly administered as needed to adultsand children or at a low dose or an increasing dose, until a sufficientneutralizing antibody response is achieved in the serum of the patient,which can be human adults or children or animals, etc.

In one embodiment, the therapeutic vaccine is combined with naturalkiller cells prepared from a patient, and grown in the lab in a largequantity, and administered for treatment of a parasitic infection,therapy of viruses, resistant bacteria, e.g., tuberculosis, leprosy,syphilis, aids, COVID-19 and its mutations, a severe viral infection,Ebola, Zika, etc., malaria, malignant or benign tumors, a pancreaticneoplasm, brain, breast, prostate, lung, cervical, uterual, or ovarytumors, intestinal, colon, neoplastic lesions or melanoma, and otherskin tumors, breast, prostate bladder cancer, kidney, brain, sarcomas,lung cancers, and spinal cord tumors, genital tumors, etc. where thetreatment is personalized by obtaining natural killer cells from thesame patient and grow them in the culture with the organisms.

In one embodiment, a tumor becomes resistant to checkpoint inhibitors,and creates a milieu in which the newly grown tumor cells becomeresistant to the standard immune therapies which include check pointinhibitors. In order to treat these conditions, one administers acombination of two different therapeutic vaccines, one directed towardthe existing tumor cells plus one or two antineoplastic medications incombination with another vaccine that is directed toward anotherantigen, e.g., against a bacteria, to restimulate the cellular immuneresponse (killer cells) and humoral immune response of the body againstthe therapy-resistant tumor cells that kills and removes them whensimultaneously one administers a cell pathway inhibitor with immunestimulators, such as toll-like receptor 4 and anti-VEGFs, such asBevacizumab, Cilengitide, etc. as a cocktail and/or with monoamineoxidase inhibitors, melatonin and spermidine and to prevent exhaustionof the cellular immune response.

In one embodiment, a large tumor can receive surgical excision and acombination of thermotherapy with one or more immune therapy medicationsand/or PARP inhibitor to prevent mutation of the tumor and an antitumormedication at a non-toxic dose in combination with administration oftherapeutic vaccines that can be repeatedly administered with differentantigens and natural killer cells to remove the dead cells or destroythe remaining tumor cells, thus stimulating the immune cellular responsewith natural killer cells over a period of time while adding toll-likereceptor 4 or an adjuvant, or pegylated interferon to the cocktailand/or a monoamine oxidase inhibitor and spermidine and an anti-VEGF toprevent exhaustion of the cellular immune response.

In one embodiment for cancer therapy, additional thermotherapy with orwithout anti-VEGFs that weakens the tumor's ability to resist immunetherapy which is administered with or without PARP inhibitors to preventmutation of the tumor while improving the tumor microenvironment whichmitigates tumor's resistance and when checkpoint inhibitors may not beworking.

In one embodiment, some tumors develop resistance to checkpointinhibitors and continue to grow, to prevent additional growth,intravenous, intra-arterial, or local administration, etc. of killercells, antineoplastic medication, such as PARP inhibitors, and naturalkiller cells and/or a pan-caspase inhibitor and/or toll-like receptor 4,etc. enhance the immune response to kill and remove the dead tumorcells.

In one or more embodiments, the steps of the therapeutic vaccines aresimilar, for all viruses, bacteria, fungi, parasites or tumor cells,collectively called “pathogens” namely:

(1) growing the organism; (2) killing the organism with a high dose ofat least two medications that damage RNA and DNA of the viruses,bacteria, fungi, parasites or tumor cells; (3) filtering out the freetoxic components, obtaining the antigens and adding medications at anon-toxic level with or without a PARP inhibitor or peptide nucleic acidor beta-propiolactone, etc.; (4) adding one more anti-inflammatorypathway inhibitors and anti-pathogenic medications; and (5) adding oneor more adjuvants, such as toll-like receptor 4, or saponin, etc. toenhance an immune response, as a therapeutic vaccine that can be usedprophylactically, or for treatment as needed.

In one embodiment, the first step of growing viruses, bacteria, fungi,parasites or tumor cells is performed, then the second step of damagingthe RNA and/or DNA is done either with a toxic dose of methylene blue >4mg/liter alone or with the use of peptide-like molecules called“peptoids” or other biomimetic molecules that can inactivate viruses,etc. by damaging the organism's DNA/RNA and inhibiting, e.g., bacterial,viral, fungal, parasitic, or tumor repair or mutation, or the productionneeded for the organism's survival. The medication may further includePARP inhibitors.

In one embodiment, methylene blue, peptoids or proteases can be combinedto damage the viral membranes and can be used in vitro with or withouttoxic doses of antivirals, antibacterials, antifungals, antiparasiticsor anti-neoplastic medications, such as mycophenolic acid oriododeoxyuridine and methisazone or Masitinib a proteinase inhibitor orwith or without monoclonal antibody-coated nanoparticles or polyclonalantibody-coated nanoparticles to kill the organisms, then afterfiltering the medications, the dead viruses, bacteria, fungi, parasitesor tumor cell antigens are used as a vaccine antigen including theirproteins, glycoproteins, saccharides, etc. which are now combined withnon-toxic doses of antiviral, antibacterial, antifungal, antiparasitics,or antineoplastic medications alone depending on the organism with orwithout PARP inhibitors or anti-inflammatory pathway inhibitors, such asWnt, Rock, GSK, integrin inhibitors, and mycophenolic acid administeredat non-toxic concentrations and volumes to prevent an excessive immuneresponse, with toll-like receptors or other adjuvants, etc., to enhancean immune response administered intramuscularly, or by nasal inhalation,spray, etc. or orally as a capsule or injected subcutaneously orinjected inside a body cavity or subcutaneously to damage the viruses,bacteria, fungi, parasites, or tumors and inducing a cellular andenhancing a humoral and cellular immune response, with or without ananticoagulant, such as low molecular weight heparin, heparin mimetics,n-acethylsystein, Abelacimab, etc., to prevent blood clotting and thetherapeutic vaccine can be repeatedly administered as needed, or at lowdose or increasing dose until a sufficient neutralizing antibodyresponse is achieved in the serum of the patient, which may be humanadults or children or animals.

In one embodiment, the therapeutic vaccine can be delivered with atemporary nasal implant for prophylaxis or therapeutic indications, thetherapeutic vaccine uses antigenic material from the bacteria, viruses,fungi, parasites, or tumor cells in which the DNA and/or RNA is damagedin vitro by numerous medications such as gold nanoparticles, methyleneblue, antineoplastic medications, peptoids, etc., where the peptides,protein glycoproteins, saccharides, or PNA, etc. and antigenic moleculesof the organism are used to induce a humoral or cellular immune responsewith or without PARP inhibitors to prevent live organisms from mutatingwith or without toll-like receptors while other adjunct medications areantivirals, antibacterials, antiparasitics, antifungals, oranti-neoplastic medications depending on the organism, with or withoutculture-grown killer cells as needed or immunosuppressive drugs, such asmycophenolic acid, etc., and inflammatory cell pathway inhibitor(s) areadded, with anticoagulants or mono or polyclonal antibody-coatednanoparticles as a cocktail or one or more combinations of thesemedications are administered preferentially through the nasal inhalationor as an implant with or without a slow release antibody-coatedtemporary porous implant as prophylaxis or therapeutic when the patientis already infected or alternatively administered orally,intramuscularly, locally, or subcutaneously to a human patient and/or toan animal.

In one embodiment, the temporary nasal implant is sprayed with atherapeutic vaccine prior to implantation to release themedication/vaccine slowly in the nose, etc.

In one embodiment, in order to vaccinate against future mutations inviruses, bacteria, fungi, parasites, tumor cells, etc., the followingsteps are performed:

-   -   A) A variety of viruses, such as Rhinoviruses, Coxsackie        viruses, Adenoviruses and coronaviruses SAR-Cov-2 and its        mutations (Covid-19), alpha, beta, and delta, Omicron etc.        mutations, respiratory syncytial virus (RSV), Epstein Barr Virus        (EBV), H. influenzae type b (Hib) influenza, Human parainfluenza        viruses (HPIVs) viruses and RSV Middle East respiratory virus,        pandemic H1N1, and H7N9 and their mutations, influenza viruses,        Epstein-Barr viruses, measles virus, enteroviruses,        varicella-zoster virus and arboviruses, Japanese encephalitis        virus, West Nile virus, and Murray Valley encephalitis virus,        AIDS, ebola, etc. are grown on yeast to multiply and        simultaneously mutate, then as with the method of producing a        therapeutic vaccine, the DNA and/or RNA of the virus and yeast        is damaged by medications, such as gold nanoparticles (GNP),        methylene blue at high concentrations >5 mg/liter or        antineoplastic medications, peptoids, etc., or PNA, or PARP        inhibitors, etc.    -   B) Then, the peptides, protein glycoproteins or saccharides,        molecules of the filtered organism plus yeast wall, etc. is        separated from the culture media for examination of potentially        mutated viruses, etc.    -   C) After which, the antigenic material is used to induce a        humoral or cellular immune response combined with or without a        PARP inhibitor to prevent mutation in the organism if any of the        organisms are alive, plus toll-like receptors while other        adjunct medications may be administered.    -   D) Non-toxic doses of antivirals, antibacterials,        antiparasitics, antifungals, or anti-neoplastic medications,        depending on the organism, are added as a therapeutic vaccine        and administered to the patient to enhance an immune response        with or without culture-grown killer cells sequentially as        needed or in addition to immunosuppressive drugs, such as        mycophenolic acid, etc., and inflammatory cell pathway        inhibitor(s) are added, with anticoagulants or mono or        polyclonal antibody-coated nanoparticles as a cocktail or with        non-toxic doses or a PARP inhibitor to effectively prevent        viral, bacterial, fungal, and tumor cell mutations.    -   E) One or more combinations of these therapeutic vaccines are        administered to the patient preferentially through the nasal        inhalation, orally, intraperitoneally, intramuscularly, locally,        intravenously, subcutaneously, etc. or as a nasal temporary        implant with or without slow release antibody-coated        nanoparticles with a temporary porous nasal implant as a        therapeutic vaccine prophylaxis or when the human or animal        patient is already infected.

In one embodiment, the use of yeast as a cell culture permits theviruses not only to grow on them, but also potentially the virusesmutate rapidly, or their mutation is promoted with light, electricalpulse, etc. so that even when the mutation has not occurred in theanimal or human, this new vaccine's antigenic components containantigenic material from the mutated and unmutated viruses, therebyinducing a humoral and cellular immune response against the past,present and future mutations of the organism and when administered withor without an PARP inhibitor, etc. (such as olaparib niraparib,rucaparib, talazoparib) to effectively prevent viral, bacteria, fungaland tumor cell mutation to the animal or human.

In one embodiment, this therapeutic vaccine technology can also be usedfor treating therapy-resistant bacterial, fungal, and parasiticorganisms or against therapy-resistant tumor cells using thecomplementary components as needed, such as two or more antivirals, twoor more antibiotics, two or more antiparasitics, two or moreantifungals, and/or two or more antineoplastic medications at non-toxicconcentrations plus anti-inflammatory pathway inhibitors andanticoagulants as a cocktail or sequentially administered to the animalor human.

In one embodiment, a variety of viruses, bacteria, fungi, parasites, ortumor cells are grown on appropriate culture with or without mutationstimulating means, such as reactive oxygen species or UV light, or lightcombined with quantum dot administration to the cell culture thatgenerates an electric pulse after slow-pulsed light exposure, or focusedultrasound at temperature of 43° C. or electrical or chemical pulsestimulus leading to depolarization and repolarization cycles at a rateof 1-20 per second or more and relaxation in or focused ultrasound withor without microbubbles and imaging simultaneously the temperature andcontrolling it at 40-43° C. as described in U.S. Pat. No. 11,090,385,the entire disclosure of which is incorporated herein by reference, tochange the molecule structure of the cell or viruses or bacteria ofparasites or tumor cells, stimulating heat shock protein production,upregulating expression of the nucleic acid, and encouraging mutation inthe organism in presence of nutritious media, enhancing multiplicationof these organisms that ultimately induces viruses, the bacteria, fungi,or tumor cells not only to grow, but also divide and mutate aftermultiple generations, then as with the method of producing a therapeuticvaccine, the DNA and/or RNA of the bacteria, fungi, parasites, or tumorcells are damaged by medications, such as gold nanoparticles (GNPs),zinc NPs, or silver NPs of 1-10 nm in size, or zinc NPs with or withoutlaser or ultrasound radiation that heats up the GNPs that preferablyabsorbs the radiation which is attached to DNA or RNA of the virus,bacteria, fungi, parasites, or tumor cells and damages them with orwithout a high concentration of methylene blue >4 mg/liter that attachesto the RNA and/or DNA with or without low light radiation with orwithout GNPs that damages the DNA or RNA, or with or without toxic dosesof anti-neoplastic medications, and/or peptoids or peptide nucleic acid(PNA), etc. where the peptides, proteins, glycoproteins, or saccharides,molecules of the organism are separated from the culture media by afilter, etc. is now used to produce a therapeutic vaccine with anon-toxic dose of antivirals, antibacterials, antifungals,antiparasitics, or anti-neoplastic medication with or without PARPinhibitors to prevent mutation and are administered to a human or animalwith or without toll-like receptors to induce a humoral or cellularimmune response while other adjunct medications are administered as acocktail or separately, such as culture grown killer cells, etc. asneeded or immunosuppressive drugs, such as mycophenolic acid, etc. andanti-inflammatory cell pathway inhibitor(s), with anticoagulants or monoor polyclonal antibody-coated nanoparticles as a cocktail and/or with aPARP inhibitor (called poly (ADP-ribose) polymerase inhibitor) toeffectively prevent viral, bacteria, fungal and tumor cell mutation, oneor more combinations of these medications are administeredpreferentially through nasal inhalation, orally, intramuscularly,locally, intravenously, subcutaneously, etc. or as a nasal implant withor without slow release antibody-coated nanoparticles as prophylaxis ortherapeutic when the patient human or animal is already infected.

In one embodiment, the use of culture media and repeated generation ofthe organism can induce mutation with or without medications, such asreactive oxygen species or UV light or electrical stimulus,depolarization and repolarization cycles and/or focused ultrasound thatenhances multiplication of these organisms that ultimately induces thevirus, bacteria, fungi, or tumor cells not only to grow, but alsopotentially mutate after multiple generations of growth, which occursfaster in viruses than bacteria or tumor cells in vitro thus even whenthe mutation has not occurred in animal or human, the induction orgrowth by electrical stimulus, electrophoresis, or light creates fasternext generation variant and mutations than otherwise would happen,therefore, the new vaccine produced from these culture grown organismswhich have antigenic components from the organism and its mutationsinduces a humoral and cellular immune response against the past,present, and future mutations of the organism, thus, this acceleratedvaccine technology, has a predictive value for recognizing futuremutations if analyzed for its genetic component and useful for treatmentof therapy-resistant viruses, bacterial, fungal, and parasitic organismsor against therapy-resistant tumor cells since it can be administeredprophylactically/therapeutically and acts against future mutations ofthese organisms when used with the complementary components, such as twoor more antivirals, two or more antibiotics, two or more antiparasitics,two or more antifungals and two or more anti-neoplastic medications atnon-toxic concentrations plus anti-inflammatory cell pathway inhibitorsand anticoagulants and PARP inhibitors to effectively prevent viral,bacteria, fungal and tumor cell mutation as a cocktail or whenadministered sequentially, for intravenous, intraarterial,intramuscular, by nasal inhalation, or orally in inside a body cavity,etc.

In one embodiment, methylene blue (MB) at concentrations of >4microgram/ml in cell or tissue culture is used to damage the DNA and RNAof the viruses, bacteria, fungi, parasites, or tumor cells, with orwithout addition of peptide nucleic acid (PNA), and/or a proteaseinhibitor, and/or poly (ADP-ribose) polymerase inhibitor (PARP)inhibitors fixate the DNA or RNA, preventing them from becoming activeor mutating, similarly beta-propiolactone (BPL) can be used to damageDNA or RNA, however, beta-propiolactone is an alkylating agentdesignated by the FDA as a carcinogenic compound and preferably shouldbe used at very low concentrations. After killing the “pathogens”, thevaccine is washed and filtered to eliminate all unbound MB and BPL, thenone or more antivirals, antibacterials, antifungals, anti-parasitics,and/or anti-neoplastics are added at a nontoxic concentration with orwithout adjuvants such as viral-like particles (VLP), TLR, FICASaponin-based adjuvants (SBAs) etc. and their combinations, withanti-inflammatory cell pathway inhibitors added to the vaccine cocktailto build a therapeutic vaccine against various pathogens.

In one embodiment, combination of BPL above 1:1000 and at lowconcentrations and MB<0.26 microgram/ml reduces the toxicity and reducesthe aggregation in the culture media and increases the antiviralefficacy.

In one embodiment, the therapeutic vaccine is made of many virusesincluding sarbecoviruses, or herpes viruses, merbecoviruses and ornumerous others. In one embodiment, the therapeutic vaccine made fromone virus can be mixed with another or multiple related vaccines forviruses, etc. prior to their administration.

In one embodiment, the therapeutic vaccine made for viruses can be mixedwith a therapeutic vaccine made for bacteria, fungi, parasites, oragainst tumor cells so that all collectively stimulate cellular andhumoral response of the body, particularly in immune suppressedpatients.

In one embodiment, methylene blue at concentrations of >1 microgram/mlin a cell or tissue culture at media temperature of 24-43° C. controlledwith a proportional integral derivative system that controls thetemperature of the media at an exact desired level to enhance damage tothe viruses, bacteria, fungi, and/or tumor cells without denaturing theproteins, glycoproteins, saccharides, etc. (that occurs at temperaturesof 45-50 degrees Celsius or more) to damage selectively the DNA and RNAof the viral, bacterial, and fungal particles, or parasites or tumorcells, with or without addition of peptide nucleic acid (PNA), and/or aprotease inhibitor (Ebselen) and/or poly (ADP-ribose) polymeraseinhibitor (PARP) inhibitors fixate the DNA or RNA, preventing them frombecoming active or mutating, similarly beta-propiolactone can be used todamage DNA or RNA, however, beta-propiolactone is an alkylating agentdesignated by the FDA as a carcinogenic compound and preferably shouldbe used at very low concentrations. After killing the pathogens, thevaccine is washed and filtered to eliminate all unbound MB and BPL, thenone adds one or more antivirals, antibacterials, antifungals, antiparasitics, and/or anti-neoplastics at a nontoxic concentration with orwithout adjuvants, such as viral-like particles (VLP), TLR, etc. isadded to the vaccine cocktail to build a therapeutic vaccine againstvarious pathogens or stored at room temperature or below freezing atzero degrees C. for transport as needed.

In one embodiment, a combination of BPL above 1:1000 and at lowconcentrations and MB<0.26 microgram/ml at a temperature of 37-40degrees C. reduces the toxicity of MB and BPL, and reduces theaggregation in the culture media and increases the antiviral efficacyfor use in tissue culture, cell culture, or for administration to apatient.

In one embodiment, combination of BPL at low concentrations 1:1000 V/Vand MB of <0.25% microgram/ml at temperatures of 25-43 degrees C. intissue culture, or for administration reduces the toxicity of MB andincreases the antivirals, antibiotics, antifungals, anti parasitics andanti-neoplastics efficacy of vaccine stalk to which non-toxicconcentrations of antiviral, antibiotic, anti-fungal, antiparasitic,and/or anti neoplastic medications are added to build a therapeuticvaccine cocktail for administration intranasally, intramuscularly,orally, nasally subcutaneously, intraarterially, or using a therapeuticimplant with or without adjuvants, such as viral-like particles (VLP),TLR, etc. for delivery of the vaccine cocktail as needed.

Although the body's immune system produces peptoids to kill manypathogens, such as viral, bacterial, parasitic, fungal, or neoplasticcells, these peptoids do not discriminate between the pathogen and thenormal tissue. This means that the peptoids or the syntheticallyproduced mimetic counter parts, can also damage normal tissue. Thepeptide can be produced synthetically that works the same way, i.e.,penetrating the membrane of viruses, bacteria, fungi, parasites or tumorcells and latch to DNA or RNA preventing their function or replicationof the pathogen while maintaining the protein, glycoprotein andsaccharides antigenicity of the organism with or without adjuvants, suchas viral-like particles (VLP), TLRs, Specol, Titermax adjuvants, Ribiadjuvant, aluminum salt adjuvants, etc.

In one embodiment, peptoids are easy to make, such as LL-37, and are apart of cathelicidins host defense peptides when added to the tissueculture or cell culture in preparation of therapeutic vaccine penetratesthe viral or the pathogen's envelope and attach to RNA and DNApreventing them from being activated. Initially the LL-37 binds to thesurface membrane of the pathogen at low concentrations of 8 μM, thentranslocates in the preplasmic space within <30 minutes and stops thegrowth of the pathogen leading to lysis of the pathogen, one also canadd antiviral, anti-bacterial, antifungal, antiparasitic, orantineoplastic medication to the tissue culture or cell culture whichnow penetrates the pathogen damaged membrane by LL-37 killing theseorganisms, then the culture media is washed and filtered to obtain theantigenic proteins, saccharides, glycoproteins from the organism,subsequently one adds non-toxic doses of antivirals, antibiotics,antifungals, anti-parasitics, and/or anti-neoplastics to create atherapeutic vaccine which can be stored with or without BAC, adjuvants,or anti-inflammatory agents and kept at a low temperature without theneed to freeze it, though freezing the vaccine will not affect itsefficacy and can be melted before its application, to be administered asneeded by inhalation, orally, subcutaneously or intramuscularly orinjected inside a tumor or in nasal implant.

In one embodiment, methylene blue and beta-propiolactone (BPL)at >1/2000 V/V can be used both at low concentrations, combinations toprevent the side effects of viral aggregation, e.g., methylene blue atdoses of <0.5 microgram/ml and BPL at <0.5 mg/ml with or withoutanti-virals, etc. used for vaccine production in tissue or cell culturewith or without LL-37 peptoids that are subsequently washed and filteredto remove free methylene blue and or beta-propiolactone or LL37 awayfrom the culture medium while adding an anti-inflammatory agent, such assteroids or inflammatory cell pathway inhibitors to it, with or withouttoll-like receptors which is stimulated in presence of other adjuvantsto enhance the immune response after administration to a patient and oneor more antivirals, antibacterials, antifungals, antiparasitics, oranti-neoplastics with or without PARP inhibitors, etc. medication atnon-toxic doses or low concentrations as a therapeutic vaccine, or fortreatment, or prophylaxis, in viral, bacterial, fungal, parasitic,and/or neoplastic pathogens, to be administered as needed by inhalation,orally, subcutaneously, intramuscularly, or injected inside a tumor orinside a cavity, such as a nasal implant.

In one embodiment, for production of the therapeutic vaccine LL-37, apeptoid at low concentrations enhances the effect of antiviral,antibacterial, antifungal, or antineoplastic medication used in thetissue culture or cell culture for production of vaccines.

In one embodiment, for production of therapeutic vaccine Nsp13inhibitors, MB or BPL, such as bananin, and chromone-4c at lowconcentrations enhances the effect of antiviral, antibacterial,antifungal, and/or anti-neoplastic medication used in tissue culture orcell culture vaccination that can be washed and filtered and used withantiviral, antibacterial, antifungal, or antineoplastic medication atnon-toxic concentrations as a cocktail with adjuvants in therapeuticvaccine production.

In one embodiment, for production of a therapeutic vaccine with PARPinhibitors and a protease inhibitor Ebselen or a combination withrifampin and inflammatory cell pathway inhibitors enhances the effect ofan antiviral, antibacterial, antifungal, or anti-neoplastic medicationused in vaccination specifically for nasal application to enhancerecovery from diseases of the brain and lung by the above-describedpathogens and preventing future Alzheimer diseases after viralinfections.

In one embodiment, peptoids and beta-propiolactone or methylene blue atlow concentrations and peptide nucleic acid (PNA) can be combined toblock DNA and RNA and can be used for vaccine production in tissue orcell culture of viruses, bacteria, fungi, parasites or cancer cellswhere the DNA and RNA of the organism is damaged by PNA, leaving theprotein glycoproteins and saccharides intact to act immunogenic, thenthe dead organism in the tissue culture is washed to remove freemethylene blue or beta-propiolactone, to which now depending on theorganism, antiviral, antibacterial, antiparasitic, antifungal, and/orantineoplastic medication is added at a non-toxic concentrations, thenone adds adjuvants for enhancing the immune response, and steroids oranti-inflammatory cell pathway inhibitors, to reduce an overactiveimmune response. The therapeutic vaccine cocktail is now stored inrefrigerator to be administered to the person as needed by inhalation,orally, subcutaneously, intramuscularly, or injected inside a tumor.

In one embodiment, in a tissue culture, the peptoid LL-37 and peptidenucleic acid can be used to make a therapeutic vaccine with anantineoplastic medication, etc. to damage the RNA or DNA in the viral,bacterial, fungal, parasitic, or tumor cell in the culture media tocreate a peptoid therapeutic vaccine, though if needed, methylene blueor beta-propiolactone at a very low concentration or peptide nucleicacid (PNA) or PARP inhibitors can be added, without the use of heat,light, or the potentially carcinogenic medications, the vaccine/inculture medium is then washed and filtered to remove free methylene blueand/or beta-propiolactone and use the remaining proteins, glycoproteins,saccharides, etc. to make a therapeutic vaccine, with additionalantivirals, antibacterials, anti parasitics, antifungals, and/oranti-neoplastic medications, plus anti-inflammatory pathway inhibitorsto reduce the inflammatory response or add VLP, toll-like receptors, oroval albumin or aluminum-based compound called adjuvant or recombinantspider silk protein or Saponin-based adjuvants (SBAs), etc. to thevaccine to stimulate an immune response against the pathogens in thebody. In this embodiment, peptoids and/or synthetic peptoids are beingused for the production of a new vaccine.

In one embodiment, the therapeutic vaccine can be administered at lowconcentrations in young children or elderly or immune suppressed, etc.to gradually initiate the immune response and increase the dose atdifferent intervals of one month and more until satisfactoryneutralizing antibodies (NA) are present in the blood without causing asside effects to the patient.

In one embodiment, the therapeutic vaccine (i.e., the vaccine andantivirals) is administered to patients with previous viral diseases,such as herpes, or viruses with CNS affinity to prevent reactivation ofthe hidden or latent herpes viruses or other viruses such as EBV in thepatient after vaccination against the same or another virus, e.g.,coronaviruses and their mutations, etc. or antivirals are added againstanother viral infection to prevent reactivation of the second latentvirus residing in the body (e.g., in the eye, brain, or nasal or oralcavity etc.).

In one embodiment, the nasal inhalation or nasal implantation of thetherapeutic vaccine provides not only general immunity to the person oranimal, but simultaneously creates a mucosal immunity in the nasalmucosa, the bronchi, lung mucosa and in the brain, through the olfactorynerves, which is important in treatment of viruses that are transmittedmostly through air, etc.

In one embodiment, the therapeutic vaccine is administered with anantibiotic such as rifampin or rifampicin with or without pathwayinhibitors by inhalation to prevent simultaneous co-existence of thebacteria specially in immunosuppressed patients.

In one embodiment, in a population affected with a virus aftervaccination, the measurement of a neutralizing antibody (NA) in thecirculation of a patient indicates the duration of the effect of thevaccine in a patient, repeated examination of a small sample of thepopulation can provide not only the information on the duration of theimmunity, but also the effect of NA on the mutations, therebyeliminating the need for a large scale evaluation of the entirepopulation.

In one embodiment, the nasal therapeutic implants for both nostrils areadministered repeatedly after 3-6 months or more, may serve as aprophylaxis, vaccination, and/or therapeutic for the patient and prolongthe duration of immunity in the patients and the general population, andis economical compared to systemic administration of larger doses,thereby preventing spread of the disease.

In one embodiment, one can produce a combination vaccine made ofnumerous viruses or mutations so that the therapeutic vaccine describedwith the methodology in this application can used against numerousviruses, RNA or DNA viruses (see the lists above, etc.) or administeredat low concentrations with other viral therapeutic vaccines such as mRNAvaccines, administration of low doses at low concentrations orally,through the nose, as an implant, by mouth, or intramuscularly, thevaccination can be repeated once a month or every three months or longerwhile examining the serum antibodies against the viruses.

In one embodiment, the described methodology can be used against chronicbacterial infections, or viral infections which are therapy-resistant,such as the use of rifampin in therapy resistant tuberculosis, leprosy,herpes, zoster virus, Epstein Bar infection, etc.

In one embodiment, the above-described methodology can be used againstall fungi, to be administered as needed by inhalation, topically,orally, subcutaneously, intramuscularly, injected inside the lesion ortumors, injected in a body cavity, or via a nasal implant, etc.

In one embodiment, the methodology of creating a therapeutic vaccine canbe used for treatment of neoplastic diseases, benign or malignant,tumors, to be administered as needed by inhalation, topically, orally,subcutaneously, intramuscularly, or injected inside a tumor or a bodycavity, such as bladder, etc.

In one embodiment, this therapeutic vaccine can be used againstparasitic infections regardless of their location along with specificmedication described to be administered as needed, topically, orally,subcutaneously, intramuscularly, or injected intravenously, etc.

In one embodiment, the therapeutic vaccine can be applied topically, onthe mucosal, or skin surface, can be inhaled or delivered through anasal implant, or taken orally as pills, or injected locally,subcutaneously, inside a body cavity, subcutaneously or intramuscularly,or administered as a nasal implant, etc.

In one embodiment, after COVID infection, in unvaccinated patients, thesymptoms of COVID last long and may not disappear soon, in these casesthere is an elevated level of interferon in the body as if the infectionhas never left the patient, the symptoms could be related to chronicinflammation in the brain leading potentially to Alzheimer or lung(pulmonary fibrosis) or kidney or other organs, heart disease, andchronic fatigue syndrome.

In one embodiment, these patients can be treated with a therapeuticvaccine by nasal administration in addition to the use of Ebselen, aprotease inhibitor, which is attached to Mpro in combination withrifampicin and the inflammatory pathway inhibitors, such as rho kinaseinhibitors and for the kidney involvement, the systemic, oral or lowdose intraperitoneal or intravenous administration might be desirableafter initial inhalation therapy with the therapeutic vaccine toreactivate immune response to remove the antigenic material from thebody and reduce inflammatory process, a combination with baricitinib canalso be a desirable therapy.

In one embodiment, the therapeutic vaccine with or without adjuvantssaponin or TLR agonist can be used without exception for all viruses,bacteria, fungi, parasites, benign or malignant lesions, and might havea role in management of autoimmune diseases or chronic inflammatoryprocesses, such as Alzheimer's disease, Parkinson's disease, rheumatoiddisease, etc. though the general principles are described, specificvariations or additions such as diphenhydramine, lactoferrin, lenzilumab(an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF)monoclonal antibody), and inflammatory cell pathway inhibitors, etc. areapplied for each therapy.

In one embodiment, methylene blue at concentrations or >4 microg/ml incell or tissue culture is used to damage the DNA and RNA of the viruses,bacteriae, and fungi or parasites or tumor cells, with or withoutaddition of peptide nucleic acid (PNA), and/or a protease inhibitor andor poly (ADP-ribose) polymerase inhibitor (PARP) inhibitors to fixatethe DNA or RNA, preventing them from becoming active or mutating,similarly beta-propiolactone can be used to damage DNA or RNA, however,beta-propiolactone is an alkylating agent designated by the FDA as acarcinogenic compound and preferably should be used at very lowconcentrations. After killing the pathogens, the vaccine is washed andfiltered to eliminate all unbound MB and BPL, then one adds one or moreantivirals, antibacterials, antifungi, anti parasitics, anti-neoplasticsat a nontoxic concentration with or without adjuvants, such asviral-like particles (VLP), TLR, FICA and Saponin-based adjuvants(SBAs), etc. or their combinations is added to the vaccine cocktail tobuild a therapeutic vaccine against various pathogens.

In one embodiment, combination of BPL above 1:1000 and at lowconcentrations and MB<0.26 Microgam/ml reduces the toxicity and reducesthe aggregation in the cuture media and increases the antiviral efficacy

In one embodiment, the therapeutic vaccine is made of many virusesincluding sarbecoviruses and merbecoviruses and/or numerous others. Inone embodiment, the therapeutic vaccine made from one virus can be mixedwith another or multiple related viruses prior to their administration.

In one embodiment, the therapeutic vaccine made for viruses can be mixedwith therapeutic vaccine made for bacteria, fungi, parasites, or againsttumor cells so that all collectively stimulate cellular and humoralresponse of the body particularly in immune suppressed patients.

In one embodiment, methylene blue blue and its derivatives atconcentrations or >2 microg/ml in cell or tissue or cell culture at amedia temperature of 24-43C is controlled with a proportional integralderivative (PID) system that controls the temperature of the media at anexact desired level to enhance damage to the viruses, bacteria, fungi,or tumor cells without denaturing the proteins, glycoproteins,saccharides, etc. (that occurs at temperatures of 47-50 or more Celsius)to damage selectively the DNA and RNA of the viral, bacterial, and fungior parasites or tumor cells, with or without addition of peptide nucleicacid (PNA), and/or a protease inhibitor (Ebselen) and/or poly(ADP-ribose) polymerase inhibitor (PARP) inhibitors fixate the DNA orRNA, preventing them from becoming active or mutating, similarlybeta-propiolactone can be used to damage the DNA or RNA, however,beta-propiolactone is an alkylating agent designated by the FDA as acarcinogenic compound and preferably should be used at very lowconcentrations. After killing the pathogens, the vaccine is washed andfiltered to eliminate all unbound MB blue and its derivatives and BPL,then one adds one or more antivirals, antibacterials, antifungi,anti-parasitics, and/or anti-neoplastics at a nontoxic concentration orin combination with Monocolonal Antibodies (MABs) with or withoutadjuvants, such as viral-like particles (VLP), TLR, etc. is added to thevaccine cocktail to build a therapeutic vaccine against variouspathogens or stored at room temperature or below or frozen at zerodegree C. for transport as needed.

In one embodiment, a combination of BPL above 1:1000 and at lowconcentrations and MB blue and its derivatives <0.26 Microgam/ml at atemperature of 37-40 degrees C. reduces the toxicity of MB and BPL andreduces the aggregation in the cuture media and increases the antiviralefficacy for use in tissue culture, cell culture, or for administrationto a patient.

In one embodiment, combination of BPL and at low concentrations of1:1000 V/V and MB of <0.25% microgral/ml at tempretures of 25-43 C intissue culture or for administration reduces the toxicity of methyleneblue and its derivatives and increases the antivirals, antibiotics,antifungals, anti parasitics and anti-neoplastic's efficacy of vaccinestalk to which non-toxic concentrations of antivirals, antibiotics,anti-fungals, antiparasitic, or anti-neoplastic medications are added tobuild a therapeutic vaccine cocktail for administration intranasally,intramuscularly, orally, subcutaneously, or intraarterially or using atherapeutic implant with or without adjuvants, such as viral likeparticles (VLP), TLR, etc. for delivery of the vaccine cocktail asneeded.

Although the body's immune system produces peptoids to kill manypathogens, such as viral, bacteria, parasitic, fungal, or neoplasticcells, these peptoids do not discriminate between the pathogen and thenormal tissue. This means that the peptoids or the syntheticallyproduced mimetic counterparts, can also damage normal tissue. Thepeptide can be produced synthetically that works the same way, i.e.,penetrating the membrate of viruses, bacteria, fungi, parasites, ortumor cells and latches to NAD or ARN preventing their function orreplication of the pathogen, while maintaining the protein,glycoprotein, and saccharides antigenicity of the organism with orwithout adjuvants such as viral-like particles (VLP), TLRs, etc.

In one embodiment, peptoids are easy to make, such as LL-37, and are apart of Cathelicidins host defense peptides when added to the tissueculture or cell culture in preparation of therapeutic vaccine penetratesthe viral or other pathogen's envelope and attaches to RNA and DNApreventing them from being activated. Initially, the LL-37 binds to thesurface membrane of the pathogen at low concentrations of 8 μM, thentranslocates in the preplasmic space within <30 minutes and stops thegrowth of the pathogen leading to lysis of the pathogen, one also canadd antiviral, or anti-bacterials, antifungals or antiparasites orantineoplastic medication to the tissue culture which now penetrates thepathogen damaged membrane by LL-37 killing these organisms, then theculture media is washed and filtered to obtain the antigenic proteins,saccharides, glycoproteins from the organism, subsequently one addsnon-toxic doses of antivirals, antibiotics, antifungals, antiparsites,or antineoplastics to create a therapeutic vaccine which can be storedwith or without BAC, or adjuvants or anti-inflammatory agents and keptat a low temperature without the need to freeze it, though freezing thevaccine will not affect its efficacy and can be melted before itsapplication, to be administered as needed by inhalation, orally,subcutaneously or intramuscularly or injected inside a tumor or in anasal implant.

In one embodiment, MB and beta-Propiolactone (at >1/2000 V/V) can beused both at low concentrations to prevent the side effects of viralaggregation, e.g., methylene blue derivatives at doses of <0.5microgram/ml and BPL at <0.5 mg/ml with or without anti-virals, etc.used for vaccine production in tissue or cell culture with or withoutthe LL-37 peptoid that are subsequently washed and filtered to removefree methylene blue and or beta-propiolactone away from the culturemedium while adding an anti-inflammarory agent, such as a steroid orinflammatory cell pathway inhibitors to it, with or without Toll-likeReceptors which is stimulated in presence of LL-37 or other adjuvants toenhance the immune response after administration to a patient and one ormore antivirals or antibacterials, antifungi, antiparasites, and/orantineoplastic medications at a non-toxic doses or low concentrations asa therapeutic vaccine or for treatment or prophylaxis, in viral,bacterial, fungal, parasitic and neoplastic pathogens, to beadministered as needed by inhalation, orally, subcutaneously orintramuscularly or injected inside a tumor or as a nasal implant.

In one embodiment, for production of a therapeutic vaccine, the LL-37peptoid enhances the effect of antivirals, antibacterials, antifungals,or anti-neoplastic medication used in vaccination.

In one embodiment, for production of therapeutic vaccine Nsp13inhibitors, MB blue and its derivatives or BPL, such as bananin, andchromone-4c at low concentrations enhances the effect of antivirals,antibacterials, antifungals, or anti-neoplastic medication used intissue culture or cell culture vaccination that can be washed andfiltered and used with antivirals, antibacterials, antifungals, oranti-neoplastic medication at non-toxic concentrations as a cocktailwith adjuvants in therapeutic vaccine production.

In one embodiment, for production of a therapeutic vaccine with aprotease inhibitor, Ebselen or a combination with rifampin andinflammatory cell pathway inhibitors enhances the effect of antivirals,antibacterials, antifungals, or antineoplastic medications used invaccination specifically for nasal application to cover disease of thebrain and lung by the above-described pathogens and preventing futureAlzheimer diseases after viral infections.

In one embodiment, peptoids and betapropiolactone or methylene blue andits derivatives at low concentrations and a peptide nucleic acid (PNA)can be combined to block DNA and RNA and can be used for vaccineprediction in tissue or cell culture of viruses, bacteria, fungi,parasites or cancer cells where the DNA and RNA of the organism isdamaged by PNA leaving the protein glycoproteins and saccharide intactto act immunogenic, then the dead organism in tissue culture is washedto remove free methylene blue blue and its derivatives or betapropiolactone, to which now depending on the organism antiviral,antibacterial, antiparasitic, antifungal, or anti-neoplastic medicationis added at a non-toxic concentrations, then one adds adjuvants forenhancing immune response, and steroids or anti-inflammatory cellpathway inhibitors, to reduce overactive immune response. Thetherapeutic vaccine is now stored in refrigerator to be administered tothe person as needed by inhalation, orally, subcutaneously, orintramuscularly or injected inside a tumor.

In one embodiment, in tissue culture, the peptoid LL-37 and peptidenucleic acid can be used to make a therapeutic vaccine with anantineoplastic medication, etc. to damage the RNA or DNA in the viral,bacterial, fungi, parasitic, or tumor cell in the culture media tocreate a peptoid therapeutic vaccine, though if needed methylene blueblue and its derivatives or beta-propiolacone at a very lowconcentration or peptide nucleic acid (PNA) can be added, without theuse of heat or light or the potentially carcinogenic medications, thevaccine in culture medium is then washed and filtered to remove freemethylene blue blue and its derivatives and/or beta-propiolactone anduse the remaining proteins, glucoproteins, saccharides, etc. to make atherapeutic vaccine, with additional antivirals or antibacterials oranti-parasites or antifungals, or anti-neoplastics plus pathwayinhibitors to reduce inflammatory response or add VLP, Toll LikeReceptors, or oval albumin or aluminum-based compound called adjuvantsor recombinant spider silk proteins or Saponin-based adjuvants (SBAs),etc. to the vaccine to stimulate an immune response against thepathogens in the body.

In one embodiment, the therapeutic vaccine (i.e., vaccine andantivirals) when administered to a patient with a previous viraldisease, such as Herpes, prevents reactivation of the Herpes viruses inthe patient after vaccination against another virus, e.g., coronavirusesand their mutations, etc.

In one embodiment, the nasal inhalation or nasal implant with thetherapeutic vaccine provides not only general immunity to the person oranimal, but simultaneously create a mucosal immunity in the nasalmucosa, the bronchi, lung mucosa and in the brain through the olfactorynerves which is important in treatment of viruses that are transmittedmostly through air, etc.

In one embodiment, the therapeutic vaccine is administered with anantibiotic, such as rifampin or Rifampicin, with or without pathwayinhibitors by inhalation to prevent simultaneous co-existence of thebacteria, especially in immunosuppressed patients.

In one embodiment, in a population affected with a virus aftervaccination, the measurement of neutralizing antibody (NA) in thecirculation of a patient indicates the duration of the effect of thevaccine in a patient, repeated examination of a small sample of thepopulation can provide not only the information on the duration of theimmunity, but also the effect of the NA on the mutations thereby,eliminating the need for a large scale evaluation of the entirepopulation.

In one embodiment, the nasal therapeutic implants for both nostrils areadministered repeatedly after 3-6 months or more, may serve as aprophylaxis, or vaccination or therapeutic for the patient and prolongthe duration of immunity in the patients and the general population, andis economical compared to systemic administration of larger doses,preventing spread of the disease.

In one embodiment, one can produce a universal vaccine if thetherapeutic vaccine described in this application is used against onevirus is used with numerous viruses, RNA or DNA viruses (see the tableabove) or administered at a low concentration of viral therapeuticvaccine, such as mRNA vaccine adminstrated at a low dose (e.g., mRNAtherapeutic vaccine at low concentration) orally, through the nose or asan implant, by mouth, or intramuscularly of the vaccine which can berepeated once a month or every three months or longer while examiningthe serum antibodies against the virus.

In one embodiment, the described therapeutic vaccine can be used againstchronic bacterial infections, therapy resistant infections withrifampin, such as in tuberculosis, leprosy, herpes, zoster infection,etc.

In one embodiment, the above-described therapeutic vaccine can be usedagainst all fungi, to be administered as needed by inhalation,topically, orally, subcutaneously, intramuscularly, or injected inside atumor of a body cavity or nasal implant, etc.

In one embodiment, the therapeutic vaccine of creating a therapeuticvaccine can be used for treatment of neoplastic diseases, benign ormalignant tumors, to be administered as needed by inhalation, topically,orally, subcutaneously, intramuscularly, or injected inside a tumor, ora body cavity, such as bladder, etc.

In one embodiment, this therapeutic vaccine can be used against theparasitic infections regardless of their location along with specificmedication described to be administered as needed by topically, orally,subcutaneously, intramuscularly, or injected intravenously, etc.

In one embodiment, the therapeutic vaccine can be applied topically, onthe mucosal or skin surface, can be inhaled or delivered through a nasalimplant, or taken orally as pills, or injected locally, subcutaneously,inside a body cavity, subcutaneously or intramuscularly or nasalimplant, etc.

In one embodiment, after COVID infection in unvaccinated patients, thesymptoms of COVID last long and may not disappear soon, in these casesthere is an elevated level of interferon in the body as if the infectionhas never left the patient, the symptoms could be related to chronicinflammation in the brain leading potentially to Alzheimer's disease orlung disease (pulmonary fibrosis) or kidney disease or diseaseassociated with other organs, heart disease and chronic fatiguesyndrome.

In one embodiment, these patients can be treated with a therapeuticvaccine by nasal administration in addition to the use of Ebselen aprotease inhibitor which is attached to Mpro in combination withrifampicin and the inflammatory pathway inhibitors, such as rho kinaseinhibitors, and for the kidney involvement the systemic, oral, or at lowdose intraperitoneal or intravenous administration might be desirableafter initial inhalation therapy with therapeutic vaccine to reactivateimmune response to remove the antigenic material from the body andreduce the inflammatory process, a combination with baricitinib can alsobe a desirable therapy.

In one embodiment, the therapeutic vaccine with or without adjuvantssaponinor TLR agonist can be used without exception on all viruses,bacteria, fungi, parasites, benign or malignant lesions and might have arole in management of autoimmune diseases or chronic inflammatoryprocesses such as Alzheimer's, Parkinson's, and rheumatois disease, etc.though the general principles are described specific variations oradditions such as diphenhydramine, lactoferrin, lenzilumab (ananti-granulocyte-macrophage colony-stimulating factor (GM-CSF)monoclonal antibody) and inflammatory cell pathway inhibitors, etc.applied for each therapy.

In one embodiment, one grows a virus in the yeast, then adds methyleneblue and its derivatives and/or antivirals or antibacterials orantifungals or a antineoplastic medication to kill the virus, bacteria,fungi, parasites, or tumor cells, separates the dead virus, bacteria,fungi, parasites, or tumor cells by a purification technique, andadministers the collected vaccine and adds non-toxic doses ofantivirals, antibacterials, anti-fungals, anti-neoplastic medicationsfor administration in humans and one or more adjuvants, by nasalinhalation, subcutaneous injection, intramuscular injection, or oralingestion, etc.

In one embodiment, the therapeutic vaccine can be combined withfluoxetine selective serotonin reuptake inhibitors (SSRI) increasing themelatonin levels and simultaneously reducing platelet aggregation inviral infections, such as COVID-19, EBV, etc. that can be administeredorally or by inhalation.

In one embodiment, the adjuvants are added to the therapeutic vaccinecombined with immunizing peptides, such as Freund's (FCA) a water in oilemulsion, or heat-killed mucobacterium tuberculosis which is releasedslowly but should be preferably by killing the bacteria using higherdoses of methylene blue and its derivatives combined with with peptidenucleic acid since mineral oil produces granulomatous response, Ribi,and Titermax or Aluminum salt adjuvants or TLR s to stimulate the immuneresponse increasing the the activity of antibodies after one or moretimes of administration.

In one embodiment, the adjuvants are added to the therapeutic vaccinecombined with immunizing peptides, such as Freund's Incomplete Adjuant(FIA) a water in oil emusion, or heat-killed mucobacterium tuberculosis.

In one embodiment, the therapeutic vaccine against viruses, bacteria,parasites, or tumor cells induces an immune response against theproteins, glycoproteins, and saccharides of the pathogen and not onlyone specific protein, such as a spike protein or mRNA therefore producesa more robust humoral and cellular response, therefore a combination ofa therapeutic vaccine with an mRNA vaccine enhances the immune responsein patients which are treated with anticancer medications that reducestheir normal immune response or in elderly patients, etc.

In one embodiment, some respiratory viruses, such as smallpox, rubella,measles varicella-zoster virus infection, cause systemic disease andsome non-systemic respiratory viruses, such as influenza viruses,SARS-CoV-2, coronaviruses, human metapneumovirus (hMPV), HSV-1 or HSV-2parainfluenza viruses, RSV primarily infect the mucosal surfaces and/orepithelial cells, and are best treated by nasal application of thetherapeutic vaccine or multiple antiviral medications or as a nasal slowrelease implant to prevent mutation of viruses and recurrent positiveviral tests that lead to propagation of the infection.

In one embodiment of growing the organism in the yeast culture, thesteps include first adding methylene blue and its derivatives and/or PNAand or antivirals, antibacterials, antifungals, or antineoplaticmedications to kill the virus, separating the dead virus, bacteria,fungi, parasites, and/or tumor cells by a purification technique,administering the collected vaccine with added non-toxic doses ofantivirals, antibacterials, and anti fungals, and/or anti-neoplasticmedications along with adjuvant(s) for administration in a human bynasal inhalation, subcutaneous injection, intramuscular injection, ororal injestion one or more times to induce an immune response.

In one embodiment, the therapeutic vaccine can be added to an mRNAvaccine or another vaccine, such as Corbevax, sinovax, Corona vac,COH04S1 spike and nucleocapsid proteins, etc. to strengthen the responseto the combination vaccine that can be administered to the patient as asingle dose or separately, one or more times.

Any of the features, attributes, or steps of the above-describedembodiments and variations can be used in combination with any of theother features, attributes, and steps and routes of administration ofthe above-described embodiments and variations as desired.

Although the invention has been shown and described with respect to acertain embodiment or embodiments, it is apparent that this inventioncan be embodied in many different forms and that many othermodifications and variations are possible without departing from thespirit and scope of this invention.

Moreover, while exemplary embodiments have been described herein, one ofordinary skill in the art will readily appreciate that the exemplaryembodiments set forth above are merely illustrative in nature and shouldnot be construed as to limit the claims in any manner. Rather, the scopeof the invention is defined only by the appended claims and theirequivalents, and not, by the preceding description.

The invention claimed is:
 1. A therapeutic vaccination method for amedical condition in a patient, the method comprising: growing viruses,bacteria, fungi, parasites, or tumor cells on a cell culture or otherappropriate medium; harvesting the viruses, bacteria, fungi, parasites,or tumor cells from the cell culture or other appropriate medium;killing the viruses, bacteria, fungi, parasites, or tumor cells in thecell culture or other appropriate medium with a dose of methylene bluethat is greater than 2.0 micrograms per milliliter so as to damage theRNA and/or the DNA of the viruses, bacteria, fungi, parasites, or tumorcells, wherein the viruses, bacteria, fungi, parasites, or tumor cellsremain in contact with the methylene blue for a period of time that issufficient for the methylene blue to penetrate the viruses, bacteria,fungi, parasites, or tumor cells and attach to RNA or DNA of theviruses, bacteria, fungi, parasites, or tumor cells and preventmultiplication of the viruses, bacteria, fungi, parasites, or tumorcells; separating the dead viruses, bacteria, fungi, parasites, or tumorcells from a remainder of the cell culture or other appropriate mediumusing a filter and/or centrifuge; depending on the type of organism,adding antivirals, antibacterials, antifungals, antiparasitics, and/oranti-neoplastic medications at non-toxic therapeutic concentrations tothe dead viruses, bacteria, fungi, parasites, or tumor cells so as toform a therapeutic vaccine; and administering the therapeutic vaccine toa patient in need thereof; wherein the therapeutic vaccinesimultaneously produces a therapeutic response and a humoral andcellular immune response to viruses, bacteria, fungi, parasites, ortumor cells in the body of the patient without resulting in deleteriousside effects to the patient.
 2. The therapeutic vaccination methodaccording to claim 1, wherein the method further comprises the step of:adding one or more adjuvants and one or more cell pathway inhibitors tothe dead viruses, bacteria, fungi, parasites, or tumor cells to preventan excessive immune response of the patient.
 3. The therapeuticvaccination method according to claim 1, wherein the method furthercomprises the steps of: administering metformin with GSK inhibitors toprotect the kidneys of the patient; and performing kidney dialysis orelectrophoresis to remove excess toxins from the body of the patient. 4.The therapeutic vaccination method according to claim 1, wherein themethod further comprises the step of: repeatedly administering thetherapeutic vaccine to the patient as needed until the viruses,bacteria, fungi, parasites, or tumor cells are eliminated and verifiedby polymerase chain reaction and/or imaging.
 5. The therapeuticvaccination method according to claim 1, wherein the step of killing theviruses, bacteria, fungi, parasites, or tumor cells in the cell cultureor other appropriate medium further comprises conjugating the methyleneblue with gold nanoparticles so as to enhance a penetration of themethylene blue into the viruses, bacteria, fungi, parasites, or tumorcells and attach to the RNA or DNA of the viruses, bacteria, fungi,parasites, or tumor cells and prevent multiplication of the viruses,bacteria, fungi, parasites, or tumor cells.
 6. The therapeuticvaccination method according to claim 1, wherein the step of killing theviruses, bacteria, fungi, parasites, or tumor cells in the cell cultureor other appropriate medium further comprises adding a peptide nucleicacid (PNA), one or more anti-neoplastic medications, and/or one or moreantivirals to the cell culture or other appropriate medium so as toenhance the effect of the methylene blue on the RNA and/or the DNA ofthe viruses, bacteria, fungi, parasites, or tumor cells.
 7. Thetherapeutic vaccination method according to claim 1, wherein the step ofadministering the therapeutic vaccine to the patient further comprisesadministering the therapeutic vaccine together with antigens, goldnanoparticles, and a low non-toxic dose of at least two additionalmedications, the at least two additional medications comprising two ormore antivirals, two or more antibacterials, two or more antifungals,two or more antiparasitics, and/or two or more anti-neoplasticmedications.
 8. The therapeutic vaccination method according to claim 7,wherein the method further comprises the step of: administering one ormore immune stimulators, spermidine, anti-depressant agents, and/ordiamidobenzimidazole (diABZI-4) to trigger the stimulator of interferongenes (STING), thereby enhancing the immune response of the patient. 9.The therapeutic vaccination method according to claim 8, wherein themethod further comprises the step of: administering Ceapin-A7 and KIRA8to eliminate damaged cells, bacteria, viruses, fungi, parasites, ortumor cells in the patient.
 10. The therapeutic vaccination methodaccording to claim 1, wherein the step of administering the therapeuticvaccine to the patient further comprises administering the therapeuticvaccine together with an mRNA vaccine or a modified mRNA vaccine and alow non-toxic dose of at least one additional medication, the at leastone additional medication comprising one or more antivirals, one or moreantibacterials, one or more antifungals, one or more antiparasitics,and/or one or more anti-neoplastic medications.
 11. The therapeuticvaccination method according to claim 10, wherein the method furthercomprises the step of: administering one or more inflammatory cellpathway inhibitors, one or more steroidal anti-inflammatory agents, oneor more non-steroidal anti-inflammatory drugs (NSAIDs), mycophenolatemofetil or other macrolides, methotrexate, an anti-TGF, at least twotypes of antibody-coated nanoparticles, and/or one or moreanticoagulants so as to create a therapeutic vaccine that can beadministered during infection to kill the viruses, bacteria, fungi,parasites, or tumor cells in the patient, and to induce a humoral andcellular immune response in the patient.
 12. The therapeutic vaccinationmethod according to claim 1, wherein the method further comprises thestep of: administering one or more inflammatory cell pathway inhibitorsto the patient together with the antivirals, antibacterials,antifungals, antiparasitics, and/or anti-neoplastic medications so thatthe therapeutic vaccine is able to be used prophylactically or fortreatment of the patient as needed, thereby increasing an immuneresponse of the patient to the organism while simultaneously treatingthe organism.
 13. The therapeutic vaccination method according to claim1, wherein the step of killing the viruses, bacteria, fungi, parasites,or tumor cells in the cell culture or other appropriate medium furthercomprises killing the viruses, bacteria, fungi, parasites, or tumorcells with a high dose of at least two medications that damage the RNAand/or DNA of the viruses, bacteria, fungi, parasites, or tumor cells;and the method further comprises the steps of: filtering the deadviruses, bacteria, fungi, parasites, or tumor cells from the remainderof the cell culture or other appropriate medium; extracting the antigensfrom the damaged viruses, bacteria, fungi, parasites, or tumor cells;and adding one or more additional medications to the extracted antigensat a low non-toxic dose to the patient, but at a dose that is stilltoxic to the organisms.
 14. The therapeutic vaccination method accordingto claim 13, wherein the method further comprises the steps of: adding apoly (ADP-ribose) polymerase (PARP) inhibitor to the therapeutic vaccinethat blocks the RNA and/or DNA repair of the viruses, bacteria, fungi,parasites, or tumor cells; adding one or more inflammatory pathwayinhibitors to the therapeutic vaccine; and adding one or more immunestimulators to the therapeutic vaccine so as to enhance the immuneresponse of the patient.
 15. The therapeutic vaccination methodaccording to claim 1, wherein the step of administering the therapeuticvaccine further comprises repeatedly administering the therapeuticvaccine as needed to the patient at a low dose or a gradually increasingdose until a sufficient neutralizing antibody response is achieved inthe serum of the patient.
 16. The therapeutic vaccination methodaccording to claim 1, wherein the therapeutic vaccine is used fortherapy-resistant bacteria, fungi, parasites, or tumors.
 17. Thetherapeutic vaccination method according to claim 1, wherein a tumor ofthe patient has become resistant to checkpoint inhibitors and hascreated a milieu in which the newly grown tumor cells are resistant tostandard immune therapy; the method further comprising the steps of:administering a combination of two different therapeutic vaccines, afirst one of the two different therapeutic vaccines directed towardexisting tumor cells and a second one of the two different therapeuticvaccines directed toward another antigen from bacteria, viruses, orfungi to re-stimulate the cellular and humoral immune response of thebody of the patient against the therapy-resistant tumor cells;administering one or two anti-neoplastic medications in combination withthe first one or the second one of the two different therapeuticvaccines; and simultaneously administering one or more cell pathwayinhibitors, immune stimulators, and/or anti-VEGFs to the patient as acocktail.
 18. The therapeutic vaccination method according to claim 17,wherein the method further comprises the step of: administeringmonoamine oxidase inhibitors, melatonin and spermidine to the patient soas to prevent exhaustion of the cellular immune response of the patient.19. The therapeutic vaccination method according to claim 1, wherein thecell culture on which the viruses, bacteria, fungi, parasites, or tumorcells are grown and harvested comprises yeast culture media that permitsthe organisms to not only grow, but also mutate rapidly such that thetherapeutic vaccine has a predictive value for mutation of the viruses,bacteria, fungi, parasites, or tumor cells even before the mutationoccurs in the patient; wherein the therapeutic vaccine containsantigenic material from the mutated and un-mutated organism such thatthe therapeutic vaccine induces a humoral and cellular immune responseagainst the past, present, and future mutations of the organism so as tokill the organism; and wherein the therapeutic vaccine is administeredsimultaneously with an anti-organism medication to effectively preventviral, bacterial, fungal, parasitic, and tumor cell mutation in thepatient.
 20. The therapeutic vaccination method according to claim 19,wherein the method further comprises the step of: administering light orelectrical pulses to the viruses, bacteria, fungi, parasites, or tumorcells grown in the yeast culture media so as to encourage the mutationof the viruses, bacteria, fungi, parasites, or tumor cells to beharvested and killed for vaccination.
 21. The therapeutic vaccinationmethod according to claim 19, wherein the method further comprises thestep of: administering a poly (ADP-ribose) polymerase (PARP) inhibitorwith the therapeutic vaccine so as to block the RNA and/or DNA repair ofthe viruses, bacteria, fungi, parasites, or tumor cells.
 22. Thetherapeutic vaccination method according to claim 1, wherein the methodfurther comprises the step of: administering the therapeutic vaccine tothe patient as topical drops, an ointment, spray for inhalation, in aninhaler, nasally by spraying powder, intravenously, by intramuscularinjection, systemically, orally as a capsule, or locally inside a tumor.23. The therapeutic vaccination method according to claim 1, wherein themethod further comprises the step of: administering the therapeuticvaccine to the patient using a conical nasal drug delivery implant, thetherapeutic vaccine being delivered to one or more nasal passageways ofa patient.
 24. The therapeutic vaccination method according to claim 23,wherein the conical nasal drug delivery implant is formed from asemi-flexible polymeric material by 3D printing the conical nasal drugdelivery implant.
 25. The therapeutic vaccination method according toclaim 23, wherein the conical nasal drug delivery implant is attached toa pair of glasses, an outer nose cover, an elastic headband configuredto be worn on the head of the patient, or is held in place by elasticcomponents on the conical nasal drug delivery implant itself.
 26. Thetherapeutic vaccination method according to claim 1, wherein the step ofkilling the viruses, bacteria, fungi, parasites, or tumor cells in thecell culture or other appropriate medium further comprises adding atleast one of beta-propiolactone (BPL), NSP13 inhibitors, bananin, andchromone-4c to the cell culture or other appropriate medium so as toenhance the effect of the methylene blue on the RNA and/or the DNA ofthe viruses, bacteria, fungi, parasites, or tumor cells; and wherein themethod further comprises the step of: washing and filtering thetherapeutic vaccine to eliminate all unbound methylene blue,beta-propiolactone, NSP13 inhibitors, bananin, and/or chromone-4c priorto adding the antivirals, the antibacterials, the antifungals, theantiparasitics, and/or the anti-neoplastic medications.
 27. Thetherapeutic vaccination method according to claim 1, wherein thetherapeutic vaccine is formed from a plurality of different virus typesand/or mixed with other related vaccines for other virus types in orderto treat both a coronavirus and another latent virus of the patient. 28.The therapeutic vaccination method according to claim 1, wherein thetherapeutic vaccine is mixed with another vaccine made for bacteria,fungi, parasites, or tumor cells so that both vaccines collectivelystimulate cellular and humoral response of the body of the patient. 29.The therapeutic vaccination method according to claim 1, wherein themethod further comprises the step of: adding synthetically producedpeptoids to the tissue culture or other appropriate medium, thesynthetically produced peptoids penetrating the envelope of the viruses,bacteria, fungi, parasites, or tumor cells, and attaching to RNA and DNAof the viruses, bacteria, fungi, parasites, or tumor cells so as toprevent the RNA and DNA from being activated.